




CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

Proposed Grant Awards

February 15, 2023





CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: MICHELLE LE BEAU, PH.D., CHIEF SCIENTIFIC OFFICER
SUBJECT: ACADEMIC RESEARCH FY2023 REVIEW CYCLE 1; AND RECRUITMENT AWARD RECOMMENDATIONS FY2023, CYCLE 23.2 AND CYCLE 23.3.
DATE: FEBRUARY 15, 2023

The Scientific Review Council (SRC) recommendations for FY2023 review cycle 1 and recruitment cycles 23.2 and 23.3 include **65** awards from eight grant mechanisms totaling **\$105,369,278**. Note applications are ranked by overall score.

Because the SRC recommendations exceed available funds for the second quarter of 2023, the Program Integration Committee voted to defer action on 25 IIRA applications totaling \$28,235,202 recommended by the SRC with overall scores of 2.8 and higher. Therefore, the Program Integration Committee recommends **40 awards** and award funding of **\$77,134,078** as presented in Table 1.

Table 1:

Grant Mechanism	SRC Recommendations		Academic Research Recommendations	
	Awards	Funding	Awards	Funding
Individual Investigator Research Awards	37	\$ 38,771,555	18	\$18,863,643
Individual Investigator Research Awards for Childhood and Adolescent Cancers	8	\$ 11,067,545	5	\$6,867,685
Individual Investigator Research Awards for Computational Systems Biology of Cancer	5	\$ 5,825,580	3	\$3,425,614
Individual Investigator Research Awards for Clinical Translation	2	\$ 3,727,462	1	\$2,000,000
Individual Investigator Research Awards for Prevention and Early Detection	4	\$ 7,978,737	4	\$7,978,737
Texas Regional Excellence in Cancer	3	\$ 17,998,422	3	\$17,998,422
Recruitment of Established Investigators	2	\$12,000,000	2	\$12,000,000
Recruitment of First-Time, Tenure Track Faculty Members	4	\$ 7,999,977	4	\$ 7,999,977
Total	65	\$ 105,369,278	40	\$77,134,078

Program Priorities Addressed:

The applications proposed to the Program Integration Committee for funding address the following Academic Research Program Priorities: recruitment of outstanding cancer researchers to Texas, a broad range of innovative, investigator-initiated research projects, computational biology and analytic methods, disparities, childhood cancers, hepatocellular cancer and implementation research. The program priorities addressed by the proposed slate of awards are displayed in Table 2 and Attachment 1.

Table 2

Program Priorities Addressed by Grant Recommendations[#]		
# Awards*	Program Priorities	Funding*
6	Recruitment of outstanding cancer researchers to Texas	\$19,999,977
34	A broad range of innovative, investigator-initiated research projects	\$57,134,101
3	Computational biology and analytic methods	\$3,425,614
5	Childhood Cancers	\$6,867,685
4	Disparities	\$17,998,422
6	Hepatocellular Cancer	\$18,421,730
5	Implementation Research (Prevention)	\$13,977,159
1	Expansion of novel clinical trials	\$2,000,000
[#] Table 2 lists the 40 grant awards recommended by Academic Research. [*] Some grant awards address more than one program priority and are double counted.		

1. Individual Investigator Research Awards (RFA R-23.1 IIRA) Slate

Peer Review Recommendations:

The Scientific Review Council recommended 37 Individual Investigator Research Awards (IIRA) totaling \$38,771,555. Due to funding limits, the Program Integration Committee recommends funding 18 IIRAs totaling \$18,863,643 and deferring 19 IIRAs with overall scores of 2.8 or higher totaling \$19,907,912 to August 2023 should funds be available.

Purpose of Individual Investigator Research Awards:

Supports applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer. Areas of interest include laboratory research, translational studies, and/or clinical investigations. Competitive renewal applications are accepted.

Individual Investigator Research Awards Funding Levels:

Up to \$350,000 per year. Exceptions permitted if extremely well justified; maximum duration: 3 years.

Table 3: Individual Investigator Research Awards Recommended for Funding

Rank	ID	Award Mechanism	Meeting Overall Score	Application Title	PI	PI Organization	Rec. Budget	Priority Met
1	RP230222	IIRA	1.1	Personalized Auricular Point Acupressure to Self-Manage Cancer-Related Pain	Yeh, Chao Hsing	The University of Texas Health Science Center at Houston	\$1,046,680	
2	RP230140	IIRA	1.1	Changes in Tumor Microenvironment That Promote Cachexia	Infante, Rodney	The University of Texas Southwestern Medical Center	\$1,050,000	
3	RP230093	IIRA	1.8	Targeting the Mlc1-GlalCAM Protein Complex in Invasive Glioma Cells	McCarty, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,050,000	
4	RP230072	IIRA	1.9	Studying and Therapeutically Targeting Ferroptosis Liability in BRCA1-Deficient Cancer	Gan, Boyi	The University of Texas M. D. Anderson Cancer Center	\$1,050,000	
5	RP230360	IIRA	1.9	Rational Design, Synthesis, and Biological Evaluation of Simplified Taccalonolide Analogs for the Treatment of Cancer	Frantz, Douglas	The University of Texas at San Antonio	\$1,049,128	
6	RP230135	IIRA	2.0	Blocking DNA Damage Response Induction of “Don’t Eat Me” Signals Converts Local Radiotherapy Into Systemic Immunotherapy	Curran, Michael	The University of Texas M. D. Anderson Cancer Center	\$1,049,905	
7	RP230344	IIRA	2.0	Development and Evaluation of Lanosterol Synthase Inhibitors in	McBrayer, Samuel	The University of Texas Southwestern	\$1,048,465	

				Preclinical GBM Models		Medical Center		
8	RP230109	IIRA	2.0	Autophagy and Tumor Endothelium	Terada, Lance	The University of Texas Southwestern Medical Center	\$1,049,994	
9	RP230373	IIRA	2.0	Mapping the Geospatial Tumor Clonal Architecture to Restore Immune Recognition in Pancreatic Cancer	Viale, Andrea	The University of Texas M. D. Anderson Cancer Center	\$1,049,985	
10	RP230224	IIRA	2.0	Enhancing Immune Responses in Pancreatic Cancer by Stromal Inhibition of HIF2	Taniguchi, Cullen	The University of Texas M. D. Anderson Cancer Center	\$1,049,997	
11	RP230382	IIRA	2.0	Characterization of 3D Genome Organization and Transcriptional Regulation in Prostate Cancer	Mani, Ram	The University of Texas Southwestern Medical Center	\$1,049,641	
12	RP230247	IIRA	2.0	A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer	Lin, Sue-Hwa	The University of Texas M. D. Anderson Cancer Center	\$1,050,000	
13	RP230334	IIRA	2.5	Elucidating the Mutagenesis Mechanism of BRAF in Melanoma	Lee, Seongmin	The University of Texas at Austin	\$1,050,000	
14	RP230391	IIRA	2.6	Understanding and Improving CAR T-Cell Therapy of T-ALL and LBL	Mamonkin, Maksim	Baylor College of Medicine	\$1,050,000	
15	RP230345	IIRA	2.6	The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T-Cell Therapy	Liu, Wenshe	Texas A&M University	\$1,050,000	

16	RP230271	IIRA	2.7	Targeting Distinct Metabolic Vulnerabilities of Aggressive Renal 17Cell Carcinoma Va18riants	Zacharias Millward, Niki	The University of Texas M. D. Anderson Cancer Center	\$1,019,997	
17	RP230050	IIRA	2.7	A Novel Therapeutic Strategy Targeting Pancreatic Cancer	Yao, Wantong	The University of Texas M. D. Anderson Cancer Center	\$1,049,854	
18	RP230261	IIRA	2.7	Investigating the Mechanism of NLRP3 Inflammasome Hyperactivation During Hepatocellular Carcinoma Development	Zhong, Zhenyu	The University of Texas Southwestern Medical Center	\$1,049,997	Liver Cancer

* All Individual Investigator Research projects address the “A broad range of innovative, investigator-initiated research projects”

Table 4: Individual Investigator Research Awards Recommended for Deferral

Rank	ID	Award Mechanism	Meeting Overall Score	Application Title	PI	PI Organization	Rec. Budget	Priority Met
1	RP230019	IIRA	2.8	Deciphering Spatial Immune Contextures Through Integrative Immunoproteogenomics	Lee, Hyun-Sung	Baylor College of Medicine	\$1,050,000	
2	RP230307	IIRA	2.8	In Vivo Chimeric Antigen Receptor Macrophages (ChARMs) for Cancer Immunotherapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$1,026,414	
3	RP230241	IIRA	2.8	PD-L1 Modifications and Membranous Localization	Li, Yong	Baylor College of Medicine	\$1,049,994	
4	RP230375	IIRA	2.8	Targeting Chitinase-3-Like-1 as a Novel Therapy for Hepatocellular Carcinoma	Ju, Cynthia	The University of Texas Health Science Center at Houston	\$1,049,769	Liver Cancer

5	RP230283	IIRA	2.8	Development of Immunotherapy and Combinatorial Therapy of Sickle Cell Trait-Associated Renal Medullary Carcinoma	Yang, Liuqing	The University of Texas M. D. Anderson Cancer Center	\$1,050,000	
6	RP230323	IIRA	2.9	Real-Time, Label-Free, Micro HSI Device and Transformer-Based Attention Networks for Oral Cancer Imaging	Fei, Baowei	The University of Texas at Dallas	\$1,048,933	
7	RP230184	IIRA	2.9	Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Drugs for Precision Cancer Medicine	Sun, Xiankai	The University of Texas Southwestern Medical Center	\$1,049,997	
8	RP230216	IIRA	2.9	Investigating Cell Competition in Liver Cancer Development	Zhu, Hao	The University of Texas Southwestern Medical Center	\$1,050,000	Liver
9	RP230381	IIRA	2.9	JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC	ZHANG, QING	The University of Texas Southwestern Medical Center	\$1,036,126	
10	RP230112	IIRA	2.9	The Evolution of Intratumor Heterogeneity of Lung Cancers With or Without Immunotherapy and Its Impact on Patient Survival	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,049,396	
11	RP230240	IIRA	2.9	Therapeutic Targeting of Androgen Receptor in Metastatic Breast Cancer	Fuqua, Suzanne	Baylor College of Medicine	\$1,050,000	
12	RP230272	IIRA	3.0	Structure-Based Improvement for Inhibitors of WNK1, a Triple-Negative Breast Cancer Signature Kinase	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	\$1,050,000	
13	RP230327	IIRA	3.0	Harnessing the Metabolic Dependencies of Mitochondrial NADK2 as a Therapeutic	Hoxhaj, Gerta	The University of Texas Southwestern Medical Center	\$1,049,997	

				Strategy for Lung Cancer				
14	RP230071	IIRA	3.0	Unexpected Mechanisms Underlying Mutation-Induced Protein Mislocalization in Hematologic Malignancies	Liszcak, Glen	The University of Texas Southwestern Medical Center	\$1,049,997	
15	RP230012	IIRA	3.0	Targeting a Non-ATPase Proteasome Subunit in Acute Myeloid Leukemia (AML)	Eiring, Anna	Texas Tech University Health Sciences Center at El Paso	\$1,050,000	
16	RP230196	IIRA	3.0	Identifying the Biological Determinants of Aggressive Meningioma	Patel, Akash	Baylor College of Medicine	\$1,047,289	
17	RP230333	IIRA	3.1	Development of a Cell Therapy Platform for Localized and Feedback-Regulated Delivery of Cytokines for the Treatment of Pancreatic Cancer	Veisch, Omid	Rice University	\$1,050,000	
18	RP230181	IIRA	3.1	Dissection of CAMKK2's Tumor Cell-Intrinsic and -Extrinsic Roles in Prostate Cancer	Frigo, Daniel	The University of Texas M. D. Anderson Cancer Center	\$1,050,000	
19	RP230197	IIRA	3.2	Targeting MYCN Disruption of the Molecular Clock and Tumor Metabolism in Neuroblastoma Oncogenesis	Barbieri, Eveline	Baylor College of Medicine	\$1,050,000	Childhood

* All Individual Investigator Research projects address the “A broad range of innovative, investigator-initiated research projects” priority.

2. Individual Investigator Research Awards for Cancer in Children and Adolescents (RFA R-23.1 IIRACCA) Slate

Peer Review Recommendations:

The Scientific Review Council recommended 8 Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA), totaling \$11,067,545. Due to funding limits, the Program Integration Committee recommends funding 5 IIRACAs totaling \$6,867,685 and deferring 3 IIRACCAs with overall scores of 2.8 and higher totaling \$4,199,860 to August 2023 should funds be available.

Purpose of Individual Investigator Research Awards for Cancer in Children and Adolescents:

Supports applications for innovative research projects addressing questions that will advance knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer in children and/or adolescents in the near or long term. Competitive renewal applications accepted.

Individual Investigator Research Awards for Cancer in Children and Adolescents Funding Levels:

Up to \$350,000 per year. Applicants that plan on conducting a clinical trial as part of the project may request up to \$150,000 in additional total costs. Exceptions permitted if extremely well justified; maximum duration: 4 years.

Table 5: Individual Investigator Research Awards for Cancer in Children and Adolescents Recommended for Funding

Rank	ID	Award Type	Meeting Overall Score	Application Title	PI	PI Organization	Rec. Budget	Priority Met*
1	RP230026	IIRACCA	1.0	Identifying Clinical Methotrexate Toxicity Phenotypes Across Phases of Pediatric Leukemia Therapy	Bernhardt, Melanie	Baylor College of Medicine	\$1,392,407	Childhood Cancers
2	RP230018	IIRACCA	1.9	Neuronal Alterations in the Midbrain Dopaminergic System Function: A Novel Mechanism of Radiation-Induced Cognitive Dysfunction	Zhang, Die	The University of Texas M. D. Anderson Cancer Center	\$1,399,730	Childhood Cancers
3	RP230120	IIRACCA	2.5	Clonal Evolution and Chemoresistance of Hepatoblastomas With	Sumazin, Pavel	Baylor College of Medicine	\$1,371,733	Childhood Cancers/ Liver

				Hepatocellular Carcinoma Features				
4	RP230154	IIRACCA	2.6	Normalizing Membrane Homeostasis in Microglia/Macrophages of Pediatric High-Grade Gliomas	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$1,400,000	Childhood Cancers
5	RP230330	IIRACCA	2.7	Integrate Whole-Slide Imaging and Genomic Data to Study Pediatric Rhabdomyosarcoma	Xiao, Guanghua	The University of Texas Southwestern Medical Center	\$1,303,815	Childhood Cancers

* All Individual Investigator Research projects address the “A broad range of innovative, investigator-initiated research projects” priority.

Table 6: Individual Investigator Research Awards for Cancer in Children and Adolescents Recommended for Deferral

Rank	ID	Award Type	Meeting Overall Score	Application Title	PI	PI Organization	Rec. Budget	Priority Met*
1	RP230143	IIRACCA	2.9	The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT	Ludwig, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,399,860	Childhood Cancers
2	RP230174	IIRACCA	3.0	Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites	Ehrlich, Lauren	The University of Texas at Austin	\$1,400,000	Childhood Cancers
3	RP230162	IIRACCA	3.1	The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma	Kitagawa, Katsumi	The University of Texas Health Science Center at San Antonio	\$1,400,000	Childhood Cancers

* All Individual Investigator Research projects address the “A broad range of innovative, investigator-initiated research projects” priority.

3. Individual Investigator Research Awards for Computational Systems Biology of Cancer (RFA R-23.1 IIRACSBC) Slate

Peer Review Recommendations:

The Scientific Review Council recommended 5 Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC), totaling \$5,825,580. Due to funding limits, the Program Integration Committee recommends funding 3 IIRACSBC totaling \$3,425,614 and deferring 2 IIRACSBC with overall scores of 2.8 and higher totaling \$2,399,966 to August 2023 should funds be available.

Purpose of Individual Investigator Research Awards for Computational Systems Biology of Cancer:

Supports applications for projects that integrate innovative computational and mathematical approaches with experimental cancer biology to address challenging questions that will advance current knowledge in etiology, biology, progression, treatment, metastasis, and immunology of cancer.

Individual Investigator Research Awards for Computational Systems Biology of Cancer Funding Levels:

Up to a maximum of \$400,000 per year. Exceptions permitted if extremely well justified; maximum duration: 3 years.

Table 7: Individual Investigator Research Awards for Computational Systems Biology of Cancer: Recommended for Funding

Rank	ID	Award Type	Meeting Overall Score	Application Title	PI	PI Organization	Rec. Budget	Priority Met*
1	RP230160	IIRACSBC	2.2	Overcoming Therapy Resistance by Integrated Computational Modeling of the Bone Metastatic Niche in Prostate and Renal Cancers	Dondossola, Eleonora	The University of Texas M. D. Anderson Cancer Center	\$1,025,623	CSBC
2	RP230363	IIRACSBC	2.6	Developing Knowledge-Guided Deep Learning Models to Predict the Binding Between T-Cell Receptors and Neoantigens for Facilitating TCR-T Therapies	Wang, Tao	The University of Texas Southwestern Medical Center	\$1,199,997	CSBC
3	RP230166	IIRACSBC	2.6	Integrative Modeling of Spatially Resolved Multiomics Data to Identify Bladder Cancer Mucosal Field Effects	Wei, Peng	The University of Texas M. D. Anderson Cancer Center	\$1,199,994	CSBC

* All Individual Investigator Research projects address the “A broad range of innovative, investigator-initiated research projects” priority.

Table 8: Individual Investigator Research Awards for Computational Systems Biology of Cancer: Recommended for Deferral

Rank	ID	Award Type	Meeting Overall Score	Application Title	PI	PI Organization	Rec. Budget	Priority Met*
1	RP230319	IIRACSBC	2.9	Computational Methods for CRISPR-Based Lineage Tracing Systems	Liu, Zhandong	Baylor College of Medicine	\$1,200,000	CSBC
2	RP230134	IIRACSBC	3.0	Therapeutic Vulnerabilities and Predictors of Response to Chemo(Immuno)Therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC)	Korkut, Anil	The University of Texas M. D. Anderson Cancer Center	\$1,199,966	CSBC Disparities

* All Individual Investigator Research projects address the “A broad range of innovative, investigator-initiated research projects” priority.

4. Individual Investigator Research Awards for Clinical Translation (RFA R-23.1 IIRACT) SLATE

Peer Review Recommendations:

The Scientific Review Council recommended 2 Individual Investigator Research Awards for Clinical Translation. Due to funding limits, the Program Integration Committee recommends funding 1 IIRACT totaling \$2,000,000 and deferring 1 IIRACT with an overall score of 2.8 and higher totaling \$1,727,462 to August 2023 should funds be available.

Purpose of Individual Investigator Research Awards for Clinical Translation:

Supports applications that propose innovative cancer clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial. Areas of interest include clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices. Clinical trial must be planned to begin when contract is awarded.

Individual Investigator Research Awards for Clinical Translation Funding Levels:

Up to \$500,000 per year. Maximum duration: 4 years. Exceptions permitted if extremely well justified.

Table 9: Individual Investigator Research Awards for Clinical Translation Recommended for Funding

Rank	ID	Award Type	Meeting Overall Score	Application Title	PI	PI Organization	Rec. Budget	Priority Met*
1	RP230285	IIRACT	2.2	Harnessing Endoplasmic Reticulum Stress to Overcome Resistance to Immunotherapy in Immune-Cold Breast Cancer	Chen, Xi	Baylor College of Medicine	\$2,000,000	Clinical Trials

* All Individual Investigator Research projects address the “A broad range of innovative, investigator-initiated research projects” priority.

Table 10: Individual Investigator Research Awards for Clinical Translation Recommended for Deferral

Rank	ID	Award Type	Meeting Overall Score	Application Title	PI	PI Organization	Rec. Budget	Priority Met*
1	RP230161	IIRACT	2.8	13C MRI With Hyperpolarized Pyruvate for Management of Glioblastoma	Park, Jae Mo	The University of Texas Southwestern Medical Center	\$1,727,462	Clinical Trials

* All Individual Investigator Research projects address the “A broad range of innovative, investigator-initiated research projects” priority.

**5. Individual Investigator Research Awards for Prevention and Early Detection
(RFA R-23.1 IIRAP) SLATE**

Peer Review Recommendations:

The Scientific Review Council recommended 4 Individual Investigator Research Awards for Prevention and Early Detection, totaling \$7,978,737. The Program Integration Committee recommends funding all 4 IIRAPs as presented in Table 10 totaling \$7,978,737.

Purpose of Individual Investigator Research Awards for Prevention and Early Detection:

Supports applications which propose clinical and population-based projects designed to develop effective prevention and early detection interventions to reduce cancer risk, mortality, and morbidity among Texans. Projects that propose such research collaborations with existing CPRIT Prevention Program awardees including the CPRIT funded [Texas Collaborative Center for Hepatocellular Cancer](#) are strongly encouraged.

Individual Investigator Research Awards for Prevention and Early Detection Funding Levels:

Up to of \$400,000 per year. Exceptions permitted if extremely well justified; maximum duration: 5 years.

Table 11: Individual Investigator Research Awards for Prevention and Early Detection Recommended for Funding

Rank	ID	Award Type	Meeting Overall Score	Application Title	PI	PI Organization	Rec. Budget	Priority Met*
1	RP230036	IIRAP	1.0	Geospatial Approaches to Melanoma Early Detection: The GAMED Project	Nelson, Kelly	The University of Texas M. D. Anderson Cancer Center	\$1,998,196	Prevention
2	RP230117	IIRAP	1.9	Randomized Controlled Trial to Assess Innovative Smoking Cessation Services for Young Adults in Texas	Chalela, Patricia	The University of Texas Health Science Center at San Antonio	\$1,992,330	Prevention
3	RP230063	IIRAP	2.1	Whole-Genome DNA Methylation Markers for Tracking and Predicting Advanced Liver Fibrosis as a Precursor of Liver Cancer in NAFLD	Tsai, Robert	Texas A&M University System Health Science Center	\$2,000,000	Prevention/ Liver Cancer
4	RP230213	IIRAP	2.6	Multicomponent Interventions to Improve Uptake and Adherence to Lung Cancer Screening	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$1,988,211	Prevention

* All Individual Investigator Research projects address the “A broad range of innovative, investigator-initiated research projects” priority.

6. The Texas Regional Excellence in Cancer Awards (RFA R-23.1 TREC) Slate

Purpose of The Texas Regional Excellence in Cancer Awards:

The Texas Regional Excellence in Cancer (TREC) award is a multicomponent award designed to strengthen cancer research at institutions located in regions of Texas that have historically received low levels of peer-reviewed cancer research funding. Applicants may request up to \$6.0 million in CPRIT funds over 5 years to support program leadership, investigator-initiated research projects, recruitment of new junior faculty, and research infrastructure. Academic research institutions located greater than 100 miles from an NCI designated Cancer Center were eligible to apply.

Peer Review Recommendations:

Reviewers were instructed to evaluate the applications based on the following criteria: (1) Will the TREC enhance the institution’s cancer research capabilities and ability of research faculty to compete successfully for peer reviewed cancer research awards?; (2) Do the individual research projects proposed have clearly defined cancer relevant goals?; (3) Will research project leaders

have formal mentoring to help them acquire preliminary data and successfully compete for independent research grant support?; (4) Does the Principal Investigator have the required experience and accomplishments to provide the necessary leadership of the TREC and to oversee mentorship of junior faculty?; (5) Is there strong institutional commitment?.

The SRC has recommended TREC applications from The University of Texas Rio Grande Valley, Texas Tech University Health Science Center at El Paso and Texas A&M University System Health Science Center.

RP230419

PI: Subhash Chauhan, Ph.D.

Title: South Texas Center of Excellence in Cancer Research (ST-CECR)

Applicant Organization: The University of Texas Rio Grande Valley

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.8

Recommended Total Budget Award and Duration: \$6,000,000

CPRIT Priorities Addressed: A broad range of innovative, investigator-initiated research projects, disparities, hepatocellular cancer.

Description

The South Texas Center of Excellence in Cancer Research (ST-CECR), led by Dr. Chauhan, will develop a comprehensive approach to reduce cancer health disparities of this region by defining novel etiological, confounding factors, and by developing the cancer health disparity research workforce in the region. Research projects will conduct basic, translational, and clinical research to improve early diagnosis and develop strategies to enhance therapeutic outcomes of chemotherapies in the Rio Grande Valley minority populations. The center will foster and promote collaboration between research projects, other Texas Institutions, engage community partners and facilitate translation of bench-side research into clinical bedside practice.

RP230420

PI: Rajkumar Lakshmanaswamy, Ph.D.

Title: Impacting Cancer Outcomes in Hispanics (ICON)

Applicant Organization: Texas Tech University Health Sciences Center at El Paso

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.8

Recommended Total Budget Award and Duration: \$6,000,000

CPRIT Priorities Addressed: A broad range of innovative, investigator-initiated research projects, disparities, hepatocellular cancer.

Description

The Impacting Cancer Outcomes in Hispanics (ICON), led by Dr. Lakshmanaswamy, will develop a center that leverages TTUHSCEP investments and strengths in cancer research to reduce the community impact of cancer through improved knowledge of biological, cultural, and behavioral determinants of cancer by developing novel biomarkers and therapeutics. The center

will consist of three research cores, and a structured mentoring and professional development program collaborating with experts at six other institutions to create a critical mass of successful cancer researchers focused on biological, clinical, and translational research to improve Hispanic cancer outcomes. Three early-stage researchers studying leukemia, breast, and liver cancers, will be guided by experts and resources in the three integrated cores: biostatistics, data science and informatics core, a new tumor biorepository, and a new research service core. These components will be supported by collaborations with experts at six other medical schools including experts from five NCI designated cancer centers.

RP230204**PI:** Kenneth Ramos, M.D., Ph.D.**Title:** Gene-Environment: Lifestyle Interactions in Cancer**Applicant Organization:** Texas A&M University System Health Science Center**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.8**Recommended Total Budget Award and Duration:** \$5,998,422**CPRIT Priorities Addressed:** A broad range of innovative, investigator-initiated research projects, prevention.

Description

The TREC from Texas A&M University System Health Science Center, led by Dr. Kenneth Ramos, will take advantage of the vast resources available to Texas A&M University to establish the infrastructure required to advance a cohesive vision to address unmet needs in cancer prevention and treatment at the regional and national levels. The program will draw from a talented pool of investigators from eight different academic units to study how biology and genes are modified by environmental and lifestyle factors to influence cancer risk and how to effectively use this knowledge to increase precision in cancer prevention and healthcare delivery. The key components of the center include an administrative core, a single cell 'omics core, a recruitment committee, a mentoring team, and an evaluation team. The TREC initiative will build a critical mass of cancer researchers at Texas A&M University, facilitate collaborations within and outside the institution, and support innovative cancer research that improves cancer prevention and the development of cures for these devastating diseases.

7. RECRUITMENT OF ESTABLISHED INVESTIGATORS SLATE FY23.2 AND FY23.3

Peer Review Recommendations

The applications were evaluated and scored by the Scientific Review Council (SRC) to determine the candidates' potential to make a significant contribution to the cancer research program of the nominating institution. Review criteria focused on the overall impression of the candidate and his/her potential for continued superb performance as a cancer researcher, scientific merit of the proposed research program, his/her long-term impact on the field of cancer research, and strength of the institutional commitment to the candidate.

Purpose of Recruitment of Established Investigators Awards:

The aim is to recruit outstanding senior research faculty with distinguished professional careers and established cancer research programs to academic institutions in Texas.

Funding levels for Recruitment of Established Investigators Awards:

Up to \$6 million over a period of 5 years.

Recommended Awards:

Three Recruitment of Established Investigators grant applications were submitted and two were recommended by the Scientific Review Council for an Established Investigators Award.

RR230020

Candidate: Hongfang Liu, Ph.D.

Funding Mechanism: Recruitment of Established Investigators

Applicant Organization: The University of Texas Health Science Center at Houston

Original Organization of Nominee: Mayo Clinic

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 2.0

Recommended Total Budget Award and Duration: \$6,000,000

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

Hongfang Liu, PhD has been nominated for a CPRIT Recruitment of an Established Investigator Award by the University of Texas Health Science Center at Houston (UTHealth Houston), and appointment as a Professor in the School of Biomedical Informatics and Director of the Center for Translational Artificial Intelligence in Medicine. Dr. Liu is currently the Dr. Richard F. Emslander Professor of Biomedical Informatics at the Mayo Clinic, where she is Co-director of Cancer Data Science and Informatics at the Comprehensive Cancer Center and the Director of Biomedical Informatics at the Center for Clinical and Translational Science.

Dr. Liu is an exceptional bioinformatician, whose research is primarily centered on facilitating the use of clinical data for clinical and translational research and health care delivery improvement via the application of data science, artificial intelligence (AI), and informatics approaches, with an emphasis on cancer. Over the course of her career, she has pioneered

machine learning and big data techniques for biomedical and clinical natural language processing (NLP), a branch of AI that focuses on enabling computers to understand text and spoken words. As a CPRIT Scholar, Dr. Liu proposes to develop the WONDER project (Real World Data-driven Precision Oncology through Data Science and Informatics Excellence in Research), which aims to accelerate real-world, data-driven oncology research through data science and informatics, using longitudinal patient records (LPRs) to achieve the following aims: 1) to develop informatics solutions for accelerating cancer information extraction from LPRs to address challenges associated with the prevalence of detailed information required for cancer research in clinical narratives; 2) to advance inclusive cohort identification for LPR-based observational studies to address the challenges associated with biased or incomplete LPR data due to disparities in cancer care; and 3) to implement a scalable cyberinfrastructure for LPR-empowered oncology research to facilitate team science collaboration in precision oncology. The WONDER project builds upon Dr. Liu's extensive research in data science and informatics, to facilitate real-world translation focused on clinical decision support empowered by AI. The recruitment of Dr. Liu to UTHealth Houston will strategically enhance the position of Texas as a national and international leader in data science, AI, and informatics applications in the diagnosis, prevention, and treatment of cancer.

RR230018**Candidate:** Rudi Fasan, Ph.D.**Funding Mechanism:** Recruitment of Established Investigators**Applicant Organization:** The University of Texas at Dallas**Original Organization of Nominee:** University of Rochester**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **2.7****Recommended Total Budget Award and Duration:** \$6,000,000**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas**Description:**

The University of Texas at Dallas (UT Dallas) has nominated Rudi Fasan, PhD for a CPRIT Recruitment of an Established Investigator Award, and appointment as endowed Distinguished Chair in Natural Sciences and Mathematics, and Professor in the Department of Chemistry and Biochemistry. A world-class synthetic chemist, Dr. Fasan's research program focuses on the design and application of new biocatalytic and chemoenzymatic methods for the discovery and development of biologically active molecules. The enzymatic strategies developed by his group are efficient tools for the synthesis and late-stage modification of complex natural products and drugs, and the discovery of inhibitors of protein-protein interactions, an important class of cancer drugs.

Building upon the above pioneering contributions, his research will focus on (1) developing new diversity-oriented enzymatic methodologies for the rapid assembly of large libraries of natural product-like molecules for high through-put screening to identify new cancer therapies; (2) developing macrocyclic peptides for selective targeting and modulation of protein-protein interactions implicated in the Hippo cell signaling pathway – a critical growth regulatory pathway that is misregulated in many human cancers; and (3) implementing an innovative

platform using unique features of cancer cells (phenotype-driven) to discover cancer-killing macrocyclic peptides. Dr. Fasan's recruitment will contribute substantially to the institutional goal of building the UT Dallas Center of Excellence in Reaction Discovery and High-Throughput Synthesis, and his natural-product-like libraries and molecular discovery platforms will provide key resources for the cancer community in Texas to support basic cancer research and the development of novel cancer therapeutics.

8. RECRUITMENT FIRST-TIME TENURE TRACK FACULTY MEMBERS SLATE FY23.2 and FY23.3

Peer Review Recommendations

The applications were evaluated and scored by the Scientific Review Council to determine the candidates' potential to make a significant contribution to the cancer research program of the nominating institution. Review criteria focused on the overall impression of the candidate and his/her potential for continued superb performance as a cancer researcher, his/her scientific merit of the proposed research program, his/her long-term contribution to and impact on the field of cancer research, and strength of the institutional commitment to the candidate.

Purpose of First Time Tenure Track Faculty Recruitment

The aim is to recruit and support very promising emerging investigators, pursuing their first faculty appointment in Texas, who can make outstanding contributions to the field of cancer research.

Funding levels for First Time Tenure Track Faculty Members Recruitment

Up to \$2 million over a period of up to 5 years.

Recommended Projects:

Out of four First-Time Tenure Track Faculty Members applications submitted, the Scientific Review Council recommended four candidates for awards.

Below is a listing of the candidates with their associated expertise.

RR230012

Candidate: Kenneth Hu, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: The University of Texas M.D. Anderson Cancer Center

Original Organization of Nominee: University of California San Francisco

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.0

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

The UT MD Anderson Cancer Center seeks to recruit Kenneth Hu, PhD as a First-time, Tenure-track Scholar and Assistant Professor in the Department of Immunology. Dr. Hu will be mentored directly by Dr. James Allison, a pioneer in the field of cancer immunotherapy. Tumors are composed of a spatially heterogeneous mixture of regions that are responsive (hot) and non-responsive (cold) to immunotherapies. The next step in improving immunotherapy efficacy is understanding how the interactions between diverse cell types generates this spatial heterogeneity and how immunotherapies interact with that landscape. Dr. Hu will tackle this goal using spatial transcriptomic analysis of solid tumors to define the spatial heterogeneity that arises from cell-cell communication networks. He will integrate data from novel transcriptomic analyses, high-plex imaging to characterize tumor and microenvironment cells, and computational methods that he has developed in his postdoctoral career to map communication networks within cancer cells, and how the effects of immunotherapies propagate unevenly due to tumor heterogeneity. Ultimately, Dr. Hu's goal is to develop new clinical interventions that can synergize with existing immunotherapies to improve outcomes, as well as to develop new spatially resolved prognostic measures to assess the response to therapy.

RR230017

Candidate: Joe Nassour, Ph.D.

Funding Mechanism: Recruitment of First Time Tenure Track Faculty Member

Applicant Organization: The University of Texas M.D. Anderson Cancer Center

Original Organization of Nominee: Salk Institute for Biological Studies

Overall Evaluation Score [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: 1.5

Recommended Total Budget Award and Duration: \$2,000,000.

CPRIT Priorities Addressed: Recruitment of outstanding cancer researchers to Texas

Description:

The UT MD Anderson Cancer Center has nominated Joe Nassour, PhD for an appointment as a First-time, Tenure-track Scholar and Assistant Professor in the Department of Experimental Radiation Oncology. The mechanisms underlying the association of cancer with aging are not fully understood, but accumulation of genetic and epigenetic alterations allowing non-malignant cells to escape the normal limitation on the number of cell divisions is a major contributor. Dr. Nassour's recent findings revealed an unusual function for autophagy – a cellular process by which cells degrade and recycle unnecessary (damaged) cellular components – and suggested that loss of autophagy function permits cell survival, escape from replicative crisis, genome instability and, ultimately, cancer initiation. He now proposes to study the molecular basis of autophagy and its role in cancer initiation. Given Dr. Nassour's unique combination of expertise in the biology of genetic instability due to DNA replication stress, autophagy, cancer and aging, this research has a high potential to advance cutting-edge translational research, and the development of novel therapeutic approaches to treat human cancer. Dr. Nassour is the recipient of a prestigious K99/R00 Pathway to Independence award from the NIH.

RR230019**Candidate:** Lu Wang, Ph.D.**Funding Mechanism:** Recruitment of First Time Tenure Track Faculty Member**Applicant Organization:** The University of Texas Health Science Center at San Antonio**Original Organization of Nominee:** University of Pennsylvania**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **1.6****Recommended Total Budget Award and Duration:** \$2,000,000.**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas, hepatocellular cancer.**Description:**

The University of Texas Health San Antonio (UTHSA) has nominated Lu Wang, PhD for a CPRIT Recruitment of a First-Time, Tenure-Track Faculty Award, and appointment as an Assistant Professor on the tenure-track in the Department of Biochemistry and Structural Biology. Dr. Wang is an exceptionally accomplished junior investigator, with specific expertise in defining epigenetic mechanisms involved in cancer, aging, embryogenesis, neuronal development, and stem cell function with several first author publications in high impact journals, such as *Cell*, *Nature Methods*, *Cancer Cell*, *Neuron*, and *Cell Reports*. She is the recipient of a prestigious National Institutes of Health Pathway to Independence K99/R00 Award, which she will bring with her to UTHSA.

Dr. Wang will focus her research program on elucidating how changes in the aging epigenome affect the development of non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Dr. Wang's research endeavors will be supported by extensive core facilities and the CPRIT-funded Center for Innovative Drug Discovery at UTHSA in developing new therapeutics for NASH-HCC. Given the high and increasing prevalence of obesity-associated NASH in South Texas, the recruitment of Dr. Wang, with her deep knowledge and first-class research expertise in epigenetic regulation of liver metabolic dysfunction, will help fulfill the institutional strategic vision of developing highly impactful programs in delineating the molecular basis and pathology of HCC, and in developing drugs to better treat this disease, thereby contributing to helping to alleviate a major health burden in UTHSA's catchment area of South Texas, and HCC within the predominantly Hispanic population.


RR230015**Candidate:** Ewan McRae, Ph.D.**Funding Mechanism:** Recruitment of First Time Tenure Track Faculty Member**Applicant Organization:** The Methodist Hospital Research Institute**Original Organization of Nominee:** Cambridge University**Overall Evaluation Score** [Rating Scale 1.0 (highest merit) to 9.0 (lowest merit)]: **2.8****Recommended Total Budget Award and Duration:** \$1,999,997**CPRIT Priorities Addressed:** Recruitment of outstanding cancer researchers to Texas**Description:**

The Houston Methodist Research Institute is nominating Dr. Ewan McRae for a CPRIT First-time, Tenure-track Faculty Scholar Award, and appointment as an Assistant Professor in the

Center for RNA Therapeutics within the Department of Cardiovascular Sciences. Dr. McRae is a talented and accomplished young scientist who focuses on a new frontier in cancer research, namely RNA biology. Dr. McRae has recently developed powerful new methodology and a pipeline for re-designing the structure of RNAs and validating the structure of “designer RNA molecules” using cryo-electron microscopy (EM). His primary objective is to improve mRNA therapies by engineering structural elements into the 5’ and 3’ untranslated regions (UTRs) of mRNAs to exploit differences in the proteins present in cancer cells and healthy cells such that the proteins differentially interact with the designer UTR elements, resulting in cell-type specific expression of the mRNA. Dr. McRae is one of the few scientists currently focused on designing RNA structures that will selectively target and interfere with cellular processes. Together, these strategies will be combined to achieve translation of an exogenous mRNA in a cell type specific manner, which will allow development of mRNA therapies to selectively kill breast cancer cells with minimal off-target effects.

Attachment #1

*Academic Research Program Priorities Addressed by Recommended Awards							
(*Some grant awards address more than one program priority and are double counted.)							
Scale	Recruitment of outstanding cancer researchers to Texas	A broad range of innovative, investigator-initiated research projects	Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions	Computational biology and analytic methods	Childhood Cancers	Hepatocellular Cancer	Population Disparities



Attachment #2
RFA Descriptions



- **Individual Investigator Research Awards (IIRA)**
Supports applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer. Areas of interest include laboratory research, translational studies, and/or clinical investigations. Competitive renewal applications accepted.
Award: Up to \$350,000 per year. Exceptions permitted if extremely well justified; maximum duration: 3 years.
- **Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)**
Supports applications for innovative mathematical and/or computational research projects addressing questions that will advance current knowledge in the (a) mechanisms that tie altered gene expression and downstream molecular mechanisms to functional cancer phenotypes and/or (b) mechanisms that tie tumor morphology to functional cancer phenotypes and/or mechanisms that tie treatment sequence and combination to evolving functional cancer phenotypes (that emerge as a result of treatment selection).
Award: Up to \$400,000 in total costs per year for up to 3 years. Exceptions permitted if extremely well justified.
- **Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)**
Supports applications for innovative research projects addressing questions that will advance knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer in children and/or adolescents in the near or long term. Competitive renewal applications accepted.
Award: Up to \$350,000 per year. Applicants that plan on conducting a clinical trial as part of the project may request up to \$500,000 in total costs. Exceptions permitted if extremely well justified; maximum duration: 4 years.
- **Individual Investigator Research Awards for Prevention and Early Detection (IIRAP)**
Supports applications which propose clinical and population-based projects designed to develop effective prevention and early detection interventions to reduce cancer risk, mortality, and morbidity among Texans. Projects that propose such research collaborations with existing CPRIT Prevention Program awardees including the CPRIT funded *Texas Collaborative Center for Hepatocellular Cancer* (<https://www.bcm.edu/research/labs-and-centers/research-centers/texas-collaborative-center-for-hepatocellular-cancer>) are strongly encouraged.

Award: Up to \$400,000 per year. Exceptions permitted if extremely well justified; maximum duration: 5 years.

- **Individual Investigator Research Awards for Clinical Translation (IIRACT)**
Supports applications that propose innovative cancer clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial. Areas of interest include clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices. Clinical trial must be planned to begin when contract is awarded
Award: Up to \$500,000 per year. Maximum duration: 4 years. Exceptions permitted if extremely well justified.
- **Texas Regional Excellence in Cancer Award (RFA R-23.1 TREC)**
Solicits applications to strengthen cancer research at institutions located in regions of Texas that have historically received low levels of peer reviewed cancer research funding.
Award: Up to \$6,000,000 (total costs); Maximum duration: 5 years.
- **Recruitment of Established Investigators (RFA R-23-1 REI):**
Recruits outstanding senior research faculty with distinguished professional careers and established cancer research programs to academic institutions in Texas.
Award: Up to \$6 million over a period of five years.
- **Recruitment of First-Time Tenure Track Faculty Members (RFA R-23-1. RFT):**
Supports very promising emerging investigators, pursuing their first faculty appointment in Texas, who have the ability to make outstanding contributions to the field of cancer research. Award: Up to \$2 million over a period up to five years.

**Ludwig Institute for
Cancer Research Ltd**

**Richard D. Kolodner
Ph.D.**

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

January 16, 2023

Dr. Mahendra C. Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Patel and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, and Individual Investigator Research Awards for Prevention and Early Detection

The SRC met on December 22, 2022 to consider the applications recommended by the peer review panels following their meetings held October 24, 2022 to October 31, 2022.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$67,370,879.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Award Mech	Meeting Overall Score	Application Title	PI	PI Organization	Recommended Budget
1	RP230026	IIRACCA	1.0	Identifying Clinical Methotrexate Toxicity Phenotypes Across Phases of Pediatric Leukemia Therapy	Bernhardt, Melanie	Baylor College of Medicine	\$1,392,407
2	RP230036	IIRAP	1.0	Geospatial Approaches to Melanoma Early Detection: The GAMED Project	Nelson, Kelly	The University of Texas M. D. Anderson Cancer Center	\$1,998,196
3	RP230222	IIRA	1.1	Personalized Auricular Point Acupressure to Self-Manage Cancer-Related Pain	Yeh, Chao Hsing	The University of Texas Health Science Center at Houston	\$1,046,680
4	RP230140	IIRA	1.1	Changes in Tumor Microenvironment That Promote Cachexia	Infante, Rodney	The University of Texas Southwestern Medical Center	\$1,050,000
5	RP230093	IIRA	1.8	Targeting the Mlc1-GlialCAM Protein Complex in Invasive Glioma Cells	McCarty, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,050,000

6	RP230018	IIRACCA	1.9	Neuronal Alterations in the Midbrain Dopaminergic System Function: A Novel Mechanism of Radiation-Induced Cognitive Dysfunction	Zhang, Die	The University of Texas M. D. Anderson Cancer Center	\$1,399,730
7	RP230117	IIRAP	1.9	Randomized Controlled Trial to Assess Innovative Smoking Cessation Services for Young Adults in Texas	Chalela, Patricia	The University of Texas Health Science Center at San Antonio	\$1,992,330
8	RP230072	IIRA	1.9	Studying and Therapeutically Targeting Ferroptosis Liability in BRCA1-Deficient Cancer	Gan, Boyi	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
9	RP230360	IIRA	1.9	Rational Design, Synthesis, and Biological Evaluation of Simplified Taccalonolide Analogs for the Treatment of Cancer	Frantz, Douglas	The University of Texas at San Antonio	\$1,049,128
10	RP230135	IIRA	2.0	Blocking DNA Damage Response Induction of "Don't Eat Me" Signals Converts Local Radiotherapy Into Systemic Immunotherapy	Curran, Michael	The University of Texas M. D. Anderson Cancer Center	\$1,049,905
11	RP230344	IIRA	2.0	Development and Evaluation of Lanosterol Synthase Inhibitors in Preclinical GBM Models	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,048,465
12	RP230109	IIRA	2.0	Autophagy and Tumor Endothelium	Terada, Lance	The University of Texas Southwestern Medical Center	\$1,049,994
13	RP230373	IIRA	2.0	Mapping the Geospatial Tumor Clonal Architecture to Restore	Viale, Andrea	The University of Texas M.	\$1,049,985

				Immune Recognition in Pancreatic Cancer		D. Anderson Cancer Center	
14	RP230224	IIRA	2.0	Enhancing Immune Responses in Pancreatic Cancer by Stromal Inhibition of HIF2	Taniguchi, Cullen	The University of Texas M. D. Anderson Cancer Center	\$1,049,997
15	RP230382	IIRA	2.0	Characterization of 3D Genome Organization and Transcriptional Regulation in Prostate Cancer	Mani, Ram	The University of Texas Southwestern Medical Center	\$1,049,641
16	RP230247	IIRA	2.0	A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer	Lin, Sue-Hwa	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
17	RP230063	IIRAP	2.1	Whole-Genome DNA Methylation Markers for Tracking and Predicting Advanced Liver Fibrosis as a Precursor of Liver Cancer in NAFLD	Tsai, Robert	Texas A&M University System Health Science Center	\$2,000,000
18	RP230285	IIRACT	2.2	Harnessing Endoplasmic Reticulum Stress to Overcome Resistance to Immunotherapy in Immune-Cold Breast Cancer	Chen , Xi	Baylor College of Medicine	\$2,000,000
19	RP230160	IIRACSBC	2.2	Overcoming Therapy Resistance by Integrated Computational Modeling of the Bone Metastatic Niche in Prostate and Renal Cancers	Dondossola , Eleonora	The University of Texas M. D. Anderson Cancer Center	\$1,025,623
20	RP230334	IIRA	2.5	Elucidating the Mutagenesis Mechanism of BRAF in Melanoma	Lee, Seongmin	The University of Texas at Austin	\$1,050,000

21	RP230120	IIRACCA	2.5	Clonal Evolution and Chemoresistance of Hepatoblastomas With Hepatocellular Carcinoma Features	Sumazin, Pavel	Baylor College of Medicine	\$1,371,733
22	RP230213	IIRAP	2.6	Multicomponent Interventions to Improve Uptake and Adherence to Lung Cancer Screening	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$1,988,211
23	RP230363	IIRACSBC	2.6	Developing Knowledge-Guided Deep Learning Models to Predict the Binding Between T-Cell Receptors and Neoantigens for Facilitating TCR-T Therapies	Wang, Tao	The University of Texas Southwestern Medical Center	\$1,199,997
24	RP230391	IIRA	2.6	Understanding and Improving CAR T-Cell Therapy of T-ALL and LBL	Mamonkin, Maksim	Baylor College of Medicine	\$1,050,000
25	RP230345	IIRA	2.6	The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T-Cell Therapy	Liu, Wenshe	Texas A&M University	\$1,050,000
26	RP230166	IIRACSBC	2.6	Integrative Modeling of Spatially Resolved Multiomics Data to Identify Bladder Cancer Mucosal Field Effects	Wei, Peng	The University of Texas M. D. Anderson Cancer Center	\$1,199,994
27	RP230154	IIRACCA	2.6	Normalizing Membrane Homeostasis in Microglia/Macrophages of Pediatric High-Grade Gliomas	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$1,400,000
28	RP230271	IIRA	2.7	Targeting Distinct Metabolic Vulnerabilities of Aggressive Renal Cell Carcinoma Variants	Zacharias Millward, Niki	The University of Texas M. D. Anderson	\$1,019,997

						Cancer Center	
29	RP230330	IIRACCA	2.7	Integrate Whole-Slide Imaging and Genomic Data to Study Pediatric Rhabdomyosarcoma	Xiao, Guanghua	The University of Texas Southwestern Medical Center	\$1,303,815
30	RP230050	IIRA	2.7	A Novel Therapeutic Strategy Targeting Pancreatic Cancer	Yao, Wantong	The University of Texas M. D. Anderson Cancer Center	\$1,049,854
31	RP230261	IIRA	2.7	Investigating the Mechanism of NLRP3 Inflammasome Hyperactivation During Hepatocellular Carcinoma Development	Zhong, Zhenyu	The University of Texas Southwestern Medical Center	\$1,049,997
32	RP230019	IIRA	2.8	Deciphering Spatial Immune Contextures Through Integrative Immunoproteogenomics	Lee, Hyun-Sung	Baylor College of Medicine	\$1,050,000
33	RP230161	IIRACT	2.8	¹³ C MRI With Hyperpolarized Pyruvate for Management of Glioblastoma	Park, Jae Mo	The University of Texas Southwestern Medical Center	\$1,727,462
34	RP230307	IIRA	2.8	In Vivo Chimeric Antigen Receptor Macrophages (ChARMs) for Cancer Immunotherapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$1,026,414
35	RP230241	IIRA	2.8	PD-L1 Modifications and Membranous Localization	Li, Yong	Baylor College of Medicine	\$1,049,994
36	RP230375	IIRA	2.8	Targeting Chitinase-3-Like-1 as a Novel Therapy for Hepatocellular Carcinoma	Ju, Cynthia	The University of Texas Health Science Center at Houston	\$1,049,769

37	RP230283	IIRA	2.8	Development of Immunotherapy and Combinatorial Therapy of Sickle Cell Trait-Associated Renal Medullary Carcinoma	Yang, Liuqing	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
38	RP230323	IIRA	2.9	Real-Time, Label-Free, Micro HSI Device and Transformer-Based Attention Networks for Oral Cancer Imaging	Fei, Baowei	The University of Texas at Dallas	\$1,048,933
39	RP230184	IIRA	2.9	Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Drugs for Precision Cancer Medicine	Sun, Xiankai	The University of Texas Southwestern Medical Center	\$1,049,997
40	RP230216	IIRA	2.9	Investigating Cell Competition in Liver Cancer Development	Zhu, Hao	The University of Texas Southwestern Medical Center	\$1,050,000
41	RP230381	IIRA	2.9	JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC	ZHANG, QING	The University of Texas Southwestern Medical Center	\$1,036,126
42	RP230319	IIRACSBC	2.9	Computational Methods for CRISPR-Based Lineage Tracing Systems	Liu, Zhandong	Baylor College of Medicine	\$1,200,000
43	RP230112	IIRA	2.9	The Evolution of Intratumor Heterogeneity of Lung Cancers With or Without Immunotherapy and Its Impact on Patient Survival	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,049,396
44	RP230143	IIRACCA	2.9	The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT	Ludwig, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,399,860

45	RP230240	IIRA	2.9	Therapeutic Targeting of Androgen Receptor in Metastatic Breast Cancer	Fuqua, Suzanne	Baylor College of Medicine	\$1,050,000
46	RP230272	IIRA	3.0	Structure-Based Improvement for Inhibitors of WNK1, a Triple-Negative Breast Cancer Signature Kinase	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	\$1,050,000
47	RP230327	IIRA	3.0	Harnessing the Metabolic Dependencies of Mitochondrial NADK2 as a Therapeutic Strategy for Lung Cancer	Hoxhaj, Gerta	The University of Texas Southwestern Medical Center	\$1,049,997
48	RP230071	IIRA	3.0	Unexpected Mechanisms Underlying Mutation-Induced Protein Mislocalization in Hematologic Malignancies	Liszcak, Glen	The University of Texas Southwestern Medical Center	\$1,049,997
49	RP230012	IIRA	3.0	Targeting a Non-ATPase Proteasome Subunit in Acute Myeloid Leukemia (AML)	Eiring, Anna	Texas Tech University Health Sciences Center at El Paso	\$1,050,000
50	RP230174	IIRACCA	3.0	Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites	Ehrlich, Lauren	The University of Texas at Austin	\$1,400,000
51	RP230196	IIRA	3.0	Identifying the Biological Determinants of Aggressive Meningioma	Patel, Akash	Baylor College of Medicine	\$1,047,289
52	RP230134	IIRACSBC	3.0	Therapeutic Vulnerabilities and Predictors of Response to Chemo(Immuno)Therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC)	Korkut, Anil	The University of Texas M. D. Anderson Cancer Center	\$1,199,966
53	RP230333	IIRA	3.1	Development of a Cell Therapy Platform for Localized and Feedback-Regulated Delivery of Cytokines for the	Veisheh, Omid	Rice University	\$1,050,000

				Treatment of Pancreatic Cancer			
54	RP230162	IIRACCA	3.1	The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma	Kitagawa, Katsumi	The University of Texas Health Science Center at San Antonio	\$1,400,000
55	RP230181	IIRA	3.1	Dissection of CAMKK2's Tumor Cell-Intrinsic and - Extrinsic Roles in Prostate Cancer	Frigo, Daniel	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
56	RP230197	IIRA	3.2	Targeting MYCN Disruption of the Molecular Clock and Tumor Metabolism in Neuroblastoma Oncogenesis	Barbieri, Eveline	Baylor College of Medicine	\$1,050,000

Individual Investigator Research Awards (IIRA)
 Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
 Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
 Individual Investigator Research Awards for Clinical Translation (IIRACT)
 Individual Investigator Research Awards for Prevention and Early Detection (IIRAP).

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

January 16, 2023

Dr. Mahendra C. Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Patel and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for the Texas Regional Excellence in Cancer Awards.

The SRC met on December 22, 2022 to consider the applications recommended by the peer review panels following their meetings held on December 5, 2022.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$17,998,422.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Mec.	Meeting Overall Score	Application Title	PI	PI Organization	Recommended Budget
1	RP230419	TREC	2.8	South Texas Center of Excellence in Cancer Research (ST-CECR)	CHAUHAN, SUBHASH	The University of Texas Rio Grande Valley	\$6,000,000
2	RP230420	TREC	2.8	Impacting Cancer Outcomes in Hispanics (ICOHN)	LAKSHMANASWAMY, RAJKUMAR	Texas Tech University Health Sciences Center at El Paso	\$6,000,000
3	RP230204	TREC	2.8	Gene-Environment: Lifestyle Interactions in Cancer	Ramos, Kenneth	Texas A&M University System Health Science Center	\$5,998,422

TREC – Texas Regional Excellence in Cancer

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

January 16, 2023

Dr. Mahendra C. Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov


Dear Dr. Patel and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of recruitment grant recommendations. The SRC met on on November 6, 2022 (Cycle 23.2) and January 12, 2023 (Cycle 23.3) to review and finalize applications submitted to CPRIT under the Recruitment of Established Investigator and Recruitment of First-Time, Tenure Track Faculty Members RFA mechanisms.

The SRC recommends six applications, which are included on the attached list. The recommended funding amounts and the overall evaluation scores are stated for the grant applications. There were no recommended changes to funding amounts, goals, timelines, or project objectives requested. The total amount for the applications recommended is \$19,999,977

The recommendation meets the SRC's standards for funding. These include selecting candidates at all career levels that have demonstrated academic excellence, innovation, excellent training, commitment to cancer research and exceptional potential for achieving future impact in basic, translational, population based or clinical research.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Award Mechanism	Final Overall Score	Application Title	Candidate	Organization	Budget
1	RR230012	RFTFM	1.0	Recruitment of First-Time, Tenure-Track Faculty Members: Kenneth Hu	Kenneth Hu	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
2	RR230017	RFTFM	1.5	Recruitment of First-Time, Tenure-Track Faculty Members: Joe Nassour	Joe Nassour	The University of Texas M. D. Anderson Cancer Center	\$2,000,000
3	RR230019	RFTFM	1.6	Recruitment of First-Time Tenure Track, Lu Wang	Lu Wang	The University of Texas Health Science Center at San Antonio	\$2,000,000
4	RR230020	REI	2.0	Nomination of Dr Hongfang Liu for CPRIT Recruitment of Established Investigators	Hongfang Liu	The University of Texas Health Science Center at Houston	\$6,000,000
5	RR230018	REI	2.7	Nomination of Dr Rudi Fasan for CPRIT Recruitment of Established Investigators	Rudi Fasan	The University of Texas at Dallas	\$6,000,000
6	RR230015	RFTFM	2.8	Recruitment of First-Time, Tenure-Track Faculty Members: Dr Ewan McRae	Ewan McRae	The Methodist Hospital Research Institute	\$1,999,977

RFTFM- Recruitment of First-Time Tenure Track Faculty

REI- Recruitment of Established Investigators



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: CPRIT OVERSIGHT COMMITTEE
FROM: RAMONA MAGID, CHIEF PREVENTION OFFICER
SUBJECT: PREVENTION GRANT RECOMMENDATIONS – FY 2023 CYCLE 1
DATE: FEBRUARY 2, 2023

Summary and Recommendation:

The Program Integration Committee (PIC) has completed its review of the recommendations forwarded by the Prevention Review Council (PRC) and recommends awarding 8 projects for FY 2023 Cycle 1 totaling \$13,577,257. The grant recommendations are presented in three slates.

Grant Mechanism	Number	Amount
<i>Cancer Screening and Early Detection</i>	4	\$ 9,421,420
<i>Dissemination of CPRIT-Funded Cancer Control Interventions</i>	2	\$ 898,685
<i>Primary Prevention of Cancer</i>	2	\$ 3,257,152
TOTAL	8	\$13,577,257

Background:

FY 2023 Cycle 1 (23.1)

CPRIT released three RFAs in May 2022 for the first review cycle of FY 2023. Nineteen applications requesting \$27,382,487 were submitted; thirteen applications requesting \$21,768,390 underwent peer review discussion by teleconference on December 5, 2022. The PRC met January 6, 2023, to finalize recommendations to the Program Integration Committee.

Program Priorities Addressed

All the recommended applications address more than one of the Prevention Program priorities. See the attached chart for additional detail.

<u>Number of Applications Addressing Priorities</u>		<u>Amount</u>
8	Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence	\$13,577,257
8	Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence	\$13,577,257
8	Prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services	\$13,577,257

Prevention Program Slates

Cancer Screening and Early Detection

Mechanism:

This award mechanism seeks to support the delivery of evidence-based clinical services to screen for cancer and pre-cancer in underserved populations who do not have adequate access to cancer early detection interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community, have nationally recommended screening methods, and use evidence-based methods to screen for these cancers.

Award: Maximum of \$1M for new projects and \$2.5M for expansion projects; maximum duration of 5 years

Recommended projects (4): \$9,421,420

Nine applications were submitted in this mechanism. Four Cancer Screening and Early Detection projects are recommended.

Project Descriptions

PP230013	Community Expansion and Re-engagement for Breast Cancer Screening and Patient Navigation	Argenbright, Keith E	The University of Texas Southwestern Medical Center	2.7	\$2,500,000
CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services					

This project is a breast cancer screening program to include community outreach and health promotion, comprehensive breast cancer screening and follow-up care supported by nurse-driven clinical navigation, along with centralized reimbursement for local providers, leveraging funds aggregated through the UTSW-MCI contract with Texas Breast and Cervical Cancer Service (BCCS), CPRIT, and other local philanthropic support to ensure patients receive high quality care with no financial burden. The project will also assess social determinants of health (SDoH) associated with breast cancer repeat screening and discordant engagement in different cancer screening modalities to maximize the impact. The project will leverage existing centralized processes to optimize delivery of breast cancer screening services to rural and medically underserved patients, addressing key stress points across the screening continuum exacerbated by the COVID-19 pandemic.

PP230046	Screen, Treat, or Prevent (STOP) Hepatocellular Cancer-Hepatitis C (HCC-HCV): Expansion to All Adults	Jain, Mamta K	The University of Texas Southwestern Medical Center	2.7	\$2,499,616
CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services					

This project plans to increase screening from those born between 1945 to 1965, offering Hepatitis B and C screening and diagnostics, as well as Hepatitis B vaccination, to all adults 18 to 79 years of age. A multi-faceted comprehensive intervention will include patient and provider education; electronic medical record with alerts for eligibility; performance monitoring and feedback, patient navigation; and treatment/cure of HCV and treatment/vaccination for HBV. The sites will include 13 clinics in Dallas County affiliated with the Parkland safety-net system and 4 federally qualified health centers in South Texas. The project will increase HCV treatment and HBV vaccination among eligible adults in accordance with guidelines across 15 medically underserved counties in Dallas County and South Texas and provide navigation to care.

PP230038	Salud en Mis Manos (SEMM): An Evidence-Based Breast & Cervical Cancer Early Detection and Prevention Program for Underserved Latinas.	Savas, Lara S	The University of Texas Health Science Center at Houston	3.1	\$2,499,492
CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services					

The proposed maintenance and expansion of the community- and clinic- based Salud en Mis Manos (SEMM) program, provides a comprehensive and evidence-based approach to increase B&C cancer screenings, and HPV vaccination, among Latinas in rural and medically underserved areas (MUAs). The SEMM program uses a community-engaged approach to develop a network of organizational and clinics partners to disseminate the SEMM social marketing campaigns that promote cancer prevention messages and community outreach. The SEMM program core components include community health worker (CHW)-delivered education, health coaching navigation (HCN) and clinical service delivery. This maintenance and expansion proposal will continue to serve underserved women in the current 31 counties and will expand to an addition 5 counties, including Starr County in the Lower Rio Grande Valley (LRGV) and Moore, Parmer, Potter and Randall in the Panhandle.

PP230041	PP190052 - Integrated lung cancer screening and tobacco cessation in an urban safety-net system	Gerber, David E	The University of Texas Southwestern Medical Center	3.1	\$1,922,312
<p>CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services</p>					

The project will sustain and expand an existing lung cancer screening and tobacco cessation program—with particular effort in South Dallas—through Parkland Health, the safety net provider in Dallas County (Texas Public Health Region 3). To improve screening adherence and tobacco quit attempts, Parkland-based nurse navigators will provide education, logistical support, and psychosocial support through telephone, video, and on-site interactions. Navigators will target Dallas County zip codes with the greatest lung cancer risk and most pronounced health disparities according to the SocioNeeds Index (which incorporates poverty, income, unemployment, occupation, education, and language). Population outreach and education—conducted in concert with Parkland Community Health Workers who live and work in the prioritized geographic area—will be modeled off a successful program of co-created messaging to increase vaccination uptake. Provider education, audit, and feedback will be delivered by a Parkland-based physician champion.

Dissemination of CPRIT-Funded Cancer Control Interventions

Mechanism:

This award mechanism seeks to fund projects that will facilitate the dissemination and implementation of successful CPRIT-funded, evidence-based cancer prevention and control interventions across Texas. The proposed project should be able to develop one or more "products" based on the results of the CPRIT-funded intervention. The proposed project should also identify and assist others to prepare to implement the intervention and/or prepare for grant funding.

Award: Maximum of \$450,000; Maximum duration of 3 years

Recommended projects (2): \$898,685

Six applications were submitted in this mechanism. Two Dissemination of CPRIT-Funded Cancer Control Interventions projects are recommended.

Project Descriptions

PP230033	All for Them Texas: A multifaceted dissemination and implementation approach to increase HPV vaccination	Cucarro, Paula	The University of Texas Health Science Center at Houston	3.0	\$449,959
CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services					

Implementing All for Them (IM-AFT) will be a multifaceted implementation strategy designed for use by schools, school districts, and community health centers interested in impacting adolescent vaccinations, focusing on HPV vaccination, in their communities. The project will use Implementation Mapping, a systematic approach to implementation planning that integrates theory, empirical evidence, and stakeholder feedback to develop methods and strategies to enhance AFT adoption, implementation, and maintenance. A needs, assets, and readiness assessment will be conducted to identify barriers and facilitators of implementation and understand potential implementers' readiness. Core strategies will comprise a web-based implementation toolkit, training course, and technical assistance program. Training components will include formats for maximum flexibility in supporting AFT adopters in preparing to effectively implement the toolkit in diverse settings. Technical assistance will be provided via a four-part ECHO series to prepare users for AFT implementation in the field and to build a collaborative learning community among potential implementers for enhanced sustainability.

PP230002	Taking Texas Tobacco Free: Dissemination to and Implementation within Lung Cancer Screening Programs	Reitzel, Lorraine	University of Houston	3.0	\$448,726
CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services					

Taking Texas Tobacco Free (TTTF) will be fully scaled-out for application in low dose computed tomography (LDCT) centers. TTTF implementation will include the: 1) initiation of tobacco-free workplace policies; 2) provision of education and specialized training with a focus on how to facilitate trauma-informed, community-tailored tobacco use cessation and relapse prevention with patients via behavioral intervention and medicinal aids while enabling capacity for a sustainable center-led training program; 3) provision of resources to educate and motivate patients and providers for tobacco use disorder care provision; and 4) engagement and education of the community around these topics. Active and passive dissemination strategies will include a step-by-step implementation/replication guide and toolkit with training materials, tailored materials for passive dissemination, web-based and social media program promotion, and hands-on technical assistance. Iterative stakeholder feedback will guide implementation.

Primary Prevention of Cancer

Mechanism:

This award mechanism focuses on increasing implementation of evidence-based strategies to ensure that all Texans benefit from the cancer prevention knowledge that we currently have. CPRIT seeks to fund multilevel interventions to reduce cancer risk, disease burden, and cancer disparities. Modifiable risk behaviors include tobacco use, obesity, physical inactivity, unhealthy eating, alcohol use, sun exposure, HPV vaccination, Hepatitis B vaccination, and environmental/occupational cancer exposures. Applications should also assess and address social determinants that contribute to cancer burden and disparities (e.g., cultural factors, unmet needs, access barriers). Interventions and communications should be structured to address the unique circumstances of the population to be served.

Award: Maximum of \$1M for new projects and \$2.5M for expansion projects; maximum duration of 60 months

Recommended projects (2): \$3,257,152

Thirteen applications were submitted in this mechanism. Two Primary Prevention of Cancer applications are recommended.

Project Descriptions

PP230018	Implementation and Evaluation of an Evidence-Based Multilevel Lifestyle Intervention for Underserved Rural Populations in South Texas: Tu Salud ¡Si Cuenta!	Reininger, Belinda	The University of Texas Health Science Center at Houston	2.5	\$999,254
----------	---	--------------------	--	-----	-----------

CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services

This project will employ evidence-based strategies to build the capacity needed in two rural counties to implement the multilevel intervention Tu Salud ¡Si Cuenta! (TSSC) model. Through partnerships with local organizations and municipalities, the project will train stakeholders on policy and environmental change related to physical activity and food choice, train community health workers (CHWs) on delivering the evidence based TSSC Outreach Modules, assist stakeholders with conducting an assessment/action planning process, and support local CHWs as they deliver the TSSC outreach modules to individuals. The project will build capacity in two rural counties (Duval and Willacy) for the implementation of an evidence-based, multilevel intervention focused on healthy lifestyles to prevent cancer and implement and evaluate the enhanced TSSC intervention that includes components related to reduced alcohol intake and social determinants of health (SDOH) needs in two underserved South Texas border counties (Cameron and Hidalgo) to promote cancer prevention through healthy lifestyles.

PP230043	School-based Human Papillomavirus Vaccination Program in the Rio Grande Valley: Continuation and Expansion in Hidalgo, Cameron, and Willacy Counties	Rodriguez, Ana M	The University of Texas Medical Branch at Galveston	3.2	\$2,257,898
<p>CPRIT Priorities addressed: Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence; prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services</p>					

The project provides the HPV vaccine in an alternative setting (schools) and creates support for HPV vaccination through education and outreach. This proposal looks to expand a successful model to Cameron and Willacy Counties, to provide services to 14 additional schools from 8 school districts. The broad aim of the expansion is to reduce obstacles to HPV vaccination in the underserved area of the RGV and improve prioritization of HPV vaccination after the COVID-19 pandemic caused declines in vaccination rates. The project will increase HPV vaccination uptake in a cohort of students aged 11-15 in school districts in Hidalgo, Cameron, and Willacy Counties. Activities will include the continuation of the outreach and education campaign in Hidalgo County and expanding to Cameron and Willacy Counties; a school-based HPV vaccination program in 6 school districts; and expansion of program activities and support services (follow-up navigation, data collection, tracking, systems improvement, Immtrac efficiency).



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS


Cycle 23.1 Recommended Prevention Program Awards

App. ID	Mech	Application Title	PD	Organization	Score	Rank Order	Budget
PP230018	PPC	Implementation and Evaluation of an Evidence-Based Multilevel Lifestyle Intervention for Underserved/Rural Populations in South Texas: Tu Salud ¡Si Cuenta!	Reininger, Belinda	The University of Texas Health Science Center at Houston	2.5	1	\$999,254
PP230013	CSD	Community Expansion and Re-engagement for Breast Cancer Screening and Patient Navigation	Argenbright, Keith E	The University of Texas Southwestern Medical Center	2.7	2	\$2,500,000
PP230046	CSD	Screen, Treat, or Prevent (STOP) Hepatocellular Cancer-Hepatitis C (HCC-HCV): Expansion to All Adults	Jain, Mamta K	The University of Texas Southwestern Medical Center	2.7	3	\$2,499,616
PP230033	DI	All for Them Texas: A multifaceted dissemination and implementation approach to increase HPV vaccination	Cucarro, Paula	The University of Texas Health Science Center at Houston	3.0	4	\$449,959
PP230002	DI	Taking Texas Tobacco Free: Dissemination to and Implementation within Lung Cancer Screening Programs	Reitzel, Lorraine	University of Houston	3.0	5	\$448,726
PP230038	CSD	Salud en Mis Manos (SEMM): An Evidence-Based Breast & Cervical Cancer Early Detection and Prevention Program for Underserved Latinas.	Savas, Lara S	The University of Texas Health Science Center at Houston	3.1	6	\$2,499,492
PP230041	CSD	PP190052 - Integrated lung cancer screening and tobacco cessation in an urban safety-net system	Gerber, David E	The University of Texas Southwestern Medical Center	3.1	7	\$1,922,312
PP230043	PPC	School-based Human Papillomavirus Vaccination Program in the Rio Grande Valley: Continuation and Expansion in Hidalgo, Cameron, and Willacy Counties	Rodriguez, Ana M	The University of Texas Medical Branch at Galveston	3.2	8	\$2,257,898

CSD: Cancer Screening and Early Detection
DI: Dissemination of CPRIT-Funded Cancer Control Interventions
PPC: Primary Prevention of Cancer

Prevention Program Priorities Addressed by Recommended Awards February 15, 2023

<p align="center">Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence</p>	<p align="center">Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence</p>	<p align="center">Prioritize populations with obstacles to cancer prevention, detection, diagnostic testing, treatment, and survivorship services</p>	<p align="center">Prevention Program Assessment</p>
---	---	--	--



Note: Some grant awards address more than one program priority and will be double counted.

Dr. Mahendra Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com
Via email to kirtikpatel@hotmail.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Dr. Patel,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the FY2023 Cycle 1 Cancer Screening and Early Detection (CSD), Dissemination of CPRIT-Funded Cancer Control Interventions (DI), and Primary Prevention of Cancer (PPC) grant awards.

The PRC met on January 13, 2023, to consider the applications recommended by the peer review panel following their December 5, 2023 meeting. The PRC recommends 8 projects totaling \$13,577,257.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment

App ID	Mechanis	Application Title	PD	Organization	Requested Budget	Score	Rank Order
PP230018	PPC	Implementation and Evaluation of an Evidence-Based Multilevel Lifestyle Intervention for Underserved/Rural Populations in South Texas: Tu Salud ¡Si	Reininger, Belinda	The University of Texas Health Science Center at Houston	\$999,254	2.5	1
PP230013	CSD	Community Expansion and Re-engagement for Breast Cancer Screening and Patient Navigation	Argenbright, Keith E	The University of Texas Southwestern Medical Center	\$2,500,000	2.7	2
PP230046	CSD	Screen, Treat, or Prevent (STOP) Hepatocellular Cancer-Hepatitis C (HCC-HCV): Expansion to All Adults	Jain, Mamta K	The University of Texas Southwestern Medical Center	\$2,499,616	2.7	3
PP230033	DI	All for Them Texas: A multifaceted dissemination and implementation approach to increase HPV vaccination	Cucarro, Paula	The University of Texas Health Science Center at Houston	\$449,959	3.0	4
PP230002	DI	Taking Texas Tobacco Free: Dissemination to and Implementation within Lung Cancer Screening Programs	Reitzel, Lorraine	University of Houston	\$448,726	3.0	5
PP230038	CSD	Salud en Mis Manos (SEMM): An Evidence-Based Breast & Cervical Cancer Early Detection and Prevention Program for Underserved Latinas.	Savas, Lara S	The University of Texas Health Science Center at Houston	\$2,499,492	3.1	6
PP230041	CSD	PP190052 - Integrated lung cancer screening and tobacco cessation in an urban safety-net system	Gerber, David E	The University of Texas Southwestern Medical Center	\$1,922,312	3.1	7

PP230043	PPC	School-based Human Papillomavirus Vaccination Program in the Rio Grande Valley: Continuation and Expansion in Hidalgo, Cameron, and Willacy Counties	Rodriguez, Ana M	The University of Texas Medical Branch at Galveston	\$2,257,898	3.2	8
----------	-----	--	------------------	---	-------------	-----	---

CSD Cancer Screening and Early Detection
DI Dissemination of CPRIT-Funded Cancer Control Interventions
PPC Primary Prevention of Cancer



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

February 3, 2023

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendation for funding 48 grant applications totaling \$90,711,335. The PIC recommendations for 40 academic research and eight prevention grant awards are attached.

Additionally at their February 1 meeting, the PIC unanimously deferred 25 academic research and six product development research award recommendations. To read the explanation for deferral and see the list of deferred applications, please refer to the separate letter provided to Oversight Committee members on the portal.

Dr. Michelle Le Beau, CPRIT's Chief Scientific Officer, and Ramona Magid, CPRIT's Chief Prevention Officer, have prepared overviews of the recommended academic research and prevention research slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all the information considered by each Review Council is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on February 15, 2023. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email, or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself, Dr. Le Beau, and Ms. Magid are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas.

Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts,
Chief Executive Officer

ACADEMIC RESEARCH GRANT AWARD RECOMMENDATIONS

The PIC unanimously recommends approval of 40 academic research grant proposals totaling \$77,134,078. The recommended grant proposals were submitted in response to the following grant mechanisms: *Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Translation; Individual Investigator Research Awards for Prevention and Early Detection; Texas Regional Excellence in Cancer Award (TREC); Recruitment of Established Investigators; and Recruitment of First-Time, Tenure-Track Faculty Members (RFT)*.

The Scientific Review Council (SRC) provided the prioritized list of 65 recommendations for grant awards to the presiding officers on January 17, 2023. Upon recommendation from CPRIT’s Chief Scientific Officer, the PIC deferred 25 applications recommended by the SRC and recommended the remaining 40 to the Oversight Committee. The list of deferred applications can be found in the separate letter provided to Oversight Committee members.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

	IIRA	IIRA-CCA	IIRA-CSBC	IIRA-CT	IIRAP	TREC	REI	RFTFM
Statutory Funding Priority	<i>IIRA: Individual Investigator Research Awards; IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents; IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer; IIRACT: Individual Investigator Research Awards for Clinical Translation; IIRAP: Individual Investigator Research Awards for Prevention and Early Detection; TREC: Texas Regional Excellence in Cancer Award (TREC); REI: Recruitment of Established Investigators; RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
Could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;	✓	✓	✓	✓	✓	✓	✓	✓
Strengthen and enhance fundamental science in cancer research;	✓	✓	✓	✓	✓	✓	✓	✓
Ensure a comprehensive coordinated approach to cancer research;	✓	✓	✓	✓	✓	✓	✓	✓
Are interdisciplinary or interinstitutional;	✓	✓	✓	✓	✓	✓		
Address federal or other major research sponsors' priorities in	✓	✓	✓	✓	✓	✓	✓	✓

Statutory Funding Priority	IIRA	IIRA-CCA	IIRA-CSBC	IIRA-CT	IIRAP	TREC	REI	RFTFM
	<i>IIRA: Individual Investigator Research Awards; IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents; IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer; IIRACT: Individual Investigator Research Awards for Clinical Translation; IIRAP: Individual Investigator Research Awards for Prevention and Early Detection; TREC: Texas Regional Excellence in Cancer Award (TREC); REI: Recruitment of Established Investigators; RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>							
emerging scientific or technology Fields in the area of cancer prevention or cures for cancer;								
Are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;	✓	✓	✓	✓	✓	✓		
Are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state	✓	✓	✓	✓	✓	✓		
Have a demonstrable economic development benefit to this stat	✓	✓	✓	✓	✓	✓	✓	✓
Enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources	✓	✓	✓	✓	✓	✓	✓	✓
Expedite innovation and product development, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or technology research capabilities						✓		
Address the goals of the Texas Cancer Plan	✓	✓	✓	✓	✓	✓	✓	✓

Academic Research Award Recommendations Cycle 23.1 Individual Investigator Award Mechanisms							
<i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>TREC: Texas Regional Excellence in Cancer Award (TREC)</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
1	RP230026	IIRACCA	Identifying Clinical Methotrexate Toxicity Phenotypes Across Phases of Pediatric Leukemia Therapy	Bernhardt, Melanie	Baylor College of Medicine	\$1,392,407	1.0
2	RP230036	IIRAP	Geospatial Approaches to Melanoma Early Detection: The GAMED Project	Nelson, Kelly	The University of Texas M. D. Anderson Cancer Center	\$1,998,196	1.0
3	RP230222	IIRA	Personalized Auricular Point Acupressure to Self- Manage Cancer-Related Pain	Yeh, Chao Hsing	The University of Texas Health Science Center at Houston	\$1,046,680	1.1
4	RP230140	IIRA	Changes in Tumor Microenvironment That Promote Cachexia	Infante, Rodney	The University of Texas Southwestern Medical Center	\$1,050,000	1.1
5	RP230093	IIRA	Targeting the Mlc1-GlialCAM Protein Complex in Invasive Glioma Cells	McCarty, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,050,000	1.8
6	RP230018	IIRACCA	Neuronal Alterations in the Midbrain Dopaminergic System Function: A Novel Mechanism of	Zhang, Die	The University of Texas M. D. Anderson Cancer Center	\$1,399,730	1.9

Academic Research Award Recommendations Cycle 23.1 Individual Investigator Award Mechanisms <i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>TREC: Texas Regional Excellence in Cancer Award (TREC)</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
			Radiation Induced Cognitive Dysfunction				
7	RP230117	IIRAP	Randomized Controlled Trial to Assess Innovative Smoking Cessation Services for Young Adults in Texas	Chalela, Patricia	The University of Texas Health Science Center at San Antonio	\$1,992,330	1.9
8	RP230072	IIRA	Studying and Therapeutically Targeting Ferroptosis Liability in BRCA1-Deficient Cancer	Gan, Boyi	The University of Texas M. D. Anderson Cancer Center	\$1,050,000	1.9
9	RP230360	IIRA	Rational Design, Synthesis, and Biological Evaluation of Simplified Taccalonolide Analogs for the Treatment of Cancer	Frantz, Douglas	The University of Texas at San Antonio	\$1,049,128	1.9
10	RP230135	IIRA	Blocking DNA Damage Response Induction of “Don’t Eat Me” Signals Converts Local Radiotherapy Into Systemic Immunotherapy	Curran, Michael	The University of Texas M. D. Anderson Cancer Center	\$1,049,905	2.0
11	RP230344	IIRA	Development and Evaluation of Lanosterol	McBrayer, Samuel	The University of Texas Southwestern	\$1,048,465	2.0

Academic Research Award Recommendations Cycle 23.1 Individual Investigator Award Mechanisms							
<i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>TREC: Texas Regional Excellence in Cancer Award (TREC)</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
			Synthase Inhibitors in Preclinical GBM Models		Medical Center		
12	RP230109	IIRA	Autophagy and Tumor Endothelium	Terada, Lance	The University of Texas Southwestern Medical Center	\$1,049,994	2.0
13	RP230373	IIRA	Immune Recognition in Pancreatic Cancer	Viale, Andrea	The University of Texas M.D. Anderson Cancer Center	\$1,049,985	2.0
14	RP230224	IIRA	Enhancing Immune Responses in Pancreatic Cancer by Stromal Inhibition of HIF2	Taniguchi, Cullen	The University of Texas M.D. Anderson Cancer Center	\$1,049,997	2.0
15	RP230382	IIRA	Characterization of 3D Genome Organization and Transcriptional Regulation in Prostate Cancer	Mani, Ram	The University of Texas Southwestern Medical Center	\$1,049,641	2.0
16	RP230247	IIRA	A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer	Lin, Sue-Hwa	The University of Texas M. D. Anderson Cancer Center	\$1,050,000	2.0
17	RP230063	IIRAP	Whole-Genome DNA Methylation Markers for Tracking and	Tsai, Robert	Texas A&M University System Health Science	\$2,000,000	2.1

Academic Research Award Recommendations Cycle 23.1 Individual Investigator Award Mechanisms							
<i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>TREC: Texas Regional Excellence in Cancer Award (TREC)</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
			Predicting Advanced Liver Fibrosis as a Precursor of Liver Cancer in NAFLD		Center		
18	RP230285	IIRACT	Harnessing Endoplasmic Reticulum Stress to Overcome Resistance to Immunotherapy in Immune-Cold Breast Cancer	Chen , Xi	Baylor College of Medicine	\$2,000,000	2.2
19	RP230160	IIRACSBC	Overcoming Therapy Resistance by Integrated Computational Modeling of the Bone Metastatic Niche in Prostate and Renal Cancers	Dondossola, Eleonora	The University of Texas M. D. Anderson Cancer Center	\$1,025,623	2.2
20	RP230334	IIRA	Elucidating the Mutagenesis Mechanism of BRAF in Melanoma	Lee, Seongmin	The University of Texas at Austin	\$1,050,000	2.5
21	RP230120	IIRACCA	Clonal Evolution and Chemoresistance of Hepatoblastomas With Hepatocellular Carcinom Features	Sumazin, Pavel	Baylor College of Medicine	\$1,371,733	2.5

Academic Research Award Recommendations Cycle 23.1 Individual Investigator Award Mechanisms <i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>TREC: Texas Regional Excellence in Cancer Award (TREC)</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
22	RP230213	IIRAP	Multicomponent Interventions to Improve Uptake and Adherence to Lung Cancer Screening	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$1,988,211	2.6
23	RP230363	IIRACSBC	Developing Knowledge-Guided Deep Learning Models to Predict the Binding Between T-Cell Receptors and Neoantigens for Facilitating TCR-T Therapies	Wang, Tao	The University of Texas Southwestern Medical Center	\$1,199,997	2.6
24	RP230391	IIRA	Understanding and Improving CAR T-Cell Therapy of T-ALL and LBL	Mamonkin, Maksim	Baylor College of Medicine	\$1,050,000	2.6
25	RP230345	IIRA	The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T-Cell Therapy	Liu, Wenshe	Texas A&M University	\$1,050,000	2.6
26	RP230166	IIRACSBC	Integrative Modeling of Spatially Resolved Multiomics Data to Identify Bladder Cancer Mucosal Field Effects	Wei, Peng	The University of Texas M. D. Anderson Cancer Center	\$1,199,994	2.6

Academic Research Award Recommendations Cycle 23.1 Individual Investigator Award Mechanisms							
<i>IIRA: Individual Investigator Research Awards</i> <i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i> <i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i> <i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i> <i>IIRAP: Individual Investigator Research Awards for Prevention and Early Detection</i> <i>TREC: Texas Regional Excellence in Cancer Award (TREC)</i>							
Rank	App. ID	Mechanism	Application Title	PI	Organization	Budget	Final Score
27	RP230154	IIRACCA	Normalizing Membrane Homeostasis in Microglia/Macrophages of Pediatric High-Grade Gliomas	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$1,400,000	2.6
28	RP230271	IIRA	Targeting Distinct Metabolic Vulnerabilities of Aggressive Renal Cell Carcinoma Variants	Zacharias Millward, Niki	The University of Texas M. D. Anderson Cancer Center	\$1,019,997	2.7
29	RP230330	IIRACCA	Integrate Whole-Slide Imaging and Genomic Data to Study Pediatric Rhabdomyosarcoma	Xiao, Guanghua	The University of Texas Southwestern Medical Center	\$1,303,815	2.7
30	RP230050	IIRA	A Novel Therapeutic Strategy Targeting Pancreatic Cancer	Yao, Wantong	The University of Texas M. D. Anderson Cancer Center	\$1,049,854	2.7
31	RP230261	IIRA	Investigating the Mechanism of NLRP3 Inflammasome Hyperactivation During Hepatocellular Carcinoma Development	Zhong, Zhenyu	The University of Texas Southwestern Medical Center	\$1,049,997	2.7

Academic Research Award Recommendations <i>Cycle 23.1 Texas Regional Excellence in Cancer Award (TREC)</i>						
Rank	App. ID	Title	PI	Organization	Budget	Final Score
1	RP230419	South Texas Center of Excellence in Cancer Research (STCECR)	CHAUHAN, SUBHASH	The University of Texas Rio Grande Valley	\$6,000,000	2.8
2	RP230420	Impacting Cancer Outcomes in Hispanics (ICOHN)	LAKSHMANASWAMY, RAJKUMAR	Texas Tech University Health Sciences Center at El Paso	\$6,000,000	2.8
3	RP230204	Gene-Environment: Lifestyle Interactions in Cancer	Ramos, Kenneth	Texas A&M University System Health Science Center	\$5,998,422	2.8

Academic Research Recruitment Award Recommendations Cycles 23.2 – 23.3						
<i>REI: Recruitment of Established Investigators</i>						
<i>RFTFM: Recruitment of First-Time, Tenure-Track Faculty Members</i>						
Rank	App. ID	Mechanism	Candidate	Organization	Budget	Final Score
1	RR230012	RFTFM	Kenneth Hu, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
2	RR230017	RFTFM	Joe Nassour, Ph.D.	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.5
3	RR230019	RFTFM	Lu Wang, Ph.D.	The University of Texas Health Science Center at San Antonio	\$2,000,000	1.6
4	RR230020	REI	Hongfang Liu, Ph.D.	The University of Texas Health Science Center at Houston	\$6,000,000	2.0
5	RR230018	REI	Rudi Fasan, Ph.D.	The University of Texas at Dallas	\$6,000,000	2.7
6	RR230015	RFTFM	Ewan McRae, Ph.D.	The Methodist Hospital Research Institute	\$1,999,977	2.8

PREVENTION GRANT AWARD RECOMMENDATIONS

The PIC unanimously recommends approval of eight prevention grant proposals totaling \$13,577,257. The recommended grant proposals were submitted in response to the *Cancer Screening and Early Detection; Dissemination of CPRIT-Funded Cancer Control Interventions; and Primary Prevention of Cancer* grant mechanisms. The Prevention Review Council (PRC) provided the prioritized list of the recommendation for the award to the presiding officers on January 18, 2023. The PIC approved the award recommendations as presented by the PRC.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these prevention proposals met the following CPRIT funding priorities:

- Strengthen and enhance fundamental science in cancer research;
- Ensure a comprehensive coordinated approach to cancer research;
- Are interdisciplinary or interinstitutional;
- Have a demonstrable economic development benefit to this state; and
- Address the goals of the Texas Cancer Plan

Prevention Award Recommendations							
<i>CSD: Cancer Screening and Early Detection</i>							
<i>DI: Dissemination of CPRIT-Funded Cancer Control Interventions</i>							
<i>PPC: Primary Prevention of Cancer</i>							
Rank	App. ID	Mechanism	Application Title	PD	Organization	Budget	Final Score
1	PP230018	PPC	Implementation and Evaluation of an Evidence-Based Multilevel Lifestyle Intervention for Underserved/Rural Populations in South Texas: Tu Salud ¡Si Cuenta!	Reininger, Belinda	The University of Texas Health Science Center at Houston	\$999,254	2.5
2	PP230013	CSD	Community Expansion and Re-engagement for Breast Cancer Screening and Patient Navigation	Argenbright, Keith E	The University of Texas Southwestern Medical Center	\$2,500,000	2.7

Prevention Award Recommendations							
<i>CSD: Cancer Screening and Early Detection</i>							
<i>DI: Dissemination of CPRIT-Funded Cancer Control Interventions</i>							
<i>PPC: Primary Prevention of Cancer</i>							
Rank	App. ID	Mechanism	Application Title	PD	Organization	Budget	Final Score
3	PP230046	CSD	Screen, Treat, or Prevent (STOP) Hepatocellular Cancer-Hepatitis C (HCC-HCV): Expansion to All Adults	Jain, Mamta K	The University of Texas Southwestern Medical Center	\$2,499,616	2.7
4	PP230033	DI	All for Them Texas: A multifaceted dissemination and implementation approach to increase HPV vaccination	Cucarro, Paula	The University of Texas Health Science Center at Houston	\$449,959	3.0
5	PP230002	DI	Taking Texas Tobacco Free: Dissemination to and Implementation within Lung Cancer Screening Programs	Reitzel, Lorraine	University of Houston	\$448,726	3.0
6	PP230038	CSD	Salud en Mis Manos (SEMM): An Evidence-Based Breast & Cervical Cancer Early Detection and Prevention Program for Underserved Latinas.	Savas, Lara S	The University of Texas Health Science Center at Houston	\$2,499,492	3.1
7	PP230041	CSD	PP190052 - Integrated lung cancer screening and tobacco cessation in an	Gerber, David E	The University of Texas Southwestern Medical Center	\$1,922,312	3.1

Prevention Award Recommendations							
<i>CSD: Cancer Screening and Early Detection</i>							
<i>DI: Dissemination of CPRIT-Funded Cancer Control Interventions</i>							
<i>PPC: Primary Prevention of Cancer</i>							
Rank	App. ID	Mechanism	Application Title	PD	Organization	Budget	Final Score
			urban safety-net system				
8	PP230043	PPC	School-based Human Papillomavirus Vaccination Program in the Rio Grande Valley: Continuation and Expansion in Hidalgo, Cameron, and Willacy Counties	Rodriguez, Ana M	The University of Texas Medical Branch at Galveston	\$2,257,898	3.2



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

February 3, 2023

Dear Oversight Committee Members:

Pursuant to Tex. Admin. Code § 703.7(d), this letter serves as notification of the list of grant applications deferred by the PIC. At their meeting on February 1, members of the PIC unanimously agreed to defer 25 Academic Research and six Product Development Research grant application recommendations from the Scientific Review Council (SRC) and Product Development Review Council (PDRC), respectively. The attached tables list the application ID, grant mechanism, and institution of each deferred grant application.

Dr. Michelle Le Beau, CPRIT's Chief Scientific Officer, and Dr. Ken Smith, CPRIT's Chief Product Development Officer, recommended deferral of the 31 grant applications because of budget constraints for the remainder of FY2023. Both the SRC's and PDRC's recommendations exceeded the amount of agency funds available for each program. To reduce the funding amount recommended to the Oversight Committee, Dr. Le Beau suggested deferring 25 academic research applications that scored 2.8 or higher during peer review. Dr. Smith recommended deferring the six product development recommendations to allow him time to negotiate budget reductions with the companies.

The PIC may consider and recommend the deferred applications at a future FY2023 meeting. No Oversight Committee action is necessary at this time.

Sincerely,
Wayne R. Roberts
Chief Executive Officer

Table 1. Deferred Academic Research Grant Applications

Deferred Academic Research Grant Applications		
<i>IIRA: Individual Investigator Research Awards</i>		
<i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i>		
<i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i>		
<i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i>		
Application ID	Mechanism	Institution
RP230012	IIRA	Texas Tech University Health Sciences Center at El Paso
RP230019	IIRA	Baylor College of Medicine
RP230071	IIRA	The University of Texas Southwestern Medical Center
RP230112	IIRA	The University of Texas M. D. Anderson Cancer Center
RP230134	IIRACSBC	The University of Texas M. D. Anderson Cancer Center
RP230143	IIRACCA	The University of Texas M. D. Anderson Cancer Center
RP230161	IIRACT	The University of Texas Southwestern Medical Center
RP230162	IIRACCA	The University of Texas Health Science Center at San Antonio
RP230174	IIRACCA	The University of Texas at Austin
RP230181	IIRA	The University of Texas M. D. Anderson Cancer Center
RP230184	IIRA	The University of Texas Southwestern Medical Center
RP230196	IIRA	Baylor College of Medicine
RP230197	IIRA	Baylor College of Medicine
RP230216	IIRA	The University of Texas Southwestern Medical Center
RP230240	IIRA	Baylor College of Medicine
RP230241	IIRA	Baylor College of Medicine
RP230272	IIRA	The University of Texas Southwestern Medical Center
RP230283	IIRA	The University of Texas M. D. Anderson Cancer Center

Deferred Academic Research Grant Applications		
<i>IIRA: Individual Investigator Research Awards</i>		
<i>IIRACCA: Individual Investigator Research Awards for Cancer in Children and Adolescents</i>		
<i>IIRACSBC: Individual Investigator Research Awards for Computational Systems Biology of Cancer</i>		
<i>IIRACT: Individual Investigator Research Awards for Clinical Translation</i>		
Application ID	Mechanism	Institution
RP230307	IIRA	The University of Texas M. D. Anderson Cancer Center
RP230319	IIRACSBC	Baylor College of Medicine
RP230323	IIRA	The University of Texas at Dallas
RP230327	IIRA	The University of Texas Southwestern Medical Center
RP230333	IIRA	Rice University
RP230375	IIRA	The University of Texas Health Science Center at Houston
RP230381	IIRA	The University of Texas Southwestern Medical Center

Table 2. Deferred Product Development Research Grant Applications

Deferred Product Development Research Grant Applications		
<i>SEED: SEED Awards for Product Development Research</i>		
<i>TNTC: Texas New Technologies Company Awards for Product Development Research</i>		
<i>TTC: Texas Therapeutics Company Awards for Product Development Research</i>		
Application ID	Mechanism	Company
DP230062	TTC	7 Hills Pharma LLC
DP230064	SEED Therapeutics	OmniNano Pharmaceuticals LLC
DP230066	TTC	Pulmotect, Inc.
DP230071	TTC	Allterum Therapeutics, LLC
DP230076	TTC	OncoResponse
DP230079	TNTC	Resilience Texas LLC dba CTMC



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: VINCE BURGESS, CHIEF COMPLIANCE OFFICER
SUBJECT: COMPLIANCE CERTIFICATION – FEBRUARY 2023 AWARDS
DATE: FEBRUARY 3, 2023

Summary and Recommendation:

As CPRIT's Chief Compliance Officer, I am responsible for reporting to the Oversight Committee regarding the agency's compliance with applicable statutory and administrative rule requirements during the grant review process. I have reviewed the compliance pedigrees for the grant applications submitted to CPRIT for the:

- Recruitment of Established Investigators
- Recruitment of First-Time, Tenure-Track Faculty Members
- Individual Investigator Research Awards
- Individual Investigator Research Awards for Childhood and Adolescent Cancers
- Individual Investigator Research Awards for Computational Systems Biology of Cancer
- Individual Investigator Research Awards for Clinical Translation
- Individual Investigator Research Awards for Prevention and Early Detection
- Texas Regional Excellence in Cancer
- Cancer Screening and Early Detection
- Dissemination of CPRIT-Funded Cancer Control Interventions
- Primary Prevention of Cancer

I have conferred with staff at CPRIT and General Dynamics Information Technology (GDIT), CPRIT's contracted third-party grants administrator, regarding the academic research and prevention awards and studied the supporting grant review documentation, including third-party observer reports for the peer review meetings. I am satisfied that the application review process that resulted in the above mechanisms recommended by the Program Integration Committee (PIC) followed applicable laws and agency administrative rules. I certify the academic research and prevention award recommendations for the Oversight Committee's consideration.

Background:

CPRIT's Chief Compliance Officer must report to the Oversight Committee regarding compliance with the statute and the agency's administrative rules. Among the Chief Compliance Officer's responsibilities is the obligation "to ensure that all grant proposals comply with this chapter and rules adopted under this chapter before the proposals are submitted to the oversight committee for approval." Texas Health & Safety Code § 102.051(c) and (d).

CPRIT uses a compliance pedigree process to formally document compliance for the grant award process. The compliance pedigree tracks the grant application as it moves through the review process and documents compliance with applicable laws and administrative rules. A compliance pedigree is created for each application; the information related to the procedural steps listed on the pedigree is entered and attested to by GDIT employees and CPRIT employees. CPRIT relies on GDIT to accurately record a majority of the information on the pedigree from the pre-receipt stage to final Review Council recommendation. To the greatest extent possible, information reported in the compliance pedigree is imported directly from data contained in CPRIT's Application Receipt System (CARS), the grant application database managed by GDIT. This is done to minimize the opportunity for error caused by manual data entry.

No Prohibited Donations:

Although CPRIT is statutorily authorized to accept gifts and grants pursuant to Texas Health & Safety Code § 102.054, the statute prohibits CPRIT from awarding a grant to an applicant who has made a gift or grant to CPRIT, or a nonprofit organization established to provide support to CPRIT. I note that Texas Health & Safety Code § 102.251(a)(3) specifically addresses "donors from any nonprofit organization established to provide support to the institute compiled from information made available under § 102.262(c)." To the best of my knowledge, there are no nonprofit organizations that have been established to provide support to CPRIT on or after June 14, 2013, the effective date of this statutory change. The only nonprofit organization established to provide support to the Institute was the CPRIT Foundation; however, the CPRIT Foundation ceased operations and changed its name and its purpose prior to June 14, 2013. The institute has received no donations from the CPRIT Foundation made on or after June 14, 2013.

I have reviewed the list of donors to CPRIT maintained by CPRIT (and listed on CPRIT's website) and compared the donors to the list of applicants. No donors to CPRIT have submitted applications for grant awards during the award cycles that are the subject of this report.

Pre-Receipt Compliance:

The activities listed on a compliance pedigree in the pre-receipt stage cover the period beginning with CPRIT's approval and issuance of the Request for Applications (RFA) through the submission of grant applications. For the period covering these RFAs, CPRIT published the

RFAs on the Texas.gov eGrants website. The RFA specifies a deadline and mandates that only those applications submitted electronically through CPRIT's Application Receipt System (CARS) are eligible for consideration. CARS blocks an application from being submitted once the deadline passes. Occasionally, an applicant may have technical difficulties that prevent the applicant from completing the application submission. When this occurs, the applicant may appeal to CPRIT (through the CPRIT Helpdesk that is managed by GDIT) to allow for a submission after the deadline. The program officer considers any requests for extension and may approve an extension for good cause. When a late filing request is approved, the applicant is notified, and CARS is reopened for a brief period – usually two to three hours – the next business day.

Academic Research:

For recruitment cycles 23.2 and 23.3, three applications were received for the Recruitment of Established Investigators RFA and four applications were received in response to the Recruitment of First-Time, Tenure Track Faculty Members RFA.

In response to the academic, non-recruitment RFAs for cycle 23.1, CPRIT received 333 applications. Two applications were administratively withdrawn, and two applications were voluntarily withdrawn by the applicant.

All academic research RFAs were posted on the Texas.gov eGrants website and all applications were submitted through CARS.

Prevention:

For prevention cycle 23.1, nine applications were received for the Cancer Screening and Early Detection RFA, six applications were received for the Dissemination of CPRIT-Funded Cancer Control Interventions RFA, and 13 applications were received for the Primary Prevention of Cancer RFA. Four prevention applications were administratively withdrawn for being non-responsive to the RFA.

All prevention RFAs were posted on the Texas.gov eGrants website and all applications were submitted through CARS. Two applicants requested an extension to submit an application after the deadline. The program officer determined that there was good cause for both requests and the deadline was extended.

Receipt, Referral, and Assignment Compliance:

Once applications have been submitted through CARS, GDIT staff reviews the applications for compliance with RFA directions. If an applicant does not comply with the directions, GDIT notifies the program officer, and the program officer makes the final decision whether to administratively

withdraw the application. Recruitment grant applications are assigned to the Scientific Review Council members for peer review. All other academic research, product development research, and prevention applications are assigned by the peer review panel chair to their respective peer review panels. Prior to distribution of the applications, reviewers are given summary information about the applicant, including the Project Director and collaborators. Reviewers must sign a conflict of interest agreement and confirm that they do not have a conflict of interest with the application before they are provided with the full application.

The pedigrees attest that a conflict of interest statement was signed by each primary reviewer for each Grant Application.

Academic Research:

Four academic research, non-recruitment applications were withdrawn during this cycle: two applications were administratively withdrawn prior to peer review, one application was voluntarily withdrawn by the applicant prior to assignment and one application was withdrawn by the applicant after peer review but prior to the Scientific Review Council (SRC) meeting.

Prevention:

Four prevention applications were administratively withdrawn prior to peer review assignment.

Peer Review:

Primary reviewers (typically three) must submit written critiques for each of their assigned applications prior to the peer review meeting. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application.

Following the peer review meeting, each participating peer reviewer must sign a post-review peer review statement certifying that the reviewer knew of and understood CPRIT's conflict of interest policy and followed the policy for this review process. After the peer review meetings, a final score report from the review committee is delivered to the Review Council for additional review.

Academic Research:

For the recruitment awards, the applications are reviewed by the Scientific Review Council (SRC), which assigns two members of the SRC to be primary reviewers. I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. Sign out sheets are used to document when a reviewer with a conflict of interest associated with a particular application leaves the room (or disengages from the conference call) during the discussion and scoring of the application. No conflicts of interest were declared by the SRC for recruitment cycles 23.2 and 23.3.

I reviewed and confirmed that the post review conflict of interest statements were signed by the six SRC members that attended the 23.2 Recruitment Review Panel meeting on November 10, 2022 and the eight SRC members that attended the 23.3 Recruitment Review Panel on January 12, 2023.

Academic research applications (non-recruitment) are reviewed by peer review panels and recommended to the SRC. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in the Individual Investigator Mechanisms in this cycle. This process allows the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments. A total of 211 applications across the five Individual Investigator mechanism were recommended for full review and of those, 110 applications received a full onsite peer review. As documented by GDIT, reviewers with conflicts of interest did not participate in review of those applications. I reviewed supporting documentation, such as conflict of interest statements (COIs), third-party observer reports, and sign out sheets. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I also reviewed and confirmed that the post review conflict of interest statements were signed by peer review members for each review panel as well as the eight SRC members that attended the Review Council meeting on December 22, 2022.

Prevention:

For the Dissemination of CPRIT-Funded Cancer Control Interventions RFA, the applications are reviewed by the Prevention Review Council (PRC), which assigns two members of the PRC to be primary reviewers. All other Prevention applications are reviewed by peer review panels and then sent to the PRC.

I reviewed the supporting documentation, such as the sign-out sheets, third-party observer reports, and post-review peer reviewer statements. As documented by GDIT and verified by third-party observer reports, reviewers with conflicts of interest did not participate in review of those applications. All declared COIs left the room or disengaged from the conference call and did not participate in the discussion of relevant applications.

I reviewed and confirmed that the post review conflict of interest statements were signed by 10 peer review members for Prevention Panel 1 on December 5, 2022, and the three PRC members that attended the Dissemination of CPRIT-Funded Cancer Control Interventions Panel on January 6, 2023, and the PRC meeting on January 13, 2023.

Programmatic Review:

Programmatic review is conducted by the Scientific Review Council, Prevention Review Council, and Product Development Review Council for their respective awards. Each review council creates a final list of grant applications it will recommend to the PIC for grant award slates.

To the extent that any Review Council member identified a conflict of interest, I reviewed documentation confirming that the review council member did not participate in the discussion or vote on the application(s).

I also reviewed the third-party observer reports for each Review Council meeting. The third-party observer reports document that the Review Council discussions were limited to the merits of the applications and established evaluation criteria and that conflicted reviewers, if applicable, exited the room or the conference call when the application was discussed.

For the Academic Research and Prevention awards, I reviewed and confirmed that the Review Council recommendations corresponded to RFAs that had been released. I also confirmed that the pedigrees reflect the date of the Review Council meeting and that the applications were recommended by the Review Council.

Academic Research:

The SRC met on December 22, 2022, to consider 59 applications recommended by the peer review panels following their meetings held on October 24-31 and November 29, 2022. After review of these applications, the SRC recommended 59 applications to the Program Integration Committee (PIC) for consideration. In addition, six academic recruitment applications were recommended to the PIC by the SRC at their meetings on November 10, 2023, and January 12, 2023.

Four Individual Investigator Research Awards grant applications and two Individual Investigator Research Awards for Cancer in Children and Adolescents grant applications are not recommended for funding with scores that are the same as or more favorable than some applications that were recommended within each mechanism. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

Prevention:

Eight applications were recommended by the peer review panel to the PRC. After review and discussion of these applications, the PRC recommended all eight applications to the PIC for consideration.

The PRC took no action on one application that was submitted for the Cancer Screening and Early Detection RFA and one application that was submitted for the Dissemination of CPRIT-Funded Cancer Control Interventions RFA.

Program Integration Committee (PIC) Review:

Texas Health & Safety Code § 102.051(d) requires the Chief Compliance Officer to attend and observe the PIC meetings to ensure compliance with CPRIT's statute and administrative rules. CPRIT's statute requires that, at the time the PIC's final Grant Award recommendations are formally submitted to the Oversight Committee, the Chief Executive Officer shall prepare a written affidavit for each Grant Application recommended by the PIC containing relevant information related to the Grant Application recommendations.

I attended the February 1, 2023, PIC meeting as an observer and confirm that the PIC review process complied with CPRIT's statute and administrative rules. All five PIC members were present for the meeting.

The PIC considered 73 applications that were recommended by the SRC and PRC. Because the SRC recommendations exceeded available funds, Dr. Le Beau recommended 40 of the 65 academic research applications be recommended to the Oversight Committee and defer action on the remaining 25 Individual Investigator applications recommended by the SRC with overall scores of 2.8 and higher. The PIC voted to recommend 48 applications to move forward to the Oversight Committee.

Similarly, Dr. Smith recommended that the PIC defer the six grant applications recommended by the Product Development Review Council on January 30. The recommendations exceeded the amount of funds available for product development awards for the remainder in the fiscal year. Dr. Smith explained that deferring the six product development application recommendations would allow him time to negotiate budget reductions with the companies. The PIC voted to defer all PDRC recommendations until the May 2023 PIC meeting.

A review of the CEO affidavits confirms that such affidavits were executed and provided for each grant application recommendation.

CEO Affidavit Supporting Information



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Prevention
FY 2023—Cycle 1
*Cancer Screening and Early Detection***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA P-23.1-CSD

Cancer Screening and Early Detection

**Please also refer to the Instructions for Applicants document,
which will be posted on June 2, 2022**

Application Receipt Opening Date: June 2, 2022
Application Receipt Closing Date: August 31, 2022

FY 2023

Fiscal Year Award Period
September 1, 2022-August 31, 2023

TABLE OF CONTENTS

1. ABOUT CPRIT.....	5
1.1 PREVENTION PROGRAM PRIORITIES.....	5
2. FUNDING OPPORTUNITY DESCRIPTION.....	6
2.1 SUMMARY	6
2.2 PROJECT OBJECTIVES	7
2.3 AWARD DESCRIPTION.....	7
2.4 PRIORITIES.....	10
2.5 SPECIFIC AREAS OF EMPHASIS.....	11
2.6 OUTCOME METRICS.....	12
2.7 FUNDING INFORMATION	13
2.8 ELIGIBILITY	14
2.9 RESUBMISSION POLICY	15
2.10 EXPANSION POLICY	16
3. KEY DATES.....	17
4. APPLICATION SUBMISSION GUIDELINES	17
4.1 <i>INSTRUCTIONS FOR APPLICANTS</i> DOCUMENT	17
4.2 ONLINE APPLICATION RECEIPT SYSTEM.....	17
4.3 SUBMISSION DEADLINE EXTENSION	18
4.4 APPLICATION COMPONENTS	18
4.4.1 <i>Abstract and Significance (5,000 characters)</i>	18
4.4.2 <i>Goals and Objectives (700 characters each)</i>	19
4.4.3 <i>Project Timeline (2 pages)</i>	20
4.4.4 <i>Project Plan (12 pages; fewer pages permissible)</i>	20
4.4.5 <i>People Reached (Indirect Contact)</i>	23
4.4.6 <i>Number of Services Delivered (Direct Contact)</i>	23
4.4.7 <i>Number of Clinical Services Delivered</i>	23
4.4.8 <i>Number of Unique People Served (Direct Contact)</i>	23
4.4.9 <i>References</i>	23
4.4.10 <i>Resubmission Summary</i>	23
4.4.11 <i>Most Recently Funded Relevant Project Summary (3 pages)</i>	24
4.4.12 <i>CPRIT Grants Summary</i>	24
4.4.13 <i>Budget and Justification</i>	25
4.4.14 <i>Current and Pending Support and Sources of Funding</i>	26
4.4.15 <i>Biographical Sketches</i>	27
4.4.16 <i>Collaborating Organizations</i>	27
4.4.17 <i>Letters of Commitment (10 pages)</i>	27
5. APPLICATION REVIEW.....	27
5.1 REVIEW PROCESS OVERVIEW	27
5.2 REVIEW CRITERIA	29
5.2.1 <i>Primary Evaluation Criteria</i>	29
5.2.2 <i>Secondary Evaluation Criteria</i>	31
6. AWARD ADMINISTRATION	32

7. CONTACT INFORMATION33
7.1 HELPDESK33
7.2 PROGRAM QUESTIONS33
8. RESOURCES.....34
9. REFERENCES35
APPENDIX A: KEY TERMS.....36
APPENDIX B: WRITING GOALS AND OBJECTIVES.....39

RFA VERSION HISTORY

Rev 5/6/2022 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and enhance the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1 Prevention Program Priorities

Legislation from the 83rd Texas Legislature requires that CPRIT's Oversight Committee establish program priorities on an annual basis. The priorities are intended to provide transparency in how the Oversight Committee directs the orientation of the agency's funding portfolio. The Prevention Program's principles and priorities will also guide CPRIT staff and the Prevention Review Council on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

Established Principles:

- Fund evidence-based interventions and their dissemination
- Support the prevention continuum of primary, secondary, and tertiary (includes survivorship) prevention interventions

CPRIT's Cross-Program Priorities:

- Prevention and early detection initiatives
- Translation of Texas research (discoveries) to innovations
- Enhance Texas' research capacity and life science infrastructure

Prevention Program Priorities

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize underserved populations
- Program assessment to identify best practices, use as a quality improvement tool, and guide future program direction

2. FUNDING OPPORTUNITY DESCRIPTION

2.1 Summary

The ultimate goals of the CPRIT Prevention Program are to reduce overall cancer incidence and mortality and to improve the lives of individuals who have survived or are living with cancer. The ability to reduce cancer death rates depends in part on the application of currently available evidence-based technologies and strategies. CPRIT fosters the primary, secondary, and tertiary prevention of cancer in Texas by providing financial support for a wide variety of evidence-based risk reduction, early detection, and survivorship interventions.

This award mechanism seeks to support the delivery of evidence-based clinical services to screen for cancer and precancer in underserved populations who do not have adequate access to screening and early detection interventions and health care, bringing together networks of public health and community partners to carry out programs tailored for their communities. Projects should identify cancers that cause the most burden in the community, have nationally recommended screening methods, and use evidence-based methods to screen for these cancers. Delivery of clinical services is restricted to residents of Texas.

Partnerships with other organizations that can support and leverage resources are strongly encouraged. A coordinated submission of a collaborative partnership program in which all partners have a substantial role in the proposed project is preferred.

2.2 Project Objectives

CPRIT seeks to fund projects that will do the following:

- Deliver comprehensive projects comprising all of the following: public and/or professional education, outreach, delivery of clinical services, follow-up navigation to diagnosis and cancer treatment, and system and/or policy improvements.
- Offer effective and efficient systems of delivery of screening services based on the existing body of knowledge about and evidence in ways that far exceed current performance in a given service area.
- Implement policy changes and/or system improvements that are sustainable over time (eg, decrease wait times between positive screen and diagnostic tests and treatment through improved navigation, reminder systems) and treatment.
- Provide tailored, culturally appropriate outreach and accurate information on early detection and prevention to the public and health care professionals that results in a health impact that can be measured.

2.3 Award Description

The Cancer Screening and Early Detection RFA solicits applications for eligible projects up to 5 years in duration that will deliver evidence-based clinical services in cancer screening for breast, cervical, colorectal, liver, and lung cancers according to established and current national guidelines and criteria. Nonmetropolitan (rural) and/or medically underserved populations must be included in the defined service area.

The following are required components of the project:

- **Geographic Area to be Served:** Clinical service delivery to nonmetropolitan/medically underserved area (MUA) counties must be included in the defined service area. Rural and MUA counties may be identified via web-based tools from the [Texas Department of State Health Services](#) and [US Department of Health and Human Services](#). Service to urban/nonmedically underserved counties is allowable if the project proposes to also serve nonmetropolitan/medicallyunderserved counties.
- **Comprehensive Projects:** Comprehensive projects include a continuum of services and systems and policy changes and comprise all of the following: Public and professional

education and training, outreach, delivery of screening and diagnostic services, follow-up navigation to treatment services for those diagnosed with cancer and precancer, data collection and tracking, and systems improvement.

- **Evidence Based:** CPRIT's secondary prevention grants are intended to fund effective and efficient systems of delivery of early detection services based on the existing body of knowledge about and evidence for screening for both primary and secondary cancers in ways that far exceed current performance in a given service area. The provision of clinical services, including rescreening at the appropriate interval, must comply with established and current national guidelines (eg, US Preventive Services Task Force [USPSTF], American Cancer Society).

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data (eg, availability of resources and screening coverage) for the target population and target service region are required. If no baseline data exist, the applicant must present clear plans and describe method(s) of measurement used to collect the data necessary to establish a baseline.

- **Clinical Service and Community Partner Networks.** If applicable to the proposed project, applicants are encouraged to coordinate and describe a collaboration of clinical service providers and community partners that can deliver outreach, education, clinical, and navigation services to the most counties and the most people possible in a selected service region. Partnerships with other organizations that can support and leverage resources (ie, community-based organizations, local and voluntary agencies, nonprofit agencies, groups that represent priority populations,) are encouraged. Letters of commitment or memoranda of understanding describing their specific role in the partnership will strengthen the application.

In cases where the project proposes to work with multiple clinical providers, the Program Director (PD) should facilitate the establishment of standard protocols for all clinical service providers in the network as well as standard systems, policies, and procedures for the participating clinical service providers and organizations. These may include, but are not limited to, patient tracking and timely follow-up of all abnormal screening results and/or diagnoses of cancer.

This mechanism will fund case management/patient navigation to screening, to diagnostic testing, and to treatment. Applicants must ensure that there is access to needed diagnostic testing for those with an abnormal screening exam, and to treatment services for patients with precancer or cancers that are detected as a result of the project and must describe the process for ensuring access to diagnostic and treatment services.

Applicants should not request funds for any of the above components if these components are already being funded from other sources. If clinical services are being provided and paid by others, the applicant must demonstrate and report on the outcomes and services that are delivered to the people navigated by the program.

CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area) in the provision of evidence-based clinical services, changes in provider practice, systems changes, and cost-effectiveness. Applicants must demonstrate how these outcomes will ultimately impact incidence mortality, morbidity, and disparities.

Under this RFA, CPRIT **will not** consider the following:

- Projects focused solely on metropolitan counties that are not medically underserved.
- **Projects focused solely on primary cancer prevention services.** Applicants should apply under the Primary Prevention of Cancer (PPC) RFA. Primary prevention services are allowable under this RFA if combined with cancer screening/early detection services (eg, Hepatitis B vaccination with Hepatitis C screening, HPV vaccination with cervical cancer screening).
- Projects focusing solely on systems and/or policy change or solely on education and/or outreach that do not include the navigation to and delivery of cancer screening and early detection services.
- **Projects focusing on screening the general population for genetic disposition to cancer.**
- **Projects focusing solely on case management/patient navigation services.** Case management/patient navigation services must be paired with the delivery of a clinical cancer screening service and reported to CPRIT, including those services delivered by another provider. Furthermore, while navigation to the point of treatment of cancer is required when cancer is discovered through a CPRIT-funded project, applications seeking

funds to provide coordination of care while an individual is in treatment are not allowed under this RFA.

- Clinical tests/services proposed as part of the project that do not comply with established and current national guidelines and criteria and/or have not been recommended by the USPSTF due to lack of evidence available to draw reliable conclusions about benefits and harms of the tests. These include, but are not limited to, breast self-exams, clinical breast exams, and prostate specific antigen (PSA) tests.
- **Prevention/Intervention research projects.** Applicants interested in prevention research should review CPRIT's Academic Research RFAs (available at <http://www.cprit.texas.gov>).
- Resources for the treatment of cancer, or viral treatment for hepatitis.

2.4 Priorities

Types of Cancer: Applications addressing any cancer type(s) that can be prevented or detected early (breast, cervix, colorectal, liver, lung) and are responsive to this RFA will be considered for funding. See [section 2.5](#) for specific areas of emphasis. All services must comply with established and current national guidelines and USPSTF criteria.

Lung cancer screening projects must also meet the Centers for Medicare and Medicaid Services (CMS) eligibility criteria for radiologists and facilities. CMS also requires delivery of smoking cessation counseling if LDCT screening is offered; for funding through this mechanism, CPRIT requires that robust evidence-based cessation interventions be delivered. Shared decision-making about the eligibility, risks, and benefits of annual lung cancer screening between the health care provider and patient is required.

The Prevention Program's priorities for funding include the following:

1) **Populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.**

CPRIT-funded programs must address one or more of these priority populations:

- Underinsured and uninsured individuals
- Medically underresourced communities
- Racial, ethnic, and cultural minority groups

- Populations with low screening rates, high incidence rates, and high mortality rates, focusing on individuals never before screened or who are significantly out of compliance with nationally recommended screening guidelines (more than 5 years for breast/cervical cancers).

The age of the priority population and frequency of screening/rescreening for provision of clinical services described in the application must comply with established and current national guidelines (eg, USPSTF, American Cancer Society). Provide the national guideline that will be followed.

2) Geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.

While disparities and needs exist across the state, CPRIT will also prioritize applications proposing to serve geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence. For this RFA, projects must propose to serve nonmetropolitan and/or medically underresourced areas of the state. In addition, projects addressing areas of emphasis (see [section 2.5](#)) will receive priority consideration.

Geographic and Population Balance in Current CPRIT portfolio

At the programmatic level of review conducted by the Prevention Review Council ([section 5.1](#)), priority will be given to projects that target geographic regions of the state and population subgroups that are not adequately covered by the current CPRIT Prevention project portfolio (see <https://www.cprit.texas.gov/our-programs/prevention/portfolio-maps> and <https://www.cprit.texas.gov/grants-funded?search=prevention>).

2.5 Specific Areas of Emphasis

CPRIT has identified the following areas of emphasis for this cycle of awards.

<u>Secondary Prevention - Screening and Early Detection Services</u>
Breast Cancer
<ul style="list-style-type: none"> • Decreasing disparities in mortality rates of breast cancer in racial/ethnic populations. The mortality rate is significantly higher in Black women than in other populations. • Increasing screening/detection rates in medically underserved areas of the state.
Cervical Cancer
<ul style="list-style-type: none"> • Decreasing disparities in incidence and mortality rates of cervical cancer in racial/ethnic populations. Hispanic women have the highest incidence rates while Black women have the highest mortality rates.

<ul style="list-style-type: none"> Increasing screening/detection rates in medically underserved areas of the state.
Colorectal Cancer
<ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of colorectal cancer in racial/ethnic populations. Blacks have the highest incidence and mortality rates, followed by non-Hispanic Whites and Hispanics.
<ul style="list-style-type: none"> Increasing screening/detection rates in Public Health Region (PHR) 2, 4, 5, and 9, where the highest rates of cancer incidence and mortality are found. Decreasing incidence and mortality rates in nonmetropolitan counties. Incidence and mortality rates are higher in nonmetropolitan counties compared with metropolitan counties.
Liver Cancer
<ul style="list-style-type: none"> Screening for hepatitis C virus (HCV) infection in populations at high risk of infection.
<ul style="list-style-type: none"> Increasing screening rates in PHR 8, 9, 10, and 11. Incidence and mortality rates are highest in PHR 10 and 11.
Lung Cancer
<ul style="list-style-type: none"> Decreasing disparities in incidence and mortality rates of lung cancer in racial/ethnic populations. Blacks have higher mortality rates than Hispanics and non-Hispanic Whites. Increasing screening/early detection rates in PHR 2, 4, and 5, where the highest rates of cancer incidence and mortality are found.

2.6 Outcome Metrics

Applicants are required to clearly describe their assessment and evaluation methodology. The applicant is required to describe final outcome measures for the project. Output measures that are associated with the final outcome measures should be identified in the project plan and will serve as a measure of program effectiveness. Planned policy or system changes/improvements should be identified and the plan for qualitative analysis described. **Baseline data for each measure proposed are required.** In addition, applicants should describe how funds from the CPRIT grant will improve outcomes over baseline. If the applicant is not providing baseline data for a measure, the applicant must provide a well-justified explanation and describe clear plans and method(s) of measurement to collect the data necessary to establish a baseline.

Reporting Requirements

Funded projects are required to report quantitative output and outcome metrics (as appropriate for each project) through the submission of quarterly progress reports, annual reports, and a final report.

If clinical services are being paid for and provided by others, the applicant is required to report on

the number of clinical services and outcomes (eg, cancers detected) that are delivered to the people navigated by the program.

2.7 Funding Information

The total amount of funding that applicants may request is dependent on the project type. Use the table below to determine the maximum amount of funding and the maximum number of years that may be requested.

Project Type	Maximum Amount of Total Funding	Maximum Duration
New project	\$1 million	3 years
Initial Expansion Project	\$2 million	3 years
Maintenance Expansion Project	\$2.5 million	5 years

A **significant expansion** in the geographic area and/or clinical services provided for the initial expansion, or number of clinical services delivered for any subsequent expansion, as described in [section 2.3](#), is required. Grant funds may be used to pay for clinical services, navigation services, salary and benefits, project supplies, equipment, costs for outreach and education of populations, and travel of project personnel to project site(s). Applicants must ensure that there is access to treatment services for patients with precancers or cancers that are detected as a result of the program and must describe access to treatment services in their application.

Requests for funds to support construction or renovation or requests to support lobbying will not be approved under this mechanism. Cost sharing for equipment purchases is encouraged. Grantees may request funds for travel for 2 project staff to attend CPRIT’s conference.

The budget should be proportional to the number of individuals receiving programs and services, and a significant proportion of funds is expected to be used for program delivery as opposed to program development. In addition, CPRIT funding should not be used to replace existing funding, supplant funds that would normally be expended by the applicant’s organization, or make up for funding reductions from other sources.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

2.8 Eligibility

- The applicant must be a Texas-based entity, such as a community-based organization, health institution, government organization, public or private company, college or university, or academic health institution.
- The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The designated PD will be responsible for the overall performance of the funded project. The PD must have relevant education and management experience and must reside in Texas during the project performance time.
- The evaluation of the project must be headed by a professional who has demonstrated expertise in the field and who resides in Texas during the time that the project is conducted.
- The applicant may submit more than 1 application, but each application must be for distinctly different services without overlap in the services provided. Applicants who do not meet this criterion will have all applications administratively withdrawn without peer review.
- If an organization has a current CPRIT grant that is the same or similar to the prevention intervention being proposed, the applicant must explain how the projects are nonduplicative or complementary.
- If the applicant or a partner is an existing Department of State Health Services (DSHS) contractor, CPRIT funds may not be used as a match, and the application must explain how this grant complements or leverages existing state and federal funds.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.

- An applicant organization is eligible to receive a grant award only if the applicant certifies that the applicant organization, including the PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation created to benefit CPRIT.
- The applicant must report whether the applicant organization, the PD, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, (whether slated to receive salary or compensation under the grant award or not), are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. CPRIT grants are funded on a reimbursement-only basis. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 6](#). All statutory provisions and relevant administrative rules can be found [on the CPRIT website](#).

2.9 Resubmission Policy

- **One resubmission** is permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. All applications in response to this RFA will be considered NEW submissions and no resubmission summary form will be available. Responses to summary statement weaknesses should be included within the project plan.
- Reviewers of resubmissions are asked to assess whether the resubmission adequately addresses critiques from the previous review. **Applicants should note that addressing previous critiques is advisable; however, it does not guarantee the success of the resubmission.** All resubmitted applications must conform to the structure and guidelines outlined in this RFA.

2.10 Expansion Policy

- Expansion grants are intended to fund expansion of currently or previously funded projects that have demonstrated exemplary success, as evidenced by progress reports and project evaluations, and desire to further enhance their impact on priority populations. Detailed descriptions of **results, barriers, outcomes, and impact of the currently or previously funded project are required** (see outline of Most Recently Funded Project Summary, [section 4.4.12](#)).
- Proposed expansion projects should NOT be new projects but should closely follow the intent and core elements of the currently or previously funded project. Established infrastructure/processes and fully described prior project results are required. Expansion of current projects into geographic areas not well served by the CPRIT Prevention portfolio (see maps at <http://www.cprit.state.tx.us/our-programs/prevention/portfolio-maps>) will receive priority consideration.
- CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area). It is expected that baselines will have already been established and that continued improvement over baseline is demonstrated in the current application. However, in the case of a proposed expansion where no baseline data exist for the priority population, the applicant must present clear plans and describe method(s) of measurement used to collect the data necessary to establish a baseline. Applicants must demonstrate how these outcomes will ultimately impact cancer incidence, mortality, morbidity, or quality of life.
- CPRIT also expects that applications for continuation **will not** require startup time, that applicants can demonstrate that they have overcome barriers encountered, and that applicants have identified **lasting systems changes** that improve results, efficiency, and sustainability. Leveraging of resources and plans for dissemination are expected and should be well described.

Requirements for Initial and Maintenance Expansion Projects

- **Initial Expansion:** For the first expansion application, eligible applicants should propose to expand their programs to include additional types of prevention clinical services or to expand current clinical services into additional counties. In either case, the expansion must

include the delivery of services to nonmetropolitan (rural) and/or medically underserved counties in the state. These may be identified via web-based tools from the [Texas Department of State Health Services](#) and [US Department of Health and Human Services](#).

- **Maintenance Expansion:** For a subsequent expansion, additional clinical services and/or expansion to additional counties is optional; however, the counties and the practices offered in the first expansion should not be decreased. The number of services delivered during the maintenance expansion must be increased substantially such that the cost per clinical service is similar to the initial expansion if no further geographic or preventive service expansion is proposed.

3. KEY DATES

RFA release	May 6, 2022
Online application opens	June 2, 2022, 7 AM central time
Application due	August 31, 2022, 4 PM central time
Application review	September 2022-January 2023
Award notification	February 2023
Anticipated start date	March 1, 2023

Applicants will be notified of peer review panel assignment prior to the peer review meeting dates.

4. APPLICATION SUBMISSION GUIDELINES

4.1 *Instructions for Applicants* document

It is **imperative** that applicants read the accompanying instructions document for this RFA that will be available June 2, 2022 (<https://CPRITGrants.org>). Requirements may have changed from previous versions.

4.2 Online Application Receipt System

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The PD must create a user account in the system to start and submit an application. The Co-PD, if applicable, must also create a user account to participate in the

application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (an individual who will help manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on June 2, 2022, and must be submitted by 4 PM central time on August 31, 2022. Detailed instructions for submitting an application are in the *Instructions for Applicants* document, posted on CARS.

Submission of an application is considered an acceptance of the terms and conditions of the RFA.

4.3 Submission Deadline Extension

The submission deadline may be extended for grant applications upon a showing of good cause. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records.

4.4 Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Refer to the *Instructions for Applicants* document for details.

Submissions that are missing 1 or more components or do not meet the eligibility requirements may be administratively withdrawn without review.

4.4.1 Abstract and Significance (5,000 characters)

Clearly explain the problem(s) to be addressed, the approach(es) to the solution, and how the application is responsive to this RFA. In the event that the project is funded, the abstract will be made public; therefore, no proprietary information should be included in this statement. Initial compliance decisions are based in part upon review of this statement.

The abstract format is as follows (use headings as outlined below):

- **Need:** Include a description of need in the specific service area. Include rates of incidence, mortality, and screening in the service area compared to overall Texas rates. Describe barriers, plans to overcome these barriers, and the priority population to be served.

- **Overall Project Strategy:** Describe the project and how it will address the identified need. Clearly explain what the project is and what it will specifically do, including the services to be provided and the process/system for delivery of services and outreach to the priority population.
- **Specific Goals:** State specifically the overall goals of the proposed project; include the estimated overall numbers of clinical services delivered and number of people (public and/or professionals) served.
- **Significance and Impact:** Explain how the proposed project, if successful, will have a major impact on cancer prevention and control for the population proposed to be served and for the State of Texas.

4.4.2 Goals and Objectives (700 characters each)

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within both the stated Objective **and** the Measure sections (eg, Measure: 1, 500 individuals, ages 45 – 75, will be screened for colorectal cancer during the grant period). Applications may be returned for revision if the proposed metric is not included within the Measure section. Refer to the Instructions for Applicants document for details.

One goal with three objectives addressing navigation into diagnosis and into treatment is required for all proposals and will be prepopulated into the application. This goal is not modifiable by the applicant. Applicants may add a maximum of 3 additional goals with 3 outcome objectives each. Projects will be evaluated annually on progress toward all outcome goals and objectives. See [Appendix B](#) for instructions on writing outcome goals and objectives.

A baseline and method(s) of measurement are required for each objective. Provide both raw numbers and percent changes for the baseline and target. If a baseline has not been defined, applicants are required to explain plans to establish baseline and describe method(s) of measurement.

4.4.3 Project Timeline (2 pages)

Provide a project timeline for project activities that includes deliverables and dates. Use Years 1, 2, 3, and Months 1, 2, 3, etc, as applicable (eg, Year 1, Months 3-5) instead of specific months or years. Month 1 is the first full month of the grant award.

4.4.4 Project Plan (12 pages; fewer pages permissible)

The required project plan format follows. Applicants must use the headings outlined below.

Background: Briefly present the rationale behind the proposed services, emphasizing the critical barriers to current service delivery that will be addressed. Identify the evidence-based service to be implemented for the priority population. Describe the race, ethnicity, age, and other defining characteristics of the population to be served.

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data for the priority population and target service area are required where applicable.

Reviewers will be aware of national and state statistics, and these should be used only to compare rates for the proposed service area. Describe the geographic region of the state that the project will serve; maps are encouraged.

Goals and Objectives: Process objectives should be included in the project plan. Outcome goals and objectives will be entered in separate fields in CARS. However, if desired, outcome goals and objectives may be fully repeated or briefly summarized here. See [Appendix B](#) for instructions on writing goals and objectives.

Components of the Project: Clearly describe the need, delivery method, and evidence base (provide references) for the services, as well as anticipated results. Be explicit about the base of evidence and any necessary adaptations for the proposed project. If an organization has a current CPRIT grant that is the same or similar to the prevention intervention being proposed, the applicant must explain how the projects are nonduplicative or complementary.

It is important to distinguish between Texas counties where the project proposes to deliver services and counties of residence of population served (see [Appendix A](#) for definitions and *Instructions for Applicants*). Only counties with service delivery should be listed in the Geographic Area to be

Served section of the application. Projecting counties of residence of population served is not required but may be described in the project plan.

Clearly demonstrate the ability to provide the proposed service and describe how results will be improved over baseline and the ability to reach the priority population. Describe the method(s) that will be used to recall for appropriate rescreening those individuals who have been screened through this project.

If clinical services are being paid for and provided by others, the applicant must explain and report on the number of clinical services and outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program. Applicants must also clearly describe **access to treatment services** should precancer or cancer be detected. Include how and by whom any positive screening results will be delivered to a program participant.

Evaluation Strategy: A strong commitment to evaluation of the project is required. Describe the plan for outcome and output measurements, including qualitative analysis of policy and system changes. Describe data collection and management methods, data analyses, and anticipated results. Evaluation and reporting of results should be headed by a professional who has demonstrated expertise in the field. If needed, applicants may want to consider seeking expertise at Texas-based academic cancer centers, schools/programs of public health, or the like. Applicants should budget accordingly for the evaluation activity and should involve that professional during grant application preparation to ensure, among other things, that the evaluation plan is linked to the proposed goals and objectives.

Organizational Qualifications and Capabilities: Describe the organization and its track record and success in providing health programs and services. Describe the role and qualifications of the key collaborators/partners in the project. Include information on the organization's financial stability and viability. The applicant should demonstrate how the organizational environment will contribute to a successful project. If equipment or physical resources are required to carry out the project, the applicant should describe the availability of these resources and the organizational capacity to use equipment. To ensure access to preventive services and reporting of services outcomes, applicants should demonstrate that they have provider partnerships and agreements (via memoranda of understanding) or commitments (via letters of commitment) in place.

CPRIT acknowledges that full maintenance and sustainability of projects when CPRIT funding

ends may not be feasible, especially in cases involving the delivery of clinical services. However, it is important to consider sustainability early in the life cycle of a project, particularly regarding organizational characteristics and processes that are modifiable.

Washington University in St Louis has developed a useful tool ([Program Sustainability Assessment Tool](#)) to assess program capacity for sustainability. The tool assesses several factors that contribute to program sustainability. These factors include environmental support, funding stability, partnerships, organizational capacity, program evaluation, program adaptation, communication, and strategic planning. Applicants are not required to use this tool; however, it provides practical guidance on factors that should be considered and should be included in the application to describe a program's organizational capacity for sustainability.

It is expected that steps toward building capacity for the program will be taken and plans for such be briefly described in the application. The applicant should describe the factors that will contribute to the organization's capacity to facilitate sustainability.

Dissemination and Replication: Dissemination of project results and outcomes, including barriers encountered and successes achieved, is critical to building the evidence base for cancer prevention and control efforts in the state. Dissemination efforts should consider the message, source, audience, and channel (Brownson, R.C., et al. [J Pub Health Manag Pract. 24\(2\):102-111](#), March/April 2018). Dissemination methods may include, but are not limited to, presentations at workshops and seminars, one-on-one meetings, publications, news media, social media, etc.

While passive dissemination methods are common (eg, publications, presentations at professional meetings), plans should include some active dissemination methods (eg, meetings with stakeholders, blogs, social media). Applicants should describe their dissemination plans. The plans should include the kinds of audiences to be targeted and methods for reaching the targeted audiences.

Replication by others is an additional way to disseminate the project. For applicable components, describe how the project or components of the project lend themselves to application by other communities and/or organizations in the state or expansion in the same communities. Describe what components of this project can be adapted to a larger or lower resource setting. Note that some programs may have unique resources and may not lend themselves to replication by others.

4.4.5 People Reached (Indirect Contact)

Provide the estimated overall number of people (members of the public and professionals) to be reached by the funded project. The applicant is required to itemize separately the types of indirect noninteractive education and outreach activities, with estimates, that led to the calculation of the overall estimates provided. Refer to [Appendix A](#) for definitions.

4.4.6 Number of Services Delivered (Direct Contact)

Provide the estimated overall number of services directly delivered to members of the public and to professionals by the funded project. Each individual service should be counted, regardless of the number of services one person receives. The applicant is required to itemize separately the education, navigation, and clinical activities/services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.7 Number of Clinical Services Delivered

Provide the estimated overall number of clinical services directly delivered to members of the public by the funded project. Each individual clinical service should be counted, regardless of the number of services one person receives. Separately itemize the clinical services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.8 Number of Unique People Served (Direct Contact)

Provide the estimated overall number of unique members of the public and professionals served by the funded project. One person may receive multiple services but should only be counted once here. Refer to [Appendix A](#) for definitions.

4.4.9 References

Provide a concise and relevant list of references cited for the application. The successful applicant will provide referenced evidence and literature support for the proposed services.

4.4.10 Resubmission Summary

All applications in response to this RFA will be considered NEW submissions and no resubmission summary form will be available. Responses to summary statement weaknesses should be included within the project plan.

The summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission; the applicant is not responsible for providing this document.

4.4.11 Most Recently Funded Relevant Project Summary (3 pages)

Upload a summary that outlines the progress made with the most recently funded relevant CPRIT award. Applicants must describe results and outcomes of the most recently funded award and demonstrate why further funding is warranted.

Please note that a different set of reviewers from those assigned to the previously funded application may evaluate this application. Applicants should make it easy for reviewers to compare the most recently funded project with the proposed project.

In the description, include the following:

- Describe the evidence-based intervention, its purpose, and how it was implemented in the priority population. Describe any adaptations made for the population served.
- List approved goals and objectives of the most recently funded grant.
- For each objective, provide milestones/target dates and target metrics as compared to actual completion dates and metrics.
- Include a discussion of objectives not fully met. Explain any barriers encountered and strategies used to overcome these.
- For the most recently funded project, describe major activities; significant results, including major findings, developments or conclusions (both positive and negative); and key outcomes.
- Describe steps taken toward sustainability for components of the project. Fully describe systems or policy improvements and enhancements.
- Describe how project results were disseminated or plans for future dissemination of results.

4.4.12 CPRIT Grants Summary

Use the template provided on CARS (<https://CPRITGrants.org>). Provide a listing of **all** projects funded by the CPRIT Prevention program for the PD and the Co-PD, regardless of their connection to this application.

4.4.13 Budget and Justification

Provide a brief outline and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, travel, equipment, supplies, contractual expenses, services delivery, and other expenses. CPRIT funds will be distributed on a reimbursement basis.

Applications requesting more than the maximum allowed cost (total costs) as specified in [Section 2.7](#) will be administratively withdrawn.

Clearly describe any organizational cost sharing or pro bono contributions related to this project, as well as any attempts made or successes to secure other state/federal funds.

- **Average Cost per Person:** The average cost per person will be automatically calculated from the total cost of the project divided by the total number of unique people served (refer to [Appendix A](#)).
- **Average Cost per Service:** The average cost per service will be automatically calculated from the total cost of the project divided by the total number of services delivered (refer to [Appendix A](#)). A significant proportion of funds is expected to be used for program delivery as opposed to program development and organizational infrastructure.
- **Average Cost per Clinical Service:** The average cost per clinical service will be automatically calculated from the total cost of the project divided by the total number of clinical services delivered (refer to [Appendix A](#)).
- **Personnel:** The individual salary cap for CPRIT awards is \$200,000 per year. Describe the source of funding for all project personnel where CPRIT funds are not requested.
- **Travel:** PDs and related project staff are expected to attend CPRIT's conference. CPRIT funds may be used to send up to 2 people to the conference.
- **Equipment:** Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application. Justification must be provided for why funding for this equipment cannot be found elsewhere; CPRIT funding should not supplant existing funds. Cost sharing of equipment purchases is strongly encouraged.

- **Services Costs:**
 - CPRIT reimburses for services using Medicare reimbursement rates. Describe the source of funding for all services where CPRIT funds are not requested. If clinical services are being paid for and provided by others, the applicant is required to explain and report on the number of clinical services and outcomes (eg, screenings/diagnostics, vaccinations, cancer precursors, cancers detected) that are delivered to the people navigated by the program.
 - CPRIT does not allow recovery of costs related to tests that have not been recommended by the USPSTF. In several cases (eg, breast self-exams, clinical breast exams, PSA tests), the Task Force has concluded there is not enough evidence available to draw reliable conclusions about the additional benefits and harms of these tests. (See <https://www.uspreventiveservicestaskforce.org/>)
- **Other Expenses:**
 - **Incentives:** Use of incentives or positive rewards to change or elicit behavior is allowed; however, incentives may only be used based on strong evidence of their effectiveness for the purpose and in the priority population identified by the applicant. CPRIT will not fund cash incentives. The maximum dollar value allowed for an incentive per person, per activity or session, is \$25.
 - **Costs Not Related to Cancer Prevention and Control:** CPRIT does not allow recovery of any costs for services not related to cancer (eg, health physicals, HIV testing) other than those required prior to the clinical services proposed in the project.
- **Indirect/Shared Costs:** Texas law limits the amount of grant funds that may be spent on indirect/shared expenses to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in [CPRIT's Administrative Rules](#).

4.4.14 Current and Pending Support and Sources of Funding

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the funding source and duration of **all** current and pending support for the proposed project, including a capitalization table that reflects private investors, if any.

4.4.15 Biographical Sketches

The designated PD will be responsible for the overall performance of the funded project and must have relevant education and management experience. The PD/Co-PD(s) must provide a biographical sketch that describes his or her education and training, professional experience, awards and honors, and publications and/or involvement in programs relevant to cancer prevention and/or service delivery.

- Use the Co-PD Biographical Sketch section ONLY if a Co-PD has been identified.
- The evaluation professional must provide a biographical sketch in the Evaluation Professional Biographical Sketch section.
- Up to 3 additional biographical sketches for key personnel may be provided in the Key Personnel Biographical sketch section.

Each biographical sketch must not exceed 5 pages and should use either the “Prevention Programs: Biographical Sketch” template provided on the CARS (<https://CPRITGrants.org>) or the NIH Biographical Sketch format. Only biographical sketches will be accepted; do not submit resumes and/or CVs. If a position is not yet filled, please upload a job description.

4.4.16 Collaborating Organizations

List all key participating organizations that will partner with the applicant organization to provide 1 or more components essential to the success of the program (eg, evaluation, clinical services, recruitment to screening). Please be sure to also include anyone listed as key personnel and/or listed under the Current & Pending Support section.

4.4.17 Letters of Commitment (10 pages)

Applicants should provide letters of commitment and/or memoranda of understanding from community organizations, key faculty, or any other component essential to the success of the program. Letters should be specific to the contribution of each organization.

5. APPLICATION REVIEW

5.1 Review Process Overview

All eligible applications will be reviewed using a 2-stage peer review process: (1) evaluation of applications by peer review panels and (2) prioritization of grant applications by the Prevention

Review Council. In the first stage, applications will be evaluated by an independent review panel using the criteria listed below. In the second stage, applications judged to be meritorious by review panels will be evaluated by the Prevention Review Council and recommended for funding based on comparisons with applications from all of the review panels and programmatic priorities.

Programmatic considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service. The scores are only 1 factor considered during programmatic review. At the programmatic level of review, priority will be given to proposed projects that target geographic regions of the state or population subgroups that are not well represented in the current CPRIT Prevention project portfolio.

Applications approved by Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

Each stage of application review is conducted confidentially, and all CPRIT Peer Review Panel members, Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Peer Review Panel members and Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer Review Panel members are listed by panel on CPRIT's website. **By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).**

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Review Panel member, or a Review Council member.

Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

5.2 Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, identified below. Review panels consisting of experts in the field and advocates will evaluate and score each primary criterion and subsequently assign an overall score that reflects an overall assessment of the application. The overall evaluation score will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application and responsiveness to the RFA priorities.

5.2.1 Primary Evaluation Criteria

Impact

- Do the proposed services address an important problem or need in cancer prevention and control? Do the proposed project strategies support desired outcomes in cancer incidence, morbidity, and/or mortality? Do the proposed project strategies reach a priority population (eg, low income, minority, rural) at high risk of cancer?
- Will the project reach and serve/impact an appropriate number of people based on the budget allocated to providing services and the cost of providing services?
- If applicable, have partners demonstrated that the collaborative effort will provide a greater impact on cancer prevention and control than the applicant organization's effort separately?
- Does the program address adaptation, if applicable, of the evidence-based intervention to the priority population? Is the base of evidence clearly explained and referenced?

Project Strategy and Feasibility

- Does the proposed project provide services specified in the RFA?
- Are the overall program approach, strategy, and design clearly described and supported by established theory and practice? Are the proposed objectives and activities feasible within the duration of the award? Has the applicant convincingly demonstrated the short- and long-term impacts of the project?
- Has the applicant proposed policy changes and/or system improvements?
- Are possible barriers addressed and approaches for overcoming them proposed?
- Are the priority population and culturally appropriate methods to reach the priority population clearly described?
- If applicable, does the application demonstrate the availability of resources and expertise to provide case management, including follow-up for abnormal results and access to treatment?
- Does the program leverage partners and resources to maximize the reach of the services proposed? Does the program leverage and complement other state, federal, and nonprofit grants?

Outcomes Evaluation

- Are specific goals and measurable objectives for each year of the project provided?
- Are the proposed outcome measures appropriate for the services provided, and are the expected changes clinically significant?
- If clinical services are being paid for and provided by others, does the applicant explain the methods used to collect data and report on these clinical services and outcomes?
- Does the application provide a clear and appropriate plan for data collection and management and data analyses?
- Are clear baseline data provided for the priority population, or are clear plans included to collect baseline data?
- If an evidence-based intervention is being adapted in a population where it has not been implemented or tested, are plans for evaluation of barriers, effectiveness, and fidelity to the model described?
- Is the qualitative analysis of planned policy or system changes described?

Organizational Qualifications and Capabilities

- Do the organization and its collaborators/partners demonstrate the ability to provide the proposed preventive services?
- Does the described role of each collaborating organization make it clear that each organization adds value to the project and is committed to working together to implement the project?
- Have the appropriate personnel been recruited to design, implement, evaluate, and complete the project?
- Is the organization structurally and financially stable and viable?
- Does the applicant describe the program's organizational capacity for sustainability?
- Does the applicant describe steps that will be taken toward building internal capacity and partnerships?
- Does the applicant describe a plan for systems changes that are sustainable over time (eg, improve results, provider practice, efficiency, cost-effectiveness)?

5.2.2 Secondary Evaluation Criteria

Budget

- Is the budget appropriate and reasonable for the scope and services of the proposed work?
- Is the cost per person served appropriate and reasonable?
- Is the proportion of the funds allocated for direct services reasonable?
- Is the project a good investment of Texas public funds?

Dissemination and Replication

- Are plans for dissemination of the project's results and outcomes, including target audiences and methods, clearly described?
- Are active dissemination strategies included and described in the plan?
- Does the applicant describe whether and/or how the project lends itself to replication of all or some components of the project by others in the state?

6. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [Chapter 701, Section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in [CPRIT's Administrative Rules](#). Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires the PD of the award to submit quarterly, annual, and final progress reports. These reports summarize the progress made toward project goals and address plans for the upcoming year and performance during the previous year(s). In addition, quarterly fiscal reporting and reporting on selected metrics will be required per the instructions to award recipients. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract.

7. CONTACT INFORMATION

7.1 Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding the scope and focus of applications. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document (posted on June 2, 2022), which provides a step-by-step guide to using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

7.2 Program Questions

Questions regarding the CPRIT Prevention program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Prevention Program Office.

Tel: 512-305-8417

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

8. RESOURCES

- The Texas Cancer Registry. <https://www.dshs.texas.gov/tcr> or contact the Texas Cancer Registry at the Department of State Health Services.
- The Community Guide. <https://www.thecommunityguide.org/>
- Cancer Control P.L.A.N.E.T. <https://cancercontrol.cancer.gov>
- Guide to Clinical Preventive Services: Recommendations of the U.S. Preventive Services Task Force. <http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/>
- Brownson, R.C., Colditz G.A., and Proctor, E.K. (Editors). *Dissemination and Implementation Research in Health: Translating Science to Practice*. Oxford University Press, March 2012
- Program Sustainability Assessment Tool, copyright 2012, Washington University, St Louis, MO, <https://www.sustaintool.org/about-us/>
- Getting the Word Out: New Approaches for Disseminating Public Health Science Ross C. Brownson, PhD; Amy A. Eyster, PhD; Jenine K. Harris, PhD; Justin B. Moore, PhD, MS; Rachel G. Tabak, PhD, RD, **Journal of Public Health Management & Practice**. 24(2):102-111, March/April 2018. (https://journals.lww.com/jphmp/Fulltext/2018/03000/Getting_the_Word_Out_New_Approaches_for.4.aspx)
- Centers for Disease Control and Prevention: The Program Sustainability Assessment Tool: A New Instrument for Public Health Programs. http://www.cdc.gov/pcd/issues/2014/13_0184.htm
- Centers for Disease Control and Prevention: Using the Program Sustainability Tool to Assess and Plan for Sustainability. http://www.cdc.gov/pcd/issues/2014/13_0185.htm
- Cancer Prevention and Control Research Network: Putting Public Health Evidence in Action Training Workshop. <http://cpcrn.org/pub/evidence-in-action/>
- Centers for Disease Control and Prevention. Distinguishing Public Health Research and Public Health Nonresearch. <https://www.cdc.gov/os/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>

9. REFERENCES

1. <http://www.cdc.gov/hpv/parents/questions-answers.html>
2. Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services. <https://www.cancer-rates.info/tx/>

APPENDIX A: KEY TERMS

- **Activities:** A listing of the “who, what, when, where, and how” for each objective that will be accomplished
- **Capacity Building:** Any activity (eg, training, identification of alternative resources, building internal assets) that builds durable resources and enables the grantee’s setting or community to continue the delivery of some or all components of the evidence-based intervention
- **Clinical Services:** Number of clinical services such as screenings, diagnostic tests, vaccinations, counseling sessions, or other evidence-based preventive services delivered by a health care practitioner in an office, clinic, or health care system. Other examples include genetic testing or assessments, physical rehabilitation, tobacco cessation counseling or nicotine replacement therapy, case management, clinical assessments, and family history screening.
- **Counties of Residence of Population Served:** Counties where the project does not plan to have a physical presence but people who live in these counties have received services. This includes counties of residence of people or places of business of professionals who participate in or receive education, navigation or clinical services. Examples include people traveling to receive services as a result of marketing and programs accessible via the website or social media. These counties may be described in the project plan and must be reported in the quarterly progress report.
- **Counties with Service Delivery:** Counties where an activity or service will occur and the project has a physical presence for the services provided. Examples include onsite outreach and educational activities and delivery of clinical services through clinics, mobile vans, or telemedicine consults. These counties must be entered in the Geographic Area to be Served section of the application.
- **Education Services:** Number of evidence-based, culturally appropriate cancer prevention and control education and outreach services delivered to the public and to health care professionals. Examples include education or training sessions (group or individual), focus groups, and knowledge assessments. One individual may receive multiple education services.

- **Evidence-Based Program:** A program that is validated by some form of documented research or applied evidence. CPRIT’s website provides links to resources for evidence-based strategies, programs, and clinical recommendations for cancer prevention and control. To access this information, visit <https://www.cprit.state.tx.us/our-programs/prevention>.
- **Goals:** Broad statements of general purpose to guide planning. Outcome goals should be few in number and focus on aspects of highest importance to the project ([Appendix B](#)).
- **Integration:** The extent the evidence-based intervention is integrated within the culture of the grantee’s setting or community through policies and practice.
- **Navigation Services:** Number of activities/services that offer assistance to help overcome health care system barriers in a timely and informative manner and facilitate cancer screening and diagnosis to improve health care access and outcomes. Examples include patient reminders, transportation assistance, and appointment scheduling assistance. One individual may receive multiple navigation services.
- **Number of Clinical Services:** Number of [clinical services](#) delivered directly to members of the public by the funded project. One individual may receive multiple clinical services.
- **Number of Services (Direct Contact):** Number of services delivered directly to members of the public and/or professionals—direct, interactive public or professional education, outreach, training, navigation service, or clinical service, such as live educational and/or training sessions, vaccine administration, screening, diagnostics, case management/navigation services, and physician consults. One individual may receive multiple services.
- **Objectives:** Specific, **measurable**, actionable, realistic, and timely projections for outcomes; example: “Increase screening service provision in X population from Y% to Z% by 20xx.” Baseline data for the priority population must be included as part of each objective ([Appendix B](#)). The proposed metric should be included in **both** the objective and the measure.
- **People Reached (Indirect Contact):** Number of members of the public and/or professionals reached via indirect noninteractive public or professional education and outreach activities, such as mass media efforts, brochure distribution, public service announcements, newsletters, and journals. (This category includes individuals who would

be reached through activities that are directly funded by CPRIT as well as individuals who would be reached through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project).

- **Unique People Served (Direct Contact):** Number of unique members of the public and/or professionals served via direct, interactive public or professional education, outreach, training, navigation service, or clinical service. This category includes individuals who would be served through activities that are directly funded by CPRIT as well as individuals who would be served through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project.

APPENDIX B: WRITING GOALS AND OBJECTIVES

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within **both** the stated Objective and the Measure sections (eg, Measure: 2,000 individuals, ages 9-12, will initiate HPV vaccination during the grant period).

One goal with three objectives addressing navigation into diagnosis and into treatment is required for all proposals and will be prepopulated into the application. This goal is not modifiable by the applicant. Applicants may add a maximum of 3 additional goals with 3 outcome objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives.

The following has been adapted with permission from Appalachia Community Cancer Network, NIH Grant U54 CA 153604:

Develop well-defined goals and objectives.

Goals provide a roadmap or plan for where a group wants to go. Goals can be long term (over several years) or short term (over several months). Goals should be based on needs of the community and evidence-based data.

Goals should be:

- Believable – situations or conditions that the group believes can be achieved
- Attainable – possible within a designated time
- Tangible – capable of being understood or realized
- On a timetable – with a completion date
- Win-Win – beneficial to individual members and the coalition

Objectives are measurable steps toward achieving the goal. They are clear statements of specific activities required to achieve the goal. The best objectives have several characteristics in common—S.M.A.R.T. + C:

- Specific – they tell how much (number or percent), who (participants), what (action or activity), and by when (date)
 - Example: 115 uninsured individuals age 50 and older will complete colorectal cancer screening by March 31, 2018.
- Measurable – specific measures that can be collected, detected, or obtained to determine successful attainment of the objective

- Example: How many screened at an event? How many completed pre/post assessment?
- Achievable – not only are the objectives themselves possible, it is likely that your organization will be able to accomplish them
- Relevant to the mission – your organization has a clear understanding of how these objectives fit in with the overall vision and mission of the group
- Timed – developing a timeline is important for when your task will be achieved
- Challenging – objectives should stretch the group to aim on significant improvements that are important to members of the community

Evaluate and refine your objectives

Review your developed objectives and determine the type and level of each using the following information:

There are 2 types of objectives:

- Outcome objectives – measure the “what” of a program; should be in the Goals and Objectives form (see [section 4.4.2](#))
- Process objectives – measure the “how” of a program; should be in the project plan only (see [section 4.4.4](#))

There are 3 levels of objectives:

- Community-level – objectives measure the planned community change
- Program impact – objectives measure the impact the program will have on a specific group of people
- Individual – objectives measures participant changes resulting from a specific program, using these factors:
 - Knowledge – understanding (know screening guidelines; recall the number to call for screening)
 - Attitudes – feeling about something (will consider secondhand smoke dangerous; believe eating 5 or more fruits and vegetable is important)
 - Skills – the ability to do something (complete fecal occult blood test)
 - Intentions – regarding plan for future behavior (will agree to talk to the doctor, will plan to schedule a Pap test)

- Behaviors (past or current) – to act in a particular way (will exercise 30+ minutes a day, will have a mammogram)

Well-defined outcome goals and objectives can be used to track, measure, and report progress toward achievement.

Summary Table

	Outcome – Use in Goals and Objectives	Process – Use in Project Plan only
Community-level	<p>WHAT will change in a community</p> <p><i>Example: As a result of CPRIT funding, fecal immunochemical tests (FIT) will be available to 1,500 uninsured individuals age 50 and over through 10 participating local clinics and doctors.</i></p>	<p>HOW the community change will come about</p> <p><i>Example: Contracts will be signed with participating local providers to enable uninsured individuals over age 50 have access to free colorectal cancer screening in their communities.</i></p>
Program impact	<p>WHAT will change in the target group as a result of a particular program</p> <p><i>Example: As a result of this project, 200 uninsured women between 40 and 49 will receive free breast and cervical cancer screening.</i></p>	<p>HOW the program will be implemented to affect change in a group/population</p> <p><i>Example: 2,000 female clients, between 40 and 49, will receive a letter inviting them to participate in breast and cervical cancer screening.</i></p>
Individual	<p>WHAT an individual will learn as a result of a particular program, or WHAT change an individual will make as a result of a particular program</p> <p><i>Example: As a result of one-to-one education of 500 individuals, at least 20% of participants will participate in a smoking cessation program to quit smoking.</i></p>	<p>HOW the program will be implemented to affect change in an individual’s knowledge or actions</p> <p><i>Example: As a result of one-to-one counseling, all participants will identify at least 1 smoking cessation service and 1 smoking cessation aid.</i></p>

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Prevention Panel-1 (23.1 PRV-PP1)

Observation Report

Report No. 2022-12-05 23.1_PRV-PP1
Program Name: Prevention
Panel Name: 23.1 Prevention Panel-1 (23.1 _PRV-PP1)
Panel Date: December 5, 2022
Report Date: December 13, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Prevention Panel-1 (23.1_PRV-PP1) meeting. The meeting was chaired by Ross Brownson and conducted via videoconference on December 5, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and six (6) applications were not discussed
- Panelists: One (1) panel chair, nine (9) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was on a application not discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Prevention Review Council – Programmatic review

(23.1 PRC-PR)

Observation Report

Report No. 2023-01-13 23.1_PRC-PR
Program Name: Prevention
Panel Name: 23.1 Prevention Review Council – Programmatic review (23.1 _PRC-PR)
Panel Date: January 13, 2023
Report Date: January 19, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Prevention Review Council – Programmatic review (23.1_PRC-PR) meeting. The meeting was chaired by Stephen Wyatt and conducted via videoconference on January 13, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

De-Identified Overall Evaluation Scores

Cancer Screening and Early Detection

Prevention cycle 23.1

Application ID	Final Overall Evaluation Score
PP230013*	2.7
PP230046*	2.7
PP230038*	3.1
PP230041*	3.1
b ^a	3.7
ba	4.5
bc	7.8

^a The Prevention Review Council took no action on this application.

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Dr. Mahendra Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com
Via email to kirtikpatel@hotmail.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Dr. Patel,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the FY2023 Cycle 1 Cancer Screening and Early Detection (CSD), Dissemination of CPRIT-Funded Cancer Control Interventions (DI), and Primary Prevention of Cancer (PPC) grant awards.

The PRC met on January 13, 2023, to consider the applications recommended by the peer review panel following their December 5, 2023 meeting. The PRC recommends 8 projects totaling \$13,577,257.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment

App ID	Mechanis	Application Title	PD	Organization	Requested Budget	Score	Rank Order
PP230018	PPC	Implementation and Evaluation of an Evidence-Based Multilevel Lifestyle Intervention for Underserved/Rural Populations in South Texas: Tu Salud ¡Si	Reininger, Belinda	The University of Texas Health Science Center at Houston	\$999,254	2.5	1
PP230013	CSD	Community Expansion and Re-engagement for Breast Cancer Screening and Patient Navigation	Argenbright, Keith E	The University of Texas Southwestern Medical Center	\$2,500,000	2.7	2
PP230046	CSD	Screen, Treat, or Prevent (STOP) Hepatocellular Cancer-Hepatitis C (HCC-HCV): Expansion to All Adults	Jain, Mamta K	The University of Texas Southwestern Medical Center	\$2,499,616	2.7	3
PP230033	DI	All for Them Texas: A multifaceted dissemination and implementation approach to increase HPV vaccination	Cucarro, Paula	The University of Texas Health Science Center at Houston	\$449,959	3.0	4
PP230002	DI	Taking Texas Tobacco Free: Dissemination to and Implementation within Lung Cancer Screening Programs	Reitzel, Lorraine	University of Houston	\$448,726	3.0	5
PP230038	CSD	Salud en Mis Manos (SEMM): An Evidence-Based Breast & Cervical Cancer Early Detection and Prevention Program for Underserved Latinas.	Savas, Lara S	The University of Texas Health Science Center at Houston	\$2,499,492	3.1	6
PP230041	CSD	PP190052 - Integrated lung cancer screening and tobacco cessation in an urban safety-net system	Gerber, David E	The University of Texas Southwestern Medical Center	\$1,922,312	3.1	7

PP230043	PPC	School-based Human Papillomavirus Vaccination Program in the Rio Grande Valley: Continuation and Expansion in Hidalgo, Cameron, and Willacy Counties	Rodriguez, Ana M	The University of Texas Medical Branch at Galveston	\$2,257,898	3.2	8
----------	-----	--	------------------	---	-------------	-----	---

CSD Cancer Screening and Early Detection
DI Dissemination of CPRIT-Funded Cancer Control Interventions
PPC Primary Prevention of Cancer



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Prevention
FY 2023—Cycle 1
*Dissemination of CPRIT-Funded Cancer
Control Interventions***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA P-23.1-DI

Dissemination of CPRIT-Funded Cancer
Control Interventions

**Please also refer to the Instructions for Applicants document,
which will be posted on June 2, 2022**

Application Receipt Opening Date: June 2, 2022
Application Receipt Closing Date: August 31, 2022

FY 2023

Fiscal Year Award Period
September 1, 2022-August 31, 2023

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. PREVENTION PROGRAM PRIORITIES.....	4
2. FUNDING OPPORTUNITY DESCRIPTION	5
2.1. SUMMARY.....	5
2.2. PROJECT OBJECTIVES.....	6
2.3. AWARD DESCRIPTION	6
2.4. PRIORITIES	9
2.5. SPECIFIC AREAS OF EMPHASIS.....	10
2.6. OUTCOME METRICS.....	11
2.7. ELIGIBILITY	11
2.8. RESUBMISSION POLICY	13
2.9. FUNDING INFORMATION.....	13
3. KEY DATES	14
4. APPLICATION SUBMISSION GUIDELINES	14
4.1. <i>INSTRUCTIONS FOR APPLICANTS</i> DOCUMENT	14
4.2. ONLINE APPLICATION RECEIPT SYSTEM	14
4.3. SUBMISSION DEADLINE EXTENSION	15
4.4. APPLICATION COMPONENTS	15
4.4.1. <i>Abstract and Significance (5,000 characters)</i>	15
4.4.2. <i>Goals and Objectives (700 characters each)</i>	15
4.4.3. <i>Project Timeline (2 pages)</i>	16
4.4.4. <i>Project Plan (12 pages; fewer pages permissible)</i>	16
4.4.5. <i>References</i>	17
4.4.6. <i>Resubmission Summary</i>	17
4.4.7. <i>CPRIT Grants Summary</i>	18
4.4.8. <i>Budget and Justification</i>	18
4.4.9. <i>Current and Pending Support and Sources of Funding</i>	18
4.4.10. <i>Biographical Sketches</i>	18
4.4.11. <i>Collaborating Organizations</i>	19
4.4.12. <i>Letters of Commitment (10 pages)</i>	19
5. APPLICATION REVIEW	19
5.1. REVIEW PROCESS OVERVIEW	19
5.2. REVIEW CRITERIA.....	20
5.2.1. <i>Primary Evaluation Criteria</i>	21
5.2.2. <i>Secondary Evaluation Criteria</i>	22
6. AWARD ADMINISTRATION	22
7. CONTACT INFORMATION	23
7.1. HELPDESK.....	23
7.2. PROGRAM QUESTIONS	23
8. RESOURCES	24
9. REFERENCES	25
APPENDIX: WRITING GOALS AND OBJECTIVES	26

RFA VERSION HISTORY

Rev 5/6/2022 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and enhance the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1. Prevention Program Priorities

Legislation from the 83rd Texas Legislature requires that CPRIT's Oversight Committee establish program priorities on an annual basis. The priorities are intended to provide transparency in how the Oversight Committee directs the orientation of the agency's funding portfolio. The Prevention Program's principles and priorities will also guide CPRIT staff and the Prevention Review Council on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

Established Principles

- Fund evidence-based interventions and their dissemination
- Support the prevention continuum of primary, secondary, and tertiary (includes survivorship) prevention interventions

Prevention Program Priorities

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize underserved populations
- Program assessment to identify best practices, use as a quality improvement tool, and guide future program direction

2. FUNDING OPPORTUNITY DESCRIPTION

2.1. Summary

The ultimate goals of the CPRIT Prevention Program are to reduce overall cancer incidence and mortality and to improve the lives of individuals who have survived or are living with cancer. The ability to reduce cancer death rates depends in part on the application of currently available evidence-based technologies and strategies. CPRIT will foster the primary, secondary, and tertiary prevention of cancer in Texas by providing financial support for a wide variety of evidence-based risk reduction, early detection, and survivorship interventions.

The **Dissemination of CPRIT-Funded Cancer Control Interventions (DI)** award mechanism seeks to fund programs that facilitate the sharing of successful CPRIT projects and uptake of CPRIT supported project findings and products through their dissemination and implementation across Texas. **This award mechanism is open only to previously or currently funded CPRIT projects.** Applicants may request any amount of funding up to a maximum of \$450,000 in total funding over a maximum of 36 months.

The proposed program should describe and package strategies or approaches for dissemination to other settings and populations in the state. The proposed program would introduce, modify, and implement previously funded CPRIT evidence-based cancer prevention and control interventions that are evidenced-based. To be eligible, the applicant should be in a position to develop one or more “products” based on the results of a previously CPRIT-funded intervention project. Of particular interest is the dissemination of “products” that address the unique challenges to program implementation in resource-limited settings, particularly in nonmetropolitan and medically underserved areas of the state.

The proposed projects should outline the partner organizations, communities etc that would be the target recipients for the packaged strategies/products and how they would assist these targets in preparing to implement the intervention and/or preparing to apply for grant funding, if needed or appropriate.

The Center for Research in Implementation Science and Prevention website

(<https://dissemination-implementation.org/content/measures.aspx>) defines active and passive dissemination strategies as follows: “Dissemination strategies describe mechanisms and

approaches that are used to communicate and spread information about interventions to targeted users. Dissemination strategies are concerned with the packaging of the information about the intervention and the communication channels that are used to reach potential target audiences.

Passive dissemination strategies are largely ineffective and include mass mailings, publication of information including practice guidelines, and untargeted presentations to heterogeneous groups.

Active dissemination strategies include hands on technical assistance, replication guides, point-of-decision prompts for use, and mass media campaigns. It is consistently stated in the literature that dissemination strategies are necessary but not sufficient to ensure wide-spread use of an intervention.”

2.2. Project Objectives

CPRIT seeks to fund projects that will provide one or more of the following:

- Dissemination of intervention implementation resources to public health professionals, health care practitioners, health planners, policymakers, and advocacy groups;
- Dissemination of implementation plans, products, materials, and other resources about an intervention that would provide recipients with the strategies necessary to implement in other settings/systems (eg, quality improvement strategies in a health care system, changes in standards of care);
- Dissemination or scaling up of best practices (infrastructure and project resources) and evidence-based interventions for implementation (eg, implementation guides).

2.3. Award Description

The **Dissemination of CPRIT-Funded Cancer Control Interventions** RFA solicits applications from currently or previously funded CPRIT projects that have demonstrated exemplary success and have materials, policies, and other resources that have been successfully implemented and evaluated and could be scaled up and/or applied to other systems and settings. The ultimate goal is to expand successful models for the delivery of prevention interventions all across the state through adaptation or replication.

Applicants to this RFA should outline specific implementation strategies they will utilize with targeted recipients to replicate or adapt projects to other settings or populations. Implementation strategies are described as the processes, activities, and resources that are used to integrate

interventions into usual settings. Core implementation components can be staff selection, preservice and in-service training, ongoing consultation and coaching, staff and program evaluation, and systems interventions. (See <https://dissemination-implementation.org/content/measures.aspx>)

This award will support both passive and active dissemination strategies but must include two or more active dissemination strategies. This award will also support implementation strategies in the form of technical assistance, coaching, and consultation within the time period of the grant. CPRIT recognizes that there are limits to the amount of technical assistance or coaching that can be accomplished within the grant period; however, priority will be given to those projects that identify and assist potential target partners/audiences in preparing to implement the intervention and/or preparing to apply for grant funding. Examples of active dissemination strategies and implementation strategies follow.

Tools/models

- Toolkits with materials, sample policies, and procedures for implementation of CPRIT-funded programs
- Interactive websites that provide target audiences with key information on how to implement CPRIT-related interventions
- Approaches for dissemination of project implementation strategies/resources via nontraditional channels (eg, social media)
- User-friendly summaries—short issue or policy briefs that tell a story for local decision makers based on CPRIT project findings
- Brief, user-friendly case studies from program developers and recipients to illustrate key issues.

Implementation guides

- Targeted communication materials emphasizing how to disseminate project components to different populations, systems, and settings
- Step-by-step implementation guides that describe how to translate an evidence-based intervention/program to broader settings. These would include guidelines for retaining core elements of the interventions or programs while offering suggested adaptations for elements

that would enhance the adoption and sustainability of the programs in different populations, settings, or circumstances. (See Partnership for Prevention examples: <https://innovations.ahrq.gov/qualitytools/community-health-promotion-handbook-action-guides-improve-community-health>).

Training/technical assistance

- Provision of training and technical assistance to guide target partners/audiences in developing their plans to adapt, refine, and implement their projects.

In addition, target partners/audiences should be provided a discussion of barriers to dissemination; a description of personnel and necessary resources to overcome barriers to implementation of the project; a description of expected outcomes; evaluation strategies with a sample evaluation plan, and any project-specific platforms, etc.; and suggestions or ideas for project sustainability.

A priority for this RFA is the dissemination of resources and products to audiences other than researchers. Some examples of potential partners/audiences as dissemination recipients are health departments, community-based organizations, and health systems to serve as recipients. To facilitate this dissemination, audience segmentation is a strategy based on identifying subgroups within a broader target audience to disseminate more tailored messaging resulting in greater uptake of innovations. As an example, following are relevant characteristics of public health practitioners that should be taken into account in dissemination activities.

Segment	Relevant Characteristics	Messages	Channels
<ul style="list-style-type: none"> • Public health practitioners 	<ul style="list-style-type: none"> • High commitment • Wide range of professional backgrounds • Access to summaries of evidence but often not the original research • Time urgency 	<ul style="list-style-type: none"> • Make a difference in society • Improve health equity • Enhance resources 	<ul style="list-style-type: none"> • Leadership meetings • Professional associations • Brief summaries of evidence

The applicant should develop and implement a step-by-step dissemination plan that includes: 1) an introduction; 2) data showing the effectiveness of the underlying intervention (to justify dissemination); 3) relevance to priority populations and settings for dissemination; 4) target partners or strategies they will utilize to identify these critical partners; 5) dissemination framework and methods; 5) approaches for retaining core elements of the interventions or programs while offering suggested adaptations for the elements that would enhance the adoption and sustainability of the programs in different populations, settings, or circumstances; 6) procedures to assess dissemination effectiveness (evaluation plan); and 7) options/plans to help sustain effective dissemination approaches beyond the funding period.

Within the evaluation plan (#6 in the paragraph above and section 4.4.4.), the applicant should state the overall goal and objectives of the evaluation, describe rigorous evaluation methods, and describe key variables to be measured (eg, awareness, knowledge, motivation to act, changes in practice). Measures may be short term, medium term, and long term. Long-term measures may be outside the scope of the 3-year funding period. The applicant is expected to publish the results of the evaluation in a peer-reviewed journal.

Under this RFA, CPRIT **will not** consider the following:

- Applications to disseminate projects not previously or currently funded by CPRIT;
- Projects solely involving prevention/intervention research.

Applicants interested in prevention research should review CPRIT's Academic Research RFAs (available at <http://www.cprit.texas.gov>).

2.4. Priorities

Types of Cancer:

Applications addressing any cancer type(s) that are responsive to this RFA will be considered for funding. See [section 2.5](#) for specific areas of emphasis. Priority will be given to applications to disseminate and replicate projects that when implemented can address the following program priorities set by the CPRIT Oversight Committee:

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence

- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize underserved populations

Priority Populations

Priority populations are subgroups that are underserved and disproportionately affected by cancer. Insured populations are not the priority of CPRIT’s programs; however, some health promotion and education activities may include insured individuals as well as those who are underinsured or uninsured.

CPRIT-funded efforts must address 1 or more of these priority populations:

- Underinsured and uninsured individuals
- Geographically or culturally isolated populations
- Medically unserved or underserved populations
- Populations with low health literacy skills
- Racial, ethnic, and cultural minority populations, or
- Other populations with low screening rates, high incidence rates, and high mortality rates, focusing on individuals never before screened or who are significantly out of compliance with nationally recommended screening guidelines

2.5. Specific Areas of Emphasis

Applications will be considered that propose dissemination of any previously funded CPRIT project delivering an evidence-based preventive service or education and outreach program that includes navigation to services that is responsive to this RFA. However, CPRIT has identified the following area of emphasis for this cycle of awards:

- Dissemination of the programs that address the unique challenges to program implementation in resource-limited settings and populations experiencing cancer disparities.

2.6. Outcome Metrics

The applicant is required to describe how the goals and objectives for each year of the project as well as the final outcomes will be measured. The applicant should provide a clear and appropriate plan for data collection and interpretation of results to report against goals and objectives.

Reporting Requirements

Funded projects are required to report quantitative output and outcome metrics (as appropriate for each project) through the submission of quarterly progress reports, annual reports, and a final report.

- Quarterly progress report sections include, but are not limited to, the following:
 - Narrative on project progress, including the number and description of all active and passive dissemination and implementation activities undertaken
- Annual and final progress report sections include, but are not limited to, the following:
 - Key accomplishments, including discussion of barriers to dissemination
 - Progress toward goals and objectives
 - Materials produced, presentations, publications, etc
 - Economic impact of the project

2.7. Eligibility

- The applicant must be a Texas-based entity, such as a community-based organization, health institution, government organization, public or private company, college or university, or academic health institution.
- The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted.
- The designated Program Director (PD) will be responsible for the overall performance of the funded project. The PD must have relevant education and management experience and must reside in Texas during the project performance time.
- The applicant may submit more than 1 application, but each application must be for distinctly different projects without overlap in the projects. Applicants who do not meet this criterion will have all applications administratively withdrawn without peer review.

- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant organization is eligible to receive a grant award only if the applicant certifies that the applicant organization, including the PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant organization, the PD, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way (whether slated to receive salary or compensation under the grant award or not) are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. CPRIT grants are funded on a reimbursement-only basis. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 6](#). All statutory provisions and relevant administrative rules can be found [on the CPRIT website](#).

2.8. Resubmission Policy

- **One resubmission** is permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PD for a project or a change of title for a project that was previously submitted to CPRIT does not constitute a new application; the application would be considered a resubmission.
- Applicants who choose to resubmit should carefully consider the reasons for lack of prior success. Applications that received overall numerical scores of 4 or higher are likely to need considerable attention. All resubmitted applications should be carefully reconstructed; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes. A 1-page summary of the approach to the resubmission should be included. Resubmitted applications may be assigned to reviewers who did not review the original submission. Reviewers of resubmissions are asked to assess whether the resubmission adequately addresses critiques from the previous review. **Applicants should note that addressing previous critiques is advisable; however, it does not guarantee the success of the resubmission.** All resubmitted applications must conform to the structure and guidelines outlined in this RFA.

2.9. Funding Information

Applicants may request any amount of funding up to a maximum of \$450,000 in total funding over a maximum of 36 months. Grant funds may be used to pay for salary and benefits, project supplies, equipment, costs for outreach and education, and travel of project personnel to project site(s). Requests for funds to support construction, renovation, or any other infrastructure needs or requests to support lobbying will not be approved under this mechanism. Grantees may request funds for travel for 2 project staff to attend CPRIT's conference.

The budget should be well justified. In addition, CPRIT seeks to fill gaps in funding rather than replace existing funding, supplant funds that would normally be expended by the applicant's organization, or make up for funding reductions from other sources.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

3. KEY DATES

RFA release	May 6, 2022
Online application opens	June 2, 2022, 7 AM central time
Application due	August 31, 2022, 4 PM central time
Application review	September 2022-January 2023
Award notification	February 2023
Anticipated start date	March 1, 2023

4. APPLICATION SUBMISSION GUIDELINES

4.1. *Instructions for Applicants* document

It is imperative that applicants read the accompanying instructions document for this RFA that will be available June 2, 2022 (<https://CPRITGrants.org>). Requirements may have changed from previous versions.

4.2. Online Application Receipt System

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The PD must create a user account in the system to start and submit an application. The Co-PD, if applicable, must also create a user account to participate in the application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (an individual who will help manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on June 2, 2022, and must be submitted by 4 PM central time on August 31, 2022. Detailed instructions for submitting an application are in the *Instructions for Applicants* document, posted on CARS. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

4.3. Submission Deadline Extension

The submission deadline may be extended for 1 or more grant applications upon a showing of good cause. All requests for extension of the submission deadline must be submitted via email to the [CPRIT Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records.

4.4. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Refer to the *Instructions for Applicants* document for details.

Submissions that are missing 1 or more components or do not meet the eligibility requirements may be administratively withdrawn without review.

4.4.1. Abstract and Significance (5,000 characters)

Clearly explain the problem(s) to be addressed, the approach(es) to the solution, and how the application is responsive to this RFA. In the event that the project is funded, the abstract will be made public; therefore, no proprietary information should be included in this statement. Initial compliance decisions are based in part upon review of this statement.

The abstract format is as follows (use headings as outlined below):

- **Need:** Include a description of need for the proposed project.
- **Overall Project Strategy:** Describe the project and how it will address the identified need.
- **Specific Goals:** State specifically the overall goals of the proposed project.
- **Significance and Impact:** Explain how the proposed project, if successful, will have a unique and major impact on cancer prevention and control and for the State of Texas.

4.4.2. Goals and Objectives (700 characters each)

List only major **outcome** goals and **measurable** objectives for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within both the stated Objective **and** the Measure sections (eg, Measure: Number of lesson plans, handout and other materials posted online or delivered in person). Applications

may be returned for revision if the proposed metric is not included within the Measure section. Refer to the *Instructions for Applicants* document for details.

The maximum number is 3 outcome goals with 3 objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives. See [Appendix](#) for instructions on writing **outcome** goals and objectives.

A baseline and method(s) of measurement are required for each objective. Provide both raw numbers and percent changes for the baseline and target. If a baseline has not yet been defined, applicants are required to explain plans to establish baseline and describe method(s) of measurement.

4.4.3. Project Timeline (2 pages)

Provide a project timeline for project activities that includes deliverables and dates. Use Years 1 and 2 and Months 1, 2, 3, etc, as applicable (eg, Year 1, Months 3-5) instead of specific months or years. Month 1 is the first full month of the grant award.

4.4.4. Project Plan (12 pages; fewer pages permissible)

The required project plan format follows. Applicants must use the headings outlined below.

Background: Describe the findings or products to be disseminated and how and why it lends itself to replication and scalability. Describe the effectiveness of the intervention that is being proposed for replication/dissemination and the expected short- and long-term impacts of the project.

Goals and Objectives: Process objectives should be included in the project plan. Outcome goals and objectives will be entered in separate fields in CARS. However, if desired, outcome goals and objectives may be fully repeated or briefly summarized here. See [Appendix](#) for instructions on writing goals and objectives.

Components of the Project: Clearly describe the data demonstrating success of the CPRIT-funded project that justifies dissemination. Describe components of the proposed dissemination project and the dissemination approach, strategy (eg, passive and active dissemination and implementation strategies), and the products being designed or packaged. The dissemination approach and strategy should also consider the message, source, audience, and channel (Brownson, R.C., et al. [*J Pub Health Manag Pract.* 24\(2\):102-111](#), March/April 2018). Clearly describe the established theory

and practice that support the proposed approach or strategy. Describe parameters of the CPRIT-funded project that may affect its dissemination and replication, such as target audience for which it was designed, specialized resources that may be needed, or geographic considerations.

Evaluation Strategy: Describe the evaluation plan and methodology to assess dissemination effectiveness (eg, include short-term and intermediate impact of dissemination activities, knowledge and behavior change among the audience likely to adopt the project). Describe a clear and appropriate plan for data collection and interpretation of results to report against goals and objectives. If needed, applicants may want to consider seeking expertise at Texas-based academic cancer centers, schools/programs of public health, prevention research centers, or the like. Applicants should budget accordingly for the evaluation activity and should ensure, among other things, that the evaluation plan is linked to the proposed goals and objectives.

Organizational Qualifications and Capabilities: Describe the organization and its qualifications and capabilities to deliver the proposed project. Describe the role and qualifications of key collaborating organizations/partners (if applicable) and how they add value to the project and demonstrate commitment to working together to implement the project. Describe the key personnel who are in place or will be recruited to implement, evaluate, and complete the project.

4.4.5. References

Provide a concise and relevant list of references cited for the application. The successful applicant will provide referenced evidence and literature support for the proposed project.

4.4.6. Resubmission Summary

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the approach to the resubmission and how reviewers' comments were addressed. Clearly indicate to reviewers how the application has been improved in response to the critiques. Refer the reviewers to specific sections of other documents in the application where further detail on the points in question may be found. When a resubmission is evaluated, responsiveness to previous critiques is assessed.

The overall summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission; the applicant is not responsible for providing this document.

4.4.7. CPRIT Grants Summary

Use the template provided on the CARS (<https://CPRITGrants.org>). Provide a listing of **all** projects funded by the CPRIT Prevention program for the PD and the Co-PD, regardless of their connection to this application.

4.4.8. Budget and Justification

Provide a brief outline and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, travel, supplies, contractual expenses, and other expenses. CPRIT funds will be distributed on a reimbursement basis. Applications requesting more than the maximum allowed cost (total costs) as specified in [section 2.9](#) will be administratively withdrawn.

- **Personnel:** The individual salary cap for CPRIT awards is \$200,000 per year. Describe the source of funding for all project personnel where CPRIT funds are not requested.
- **Travel:** PDs and related project staff are expected to attend CPRIT's conference. CPRIT funds may be used to send up to 2 people to the conference.
- **Indirect/Shared Costs:** Texas law limits the amount of grant funds that may be spent on indirect/shared expenses to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in [CPRIT's Administrative Rules](#).

4.4.9. Current and Pending Support and Sources of Funding

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the funding source and duration of **all** current and pending support for the proposed project, including a capitalization table that reflects private investors, if any. Information for the initial funded project need not be included.

4.4.10. Biographical Sketches

The designated PD will be responsible for the overall performance of the funded project and must have relevant education and management experience. The PD must provide a biographical sketch that describes his or her education and training, professional experience, awards and honors, and publications and/or involvement in programs relevant to cancer prevention and/or service delivery.

Up to 3 additional biographical sketches for key personnel may be provided. The evaluation professional biographical sketch (see Evaluation Strategy, [section 4.4.4](#)) is optional and will count as 1 of the 3 additional biosketches. Each biographical sketch must not exceed 5 pages and must use the “Prevention Programs: Biographical Sketch” template provided on the CARS (<https://CPRITGrants.org>) or the NIH Biographical Sketch format. Only biographical sketches will be accepted; do not submit resumes and/or CVs. If a position is not yet filled, please upload a job description.

4.4.11. Collaborating Organizations

List all key participating organizations that will partner with the applicant organization to provide 1 or more components essential to the success of the program (eg, evaluation). Please be sure to also include anyone listed as key personnel and/or listed under the Current & Pending Support section.

4.4.12. Letters of Commitment (10 pages)

Applicants may provide optional letters of commitment and/or memoranda of understanding from community organizations, key faculty, or any other component essential to the success of the program.

5. APPLICATION REVIEW

5.1. Review Process Overview

All eligible applications will be reviewed and scored by the [CPRIT Prevention Review Council](#) based on the criteria in [section 5.2](#) below. Review Council members are listed on CPRIT’s website.

The Prevention Review Council will review applications and provide an overall evaluation score reflecting their overall impression of the application and responsiveness to the RFA priorities.

Additional considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service.

Applications approved by the Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC.

The grant award recommendations will be presented at an open meeting of the Oversight

Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 through 703.8](#).

Each stage of application review is conducted confidentially, and all CPRIT Prevention Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Peer Review Panel members and Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Review Panel member, or a Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

5.2. Review Criteria

The Prevention Review Council will review the applications based on the criteria below and will provide an overall evaluation score reflecting their overall impression of the application and

responsiveness to the RFA priorities. Additional considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service.

5.2.1. Primary Evaluation Criteria

Impact

- Does the applicant describe the project to be disseminated and how and why it lends itself to replication and scalability?
- Does the applicant outline the target metrics established for the CPRIT-funded project and describe the effectiveness of the intervention that is being proposed for replication/dissemination?
- Do the data (results) demonstrate success of the CPRIT-funded project and justify dissemination?
- Has the applicant convincingly demonstrated the short- and long-term impacts of the project?

Project Strategy and Feasibility

- Does the proposed project address the requirements of the RFA? Does it include a step-by-step implementation guide in Year 1?
- Are the overall project dissemination approach, strategy, and design clearly described and supported by established theory and practice and likely to result in successful dissemination and adoption? Are 2 or more active dissemination strategies described?
- Are the proposed objectives and activities feasible within the duration of the award?
- If the CPRIT-funded project is to be adapted for different populations and settings, are specific adaptations and evaluation strategies clearly outlined as a part of the project?
- Does the project identify and assist potential target audiences in preparing to implement the intervention and/or preparing to apply for grant funding?

Evaluation

- Are specific goals and measurable objectives for each year of the project provided?
- Are the proposed measures appropriate for the project?
- Does the application provide a clear and appropriate plan for data collection and interpretation of results to report against goals and objectives?

Organizational Qualifications and Capabilities

- Do the organization and its collaborators/partners (if applicable) demonstrate the ability to deliver the proposed project?
- Are the appropriate personnel in place or have they been recruited to develop, evaluate, and complete the project?

5.2.2. Secondary Evaluation Criteria

Budget

- Is the budget appropriate and reasonable for the scope of the proposed work?
- Are all costs well justified?
- Is the project a good investment of Texas public funds?

6. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's [Administrative Rules](#). Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires the PD of the award to submit quarterly, annual, and final progress reports. These reports summarize the progress made toward project goals and address plans for the upcoming year and performance during the previous year(s). In addition, quarterly fiscal reporting and reporting on selected metrics will be required per the instructions to award recipients. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract.

7. CONTACT INFORMATION

7.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding the scope and focus of applications. Before contacting the helpdesk, please refer to the *Instructions for Applicants* document (posted on June 2, 2022), which provides a step-by-step guide to using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

7.2. Program Questions

Questions regarding the CPRIT Prevention program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Prevention Program Office.

Tel: 512-305-8417

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

8. RESOURCES

- The Texas Cancer Registry. <http://www.dshs.texas.gov/tcr> or contact the Texas Cancer Registry at the Department of State Health Services.
- The Community Guide. <http://www.thecommunityguide.org/>
- Cancer Control P.L.A.N.E.T. <https://cancercontrol.cancer.gov/>
- Guide to Clinical Preventive Services: Recommendations of the U.S. Preventive Services Task Force. <http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/>
- Centers for Disease Control and Prevention: The Program Sustainability Assessment Tool: A New Instrument for Public Health Programs
http://www.cdc.gov/pcd/issues/2014/13_0184.htm
- Centers for Disease Control and Prevention: Using the Program Sustainability Tool to Assess and Plan for Sustainability. http://www.cdc.gov/pcd/issues/2014/13_0185.htm
- Cancer Prevention and Control Research Network: Putting Public Health Evidence in Action Training Workshop. <http://cpcrn.org/pub/evidence-in-action/>
- Slater MD, Kelly KJ, Thackeray R. Segmentation on a shoestring: health audience segmentation in limited-budget and local social marketing interventions. *Health Promot Pract.* 2006;7(2):170-173.
- Brownson RC, Eyster AA, Harris JK, Moore JB, Tabak RG. Getting the Word Out: New Approaches for Disseminating Public Health Science. *J Public Health Manag Pract.* 2018;24(2):102-111.
https://journals.lww.com/jphmp/Fulltext/2018/03000/Getting_the_Word_Out__New_Approaches_for.4.aspx

9. REFERENCES

1. <http://www.cdc.gov/hpv/parents/questions-answers.html>
2. Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services. <https://www.cancer-rates.info/tx/>

APPENDIX: WRITING GOALS AND OBJECTIVES

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within **both** the stated Objective and the Measure sections (eg, Measure: Number of lesson plans, handout and other materials posted online or delivered in person). The maximum number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives.

The following has been adapted with permission from Appalachia Community Cancer Network, NIH Grant U54 CA 153604:

Develop well-defined goals and objectives

Goals provide a roadmap or plan for where a group wants to go. Goals can be long term (over several years) or short term (over several months). Goals should be based on needs of the community and evidence-based data.

Goals should be

- Believable – situations or conditions that the group believes can be achieved
- Attainable – possible within a designated time
- Tangible – capable of being understood or realized
- On a timetable – with a completion date
- Win-Win – beneficial to individual members and the coalition

Objectives are measurable steps toward achieving the goal. They are clear statements of specific activities required to achieve the goal. The best objectives have several characteristics in common—S.M.A.R.T. + C:

- Specific – they tell how much (number or percent), who (participants), what (action or activity), and by when (date)
 - Example: 115 uninsured individuals age 50 and older will complete colorectal cancer screening by March 31, 2019.
- Measurable – specific measures that can be collected, detected, or obtained to determine successful attainment of the objective
 - Example: How many screened at an event? How many completed pre/post assessment?

- Achievable – not only are the objectives themselves possible, it is likely that your organization will be able to accomplish them
- Relevant to the mission – your organization has a clear understanding of how these objectives fit in with the overall vision and mission of the group
- Timed – developing a timeline is important for when your task will be achieved
- Challenging – objectives should stretch the group to aim on significant improvements that are important to members of the community

Evaluate and refine your objectives

Review your developed objectives and determine the type and level of each using the following information:

There are 2 types of objectives:

- Outcome objectives – measure the “what” of a program; should be in the Goals and Objectives form (see [section 4.4.2](#))
- Process objectives – measure the “how” of a program; should be in the project plan (see [section 4.4.4](#))

There are 3 levels of objectives:

- Community-level – objectives measure the planned community change
- Program impact – objectives measure the impact the program will have on a specific group of people
- Individual – objectives measure participant changes resulting from a specific program, using these factors:
 - Knowledge – understanding (know screening guidelines; recall the number to call for screening)
 - Attitudes – feelings about something (will consider secondhand smoke dangerous; believe eating 5 or more fruits and vegetables is important)
 - Skills – the ability to do something (complete fecal occult blood test)
 - Intentions – regarding plan for future behavior (will agree to talk to the doctor, will plan to schedule a Pap test)
 - Behaviors (past or current) – to act in a particular way (will exercise 30+ minutes a day, will have a mammogram)

Well-defined goals and objectives can be used to track, measure, and report progress toward achievement.

Summary Table

	Outcome – Use in Goals and Objectives	Process – Use in Project Plan only
Community-level	<p>WHAT will change in a community</p> <p><i>Example: As a result of CPRIT funding, FIT (fecal immunochemical tests) will be available to 1,500 uninsured individuals age 50 and over through 10 participating local clinics and doctors.</i></p>	<p>HOW the community change will come about</p> <p><i>Example: Contracts will be signed with participating local providers to enable uninsured individuals over age 50 to have access to free colorectal cancer screening in their communities.</i></p>
Program Impact	<p>WHAT will change in the target group as a result of a particular program</p> <p><i>Example: As a result of this project, 200 uninsured women between 40 and 49 will receive free breast and cervical cancer screening.</i></p>	<p>HOW the program will be implemented to affect change in a group/population</p> <p><i>Example: 2,000 female clients, between 40 and 49, will receive a letter inviting them to participate in breast and cervical cancer screening.</i></p>
Individual	<p>WHAT an individual will learn as a result of a particular program, or WHAT change an individual will make as a result of a particular program</p> <p><i>Example: As a result of one-to-one education of 500 individuals, at least 20% of participants will participate in a smoking cessation program to quit smoking.</i></p>	<p>HOW the program will be implemented to affect change in an individual's knowledge or actions</p> <p><i>Example: As a result of one-to-one counseling, all participants will identify at least 1 smoking cessation service and 1 smoking cessation aid.</i></p>

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Prevention - Dissemination of CPRIT-Funded Cancer
Control Interventions (23.1 PRV DI)
Observation Report

Report No. 2023-01-06 23.1_PRV_DI
Program Name: Prevention
Panel Name: 23.1 Prevention - Dissemination of CPRIT-Funded Cancer Control Interventions (23.1_PRV_DI)
Panel Date: January 6, 2023
Report Date: January 12, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Prevention - Dissemination of CPRIT-Funded Cancer Control Interventions (23.1_PRV_DI) meeting. The meeting was chaired by Stephen Wyatt and conducted via videoconference on January 6, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Five (5) applications were discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Prevention Review Council – Programmatic review
(23.1 PRC-PR)
Observation Report

Report No. 2023-01-13 23.1_PRC-PR
Program Name: Prevention
Panel Name: 23.1 Prevention Review Council – Programmatic review (23.1_PRC-PR)
Panel Date: January 13, 2023
Report Date: January 19, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Prevention Review Council – Programmatic review (23.1_PRC-PR) meeting. The meeting was chaired by Stephen Wyatt and conducted via videoconference on January 13, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Prevention Cycle 23.1

Awards Announced at the February 15, 2023, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Prevention Cycle 23.1 include: *Cancer Screening and Early Detection*; *Dissemination of CPRIT-Funded Cancer Control Interventions*; and *Primary Prevention of Cancer*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
No reported COIs.			
Applications not considered by the PIC or Oversight Committee:			
PP230031	Walter Calmbach	The University of Texas Health Science Center at San Antonio	R. Brownson

De-Identified Overall Evaluation Scores

Dissemination of CPRIT-Funded Cancer Control Interventions

Prevention Cycle 23.1

Application ID	Final Overall Evaluation Score
PP230002*	3.0
PP230033*	3.0
cc ^a	3.3
ca	4.0
cb	5.7

^a The Prevention Review Council took no action on this application.

* Recommended for funding.

Final Overall Evaluation Scores and Rank Order Scores

Dr. Mahendra Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com
Via email to kirtikpatel@hotmail.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Dr. Patel,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the FY2023 Cycle 1 Cancer Screening and Early Detection (CSD), Dissemination of CPRIT-Funded Cancer Control Interventions (DI), and Primary Prevention of Cancer (PPC) grant awards.

The PRC met on January 13, 2023, to consider the applications recommended by the peer review panel following their December 5, 2023 meeting. The PRC recommends 8 projects totaling \$13,577,257.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment

App ID	Mechanis	Application Title	PD	Organization	Requested Budget	Score	Rank Order
PP230018	PPC	Implementation and Evaluation of an Evidence-Based Multilevel Lifestyle Intervention for Underserved/Rural Populations in South Texas: Tu Salud ¡Si	Reininger, Belinda	The University of Texas Health Science Center at Houston	\$999,254	2.5	1
PP230013	CSD	Community Expansion and Re-engagement for Breast Cancer Screening and Patient Navigation	Argenbright, Keith E	The University of Texas Southwestern Medical Center	\$2,500,000	2.7	2
PP230046	CSD	Screen, Treat, or Prevent (STOP) Hepatocellular Cancer-Hepatitis C (HCC-HCV): Expansion to All Adults	Jain, Mamta K	The University of Texas Southwestern Medical Center	\$2,499,616	2.7	3
PP230033	DI	All for Them Texas: A multifaceted dissemination and implementation approach to increase HPV vaccination	Cucarro, Paula	The University of Texas Health Science Center at Houston	\$449,959	3.0	4
PP230002	DI	Taking Texas Tobacco Free: Dissemination to and Implementation within Lung Cancer Screening Programs	Reitzel, Lorraine	University of Houston	\$448,726	3.0	5
PP230038	CSD	Salud en Mis Manos (SEMM): An Evidence-Based Breast & Cervical Cancer Early Detection and Prevention Program for Underserved Latinas.	Savas, Lara S	The University of Texas Health Science Center at Houston	\$2,499,492	3.1	6
PP230041	CSD	PP190052 - Integrated lung cancer screening and tobacco cessation in an urban safety-net system	Gerber, David E	The University of Texas Southwestern Medical Center	\$1,922,312	3.1	7

PP230043	PPC	School-based Human Papillomavirus Vaccination Program in the Rio Grande Valley: Continuation and Expansion in Hidalgo, Cameron, and Willacy Counties	Rodriguez, Ana M	The University of Texas Medical Branch at Galveston	\$2,257,898	3.2	8
----------	-----	--	------------------	---	-------------	-----	---

CSD Cancer Screening and Early Detection
DI Dissemination of CPRIT-Funded Cancer Control Interventions
PPC Primary Prevention of Cancer



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2023—Cycle 1
*Individual Investigator Research Awards***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-23.1-IIRA

Individual Investigator Research Awards

**Please also refer to the Instructions for Applicants document,
which will be posted on March 16, 2022**

Application Receipt Opening Date: March 16, 2022

Application Receipt Closing Date: June 8, 2022

FY2023

Fiscal Year Award Period
September 1, 2022-August 31, 2023

TABLE OF CONTENTS

1. BRIEF DESCRIPTION OF RFA	4
2. ABOUT CPRIT	4
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
3. RATIONALE	5
4. RESEARCH OBJECTIVES	6
5. FUNDING INFORMATION	6
6. ELIGIBILITY	7
7. RESUBMISSION POLICY	9
8. RENEWAL POLICY	9
9. RESPONDING TO THIS RFA	9
9.1. APPLICATION SUBMISSION GUIDELINES	9
9.1.1. <i>Submission Deadline Extension</i>	10
9.2. APPLICATION COMPONENTS	10
9.2.1. <i>Abstract and Significance (5,000 characters)</i>	10
9.2.2. <i>Layperson’s Summary (2,000 characters)</i>	11
9.2.3. <i>Goals and Objectives</i>	11
9.2.4. <i>Timeline (1 page)</i>	11
9.2.5. <i>Resubmission Summary (2 pages)</i>	11
9.2.6. <i>Renewal Summary (2 pages)</i>	12
9.2.7. <i>Research Plan (10 pages)</i>	12
9.2.8. <i>Vertebrate Animals (1 page)</i>	12
9.2.9. <i>Human Subjects (2 pages)</i>	12
9.2.10. <i>Publications/References</i>	13
9.2.11. <i>Budget and Justification</i>	13
9.2.12. <i>Biographical Sketches (5 pages each)</i>	14
9.2.13. <i>Current and Pending Support</i>	14
9.2.14. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i>	14
9.2.15. <i>Previous Summary Statement</i>	14
9.3. FORMATTING INSTRUCTIONS	15
10. APPLICATION REVIEW	16
10.1. PRELIMINARY EVALUATION.....	16
10.2. FULL PEER REVIEW	16
10.3. CONFIDENTIALITY OF REVIEW	17
10.4. REVIEW CRITERIA.....	18
10.4.1. <i>Primary Criteria</i>	18
10.4.2. <i>Secondary Criteria</i>	19
11. KEY DATES	20
12. AWARD ADMINISTRATION	20
13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	21
14. CONTACT INFORMATION	22
14.1. HELPDESK.....	22
14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	22

RFA VERSION HISTORY

01/14/22 RFA released

1. BRIEF DESCRIPTION OF RFA

- Supports applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer.
- Applicants may request a maximum of \$350,000 per year for a 3-year period.
- Multi-PIs (MI) are allowed under this RFA. See the Information for Applicants (IFA) document for definition and eligibility of MIs.
- Note that CPRIT does not allow the use of the term Co-PI.
- Minimum effort for the PI and/or MIs throughout the project period is required.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure
- Achieving health equity and reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

3. RATIONALE

The goals of the CPRIT Academic Research Grants Program are to support the discovery of new information about cancer that can lead to prevention, early detection, and cures and to translate new and existing discoveries into practical advances in cancer diagnosis and treatment. CPRIT encourages applications that seek new fundamental knowledge about cancer and cancer development as well as those attempting to develop state-of-the-art technologies, tools, computational models, and/or resources for cancer research, including those with potential commercialization opportunities. This award allows experienced or early-career-stage cancer researchers the opportunity to explore new methods and approaches for investigating a question of importance that has been inadequately addressed or for which there may be an absence of an established paradigm or technical framework. CPRIT will look with special favor on new approaches to be taken or new areas of investigation to be explored by established investigators and on supporting the research programs of the most promising investigators at the beginning of their research careers. Applicants need not be trained specifically in cancer research. Indeed, CPRIT strongly encourages investigators from other fields, including the mathematical and computational modeling, physical, chemical, and engineering sciences, to bring their expertise to bear on the exceptionally challenging problems posed by cancer. CPRIT expects outcomes of supported activities to directly and indirectly benefit subsequent cancer research efforts, cancer

public health policy, and efforts to reduce cancer disparities on the continuum of cancer care—from prevention to early detection, treatment, and survivorship.

To fulfill this vision, applications may address any topic or issue related to cancer, including cancer biology, computational modeling, and systems biology, causation, prevention, detection or screening, treatment, or survivorship. Successful applicants should be working in a research environment capable of supporting potentially high-impact studies. Access to a clinical environment and interaction with translational cancer physician-scientists are highly desirable.

4. RESEARCH OBJECTIVES

CPRIT will foster cancer research in Texas by providing financial support for a wide variety of projects relevant to cancer research. This Request for Applications (RFA) solicits applications for innovative research projects addressing critically important questions that will significantly advance knowledge of the causes, prevention, and/or treatment of cancer. The goal of awards made in response to this RFA is to fund exceptionally innovative research projects with great potential impact that are directed by a single or multi-investigators. Areas of interest include laboratory research, translational studies, and/or clinical investigations. In that cancers arise from a large number of derangements of basic molecular and cellular functions and, in turn, cause many alterations in basic biological processes, almost any aspect of biology may be relevant to cancer research, more or less directly. The *degree of relevance* to cancer research is a critical criterion for evaluation of projects for funding by CPRIT ([section 10.4.1](#)). For example, are alterations in the process in question *primarily* responsible for oncogenesis or secondary manifestations of malignant transformation? Will understanding the process or interfering with it offer selective and useful insight into prevention, diagnosis, or treatment of cancer? *Successful applicants for funding from CPRIT will have addressed these questions satisfactorily.*

5. FUNDING INFORMATION

Applicants may request a maximum of \$350,000 in total costs per year for up to 3 years for research. Exceptions to these limits may be requested if extremely well justified (see [section 9.2.11](#)). Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this

funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The Principal Investigator (PI) must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- This award mechanism allows Multi-PIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for Multi-PI awards).
- For applications that include 1 PI, the PI is required to maintain a minimum 15% level of effort throughout the entire award period. For applications that include MIs, each PI is required to maintain a minimum 10% effort throughout the entire award period.
- A PI may not submit applications to this RFA and to RFA R-23.1-IIRACSBC, RFA R-23.1-IIRACCA, RFA R-23.1-IIRACT, or RFA R-23.1-IIRAP.
- A PI may submit only 1 application, either a new, resubmission or renewal application under this RFA during this funding cycle.
- A PI may be a part of only one application, whether as a single applicant or as part of a Multi-PI application, under this RFA and RFA R-23.1-IIRACSBC, RFA R-23.1-IIRACCA, RFA R-23.1-IIRACT, or RFA R-23.1-IIRAP.
- An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project Co-PIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2023).

- Applications that address prevention and early detection population-based studies, cancers in children and adolescents, computational systems biology of cancer, or innovative clinical trials should be submitted under the appropriate targeted RFA.
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity) has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether these individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines. More than 1 resubmission is not permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PI for a project or a change of title of the project that was previously submitted to CPRIT or omission or modification of an aim does not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 9.2.5](#).

8. RENEWAL POLICY

An application funded by CPRIT under this mechanism may be submitted for a competitive renewal. This policy is in effect for all awards submitted to date. See [section 9.2.6](#). Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 10.2](#).

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 16, 2022, and must be submitted by 4 PM central time on June 8, 2022. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section wisely. **Based on the Abstract and Significance statement (and the Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from further peer review (see [section 10.1](#)).** Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the research plan.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Indicate whether this research will address cancers associated with disparities. Summarize how

the proposed research creates new paradigms or challenges existing ones. Indicate whether this research plan represents a new direction for the PI.

9.2.2. Layperson’s Summary (2,000 characters)

Provide a layperson’s summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson’s summary.** The layperson’s summary will also be used by advocate reviewers ([section 10.2](#)) in evaluating the significance and impact of the proposed work.

9.2.3. Goals and Objectives

List specific goals and objectives for each year of the project. These goals and objectives will also be used during the submission and evaluation of progress reports and assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Resubmission Summary (2 pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received

overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a fresh research plan or modify the original research plan and mark the changes.

However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

9.2.6. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

9.2.7. Research Plan (10 pages)

Background: Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application. Describe the significance, innovation, and potential impact of the research.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

9.2.8. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

9.2.9. Human Subjects (2 pages)

If human subjects or human biological samples will be used, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of

this award mechanism. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

9.2.10. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.11. Budget and Justification

Provide a compelling and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses. Applicants are advised not to interpret the maximum allowable request under this award as a suggestion that they should expand their anticipated budget to this level. Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2023 is \$200,000; CPRIT FY 2023 is from September 1, 2022, through August 31, 2023. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs.

An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

9.2.12. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research.

A biographical sketch must be provided for the PI and, if applicable, any additional PIs (if a MI application), as required by the online application receipt system. Up to 2 additional biographical sketches for key personnel may be provided. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

9.2.13. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional PIs (if a MI application) must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.14. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

9.2.15. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.
- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.

- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may be preliminarily evaluated by CPRIT Scientific Research Program panel members for scientific merit and impact.

This preliminary evaluation will be based on a subset of material presented in the application—namely, Abstract and Significance, Budget and Justification, and

Biographical Sketches. Applications that do not sufficiently capture the reviewers’ interest at this stage will not be considered for further review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation stage has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

10.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and

programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.3. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules (Texas Administrative Code RULE §703.9).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services.

The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.4.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention, diagnosis, or treatment for patients? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient

preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required creativity and expertise to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of their time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer research? This is a critical criterion for evaluation of projects for CPRIT support.

10.4.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release January 14, 2022

Application

Online application opens March 16, 2022, 7 AM central time

Application due June 8, 2022, 4 PM central time

Application review June 2022–February 2023

Award

Award notification February 2023

Anticipated start date March 1, 2023

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT’s Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT’s Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT’s Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

14. CONTACT INFORMATION

14.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director of Academic Research.

Tel: 512-305-8491

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Imaging Technology and
Informatics (ITI) (23.1 AR ITI)
Observation Report

Report No. 2022-10-24 23.1_AR_ITI
Program Name: Academic Research
Panel Name: 23.1 Academic Research Imaging Technology and Informatics (ITI)
(23.1_AR_ITI)
Panel Date: October 24, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Imaging Technology and Informatics (ITI) (23.1_AR_ITI) meeting. The meeting was chaired by Martin Pomper and conducted via videoconference on October 24, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were thirteen (13) Conflicts of Interest (COIs) identified prior to and/or during the meeting. Seven (7) applications with COIs were discussed and six (6) applications with COIs were not discussed. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Review Panel - Basic Cancer

Research (23.1 AR BCR-2)

Observation Report

Report No. 2022-10-25 23.1_AR_BCR-2
Program Name: Academic Research
Panel Name: 23.1 Academic Research Review Panel - Basic Cancer Research
(23.1_AR_BCR-2)
Panel Date: October 25, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Review Panel - Basic Cancer Research (23.1_AR_BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 25, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Sixteen (16) applications were discussed, and eighteen (18) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies and answering procedural questions

Eight (8) Conflicts of Interest (COIs) were identified prior to and/or during the meeting. Three (3) applications with COIs were discussed and three (3) applications with COIs were not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Cancer Prevention Research (CPR)
(23.1 AR CPR)
Observation Report

Report No. 2022-10-26 23.1_AR_CPR
Program Name: Academic Research
Panel Name: 23.1 Academic Research Cancer Prevention Research (CPR) (23.1
_AR_CPR)
Panel Date: October 26, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Cancer Prevention Research (CPR) (23.1_AR_CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 26, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty (20) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were nine (9) Conflicts of Interest (COIs) identified prior to and/or during the meeting. Four (4) applications with COIs were discussed and five (5) applications with COIs were not discussed. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (23.1 AR C/TCR)
Observation Report

Report No. 2022-10-27 23.1_AR_C/TCR
Program Name: Academic Research
Panel Name: 23.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (23.1_AR_C/TCR)
Panel Date: October 27, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Clinical and Translational Cancer Research (C/TCR) (23.1_AR_C/TCR) meeting. The meeting was chaired by Margaret Tempero and Richard O'Reilly and conducted via videoconference on October 27, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-four (24) applications were discussed and twenty-two (22) applications were not discussed
- Panelists: Two (2) panel chairs, twenty (20) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COI) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Review Panel - Basic Cancer

Research-1 (23.1 AR BCR-1)

Observation Report

Report No. 2022-10-28 23.1_AR_BCR-1
Program Name: Academic Research
Panel Name: 23.1 Academic Research Review Panel - Basic Cancer Research-1
(23.1_AR_BCR-1)
Panel Date: October 28, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Review Panel - Basic Cancer Research-1 (23.1_AR_BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on October 28, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eighteen (18) applications were discussed, and sixteen (16) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. One (1) application with a COI was discussed and five (5) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Cancer Biology (CB)

(23.1 ACR CB)

Observation Report

Report No. 2022-10-31 23.1_ACR_CB
Program Name: Academic Research
Panel Name: 23.1 Academic Research Cancer Biology (CB) (23.1 _ACR_CB)
Panel Date: October 31, 2022
Report Date: November 1, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Cancer Biology (CB) (23.1_ACR_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on October 31, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to the observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and twenty-nine (29) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions
- CPRIT Oversight Committee members: One (1)
- CPRIT Oversight Committee member(s) participation was limited observing the proceedings

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. One (1) application with a COI was discussed and one (1) application with COI was not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and

scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research - Scientific Review Council Meeting
(23.1 SRC)
Observation Report

Report No. 2022-12-22 23.1_SRC
Program Name: Academic Research
Panel Name: 23.1 Academic Research - Scientific Review Council Meeting (23.1_SRC)
Panel Date: December 22, 2022
Report Date: December 23, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research - Scientific Review Council Meeting (23.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 22, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fifty-nine (59) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 23.1

Awards Announced at the February 15, 2023, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 23.1 include: *Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Translation; Individual Investigator Research Awards for Prevention and Early Detection; and Texas Regional Excellence in Cancer Award (TREC)*. Applications submitted in response to the five above listed Individual Investigator mechanisms went through preliminary evaluation as allowed by TAC § 703.6(e)(1). If a peer reviewer identified a conflict of interest during this stage, the application is labeled with a “pe” suffix.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT’s third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP230117pe/ RP230117	Patricia Chalela	The University of Texas Health Science Center at San Antonio	G. Coronado
RP230391pe/ RP230391	Maksim Mamonkin	Baylor College of Medicine	J. DiPersio
RP230184pe/ RP230184	Xiankai Sun	The University of Texas Southwestern Medical Center	A. Wu
RP230271pe/ RP230271	Niki Zacharias Millward	The University of Texas M. D. Anderson Cancer Center	A. Wu; W. Warren
RP230360pe/ RP230360	Douglas Frantz	The University of Texas at San Antonio	J. Conejo-Garcia

* Application not discussed during full review.

Academic Research
Cycle 23.1

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230213	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	T. Brandon
RP230272	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	A. Tomkinson; J. Petrini
RP230344	McBrayer, Samuel K	The University of Texas Southwestern Medical Center	C. Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP230021pe/ RP230021	Scherezade Mama	The University of Texas M. D. Anderson Cancer Center	K. Emmons
RP230044pe	Paul Scheet	The University of Texas M. D. Anderson Cancer Center	L. Mucci
RP230045pe	MinJae Lee	The University of Texas Southwestern Medical Center	G. Coronado
RP230069pe/ RP230069*	Sohail Rao	DHR Health Institute for Research and Development	L. Kushi
RP230097pe/ RP230097	Subrata Sen	The University of Texas M. D. Anderson Cancer Center	G. Petersen
RP230098pe	Julia Heck	University of North Texas	L. Mucci
RP230126pe/ RP230126*	Jose Rauh-Hain	The University of Texas M. D. Anderson Cancer Center	G. Coronado
RP230164pe	Jian Gu	The University of Texas M. D. Anderson Cancer Center	L. Mucci
RP230201pe/ RP230201	Edwin Ostrin	The University of Texas M. D. Anderson Cancer Center	C. Li
RP230279pe	Martha Mims	Baylor College of Medicine	C. Haiman
RP230284pe/ RP230284*	Surendranath Shastri	The University of Texas M. D. Anderson Cancer Center	K. Emmons

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230320pe	Chao Cheng	Baylor College of Medicine	L. Mucci
RP230002pe	Debananda Pati	Baylor College of Medicine	P. Grohar
RP230011pe/ RP230011*	Ziyi Li	The University of Texas M. D. Anderson Cancer Center	J. Issa
RP230292pe	Todd Aguilera	The University of Texas Southwestern Medical Center	W. Hahn
RP230394pe/ RP230394	Alexander Bishop	The University of Texas Health Science Center at San Antonio	P. Grohar
RP230208pe/ RP230208	Raquibul Hannan	The University of Texas Southwestern Medical Center	A. Ribas
RP230057pe/ RP230057*	Junjie Chen	The University of Texas M. D. Anderson Cancer Center	J. Petrini
RP230148pe	Paul Chiao	The University of Texas M. D. Anderson Cancer Center	A. Tomkinson; J. Petrini
RP230187pe	Christopher Amos	Baylor College of Medicine	A. Tomkinson
RP230210pe	Blerta Xhemalce	The University of Texas at Austin	A. Tomkinson
RP230232pe	Anthony Davis	The University of Texas Southwestern Medical Center	A. Tomkinson
RP230267pe	Alison Bertuch	Baylor College of Medicine	J. Karlseder
RP230296pe/ RP230296*	Zamal Ahmed	The University of Texas M. D. Anderson Cancer Center	A. Tomkinson; J. Petrini; W. Chazin
RP230322pe/ RP230322*	E. Paul Hasty	The University of Texas Health Science Center at San Antonio	A. Tomkinson
RP230079pe/ RP230079	Eva Sevick	The University of Texas Health Science Center at Houston	W. Warren
RP230177pe/ RP230177*	Henry Manning	The University of Texas M. D. Anderson Cancer Center	J. Gore

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230194pe/ RP230194	Jia Wu	The University of Texas M. D. Anderson Cancer Center	C. Kahn
RP230206pe/ RP230206	Jingfei Ma	The University of Texas M. D. Anderson Cancer Center	C. Kahn; D. Mankoff; J. Basilion
RP230209pe/ RP230209*	Andrew Wang	The University of Texas Southwestern Medical Center	W. Cai
RP230220pe	Ananth Madhuranthakam	The University of Texas Southwestern Medical Center	A. Wu
RP230238pe/ RP230238*	David Piwnica- Worms	The University of Texas M. D. Anderson Cancer Center	D. Mankoff
RP230252pe	Thomas Yankeelov	The University of Texas at Austin	J. Gore
RP230297pe/ RP230297*	Zhonglin Liu	The Methodist Hospital Research Institute	M. Giger
RP230395pe/ RP230395*	Yaowu Hao	The University of Texas at Arlington	A. Wu
RP230401pe	James Tour	Rice University	C. Kahn
RP230066pe/ RP230066*	FENG-CHUN YANG	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230155pe/ RP230155*	April Risinger	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230156pe/ RP230156*	Kexin Xu	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230159pe	Xiao-Dong Chen	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230189pe	Alexander Pertsemlidis	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230215pe	Gang Huang	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230265pe/ RP230265*	Yuzuru Shiio	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230293pe	Panneerdoss Subbarayalu	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230309pe	Stefano Tiziani	The University of Texas at Austin	J. Conejo-Garcia
RP230367*	Chen, Yidong	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230186*	Spencer, Jennifer	The University of Texas at Austin	G. Coronado

* Application not discussed during full review.

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards

Academic Research Cycle 23.1

Final Scores for Fully Reviewed Applications

Four Individual Investigator Research Awards grant applications are not recommended for funding with scores that are the same as or more favorable than some applications that were recommended. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

This comprehensive list of Individual Investigator Research Awards de-identified application scores created for the purpose of this CEO affidavit packet combines the information for all Academic Research review panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not. Within each panel, no application with a less favorable score was recommended ahead of an application with a more favorable score.

The Program Integration Committee (PIC) deferred 19 applications that the Scientific Review Council recommended from this mechanism. The 19 deferred applications are designated with “^” in the de-identified list. The PIC may consider the deferred applications at a later FY2023 meeting.

Application ID	Final Overall Evaluation Score
RP230222*	1.1
RP230140*	1.1
RP230093*	1.8
RP230072*	1.9
RP230360*	1.9
RP230135*	2.0
RP230344*	2.0
RP230109*	2.0
RP230373*	2.0
RP230224*	2.0
RP230382*	2.0
RP230247*	2.0
RP230334*	2.5
RP230391*	2.6
RP230345*	2.6
RP230271*	2.7
RP230050*	2.7
RP230261*	2.7

* Recommended for funding

^ Application deferred by the PIC.

Application ID	Final Overall Evaluation Score
ppa^	2.8
ppb^	2.8
ppc^	2.8
ppd^	2.8
ppe^	2.8
ppf^	2.9
ppg^	2.9
pph^	2.9
ppi^	2.9
ppj^	2.9
ppk^	2.9
pll^	3.0
ppm^	3.0
ppn^	3.0
ppo^	3.0
ppp^	3.0
ea	3.0
ppq^	3.1
ppr^	3.1
eb	3.1
ec	3.1
pps^	3.2
ed	3.2
Ee	3.3
Ef	3.3
Eg	3.3
Eh	3.3
Ei	3.3
Ej	3.3
Ek	3.3
El	3.3
Em	3.3
En	3.5
Eo	3.5
Ep	3.5
Eq	3.6
Er	3.6
Es	3.6
Et	3.6
Eu	3.6
Ev	3.7

* Recommended for funding
^ Application deferred by the PIC.

23.1 Individual Investigator Research Awards
Final Scores for Fully Reviewed Applications

Application ID	Final Overall Evaluation Score
Ew	3.7
Ex	3.7
Ey	3.7
Ez	3.7
Fa	3.7
Fb	3.7
Fc	3.7
Fd	3.7
Fe	3.7
Ff	3.7
Fg	3.7
Fh	3.7
Fi	3.7
Fj	3.7
Fk	3.7
Fl	3.8
Fm	3.8
Fn	3.8
Fo	3.9
Fp	3.9
Fq	3.9
Fr	3.9
Fs	3.9
Ft	4.0
Fu	4.0
Fv	4.0
Fw	4.0
Fx	4.0
Fy	4.0
Fz	4.0
Ga	4.0
Gb	4.0
Gc	4.0
Gd	4.0
Ge	4.0
Gf	4.0
Gg	4.0
Gh	4.0
Gi	4.0
Gj	4.0
Gk	4.0

* Recommended for funding
 ^ Application deferred by the PIC.

23.1 Individual Investigator Research Awards
 Final Scores for Fully Reviewed Applications

Application ID	Final Overall Evaluation Score
Gl	4.0
Gm	4.0
Gn	4.0
Go	4.0
Gp	4.0
Gq	4.1
Gr	4.1
Gs	4.1
Gt	4.2
Gu	4.2
Gv	4.2
Gw	4.3
Gx	4.3
Gy	4.3
Gz	4.3
Ha	4.3
Hb	4.3
Hc	4.3
Hd	4.3
He	4.3
Hf	4.3
Hg	4.3
Hh	4.3
Hi	4.3
Hj	4.3
Hk	4.3
Hl	4.3
Hm	4.4
Hn	4.6
Ho	4.7
Hp	4.7
Hq	4.7
Hr	4.7
Hs	4.7
Ht	4.7
Hu	4.7
Hv	4.7
Hw	5.0
Hx	5.0
Hy	5.0
Hz	5.0

* Recommended for funding
^ Application deferred by the PIC.

23.1 Individual Investigator Research Awards
Final Scores for Fully Reviewed Applications

Application ID	Final Overall Evaluation Score
la	5.0
lb	5.0
lc	5.0
ld	5.0
le	5.3
lf	5.3
lg	5.3
lh	5.3
lj	5.3
lj	5.6
lk	5.7
ll	5.7
lm	6.3
ln	6.3
lo	7.0

* Recommended for funding

^ Application deferred by the PIC.

Individual Investigator Research Awards

Academic Research Cycle 23.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

Application ID	Final Overall Score
X	3.33
Xa	3.67
Xb	3.67
Xc	3.67
Xd	4.00
Xe	4.00
Xf	4.00
Xg	4.00
Xh	4.00
Xi	4.00
Xj	4.00
Xk	4.00
Xl	4.00
Xm	4.00
Xn	4.00
Xo	4.00
Xp	4.00
Xq	4.33
Xr	4.33
Xs	4.33
Xt	4.33
Xu	4.33
Xv	4.33
Xv	4.33
Xx	4.33
Xy	4.33
Xz	4.33
Ya	4.33
Yb	4.33
Yc	4.33
Yd	4.33

Application ID	Final Overall Score
Ye	4.33
Yf	4.33
Yg	4.33
Yh	4.33
Yi	4.33
Yj	4.33
Yk	4.33
Yl	4.33
Ym	4.33
Yn	4.33
Yo	4.67
Yp	4.67
Yq	4.67
Yr	4.67
Ys	4.67
Yt	4.67
Yu	4.67
Yv	4.67
Yw	4.67
Yx	4.67
Yy	4.67
Yz	4.67
Za	4.67
Zb	4.67
Zc	4.67
Zd	4.67
Ze	5.00
Zf	5.00
Zg	5.00
Zh	5.00
Zi	5.00
Zj	5.00
Zk	5.00
Zl	5.00
Zm	5.33
Zn	5.33
Zo	5.33
Zp	5.67
Zq	5.67
Zr	5.67

23.1 Individual Investigator Research Awards
Final Scores for Preliminary Evaluation

Application ID	Final Overall Score
Zs	5.67
Zt	5.67
Zu	5.67
Zv	6.00
Zw	6.00
Zx	6.33
Zy	6.33

Final Overall Evaluation Scores and Rank Order Scores

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

January 16, 2023

Dr. Mahendra C. Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cpit.texas.gov

Dear Dr. Patel and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, and Individual Investigator Research Awards for Prevention and Early Detection

The SRC met on December 22, 2022 to consider the applications recommended by the peer review panels following their meetings held October 24, 2022 to October 31, 2022.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$67,370,879.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Award Mech	Meeting Overall Score	Application Title	PI	PI Organization	Recommended Budget
1	RP230026	IIRACCA	1.0	Identifying Clinical Methotrexate Toxicity Phenotypes Across Phases of Pediatric Leukemia Therapy	Bernhardt, Melanie	Baylor College of Medicine	\$1,392,407
2	RP230036	IIRAP	1.0	Geospatial Approaches to Melanoma Early Detection: The GAMED Project	Nelson, Kelly	The University of Texas M. D. Anderson Cancer Center	\$1,998,196
3	RP230222	IIRA	1.1	Personalized Auricular Point Acupressure to Self-Manage Cancer-Related Pain	Yeh, Chao Hsing	The University of Texas Health Science Center at Houston	\$1,046,680
4	RP230140	IIRA	1.1	Changes in Tumor Microenvironment That Promote Cachexia	Infante, Rodney	The University of Texas Southwestern Medical Center	\$1,050,000
5	RP230093	IIRA	1.8	Targeting the Mlc1-GlialCAM Protein Complex in Invasive Glioma Cells	McCarty, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,050,000

6	RP230018	IIRACCA	1.9	Neuronal Alterations in the Midbrain Dopaminergic System Function: A Novel Mechanism of Radiation-Induced Cognitive Dysfunction	Zhang, Die	The University of Texas M. D. Anderson Cancer Center	\$1,399,730
7	RP230117	IIRAP	1.9	Randomized Controlled Trial to Assess Innovative Smoking Cessation Services for Young Adults in Texas	Chalela, Patricia	The University of Texas Health Science Center at San Antonio	\$1,992,330
8	RP230072	IIRA	1.9	Studying and Therapeutically Targeting Ferroptosis Liability in BRCA1-Deficient Cancer	Gan, Boyi	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
9	RP230360	IIRA	1.9	Rational Design, Synthesis, and Biological Evaluation of Simplified Taccalonolide Analogs for the Treatment of Cancer	Frantz, Douglas	The University of Texas at San Antonio	\$1,049,128
10	RP230135	IIRA	2.0	Blocking DNA Damage Response Induction of "Don't Eat Me" Signals Converts Local Radiotherapy Into Systemic Immunotherapy	Curran, Michael	The University of Texas M. D. Anderson Cancer Center	\$1,049,905
11	RP230344	IIRA	2.0	Development and Evaluation of Lanosterol Synthase Inhibitors in Preclinical GBM Models	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,048,465
12	RP230109	IIRA	2.0	Autophagy and Tumor Endothelium	Terada, Lance	The University of Texas Southwestern Medical Center	\$1,049,994
13	RP230373	IIRA	2.0	Mapping the Geospatial Tumor Clonal Architecture to Restore	Viale, Andrea	The University of Texas M.	\$1,049,985

				Immune Recognition in Pancreatic Cancer		D. Anderson Cancer Center	
14	RP230224	IIRA	2.0	Enhancing Immune Responses in Pancreatic Cancer by Stromal Inhibition of HIF2	Taniguchi, Cullen	The University of Texas M. D. Anderson Cancer Center	\$1,049,997
15	RP230382	IIRA	2.0	Characterization of 3D Genome Organization and Transcriptional Regulation in Prostate Cancer	Mani, Ram	The University of Texas Southwestern Medical Center	\$1,049,641
16	RP230247	IIRA	2.0	A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer	Lin, Sue-Hwa	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
17	RP230063	IIRAP	2.1	Whole-Genome DNA Methylation Markers for Tracking and Predicting Advanced Liver Fibrosis as a Precursor of Liver Cancer in NAFLD	Tsai, Robert	Texas A&M University System Health Science Center	\$2,000,000
18	RP230285	IIRACT	2.2	Harnessing Endoplasmic Reticulum Stress to Overcome Resistance to Immunotherapy in Immune-Cold Breast Cancer	Chen , Xi	Baylor College of Medicine	\$2,000,000
19	RP230160	IIRACSBC	2.2	Overcoming Therapy Resistance by Integrated Computational Modeling of the Bone Metastatic Niche in Prostate and Renal Cancers	Dondossola , Eleonora	The University of Texas M. D. Anderson Cancer Center	\$1,025,623
20	RP230334	IIRA	2.5	Elucidating the Mutagenesis Mechanism of BRAF in Melanoma	Lee, Seongmin	The University of Texas at Austin	\$1,050,000

21	RP230120	IIRACCA	2.5	Clonal Evolution and Chemoresistance of Hepatoblastomas With Hepatocellular Carcinoma Features	Sumazin, Pavel	Baylor College of Medicine	\$1,371,733
22	RP230213	IIRAP	2.6	Multicomponent Interventions to Improve Uptake and Adherence to Lung Cancer Screening	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$1,988,211
23	RP230363	IIRACSBC	2.6	Developing Knowledge-Guided Deep Learning Models to Predict the Binding Between T-Cell Receptors and Neoantigens for Facilitating TCR-T Therapies	Wang, Tao	The University of Texas Southwestern Medical Center	\$1,199,997
24	RP230391	IIRA	2.6	Understanding and Improving CAR T-Cell Therapy of T-ALL and LBL	Mamonkin, Maksim	Baylor College of Medicine	\$1,050,000
25	RP230345	IIRA	2.6	The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T-Cell Therapy	Liu, Wenshe	Texas A&M University	\$1,050,000
26	RP230166	IIRACSBC	2.6	Integrative Modeling of Spatially Resolved Multiomics Data to Identify Bladder Cancer Mucosal Field Effects	Wei, Peng	The University of Texas M. D. Anderson Cancer Center	\$1,199,994
27	RP230154	IIRACCA	2.6	Normalizing Membrane Homeostasis in Microglia/Macrophages of Pediatric High-Grade Gliomas	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$1,400,000
28	RP230271	IIRA	2.7	Targeting Distinct Metabolic Vulnerabilities of Aggressive Renal Cell Carcinoma Variants	Zacharias Millward, Niki	The University of Texas M. D. Anderson	\$1,019,997

						Cancer Center	
29	RP230330	IIRACCA	2.7	Integrate Whole-Slide Imaging and Genomic Data to Study Pediatric Rhabdomyosarcoma	Xiao, Guanghua	The University of Texas Southwestern Medical Center	\$1,303,815
30	RP230050	IIRA	2.7	A Novel Therapeutic Strategy Targeting Pancreatic Cancer	Yao, Wantong	The University of Texas M. D. Anderson Cancer Center	\$1,049,854
31	RP230261	IIRA	2.7	Investigating the Mechanism of NLRP3 Inflammasome Hyperactivation During Hepatocellular Carcinoma Development	Zhong, Zhenyu	The University of Texas Southwestern Medical Center	\$1,049,997
32	RP230019	IIRA	2.8	Deciphering Spatial Immune Contextures Through Integrative Immunoproteogenomics	Lee, Hyun-Sung	Baylor College of Medicine	\$1,050,000
33	RP230161	IIRACT	2.8	¹³ C MRI With Hyperpolarized Pyruvate for Management of Glioblastoma	Park, Jae Mo	The University of Texas Southwestern Medical Center	\$1,727,462
34	RP230307	IIRA	2.8	In Vivo Chimeric Antigen Receptor Macrophages (ChARMs) for Cancer Immunotherapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$1,026,414
35	RP230241	IIRA	2.8	PD-L1 Modifications and Membranous Localization	Li, Yong	Baylor College of Medicine	\$1,049,994
36	RP230375	IIRA	2.8	Targeting Chitinase-3-Like-1 as a Novel Therapy for Hepatocellular Carcinoma	Ju, Cynthia	The University of Texas Health Science Center at Houston	\$1,049,769

37	RP230283	IIRA	2.8	Development of Immunotherapy and Combinatorial Therapy of Sickle Cell Trait-Associated Renal Medullary Carcinoma	Yang, Liuqing	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
38	RP230323	IIRA	2.9	Real-Time, Label-Free, Micro HSI Device and Transformer-Based Attention Networks for Oral Cancer Imaging	Fei, Baowei	The University of Texas at Dallas	\$1,048,933
39	RP230184	IIRA	2.9	Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Drugs for Precision Cancer Medicine	Sun, Xiankai	The University of Texas Southwestern Medical Center	\$1,049,997
40	RP230216	IIRA	2.9	Investigating Cell Competition in Liver Cancer Development	Zhu, Hao	The University of Texas Southwestern Medical Center	\$1,050,000
41	RP230381	IIRA	2.9	JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC	ZHANG, QING	The University of Texas Southwestern Medical Center	\$1,036,126
42	RP230319	IIRACSBC	2.9	Computational Methods for CRISPR-Based Lineage Tracing Systems	Liu, Zhandong	Baylor College of Medicine	\$1,200,000
43	RP230112	IIRA	2.9	The Evolution of Intratumor Heterogeneity of Lung Cancers With or Without Immunotherapy and Its Impact on Patient Survival	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,049,396
44	RP230143	IIRACCA	2.9	The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT	Ludwig, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,399,860

45	RP230240	IIRA	2.9	Therapeutic Targeting of Androgen Receptor in Metastatic Breast Cancer	Fuqua, Suzanne	Baylor College of Medicine	\$1,050,000
46	RP230272	IIRA	3.0	Structure-Based Improvement for Inhibitors of WNK1, a Triple-Negative Breast Cancer Signature Kinase	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	\$1,050,000
47	RP230327	IIRA	3.0	Harnessing the Metabolic Dependencies of Mitochondrial NADK2 as a Therapeutic Strategy for Lung Cancer	Hoxhaj, Gerta	The University of Texas Southwestern Medical Center	\$1,049,997
48	RP230071	IIRA	3.0	Unexpected Mechanisms Underlying Mutation-Induced Protein Mislocalization in Hematologic Malignancies	Liszcak, Glen	The University of Texas Southwestern Medical Center	\$1,049,997
49	RP230012	IIRA	3.0	Targeting a Non-ATPase Proteasome Subunit in Acute Myeloid Leukemia (AML)	Eiring, Anna	Texas Tech University Health Sciences Center at El Paso	\$1,050,000
50	RP230174	IIRACCA	3.0	Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites	Ehrlich, Lauren	The University of Texas at Austin	\$1,400,000
51	RP230196	IIRA	3.0	Identifying the Biological Determinants of Aggressive Meningioma	Patel, Akash	Baylor College of Medicine	\$1,047,289
52	RP230134	IIRACSB	3.0	Therapeutic Vulnerabilities and Predictors of Response to Chemo(Immuno)Therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC)	Korkut, Anil	The University of Texas M. D. Anderson Cancer Center	\$1,199,966
53	RP230333	IIRA	3.1	Development of a Cell Therapy Platform for Localized and Feedback-Regulated Delivery of Cytokines for the	Veisheh, Omid	Rice University	\$1,050,000

				Treatment of Pancreatic Cancer			
54	RP230162	IIRACCA	3.1	The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma	Kitagawa, Katsumi	The University of Texas Health Science Center at San Antonio	\$1,400,000
55	RP230181	IIRA	3.1	Dissection of CAMKK2's Tumor Cell-Intrinsic and - Extrinsic Roles in Prostate Cancer	Frigo, Daniel	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
56	RP230197	IIRA	3.2	Targeting MYCN Disruption of the Molecular Clock and Tumor Metabolism in Neuroblastoma Oncogenesis	Barbieri, Eveline	Baylor College of Medicine	\$1,050,000

Individual Investigator Research Awards (IIRA)
 Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
 Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
 Individual Investigator Research Awards for Clinical Translation (IIRACT)
 Individual Investigator Research Awards for Prevention and Early Detection (IIRAP).



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2023—Cycle 1
*Individual Investigator Research Awards for
Cancer in Children and Adolescents***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-23.1-IIRACCA

**Individual Investigator Research Awards
for Cancer in Children and Adolescents**

**Please also refer to the Instructions for Applicants document,
which will be posted on March 16, 2022**

Application Receipt Opening Date: March 16, 2022

Application Receipt Closing Date: June 8, 2022

FY2023

Fiscal Year Award Period
September 1, 2022-August 31, 2023

TABLE OF CONTENTS

1. BRIEF DESCRIPTION OF RFA	4
2. ABOUT CPRIT	4
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
3. RATIONALE	5
4. RESEARCH OBJECTIVES	6
5. FUNDING INFORMATION	7
6. ELIGIBILITY	7
7. RESUBMISSION POLICY	9
8. RENEWAL POLICY	9
9. RESPONDING TO THIS RFA	10
9.1. APPLICATION SUBMISSION GUIDELINES	10
9.1.1. <i>Submission Deadline Extension</i>	10
9.2. APPLICATION COMPONENTS	10
9.2.1. <i>Abstract and Significance (5,000 characters)</i>	10
9.2.2. <i>Layperson’s Summary (2,000 characters)</i>	11
9.2.3. <i>Goals and Objectives</i>	11
9.2.4. <i>Timeline (1 page)</i>	12
9.2.5. <i>Resubmission Summary (2 Pages)</i>	12
9.2.6. <i>Renewal Summary (2 pages)</i>	12
9.2.7. <i>Research Plan (10 pages)</i>	12
9.2.8. <i>Vertebrate Animals (1 page)</i>	13
9.2.9. <i>Human Subjects (2 pages)</i>	13
9.2.10. <i>Publications/References</i>	13
9.2.11. <i>Budget and Justification</i>	13
9.2.12. <i>Biographical Sketches (5 pages each)</i>	15
9.2.13. <i>Current and Pending Support</i>	15
9.2.14. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i>	15
9.2.15. <i>Previous Summary Statement</i>	15
9.3. FORMATTING INSTRUCTIONS	15
10. APPLICATION REVIEW	16
10.1. PRELIMINARY EVALUATION.....	16
10.2. FULL PEER REVIEW	17
10.3. CONFIDENTIALITY OF REVIEW	18
10.4. REVIEW CRITERIA.....	18
10.4.1. <i>Primary Criteria</i>	19
10.4.2. <i>Secondary Criteria</i>	20
11. KEY DATES	20
12. AWARD ADMINISTRATION	20
13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	21
14. CONTACT INFORMATION	22
14.1. HELPDESK.....	22
14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	22

RFA VERSION HISTORY

01/14/22 RFA released

Rev 3/16/22 Section 9.2.11 – Budget and Justification

- Added language regarding allowable reimbursement of clinical trial participation costs

1. BRIEF DESCRIPTION OF RFA

- Supports applications for innovative research project addressing questions that will advance knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents.
- Applicants may request a maximum of \$350,000 per year for a period of up to 4 years. Applicants who plan on conducting a clinical trial as part of the project may request up to \$150,000 in additional total costs per year for the time frame that the trial is active.
- Multi-PIs (MI) are allowed under this RFA. See the Information for Applicants (IFA) document for definition and eligibility of Multi-PIs.
- Note that CPRIT does not allow the use of the term Co-PI.
- Minimum effort for the PI and/or Multi-PIs throughout the project period is required.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure
- Achieving health equity and reducing cancer disparities.

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

3. RATIONALE

In recent decades, great strides have been made in reducing mortality from childhood cancers. Most of these gains have been realized in childhood leukemia and lymphoma. However, improvements in survival have been less robust in other types of childhood cancers, which make up more than 40% of total cancer cases in children and adolescents aged 0 to 19 years.

Furthermore, the overall incidence of pediatric cancer has increased at an annual rate of 0.6% since 1975, with most of the increases being seen in acute lymphoblastic leukemia, brain and central nervous system tumors, non-Hodgkin lymphoma, and testicular germ cell tumors.

Reasons for increases in these tumor types are unknown, indicating that information on the etiology of these cancers is urgently needed. Because of the high rates of survival for certain childhood and adolescent cancers, there are increasing numbers of survivors of such cancers living today. These individuals have a high rate of late effects from the cancer or its treatment, including the occurrence of additional cancers. Clearly, more effective, less-toxic treatments are needed for these diseases. However, few new therapies have been developed in recent years.

Several reasons account for the paucity of new treatments, including the lack of interest on the

part of pharmaceutical companies in developing treatments for cancers that account for only 1% of all cancer cases and the difficulty of collecting sufficient numbers of tumors for laboratory studies.

Because cancers in children and adolescents differ from those in adults with regard to genetic alterations and biological behavior, application of adult therapies to these cancers may not be successful. Therefore, this area of investigation represents an opportunity for CPRIT to deploy funding in an area of critical need that is not heavily represented in other funding portfolios.

4. RESEARCH OBJECTIVES

This Request for Applications (RFA) solicits applications for innovative research projects addressing questions that will advance current knowledge of the causes, prevention, progression, detection, or treatment of cancer in children and adolescents. Applications may address any topic related to these areas as well as projects dealing with the causes or amelioration of late effects of cancer treatment. Laboratory, clinical, or population-based studies are all acceptable. CPRIT expects the outcome of the research to reduce the incidence, morbidity, or mortality from cancer in children and/or adolescents in the near or long-term. Applications that seek to apply or develop state-of-the-art approaches, technologies, tools, treatments, and/or resources are encouraged, particularly those with potential for commercialization. Applications that address cancer disparities will be looked on with special favor. Successful applicants should be working in a research environment capable of supporting potentially high-impact studies.

The subject of applications may include, but is not limited to, the following:

- Causes of cancer in children and adolescents, including genetic factors or prenatal exposure to environmental agents;
- Identification of risk factors for cancer development;
- New methods for diagnosing cancers in children and/or adolescents;
- Development of new therapies, including targeted therapies, immunotherapies, and new drugs;
- Identification of patients at risk of developing late effects of cancer treatment;
- Improvements in quality of life for survivors of childhood and adolescent cancers; and
- Identification of the determinants for cancer outcomes and mitigation to reduce cancer disparities.

The *degree of relevance* to reducing the burden of cancer in these populations is a critical criterion for evaluation of projects for funding by CPRIT ([section 10.4.1](#)).

5. FUNDING INFORMATION

Applicants may request a maximum of \$350,000 per year for a period of up to 4 years.

Applicants who plan on conducting a clinical trial as part of the project may request up to \$150,000 in additional total costs per year for the time frame that the trial is active. Note that an individual detailed budget for conducting a clinical trial is required. If a clinical trial is proposed, the budget justification must include a timeline for the clinical trial initiation and accrual targets. Applicants should provide documentation that the proposed trial is feasible with the project timeline. Exceptions to these limits may be requested if extremely well justified. Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

Please see [section 9.2.11](#) and the IFA for additional information.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The Principal Investigator (PI) must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- This award mechanism allows Multi-PIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for Multi-PI awards).
- For applications that include 1 Principal Investigator (PI), the PI is required to maintain a minimum 15% level of effort throughout the entire award period. For applications that

include MIs, each PI is required to maintain a minimum 10% effort throughout the entire award period.

- A PI may not submit applications to this RFA and to RFA R-23.1-IIRA, RFA 23.1-IIRACSBC, RFA R-23.1-IIRACT, or RFA R-23.1-IIRAP.
- A PI may submit only 1 application, either a new, resubmission or renewal application under this RFA during this funding cycle.
- A PI may be a part of only one application, whether as a single applicant or as part of a Multi-PI application, under this RFA and RFA R-23.1-IIRA, RFA R-23.1-IIRACSBC, RFA R-23.1-IIRACT, or RFA R-23.1-IIRAP.
- An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project Co-PIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2022).
- Applications that address prevention, early detection, or population-based studies, computational systems biology of cancer, or innovative clinical trials should be submitted under the appropriate targeted RFA.
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.

- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether these individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines. More than 1 resubmission is not permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PI for a project or a change of title of the project that was previously submitted to CPRIT or omission or modification of an aim do not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 9.2.5](#).

8. RENEWAL POLICY

An application funded by CPRIT under this mechanism may be submitted for a competitive renewal. An application originally funded by CPRIT as an IIRA that is appropriate for the IIRACCA mechanism may be submitted under this RFA for a competitive renewal. See [section 9.2.6](#). Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 10.2](#).

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 16, 2022, and must be submitted by 4 PM central time on June 8, 2022. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#), within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section

wisely. **Based on the Abstract and Significance statement (and the Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from further peer review (see [section 10.1](#)).** Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the research plan.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Indicate whether this research will address cancers associated with disparities. Summarize how the proposed research creates new paradigms or challenges existing ones. Indicate whether this research plan represents a new direction for the PI.

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 10.2](#)) in evaluating the significance and impact of the proposed work.

9.2.3. Goals and Objectives

List specific goals and objectives for each year of the project. These goals and objectives will also be used during the submission and evaluation of progress reports and assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Resubmission Summary (2 Pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a fresh research plan or modify the original research plan and mark the changes. However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

9.2.6. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

9.2.7. Research Plan (10 pages)

Background: Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application. Describe the significance, innovation, and potential impact of the research.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

9.2.8. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

9.2.9. Human Subjects (2 pages)

If human subjects or human biological samples will be used, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

9.2.10. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.11. Budget and Justification

Provide a compelling and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, costs associated with the conduct of a clinical trial, animal care costs, and other expenses. Do not exceed \$350,000 per year for a period of up to 4 years. Applicants who plan on conducting a clinical trial as part of the project may request up to \$150,000 in additional total costs per year during the time frame that the clinical trial is active and must not exceed \$500,000 per year during that time frame. While there will be 1 budget for the entire project, an individual budget and budget justification for the conduct of a clinical trial **must be included**. The justification should include the statistical considerations that led to the clinical trial design, accrual milestones, and validation of biomarkers. Applicants are advised not to interpret the maximum allowable time and funding under this award as a suggestion that they should expand their anticipated work and budget to this level. Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2023 is \$200,000; CPRIT FY 2023 is from September 1, 2022, through August 31, 2023. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.
- Funds can be used to pay for costs that a cancer clinical trial participant may have associated with their participation in a clinical trial, including: 1) transportation, including car mileage, parking, bus fare, taxi or ride hailing fare exclusive of tips, and commercial economy class airfare within the borders of the State of Texas; 2) lodging.

9.2.12. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research.

A biographical sketch must be provided for the PI and, if applicable, any additional PIs (if a MI application), as required by the online application receipt system. Up to 2 additional biographical sketches for key personnel may be provided. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

9.2.13. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional PIs (if a MI application), must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.14. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

9.2.15. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components, exceed the specified page, word, or budget limits, or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only

- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may be

preliminarily evaluated by CPRIT Scientific Research Program panel members for scientific merit and impact.

This preliminary evaluation will be based on a subset of material presented in the application—namely, Abstract and Significance, Budget and Justification, and Biographical Sketches. Applications that do not sufficiently capture the reviewers' interest at this stage will not be considered for further review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation stage has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

10.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC.

The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.3. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, (Texas Administrative Code [RULE §703.9](#)).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and

subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.4.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention, diagnosis, or treatment for patients? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required creativity and expertise to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of their time (percent effort) to this project?

Relevance: Does the proposed research address cancer in children or adolescents? Is it likely to make an impact on these diseases? This is a critical criterion for evaluation of projects for CPRIT support.

10.4.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release January 14, 2022

Application

Online application opens March 16, 2022, 7 AM central time

Application due June 8, 2022, 4 PM central time

Application review June 2022–February 2023

Award

Award notification February 2023

Anticipated start date March 1, 2023

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to

exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The

demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

14. CONTACT INFORMATION

14.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director of Academic Research.

Tel: 512-305-8491

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Imaging Technology and
Informatics (ITI) (23.1 AR ITI)
Observation Report

Report No. 2022-10-24 23.1_AR_ITI
Program Name: Academic Research
Panel Name: 23.1 Academic Research Imaging Technology and Informatics (ITI)
(23.1_AR_ITI)
Panel Date: October 24, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Imaging Technology and Informatics (ITI) (23.1_AR_ITI) meeting. The meeting was chaired by Martin Pomper and conducted via videoconference on October 24, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were thirteen (13) Conflicts of Interest (COIs) identified prior to and/or during the meeting. Seven (7) applications with COIs were discussed and six (6) applications with COIs were not discussed. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Review Panel - Basic Cancer

Research (23.1 AR BCR-2)

Observation Report

Report No. 2022-10-25 23.1_AR_BCR-2
Program Name: Academic Research
Panel Name: 23.1 Academic Research Review Panel - Basic Cancer Research
(23.1_AR_BCR-2)
Panel Date: October 25, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Review Panel - Basic Cancer Research (23.1_AR_BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 25, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Sixteen (16) applications were discussed, and eighteen (18) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies and answering procedural questions

Eight (8) Conflicts of Interest (COIs) were identified prior to and/or during the meeting. Three (3) applications with COIs were discussed and three (3) applications with COIs were not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Cancer Prevention Research (CPR)
(23.1 AR CPR)
Observation Report

Report No. 2022-10-26 23.1_AR_CPR
Program Name: Academic Research
Panel Name: 23.1 Academic Research Cancer Prevention Research (CPR) (23.1
_AR_CPR)
Panel Date: October 26, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Cancer Prevention Research (CPR) (23.1_AR_CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 26, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty (20) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were nine (9) Conflicts of Interest (COIs) identified prior to and/or during the meeting. Four (4) applications with COIs were discussed and five (5) applications with COIs were not discussed. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (23.1 AR C/TCR)
Observation Report

Report No. 2022-10-27 23.1_AR_C/TCR
Program Name: Academic Research
Panel Name: 23.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (23.1_AR_C/TCR)
Panel Date: October 27, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Clinical and Translational Cancer Research (C/TCR) (23.1_AR_C/TCR) meeting. The meeting was chaired by Margaret Tempero and Richard O'Reilly and conducted via videoconference on October 27, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-four (24) applications were discussed and twenty-two (22) applications were not discussed
- Panelists: Two (2) panel chairs, twenty (20) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COI) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Review Panel - Basic Cancer

Research-1 (23.1 AR BCR-1)

Observation Report

Report No. 2022-10-28 23.1_AR_BCR-1
Program Name: Academic Research
Panel Name: 23.1 Academic Research Review Panel - Basic Cancer Research-1
(23.1_AR_BCR-1)
Panel Date: October 28, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Review Panel - Basic Cancer Research-1 (23.1_AR_BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on October 28, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eighteen (18) applications were discussed, and sixteen (16) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. One (1) application with a COI was discussed and five (5) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Cancer Biology (CB)

(23.1 ACR CB)

Observation Report

Report No. 2022-10-31 23.1_ACR_CB
Program Name: Academic Research
Panel Name: 23.1 Academic Research Cancer Biology (CB) (23.1 _ACR_CB)
Panel Date: October 31, 2022
Report Date: November 1, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Cancer Biology (CB) (23.1_ACR_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on October 31, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to the observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and twenty-nine (29) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions
- CPRIT Oversight Committee members: One (1)
- CPRIT Oversight Committee member(s) participation was limited observing the proceedings

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. One (1) application with a COI was discussed and one (1) application with COI was not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and

scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research - Scientific Review Council Meeting
(23.1 SRC)
Observation Report

Report No. 2022-12-22 23.1_SRC
Program Name: Academic Research
Panel Name: 23.1 Academic Research - Scientific Review Council Meeting (23.1_SRC)
Panel Date: December 22, 2022
Report Date: December 23, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research - Scientific Review Council Meeting (23.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 22, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fifty-nine (59) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 23.1

Awards Announced at the February 15, 2023, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 23.1 include: *Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Translation; Individual Investigator Research Awards for Prevention and Early Detection; and Texas Regional Excellence in Cancer Award (TREC)*. Applications submitted in response to the five above listed Individual Investigator mechanisms went through preliminary evaluation as allowed by TAC § 703.6(e)(1). If a peer reviewer identified a conflict of interest during this stage, the application is labeled with a “pe” suffix.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT’s third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP230117pe/ RP230117	Patricia Chalela	The University of Texas Health Science Center at San Antonio	G. Coronado
RP230391pe/ RP230391	Maksim Mamonkin	Baylor College of Medicine	J. DiPersio
RP230184pe/ RP230184	Xiankai Sun	The University of Texas Southwestern Medical Center	A. Wu
RP230271pe/ RP230271	Niki Zacharias Millward	The University of Texas M. D. Anderson Cancer Center	A. Wu; W. Warren
RP230360pe/ RP230360	Douglas Frantz	The University of Texas at San Antonio	J. Conejo-Garcia

* Application not discussed during full review.

Academic Research
Cycle 23.1

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230213	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	T. Brandon
RP230272	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	A. Tomkinson; J. Petrini
RP230344	McBrayer, Samuel K	The University of Texas Southwestern Medical Center	C. Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP230021pe/ RP230021	Scherezade Mama	The University of Texas M. D. Anderson Cancer Center	K. Emmons
RP230044pe	Paul Scheet	The University of Texas M. D. Anderson Cancer Center	L. Mucci
RP230045pe	MinJae Lee	The University of Texas Southwestern Medical Center	G. Coronado
RP230069pe/ RP230069*	Sohail Rao	DHR Health Institute for Research and Development	L. Kushi
RP230097pe/ RP230097	Subrata Sen	The University of Texas M. D. Anderson Cancer Center	G. Petersen
RP230098pe	Julia Heck	University of North Texas	L. Mucci
RP230126pe/ RP230126*	Jose Rauh-Hain	The University of Texas M. D. Anderson Cancer Center	G. Coronado
RP230164pe	Jian Gu	The University of Texas M. D. Anderson Cancer Center	L. Mucci
RP230201pe/ RP230201	Edwin Ostrin	The University of Texas M. D. Anderson Cancer Center	C. Li
RP230279pe	Martha Mims	Baylor College of Medicine	C. Haiman
RP230284pe/ RP230284*	Surendranath Shastri	The University of Texas M. D. Anderson Cancer Center	K. Emmons

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230320pe	Chao Cheng	Baylor College of Medicine	L. Mucci
RP230002pe	Debananda Pati	Baylor College of Medicine	P. Grohar
RP230011pe/ RP230011*	Ziyi Li	The University of Texas M. D. Anderson Cancer Center	J. Issa
RP230292pe	Todd Aguilera	The University of Texas Southwestern Medical Center	W. Hahn
RP230394pe/ RP230394	Alexander Bishop	The University of Texas Health Science Center at San Antonio	P. Grohar
RP230208pe/ RP230208	Raquibul Hannan	The University of Texas Southwestern Medical Center	A. Ribas
RP230057pe/ RP230057*	Junjie Chen	The University of Texas M. D. Anderson Cancer Center	J. Petrini
RP230148pe	Paul Chiao	The University of Texas M. D. Anderson Cancer Center	A. Tomkinson; J. Petrini
RP230187pe	Christopher Amos	Baylor College of Medicine	A. Tomkinson
RP230210pe	Blerta Xhemalce	The University of Texas at Austin	A. Tomkinson
RP230232pe	Anthony Davis	The University of Texas Southwestern Medical Center	A. Tomkinson
RP230267pe	Alison Bertuch	Baylor College of Medicine	J. Karlseder
RP230296pe/ RP230296*	Zamal Ahmed	The University of Texas M. D. Anderson Cancer Center	A. Tomkinson; J. Petrini; W. Chazin
RP230322pe/ RP230322*	E. Paul Hasty	The University of Texas Health Science Center at San Antonio	A. Tomkinson
RP230079pe/ RP230079	Eva Sevick	The University of Texas Health Science Center at Houston	W. Warren
RP230177pe/ RP230177*	Henry Manning	The University of Texas M. D. Anderson Cancer Center	J. Gore

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230194pe/ RP230194	Jia Wu	The University of Texas M. D. Anderson Cancer Center	C. Kahn
RP230206pe/ RP230206	Jingfei Ma	The University of Texas M. D. Anderson Cancer Center	C. Kahn; D. Mankoff; J. Basilion
RP230209pe/ RP230209*	Andrew Wang	The University of Texas Southwestern Medical Center	W. Cai
RP230220pe	Ananth Madhuranthakam	The University of Texas Southwestern Medical Center	A. Wu
RP230238pe/ RP230238*	David Piwnica- Worms	The University of Texas M. D. Anderson Cancer Center	D. Mankoff
RP230252pe	Thomas Yankeelov	The University of Texas at Austin	J. Gore
RP230297pe/ RP230297*	Zhonglin Liu	The Methodist Hospital Research Institute	M. Giger
RP230395pe/ RP230395*	Yaowu Hao	The University of Texas at Arlington	A. Wu
RP230401pe	James Tour	Rice University	C. Kahn
RP230066pe/ RP230066*	FENG-CHUN YANG	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230155pe/ RP230155*	April Risinger	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230156pe/ RP230156*	Kexin Xu	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230159pe	Xiao-Dong Chen	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230189pe	Alexander Pertsemliadis	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230215pe	Gang Huang	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230265pe/ RP230265*	Yuzuru Shiio	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230293pe	Panneerdoss Subbarayalu	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230309pe	Stefano Tiziani	The University of Texas at Austin	J. Conejo-Garcia
RP230367*	Chen, Yidong	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230186*	Spencer, Jennifer	The University of Texas at Austin	G. Coronado

* Application not discussed during full review.

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards for Cancer in Children and Adolescents

Academic Research Cycle 23.1

Final Scores for Fully Reviewed Applications

Two Individual Investigator Research Awards for Cancer in Children and Adolescents grant applications are not recommended for funding with scores that are the same as some applications that were recommended. An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding.

This comprehensive list of Individual Investigator Research Awards de-identified application scores created for the purpose of this CEO affidavit packet combines the information for all Academic Research review panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not. Within each panel, no application with a less favorable score was recommended ahead of an application with a more favorable score.

The Program Integration Committee (PIC) deferred three applications that the Scientific Review Council recommended from this mechanism. The three deferred applications are designated with “^” in the de-identified list. The PIC may consider the deferred applications at a later FY2023 meeting.

Application ID	Final Overall Evaluation Score
RP230026*	1.0
RP230018*	1.9
RP230120*	2.5
RP230154*	2.6
RP230330*	2.7
qqa^	2.9
qqb^	3.0
qqc^	3.1
Ja	3.1
Jb	3.1
Jc	3.5
Jd	3.6
Je	3.8
Jf	4.0
Jg	4.3
Jh	4.3
Ji	4.7

* Recommended for Funding

T^ Application deferred by the PIC.

Jj	5.0
Jk	5.0
Jl	5.3
Jm	5.7

* Recommended for Funding
T^ Application deferred by the PIC.

Individual Investigator Research Awards for Cancer in Children and Adolescents

Academic Research Cycle 23.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

Application ID	Final Overall Score
Zza	3.67
Zzb	3.67
Zzc	4.00
Zzd	4.33
Zze	4.33
Zzf	4.67
Zzg	4.67
Zzh	5.67

Final Overall Evaluation Scores and Rank Order Scores

**Ludwig Institute for
Cancer Research Ltd**

**Richard D. Kolodner
Ph.D.**

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

January 16, 2023

Dr. Mahendra C. Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cpit.texas.gov

Dear Dr. Patel and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, and Individual Investigator Research Awards for Prevention and Early Detection

The SRC met on December 22, 2022 to consider the applications recommended by the peer review panels following their meetings held October 24, 2022 to October 31, 2022.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$67,370,879.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Award Mech	Meeting Overall Score	Application Title	PI	PI Organization	Recommended Budget
1	RP230026	IIRACCA	1.0	Identifying Clinical Methotrexate Toxicity Phenotypes Across Phases of Pediatric Leukemia Therapy	Bernhardt, Melanie	Baylor College of Medicine	\$1,392,407
2	RP230036	IIRAP	1.0	Geospatial Approaches to Melanoma Early Detection: The GAMED Project	Nelson, Kelly	The University of Texas M. D. Anderson Cancer Center	\$1,998,196
3	RP230222	IIRA	1.1	Personalized Auricular Point Acupressure to Self-Manage Cancer-Related Pain	Yeh, Chao Hsing	The University of Texas Health Science Center at Houston	\$1,046,680
4	RP230140	IIRA	1.1	Changes in Tumor Microenvironment That Promote Cachexia	Infante, Rodney	The University of Texas Southwestern Medical Center	\$1,050,000
5	RP230093	IIRA	1.8	Targeting the Mlc1-GlialCAM Protein Complex in Invasive Glioma Cells	McCarty, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,050,000

6	RP230018	IIRACCA	1.9	Neuronal Alterations in the Midbrain Dopaminergic System Function: A Novel Mechanism of Radiation-Induced Cognitive Dysfunction	Zhang, Die	The University of Texas M. D. Anderson Cancer Center	\$1,399,730
7	RP230117	IIRAP	1.9	Randomized Controlled Trial to Assess Innovative Smoking Cessation Services for Young Adults in Texas	Chalela, Patricia	The University of Texas Health Science Center at San Antonio	\$1,992,330
8	RP230072	IIRA	1.9	Studying and Therapeutically Targeting Ferroptosis Liability in BRCA1-Deficient Cancer	Gan, Boyi	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
9	RP230360	IIRA	1.9	Rational Design, Synthesis, and Biological Evaluation of Simplified Taccalonolide Analogs for the Treatment of Cancer	Frantz, Douglas	The University of Texas at San Antonio	\$1,049,128
10	RP230135	IIRA	2.0	Blocking DNA Damage Response Induction of "Don't Eat Me" Signals Converts Local Radiotherapy Into Systemic Immunotherapy	Curran, Michael	The University of Texas M. D. Anderson Cancer Center	\$1,049,905
11	RP230344	IIRA	2.0	Development and Evaluation of Lanosterol Synthase Inhibitors in Preclinical GBM Models	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,048,465
12	RP230109	IIRA	2.0	Autophagy and Tumor Endothelium	Terada, Lance	The University of Texas Southwestern Medical Center	\$1,049,994
13	RP230373	IIRA	2.0	Mapping the Geospatial Tumor Clonal Architecture to Restore	Viale, Andrea	The University of Texas M.	\$1,049,985

				Immune Recognition in Pancreatic Cancer		D. Anderson Cancer Center	
14	RP230224	IIRA	2.0	Enhancing Immune Responses in Pancreatic Cancer by Stromal Inhibition of HIF2	Taniguchi, Cullen	The University of Texas M. D. Anderson Cancer Center	\$1,049,997
15	RP230382	IIRA	2.0	Characterization of 3D Genome Organization and Transcriptional Regulation in Prostate Cancer	Mani, Ram	The University of Texas Southwestern Medical Center	\$1,049,641
16	RP230247	IIRA	2.0	A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer	Lin, Sue-Hwa	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
17	RP230063	IIRAP	2.1	Whole-Genome DNA Methylation Markers for Tracking and Predicting Advanced Liver Fibrosis as a Precursor of Liver Cancer in NAFLD	Tsai, Robert	Texas A&M University System Health Science Center	\$2,000,000
18	RP230285	IIRACT	2.2	Harnessing Endoplasmic Reticulum Stress to Overcome Resistance to Immunotherapy in Immune-Cold Breast Cancer	Chen , Xi	Baylor College of Medicine	\$2,000,000
19	RP230160	IIRACSBC	2.2	Overcoming Therapy Resistance by Integrated Computational Modeling of the Bone Metastatic Niche in Prostate and Renal Cancers	Dondossola , Eleonora	The University of Texas M. D. Anderson Cancer Center	\$1,025,623
20	RP230334	IIRA	2.5	Elucidating the Mutagenesis Mechanism of BRAF in Melanoma	Lee, Seongmin	The University of Texas at Austin	\$1,050,000

21	RP230120	IIRACCA	2.5	Clonal Evolution and Chemoresistance of Hepatoblastomas With Hepatocellular Carcinoma Features	Sumazin, Pavel	Baylor College of Medicine	\$1,371,733
22	RP230213	IIRAP	2.6	Multicomponent Interventions to Improve Uptake and Adherence to Lung Cancer Screening	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$1,988,211
23	RP230363	IIRACSBC	2.6	Developing Knowledge-Guided Deep Learning Models to Predict the Binding Between T-Cell Receptors and Neoantigens for Facilitating TCR-T Therapies	Wang, Tao	The University of Texas Southwestern Medical Center	\$1,199,997
24	RP230391	IIRA	2.6	Understanding and Improving CAR T-Cell Therapy of T-ALL and LBL	Mamonkin, Maksim	Baylor College of Medicine	\$1,050,000
25	RP230345	IIRA	2.6	The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T-Cell Therapy	Liu, Wenshe	Texas A&M University	\$1,050,000
26	RP230166	IIRACSBC	2.6	Integrative Modeling of Spatially Resolved Multiomics Data to Identify Bladder Cancer Mucosal Field Effects	Wei, Peng	The University of Texas M. D. Anderson Cancer Center	\$1,199,994
27	RP230154	IIRACCA	2.6	Normalizing Membrane Homeostasis in Microglia/Macrophages of Pediatric High-Grade Gliomas	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$1,400,000
28	RP230271	IIRA	2.7	Targeting Distinct Metabolic Vulnerabilities of Aggressive Renal Cell Carcinoma Variants	Zacharias Millward, Niki	The University of Texas M. D. Anderson	\$1,019,997

						Cancer Center	
29	RP230330	IIRACCA	2.7	Integrate Whole-Slide Imaging and Genomic Data to Study Pediatric Rhabdomyosarcoma	Xiao, Guanghua	The University of Texas Southwestern Medical Center	\$1,303,815
30	RP230050	IIRA	2.7	A Novel Therapeutic Strategy Targeting Pancreatic Cancer	Yao, Wantong	The University of Texas M. D. Anderson Cancer Center	\$1,049,854
31	RP230261	IIRA	2.7	Investigating the Mechanism of NLRP3 Inflammasome Hyperactivation During Hepatocellular Carcinoma Development	Zhong, Zhenyu	The University of Texas Southwestern Medical Center	\$1,049,997
32	RP230019	IIRA	2.8	Deciphering Spatial Immune Contextures Through Integrative Immunoproteogenomics	Lee, Hyun-Sung	Baylor College of Medicine	\$1,050,000
33	RP230161	IIRACT	2.8	¹³ C MRI With Hyperpolarized Pyruvate for Management of Glioblastoma	Park, Jae Mo	The University of Texas Southwestern Medical Center	\$1,727,462
34	RP230307	IIRA	2.8	In Vivo Chimeric Antigen Receptor Macrophages (ChARMs) for Cancer Immunotherapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$1,026,414
35	RP230241	IIRA	2.8	PD-L1 Modifications and Membranous Localization	Li, Yong	Baylor College of Medicine	\$1,049,994
36	RP230375	IIRA	2.8	Targeting Chitinase-3-Like-1 as a Novel Therapy for Hepatocellular Carcinoma	Ju, Cynthia	The University of Texas Health Science Center at Houston	\$1,049,769

37	RP230283	IIRA	2.8	Development of Immunotherapy and Combinatorial Therapy of Sickle Cell Trait-Associated Renal Medullary Carcinoma	Yang, Liuqing	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
38	RP230323	IIRA	2.9	Real-Time, Label-Free, Micro HSI Device and Transformer-Based Attention Networks for Oral Cancer Imaging	Fei, Baowei	The University of Texas at Dallas	\$1,048,933
39	RP230184	IIRA	2.9	Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Drugs for Precision Cancer Medicine	Sun, Xiankai	The University of Texas Southwestern Medical Center	\$1,049,997
40	RP230216	IIRA	2.9	Investigating Cell Competition in Liver Cancer Development	Zhu, Hao	The University of Texas Southwestern Medical Center	\$1,050,000
41	RP230381	IIRA	2.9	JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC	ZHANG, QING	The University of Texas Southwestern Medical Center	\$1,036,126
42	RP230319	IIRACSBC	2.9	Computational Methods for CRISPR-Based Lineage Tracing Systems	Liu, Zhandong	Baylor College of Medicine	\$1,200,000
43	RP230112	IIRA	2.9	The Evolution of Intratumor Heterogeneity of Lung Cancers With or Without Immunotherapy and Its Impact on Patient Survival	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,049,396
44	RP230143	IIRACCA	2.9	The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT	Ludwig, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,399,860

45	RP230240	IIRA	2.9	Therapeutic Targeting of Androgen Receptor in Metastatic Breast Cancer	Fuqua, Suzanne	Baylor College of Medicine	\$1,050,000
46	RP230272	IIRA	3.0	Structure-Based Improvement for Inhibitors of WNK1, a Triple-Negative Breast Cancer Signature Kinase	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	\$1,050,000
47	RP230327	IIRA	3.0	Harnessing the Metabolic Dependencies of Mitochondrial NADK2 as a Therapeutic Strategy for Lung Cancer	Hoxhaj, Gerta	The University of Texas Southwestern Medical Center	\$1,049,997
48	RP230071	IIRA	3.0	Unexpected Mechanisms Underlying Mutation-Induced Protein Mislocalization in Hematologic Malignancies	Liszcak, Glen	The University of Texas Southwestern Medical Center	\$1,049,997
49	RP230012	IIRA	3.0	Targeting a Non-ATPase Proteasome Subunit in Acute Myeloid Leukemia (AML)	Eiring, Anna	Texas Tech University Health Sciences Center at El Paso	\$1,050,000
50	RP230174	IIRACCA	3.0	Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites	Ehrlich, Lauren	The University of Texas at Austin	\$1,400,000
51	RP230196	IIRA	3.0	Identifying the Biological Determinants of Aggressive Meningioma	Patel, Akash	Baylor College of Medicine	\$1,047,289
52	RP230134	IIRACSBC	3.0	Therapeutic Vulnerabilities and Predictors of Response to Chemo(Immuno)Therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC)	Korkut, Anil	The University of Texas M. D. Anderson Cancer Center	\$1,199,966
53	RP230333	IIRA	3.1	Development of a Cell Therapy Platform for Localized and Feedback-Regulated Delivery of Cytokines for the	Veisheh, Omid	Rice University	\$1,050,000

				Treatment of Pancreatic Cancer			
54	RP230162	IIRACCA	3.1	The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma	Kitagawa, Katsumi	The University of Texas Health Science Center at San Antonio	\$1,400,000
55	RP230181	IIRA	3.1	Dissection of CAMKK2's Tumor Cell-Intrinsic and - Extrinsic Roles in Prostate Cancer	Frigo, Daniel	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
56	RP230197	IIRA	3.2	Targeting MYCN Disruption of the Molecular Clock and Tumor Metabolism in Neuroblastoma Oncogenesis	Barbieri, Eveline	Baylor College of Medicine	\$1,050,000

Individual Investigator Research Awards (IIRA)
 Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
 Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
 Individual Investigator Research Awards for Clinical Translation (IIRACT)
 Individual Investigator Research Awards for Prevention and Early Detection (IIRAP).



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2023—Cycle 1**

***Individual Investigator Research Awards for
Computational Systems Biology of Cancer***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-23.1-IIRACSB

**Individual Investigator Research Awards for
Computational Systems Biology of Cancer**

**Please also refer to the Instructions for Applicants document,
which will be posted on March 16, 2022**

Application Receipt Opening Date: March 16, 2022

Application Receipt Closing Date: June 8, 2022

FY 2023

Fiscal Year Award Period

September 1, 2022-August 31, 2023

TABLE OF CONTENTS

1. BRIEF DESCRIPTION OF RFA.....	4
2. ABOUT CPRIT.....	4
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES.....	4
3. RATIONALE.....	5
4. RESEARCH OBJECTIVES.....	6
5. FUNDING INFORMATION.....	7
6. ELIGIBILITY.....	7
7. RESUBMISSION POLICY.....	9
8. RENEWAL POLICY.....	9
9. RESPONDING TO THIS RFA.....	10
9.1. APPLICATION SUBMISSION GUIDELINES.....	10
9.1.1. <i>Submission Deadline Extension</i>	10
9.2. APPLICATION COMPONENTS.....	10
9.2.1. <i>Abstract and Significance (5,000 characters)</i>	10
9.2.2. <i>Layperson’s Summary (2,000 characters)</i>	11
9.2.3. <i>Goals and Objectives</i>	11
9.2.4. <i>Timeline (1 page)</i>	12
9.2.5. <i>Resubmission Summary (2 pages)</i>	12
9.2.6. <i>Renewal Summary (2 pages)</i>	12
9.2.7. <i>Research Plan (10 pages)</i>	12
9.2.8. <i>Vertebrate Animals (1 page)</i>	13
9.2.9. <i>Human Subjects (2 pages)</i>	13
9.2.10. <i>Publications/References</i>	13
9.2.11. <i>Budget and Justification</i>	13
9.2.12. <i>Biographical Sketches (5 pages each)</i>	14
9.2.13. <i>Current and Pending Support</i>	14
9.2.14. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i>	15
9.2.15. <i>Previous Summary Statement</i>	15
9.3. FORMATTING INSTRUCTIONS.....	15
10. APPLICATION REVIEW.....	16
10.1. PRELIMINARY EVALUATION.....	16
10.2. FULL PEER REVIEW.....	17
10.3. CONFIDENTIALITY OF REVIEW.....	17
10.4. REVIEW CRITERIA.....	18
10.4.1. <i>Primary Criteria</i>	18
10.4.2. <i>Secondary Criteria</i>	19
11. KEY DATES.....	20
12. AWARD ADMINISTRATION.....	20
13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS.....	21
14. CONTACT INFORMATION.....	22
14.1. HELPDESK.....	22
14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS.....	22

RFA VERSION HISTORY

1/14/2022 RFA released

1. BRIEF DESCRIPTION OF RFA

- Supports applications for projects that integrate innovative computational and mathematical approaches with experimental cancer biology to address challenging questions that will advance current knowledge in the etiology, biology, progression, treatment, metastasis, and immunology of cancer.
- Applicants may request a maximum of \$400,000 per year for a period of up to 3 years.
- Multi-PIs (MI) are allowed under this RFA. See Information for Applicants for definition and eligibility of Multi-PIs.
- Note that CPRIT does not allow the use of the term Co-PI.
- Minimum effort for the PI and/or Multi-PIs throughout the project period is required.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure
- Achieving health equity and reducing cancer disparities.

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

3. RATIONALE

Cancer is a complex multiscale disease involving the interaction of dynamic processes at the molecular, cellular, and multicellular levels. These interactive processes adapt and evolve in response to both intracellular and extracellular cues, and across temporal and spatial scales, making cancer difficult to prevent and treat as well as to predict the effects of therapy. Cancer systems biology has emerged as a powerful field that employs multidimensional data as well as mathematical and computational modeling to address these complexities in cancer biology and to predict integrated mechanisms underlying cancer initiation, progression, metastasis, prognosis, and treatment response. The historic focus on single genetic alterations has now expanded to embrace a broader view of the changing cancer ecosystem and evolving patterns of genotypes and phenotypes associated with progression and therapeutic intervention, facilitated by an explosion in the quantity of experimental data available from high-throughput technologies, such as genomics/epigenomics, transcriptomics, metabolomics, and proteomics. Systems analyses and predictive modeling are proving to be valuable tools to convert these large data sets, spanning different length and time scales, into predictions that can then be experimentally tested or validated in a disease-relevant context, thereby enabling cancer biologists and oncologists to understand and predict how one alteration effects an entire tumor system, increasing our understanding of tumor biology, treatment options, and patient outcomes.

4. RESEARCH OBJECTIVES

This Request for Applications (RFA) solicits applications for innovative research projects in cancer systems biology. CPRIT has adopted the National Cancer Institute's (NCI) definition of cancer systems biology as "a holistic approach to the study of the complexities of cancer through the explicit integration of experimental biology and computational and mathematical methods to build predictive models of cancer that are tested and validated in a disease-relevant context" (<https://www.cancer.gov/about-nci/organization/dcb/research-programs/csbc>). Examples of projects responsive to this RFA include, but are not limited to, scientific proposals addressing the following:

- Developing integrated models of genetic/epigenetic, chemical, cytoplasmic/network, microenvironment, and structural features across space and time scales to understand the mechanisms of cancer initiation, progression, metastasis, and therapeutic response;
- Characterization of cellular interactions and their impact on local, systemic, and evolving cellular behaviors that underlie cancer processes, such as initiation, progression, and metastasis;
- Delineation of the interactions between tumor and nontumor components, eg, tumor-immune cell interactions, and involvement in mediating the response or resistance to therapy;
- Integration of the biology underlying normal physiological processes, such as development, aging, metabolism, immunity, or chronic inflammation, to inform cancer development, progression, metastasis, or treatment response;
- Elucidation of the mechanism(s) by which external factors, such as the microbiome, affect tumor biology, including therapeutic response;
- Application of systems biology approaches, eg, network and multiscale modeling, to discover targetable molecular or cellular mechanisms and to test biologically informed therapies, sequences of therapies and combinations of therapies that incorporate variables such as toxicities, dose, and timing; and
- Integration of molecular and cellular oncogenic processes with population-level risk factors, such as obesity or chronic inflammation, or environmental factors that may differentially impact patient populations and influence cancer disparities.

Partnering of mathematical or computational scientists with cancer biologists or oncologists is highly recommended to form a truly interdisciplinary team that can both develop and validate models leading to a deeper integrated understanding of cancer progression and treatment.

NCI established the Cancer Systems Biology Consortium ([CSBC](#)) to support computational systems biology approaches to cancer research in recognition of the potential for the integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research. The CSBC website includes descriptions of the CSBC portfolio of NCI-funded projects that are examples of the type of applications this RFA seeks to attract. Applications that propose projects focused on purely bioinformatic analyses of omics data or propose correlative studies without a mathematical or computational model are not responsive to this RFA. CPRIT expects the outcomes of activities supported by this RFA to lead to new insights into cancer biology or clinical outcomes in the long term. The degree of relevance to reducing the burden of cancer is a critical criterion for evaluation of projects for funding by CPRIT ([section 10.4.1](#)).

5. FUNDING INFORMATION

Applicants may request a maximum of \$400,000 in total costs per year for up to 3 years. Exceptions to these limits may be requested if extremely well justified (see [section 9.2.11](#)). Funds may be used for salary and fringe benefits, research supplies, equipment, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.

- The Principal Investigator (PI) must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- This award mechanism allows Multi-PIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for Multi-PI awards).
- For applications that include 1 PI, the PI is required to maintain a minimum 15% level of effort throughout the entire award period. For applications that include MIs, each PI is required to maintain a minimum 10% effort throughout the entire award period.
- A PI may not submit applications to this RFA and to RFA R-23.1-IIRA, RFA R-23.1-IIRACCA, RFA R-23.1-IIRACT, or RFA R-23.1-IIRAP during this funding cycle.
- A PI may submit only 1 application, either a new, resubmission or renewal application under this RFA during this funding cycle.
- A PI may be a part of only one application, whether as a single applicant or as part of a Multi-PI application, under this RFA and RFA R-23.1-IIRA, RFA R-23.1-IIRACCA, RFA R-23.1-IIRACT, or RFA R-23.1-IIRAP.
- An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project Co-PIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2023).
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the

grant applicant's organization or institution is related to a CPRIT Oversight Committee member.

- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether these individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** if the proposed project meets the IIRACSBC research objectives (see [section 4](#)) and follows all resubmission guidelines. More than 1 resubmission is not permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PI for a project or a change of title of the project that was previously submitted to CPRIT does not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 9.2.5](#).

8. RENEWAL POLICY

An application originally funded by CPRIT as an IIRA or IIRACB mechanism may be submitted under this RFA for a competitive renewal if the proposed project meets the IIRACSBC research objectives. See [section 4](#) and [section 9.2.6](#). Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 10.2](#).

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 16, 2022, and must be submitted by 4 PM central time on June 8, 2022. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grant applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section

wisely. **Based on the Abstract and Significance statement (and the Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from further peer review (see [section 10.1](#)).** Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the research plan.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Indicate whether this research will address cancers associated with disparities. Summarize how the proposed research creates new paradigms or challenges existing ones. Indicate whether this research plan represents a new direction for the PI.

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, treatment, or survivorship. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 10.2](#)) in evaluating the significance and impact of the proposed work.

9.2.3. Goals and Objectives

List specific goals and objectives for each year of the project. These goals and objectives will also be used during the submission and evaluation of progress reports and assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Resubmission Summary (2 pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a fresh research plan or modify the original research plan and mark the changes. However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

9.2.6. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

9.2.7. Research Plan (10 pages)

Background: Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application. Describe the significance, innovation, and potential impact of the research.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

9.2.8. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

9.2.9. Human Subjects (2 pages)

If human subjects or human biological samples will be used, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

9.2.10. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.11. Budget and Justification

Provide a compelling and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses. Applicants may request a maximum of \$400,000 in total costs per year for up to 3 years. Applicants are advised not to interpret the maximum allowable time and funding under this award as a suggestion that they should expand their anticipated work and budget to this level. Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2023 is \$200,000; CPRIT FY 2023 is from September 1, 2022, through August 31, 2023. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

9.2.12. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and, if applicable, any additional PIs (if a MI application), as required by the online application receipt system. Up to 2 additional biographical sketches for key personnel may be provided. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

9.2.13. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the

current application. At a minimum, current and pending support of the PI and, if applicable, any additional PIs (if a MI application), must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.14. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

9.2.15. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components, exceed the specified page, word, or budget limits, or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.

- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.
Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.
- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may be preliminarily evaluated by CPRIT Scientific Research Program panel members for scientific merit and impact.

This preliminary evaluation will be based on a subset of material presented in the application—namely, Abstract and Significance, Budget and Justification, and

Biographical Sketches. Applications that do not sufficiently capture the reviewers' interest at this stage will not be considered for further review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation stage has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

10.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.3. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, (Texas Administrative Code RULE §703.9).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.4.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention, diagnosis, or treatment for patients? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or

resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required experience and creativity to make a significant contribution to the research? Does the applicant investigator(s) demonstrate the required expertise to make a significant contribution in both mathematical or computational sciences and oncology, or are there appropriate collaborators or consultants with expertise in oncology or cancer biology? It is highly encouraged that applicant investigators engage such collaborators. Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of their time (percent effort) to this project?

Relevance: Does the proposed research address a significant problem related to cancer? Is it likely to make an impact on this disease? This is a critical criterion for evaluation of projects for CPRIT support.

10.4.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

11. KEY DATES

RFA

RFA release January 14, 2022

Application

Online application opens March 16, 2022, 7 AM central time

Application due June 8, 2022, 4 PM central time

Application review June 2022–February 2023

Award

Award notification February 2023

Anticipated start date March 1, 2023

12. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT’s Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT’s administrative rules related to

contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in chapter [703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

14. CONTACT INFORMATION

14.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time.

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director of Research.

Tel: 512-305-8491

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Imaging Technology and
Informatics (ITI) (23.1 AR ITI)
Observation Report

Report No. 2022-10-24 23.1_AR_ITI
Program Name: Academic Research
Panel Name: 23.1 Academic Research Imaging Technology and Informatics (ITI)
(23.1_AR_ITI)
Panel Date: October 24, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Imaging Technology and Informatics (ITI) (23.1_AR_ITI) meeting. The meeting was chaired by Martin Pomper and conducted via videoconference on October 24, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were thirteen (13) Conflicts of Interest (COIs) identified prior to and/or during the meeting. Seven (7) applications with COIs were discussed and six (6) applications with COIs were not discussed. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Review Panel - Basic Cancer

Research (23.1 AR BCR-2)

Observation Report

Report No. 2022-10-25 23.1_AR_BCR-2
Program Name: Academic Research
Panel Name: 23.1 Academic Research Review Panel - Basic Cancer Research
(23.1_AR_BCR-2)
Panel Date: October 25, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Review Panel - Basic Cancer Research (23.1_AR_BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 25, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Sixteen (16) applications were discussed, and eighteen (18) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies and answering procedural questions

Eight (8) Conflicts of Interest (COIs) were identified prior to and/or during the meeting. Three (3) applications with COIs were discussed and three (3) applications with COIs were not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Cancer Prevention Research (CPR)
(23.1 AR CPR)
Observation Report

Report No. 2022-10-26 23.1_AR_CPR
Program Name: Academic Research
Panel Name: 23.1 Academic Research Cancer Prevention Research (CPR) (23.1
_AR_CPR)
Panel Date: October 26, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Cancer Prevention Research (CPR) (23.1_AR_CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 26, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty (20) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were nine (9) Conflicts of Interest (COIs) identified prior to and/or during the meeting. Four (4) applications with COIs were discussed and five (5) applications with COIs were not discussed. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (23.1 AR C/TCR)
Observation Report

Report No. 2022-10-27 23.1_AR_C/TCR
Program Name: Academic Research
Panel Name: 23.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (23.1_AR_C/TCR)
Panel Date: October 27, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Clinical and Translational Cancer Research (C/TCR) (23.1_AR_C/TCR) meeting. The meeting was chaired by Margaret Tempero and Richard O'Reilly and conducted via videoconference on October 27, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-four (24) applications were discussed and twenty-two (22) applications were not discussed
- Panelists: Two (2) panel chairs, twenty (20) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COI) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Review Panel - Basic Cancer

Research-1 (23.1 AR BCR-1)

Observation Report

Report No. 2022-10-28 23.1_AR_BCR-1
Program Name: Academic Research
Panel Name: 23.1 Academic Research Review Panel - Basic Cancer Research-1
(23.1_AR_BCR-1)
Panel Date: October 28, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Review Panel - Basic Cancer Research-1 (23.1_AR_BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on October 28, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eighteen (18) applications were discussed, and sixteen (16) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. One (1) application with a COI was discussed and five (5) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Cancer Biology (CB)

(23.1 ACR CB)

Observation Report

Report No. 2022-10-31 23.1_ACR_CB
Program Name: Academic Research
Panel Name: 23.1 Academic Research Cancer Biology (CB) (23.1 _ACR_CB)
Panel Date: October 31, 2022
Report Date: November 1, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Cancer Biology (CB) (23.1_ACR_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on October 31, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to the observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and twenty-nine (29) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions
- CPRIT Oversight Committee members: One (1)
- CPRIT Oversight Committee member(s) participation was limited observing the proceedings

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. One (1) application with a COI was discussed and one (1) application with COI was not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and

scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a series of loops and a long horizontal stroke extending to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research - Scientific Review Council Meeting
(23.1 SRC)
Observation Report

Report No. 2022-12-22 23.1_SRC
Program Name: Academic Research
Panel Name: 23.1 Academic Research - Scientific Review Council Meeting (23.1_SRC)
Panel Date: December 22, 2022
Report Date: December 23, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research - Scientific Review Council Meeting (23.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 22, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fifty-nine (59) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 23.1

Awards Announced at the February 15, 2023, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 23.1 include: *Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Translation; Individual Investigator Research Awards for Prevention and Early Detection; and Texas Regional Excellence in Cancer Award (TREC)*. Applications submitted in response to the five above listed Individual Investigator mechanisms went through preliminary evaluation as allowed by TAC § 703.6(e)(1). If a peer reviewer identified a conflict of interest during this stage, the application is labeled with a “pe” suffix.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT’s third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP230117pe/ RP230117	Patricia Chalela	The University of Texas Health Science Center at San Antonio	G. Coronado
RP230391pe/ RP230391	Maksim Mamonkin	Baylor College of Medicine	J. DiPersio
RP230184pe/ RP230184	Xiankai Sun	The University of Texas Southwestern Medical Center	A. Wu
RP230271pe/ RP230271	Niki Zacharias Millward	The University of Texas M. D. Anderson Cancer Center	A. Wu; W. Warren
RP230360pe/ RP230360	Douglas Frantz	The University of Texas at San Antonio	J. Conejo-Garcia

* Application not discussed during full review.

Academic Research
Cycle 23.1

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230213	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	T. Brandon
RP230272	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	A. Tomkinson; J. Petrini
RP230344	McBrayer, Samuel K	The University of Texas Southwestern Medical Center	C. Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP230021pe/ RP230021	Scherezade Mama	The University of Texas M. D. Anderson Cancer Center	K. Emmons
RP230044pe	Paul Scheet	The University of Texas M. D. Anderson Cancer Center	L. Mucci
RP230045pe	MinJae Lee	The University of Texas Southwestern Medical Center	G. Coronado
RP230069pe/ RP230069*	Sohail Rao	DHR Health Institute for Research and Development	L. Kushi
RP230097pe/ RP230097	Subrata Sen	The University of Texas M. D. Anderson Cancer Center	G. Petersen
RP230098pe	Julia Heck	University of North Texas	L. Mucci
RP230126pe/ RP230126*	Jose Rauh-Hain	The University of Texas M. D. Anderson Cancer Center	G. Coronado
RP230164pe	Jian Gu	The University of Texas M. D. Anderson Cancer Center	L. Mucci
RP230201pe/ RP230201	Edwin Ostrin	The University of Texas M. D. Anderson Cancer Center	C. Li
RP230279pe	Martha Mims	Baylor College of Medicine	C. Haiman
RP230284pe/ RP230284*	Surendranath Shastri	The University of Texas M. D. Anderson Cancer Center	K. Emmons

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230320pe	Chao Cheng	Baylor College of Medicine	L. Mucci
RP230002pe	Debananda Pati	Baylor College of Medicine	P. Grohar
RP230011pe/ RP230011*	Ziyi Li	The University of Texas M. D. Anderson Cancer Center	J. Issa
RP230292pe	Todd Aguilera	The University of Texas Southwestern Medical Center	W. Hahn
RP230394pe/ RP230394	Alexander Bishop	The University of Texas Health Science Center at San Antonio	P. Grohar
RP230208pe/ RP230208	Raquibul Hannan	The University of Texas Southwestern Medical Center	A. Ribas
RP230057pe/ RP230057*	Junjie Chen	The University of Texas M. D. Anderson Cancer Center	J. Petrini
RP230148pe	Paul Chiao	The University of Texas M. D. Anderson Cancer Center	A. Tomkinson; J. Petrini
RP230187pe	Christopher Amos	Baylor College of Medicine	A. Tomkinson
RP230210pe	Blerta Xhemalce	The University of Texas at Austin	A. Tomkinson
RP230232pe	Anthony Davis	The University of Texas Southwestern Medical Center	A. Tomkinson
RP230267pe	Alison Bertuch	Baylor College of Medicine	J. Karlseder
RP230296pe/ RP230296*	Zamal Ahmed	The University of Texas M. D. Anderson Cancer Center	A. Tomkinson; J. Petrini; W. Chazin
RP230322pe/ RP230322*	E. Paul Hasty	The University of Texas Health Science Center at San Antonio	A. Tomkinson
RP230079pe/ RP230079	Eva Sevick	The University of Texas Health Science Center at Houston	W. Warren
RP230177pe/ RP230177*	Henry Manning	The University of Texas M. D. Anderson Cancer Center	J. Gore

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230194pe/ RP230194	Jia Wu	The University of Texas M. D. Anderson Cancer Center	C. Kahn
RP230206pe/ RP230206	Jingfei Ma	The University of Texas M. D. Anderson Cancer Center	C. Kahn; D. Mankoff; J. Basilion
RP230209pe/ RP230209*	Andrew Wang	The University of Texas Southwestern Medical Center	W. Cai
RP230220pe	Ananth Madhuranthakam	The University of Texas Southwestern Medical Center	A. Wu
RP230238pe/ RP230238*	David Piwnica- Worms	The University of Texas M. D. Anderson Cancer Center	D. Mankoff
RP230252pe	Thomas Yankeelov	The University of Texas at Austin	J. Gore
RP230297pe/ RP230297*	Zhonglin Liu	The Methodist Hospital Research Institute	M. Giger
RP230395pe/ RP230395*	Yaowu Hao	The University of Texas at Arlington	A. Wu
RP230401pe	James Tour	Rice University	C. Kahn
RP230066pe/ RP230066*	FENG-CHUN YANG	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230155pe/ RP230155*	April Risinger	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230156pe/ RP230156*	Kexin Xu	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230159pe	Xiao-Dong Chen	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230189pe	Alexander Pertsemlidis	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230215pe	Gang Huang	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230265pe/ RP230265*	Yuzuru Shiio	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230293pe	Panneerdoss Subbarayalu	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230309pe	Stefano Tiziani	The University of Texas at Austin	J. Conejo-Garcia
RP230367*	Chen, Yidong	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230186*	Spencer, Jennifer	The University of Texas at Austin	G. Coronado

* Application not discussed during full review.

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards for Computational Systems Biology of Cancer

Academic Research Cycle 23.1

Final Scores for Fully Reviewed Applications

The Program Integration Committee (PIC) deferred two applications that the Scientific Review Council recommended from this mechanism. The two deferred applications are designated with “^” in the de-identified list. The PIC may consider the deferred applications at a later FY2023 meeting.

Application ID	Final Overall Evaluation Score
RP230160*	2.2
RP230363*	2.6
RP230166*	2.6
rra^	2.9
rrb^	3.0
Ka	3.2
Kb	4.0
Kc	4.0
Kd	4.0
Ke	4.0
Kf	4.3
Kg	5.3
Kh	5.3

* Recommended for funding

^ Application deferred by the PIC.

Individual Investigator Research Awards for Computational Systems Biology of Cancer

Academic Research Cycle 23.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

Application ID	Final Overall Score
Wa	3.33
Wb	3.67
Wc	3.67
Wd	4.00
We	4.00
Wf	4.00
Wg	4.33
Wh	4.67
Wi	5.00
Wj	5.67

Final Overall Evaluation Scores and Rank Order Scores

**Ludwig Institute for
Cancer Research Ltd**

**Richard D. Kolodner
Ph.D.**

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

January 16, 2023

Dr. Mahendra C. Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cpit.texas.gov

Dear Dr. Patel and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, and Individual Investigator Research Awards for Prevention and Early Detection

The SRC met on December 22, 2022 to consider the applications recommended by the peer review panels following their meetings held October 24, 2022 to October 31, 2022.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$67,370,879.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Award Mech	Meeting Overall Score	Application Title	PI	PI Organization	Recommended Budget
1	RP230026	IIRACCA	1.0	Identifying Clinical Methotrexate Toxicity Phenotypes Across Phases of Pediatric Leukemia Therapy	Bernhardt, Melanie	Baylor College of Medicine	\$1,392,407
2	RP230036	IIRAP	1.0	Geospatial Approaches to Melanoma Early Detection: The GAMED Project	Nelson, Kelly	The University of Texas M. D. Anderson Cancer Center	\$1,998,196
3	RP230222	IIRA	1.1	Personalized Auricular Point Acupressure to Self-Manage Cancer-Related Pain	Yeh, Chao Hsing	The University of Texas Health Science Center at Houston	\$1,046,680
4	RP230140	IIRA	1.1	Changes in Tumor Microenvironment That Promote Cachexia	Infante, Rodney	The University of Texas Southwestern Medical Center	\$1,050,000
5	RP230093	IIRA	1.8	Targeting the Mlc1-GlialCAM Protein Complex in Invasive Glioma Cells	McCarty, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,050,000

6	RP230018	IIRACCA	1.9	Neuronal Alterations in the Midbrain Dopaminergic System Function: A Novel Mechanism of Radiation-Induced Cognitive Dysfunction	Zhang, Die	The University of Texas M. D. Anderson Cancer Center	\$1,399,730
7	RP230117	IIRAP	1.9	Randomized Controlled Trial to Assess Innovative Smoking Cessation Services for Young Adults in Texas	Chalela, Patricia	The University of Texas Health Science Center at San Antonio	\$1,992,330
8	RP230072	IIRA	1.9	Studying and Therapeutically Targeting Ferroptosis Liability in BRCA1-Deficient Cancer	Gan, Boyi	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
9	RP230360	IIRA	1.9	Rational Design, Synthesis, and Biological Evaluation of Simplified Taccalonolide Analogs for the Treatment of Cancer	Frantz, Douglas	The University of Texas at San Antonio	\$1,049,128
10	RP230135	IIRA	2.0	Blocking DNA Damage Response Induction of "Don't Eat Me" Signals Converts Local Radiotherapy Into Systemic Immunotherapy	Curran, Michael	The University of Texas M. D. Anderson Cancer Center	\$1,049,905
11	RP230344	IIRA	2.0	Development and Evaluation of Lanosterol Synthase Inhibitors in Preclinical GBM Models	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,048,465
12	RP230109	IIRA	2.0	Autophagy and Tumor Endothelium	Terada, Lance	The University of Texas Southwestern Medical Center	\$1,049,994
13	RP230373	IIRA	2.0	Mapping the Geospatial Tumor Clonal Architecture to Restore	Viale, Andrea	The University of Texas M.	\$1,049,985

				Immune Recognition in Pancreatic Cancer		D. Anderson Cancer Center	
14	RP230224	IIRA	2.0	Enhancing Immune Responses in Pancreatic Cancer by Stromal Inhibition of HIF2	Taniguchi, Cullen	The University of Texas M. D. Anderson Cancer Center	\$1,049,997
15	RP230382	IIRA	2.0	Characterization of 3D Genome Organization and Transcriptional Regulation in Prostate Cancer	Mani, Ram	The University of Texas Southwestern Medical Center	\$1,049,641
16	RP230247	IIRA	2.0	A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer	Lin, Sue-Hwa	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
17	RP230063	IIRAP	2.1	Whole-Genome DNA Methylation Markers for Tracking and Predicting Advanced Liver Fibrosis as a Precursor of Liver Cancer in NAFLD	Tsai, Robert	Texas A&M University System Health Science Center	\$2,000,000
18	RP230285	IIRACT	2.2	Harnessing Endoplasmic Reticulum Stress to Overcome Resistance to Immunotherapy in Immune-Cold Breast Cancer	Chen , Xi	Baylor College of Medicine	\$2,000,000
19	RP230160	IIRACSBC	2.2	Overcoming Therapy Resistance by Integrated Computational Modeling of the Bone Metastatic Niche in Prostate and Renal Cancers	Dondossola , Eleonora	The University of Texas M. D. Anderson Cancer Center	\$1,025,623
20	RP230334	IIRA	2.5	Elucidating the Mutagenesis Mechanism of BRAF in Melanoma	Lee, Seongmin	The University of Texas at Austin	\$1,050,000

21	RP230120	IIRACCA	2.5	Clonal Evolution and Chemoresistance of Hepatoblastomas With Hepatocellular Carcinoma Features	Sumazin, Pavel	Baylor College of Medicine	\$1,371,733
22	RP230213	IIRAP	2.6	Multicomponent Interventions to Improve Uptake and Adherence to Lung Cancer Screening	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$1,988,211
23	RP230363	IIRACSBC	2.6	Developing Knowledge-Guided Deep Learning Models to Predict the Binding Between T-Cell Receptors and Neoantigens for Facilitating TCR-T Therapies	Wang, Tao	The University of Texas Southwestern Medical Center	\$1,199,997
24	RP230391	IIRA	2.6	Understanding and Improving CAR T-Cell Therapy of T-ALL and LBL	Mamonkin, Maksim	Baylor College of Medicine	\$1,050,000
25	RP230345	IIRA	2.6	The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T-Cell Therapy	Liu, Wenshe	Texas A&M University	\$1,050,000
26	RP230166	IIRACSBC	2.6	Integrative Modeling of Spatially Resolved Multiomics Data to Identify Bladder Cancer Mucosal Field Effects	Wei, Peng	The University of Texas M. D. Anderson Cancer Center	\$1,199,994
27	RP230154	IIRACCA	2.6	Normalizing Membrane Homeostasis in Microglia/Macrophages of Pediatric High-Grade Gliomas	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$1,400,000
28	RP230271	IIRA	2.7	Targeting Distinct Metabolic Vulnerabilities of Aggressive Renal Cell Carcinoma Variants	Zacharias Millward, Niki	The University of Texas M. D. Anderson	\$1,019,997

						Cancer Center	
29	RP230330	IIRACCA	2.7	Integrate Whole-Slide Imaging and Genomic Data to Study Pediatric Rhabdomyosarcoma	Xiao, Guanghua	The University of Texas Southwestern Medical Center	\$1,303,815
30	RP230050	IIRA	2.7	A Novel Therapeutic Strategy Targeting Pancreatic Cancer	Yao, Wantong	The University of Texas M. D. Anderson Cancer Center	\$1,049,854
31	RP230261	IIRA	2.7	Investigating the Mechanism of NLRP3 Inflammasome Hyperactivation During Hepatocellular Carcinoma Development	Zhong, Zhenyu	The University of Texas Southwestern Medical Center	\$1,049,997
32	RP230019	IIRA	2.8	Deciphering Spatial Immune Contextures Through Integrative Immunoproteogenomics	Lee, Hyun-Sung	Baylor College of Medicine	\$1,050,000
33	RP230161	IIRACT	2.8	¹³ C MRI With Hyperpolarized Pyruvate for Management of Glioblastoma	Park, Jae Mo	The University of Texas Southwestern Medical Center	\$1,727,462
34	RP230307	IIRA	2.8	In Vivo Chimeric Antigen Receptor Macrophages (ChARMs) for Cancer Immunotherapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$1,026,414
35	RP230241	IIRA	2.8	PD-L1 Modifications and Membranous Localization	Li, Yong	Baylor College of Medicine	\$1,049,994
36	RP230375	IIRA	2.8	Targeting Chitinase-3-Like-1 as a Novel Therapy for Hepatocellular Carcinoma	ju, Cynthia	The University of Texas Health Science Center at Houston	\$1,049,769

37	RP230283	IIRA	2.8	Development of Immunotherapy and Combinatorial Therapy of Sickle Cell Trait-Associated Renal Medullary Carcinoma	Yang, Liuqing	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
38	RP230323	IIRA	2.9	Real-Time, Label-Free, Micro HSI Device and Transformer-Based Attention Networks for Oral Cancer Imaging	Fei, Baowei	The University of Texas at Dallas	\$1,048,933
39	RP230184	IIRA	2.9	Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Drugs for Precision Cancer Medicine	Sun, Xiankai	The University of Texas Southwestern Medical Center	\$1,049,997
40	RP230216	IIRA	2.9	Investigating Cell Competition in Liver Cancer Development	Zhu, Hao	The University of Texas Southwestern Medical Center	\$1,050,000
41	RP230381	IIRA	2.9	JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC	ZHANG, QING	The University of Texas Southwestern Medical Center	\$1,036,126
42	RP230319	IIRACSBC	2.9	Computational Methods for CRISPR-Based Lineage Tracing Systems	Liu, Zhandong	Baylor College of Medicine	\$1,200,000
43	RP230112	IIRA	2.9	The Evolution of Intratumor Heterogeneity of Lung Cancers With or Without Immunotherapy and Its Impact on Patient Survival	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,049,396
44	RP230143	IIRACCA	2.9	The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT	Ludwig, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,399,860

45	RP230240	IIRA	2.9	Therapeutic Targeting of Androgen Receptor in Metastatic Breast Cancer	Fuqua, Suzanne	Baylor College of Medicine	\$1,050,000
46	RP230272	IIRA	3.0	Structure-Based Improvement for Inhibitors of WNK1, a Triple-Negative Breast Cancer Signature Kinase	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	\$1,050,000
47	RP230327	IIRA	3.0	Harnessing the Metabolic Dependencies of Mitochondrial NADK2 as a Therapeutic Strategy for Lung Cancer	Hoxhaj, Gerta	The University of Texas Southwestern Medical Center	\$1,049,997
48	RP230071	IIRA	3.0	Unexpected Mechanisms Underlying Mutation-Induced Protein Mislocalization in Hematologic Malignancies	Liszcak, Glen	The University of Texas Southwestern Medical Center	\$1,049,997
49	RP230012	IIRA	3.0	Targeting a Non-ATPase Proteasome Subunit in Acute Myeloid Leukemia (AML)	Eiring, Anna	Texas Tech University Health Sciences Center at El Paso	\$1,050,000
50	RP230174	IIRACCA	3.0	Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites	Ehrlich, Lauren	The University of Texas at Austin	\$1,400,000
51	RP230196	IIRA	3.0	Identifying the Biological Determinants of Aggressive Meningioma	Patel, Akash	Baylor College of Medicine	\$1,047,289
52	RP230134	IIRACSBC	3.0	Therapeutic Vulnerabilities and Predictors of Response to Chemo(Immuno)Therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC)	Korkut, Anil	The University of Texas M. D. Anderson Cancer Center	\$1,199,966
53	RP230333	IIRA	3.1	Development of a Cell Therapy Platform for Localized and Feedback-Regulated Delivery of Cytokines for the	Veisheh, Omid	Rice University	\$1,050,000

				Treatment of Pancreatic Cancer			
54	RP230162	IIRACCA	3.1	The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma	Kitagawa, Katsumi	The University of Texas Health Science Center at San Antonio	\$1,400,000
55	RP230181	IIRA	3.1	Dissection of CAMKK2's Tumor Cell-Intrinsic and -Extrinsic Roles in Prostate Cancer	Frigo, Daniel	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
56	RP230197	IIRA	3.2	Targeting MYCN Disruption of the Molecular Clock and Tumor Metabolism in Neuroblastoma Oncogenesis	Barbieri, Eveline	Baylor College of Medicine	\$1,050,000

Individual Investigator Research Awards (IIRA)
 Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
 Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
 Individual Investigator Research Awards for Clinical Translation (IIRACT)
 Individual Investigator Research Awards for Prevention and Early Detection (IIRAP).



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2023—Cycle 1
*Individual Investigator Research Awards for
Clinical Translation***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-23.1-IIRACT

**Individual Investigator Research Awards for
Clinical Translation**

**Please also refer to the Instructions for Applicants document,
which will be posted on March 16, 2022**

Application Receipt Opening Date: March 16, 2022

Application Receipt Closing Date: June 8, 2022

FY 2023

Fiscal Year Award Period
September 1, 2022-August 31, 2023

TABLE OF CONTENTS

1. BRIEF DESCRIPTION OF RFA	4
2. ABOUT CPRIT	4
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES.....	4
3. RATIONALE	5
4. RESEARCH OBJECTIVES	6
5. FUNDING INFORMATION	7
6. ELIGIBILITY	7
7. RESUBMISSION POLICY	9
8. RENEWAL POLICY	10
9. RESPONDING TO THIS RFA	10
9.1. APPLICATION SUBMISSION GUIDELINES	10
9.1.1. <i>Submission Deadline Extension</i>	10
9.2. APPLICATION COMPONENTS.....	10
9.2.1. <i>Abstract and Significance (5,000 characters)</i>	11
9.2.2. <i>Layperson’s Summary (2,000 characters)</i>	11
9.2.3. <i>Goals and Objectives</i>	12
9.2.4. <i>Timeline (1 page)</i>	12
9.2.5. <i>Resubmission Summary (2 pages)</i>	12
9.2.6. <i>Renewal Summary (2 pages)</i>	13
9.2.7. <i>Summary Checklist (1 page)</i>	13
9.2.8. <i>Research Plan (11 pages)</i>	13
9.2.9. <i>Vertebrate Animals (1 page)</i>	13
9.2.10. <i>Human Subjects (2 pages)</i>	13
9.2.11. <i>Protocol Documentation</i>	14
9.2.12. <i>Investigational New Drug Application (IND)/Investigational Device Exemption (IDE)</i>	14
9.2.13. <i>Publications/References</i>	14
9.2.14. <i>Budget and Justification</i>	14
9.2.15. <i>Biographical Sketches (5 pages each)</i>	15
9.2.16. <i>Current and Pending Support</i>	15
9.2.17. <i>Institutional/Collaborator Support and/or Other Certification (4 pages)</i>	16
9.2.18. <i>Previous Summary Statement</i>	16
9.3. FORMATTING INSTRUCTIONS	16
10. APPLICATION REVIEW	17
10.1. PRELIMINARY EVALUATION.....	17
10.2. FULL PEER REVIEW	18
10.3. CONFIDENTIALITY OF REVIEW	18
10.4. REVIEW CRITERIA	19
10.4.1. <i>Primary Criteria</i>	20
10.4.2. <i>Secondary Criteria</i>	20
11. KEY DATES	21
12. AWARD ADMINISTRATION	21
13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	22
14. CONTACT INFORMATION	23
14.1. HELPDESK.....	23
14.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	23

RFA VERSION HISTORY

01/14/22 RFA released

Rev 3/16/22 Section 9.2.7 – Summary Checklist

- Added the required Checklist document to the Application Component section (Section 9.2)

Section 9.2.11 – Budget and Justification

- Added language regarding allowable reimbursement of clinical trial participation cost

1. BRIEF DESCRIPTION OF RFA

- Supports applications that propose innovative cancer clinical studies that are hypothesis driven and involve patients enrolled prospectively on a clinical trial. Applications must provide documentation that the proposed trial will be ready to commence immediately upon award of the CPRIT contract and the trial goals are feasible within the project timeline.
- Applicants are required to complete a checklist (required template provided in CARS under [Current Funding Opportunities](#))
- Applicants may request a maximum of \$500,000 per year for a period of up to 4 years.
- Multi-PIs (MI) are allowed under this RFA. See the Information for Applicants (IFA) document for definition and eligibility of MIs.
- Note that CPRIT does not allow the use of the term Co-PI.
- Minimum effort for the PI and/or MIs throughout the project period is required.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for, cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure
- Achieving health equity and reducing cancer disparities.

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

3. RATIONALE

This Individual Investigator Research Awards for Clinical Translation (IIRACT) mechanism will support applications that propose innovative cancer clinical studies that are hypothesis-driven and involve patients enrolled prospectively on a clinical trial. Areas of interest include clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices. Such clinical trials offer important opportunities to incorporate biomarkers, pharmacokinetic and pharmacodynamic monitoring, and/or imaging studies to provide more precise knowledge about what works, in whom, and in which types of cancer and to guide subsequent clinical development of a novel cancer therapy.

The research supported by this mechanism is important because current clinical development of novel cancer therapeutics remains slow and expensive with many late-stage failures. Only 5% of cancer therapeutics that enter clinical evaluation will be approved, and the approval process is often measured in decades. There is an urgent need to accelerate and enhance the efficiency of this process by improving the clinical evaluation of novel cancer therapeutics through adoption

of modern trial designs that incorporate biomarkers. Such trials will build on advances in basic discovery that have identified the critical targets involved in the hallmarks of cancer and have led to mechanism-based therapeutics. Trials that are designed to determine if predictors of response and efficacy identified in preclinical models also occur in patients have the potential to accelerate therapeutic development and approvals. They also guide the development of diagnostic tests to identify those patients most likely to benefit from these new treatments. Well-conducted early-phase studies will also inform reasons for treatment failure and feed back to preclinical studies designed to overcome barriers to success identified in patients.

4. RESEARCH OBJECTIVES

The goal of the IIRACT Award is to promote clinical research that will lead to a better understanding of the clinical efficacy of a cancer therapy or diagnostic device. Applications submitted under this mechanism should propose innovative clinical studies that are hypothesis-driven and involve patients enrolled prospectively on a clinical trial.

Clinical studies of new or repurposed drugs, hormonal therapies, immune therapies, surgery, radiation therapy, stem cell transplantation, combinations of interventions, or therapeutic devices are all responsive to this Request for Applications (RFA).

Applications that propose the development and validation of a biomarker prior to use of that biomarker in a prospective clinical trial are not responsive to this RFA and should be directed to the CPRIT Individual Investigator Research Award mechanism RFA R-23.1-IIRA.

Early-phase clinical trials of agents or combinations of agents for which there are robust nonclinical data that suggest there may be clinical activity are responsive to the RFA, even if there is no biomarker, as long as the early-phase clinical trial will lead to determining if the activity observed in the laboratory can be replicated in patients.

Additional examples of the types of studies appropriate for the IIRACT award include, but are not limited to, phase 1 or small phase 2 trials of new agents, repurposed agents, radiation therapy, surgery, or combinations of interventions where the trial design incorporates biomarker and/or imaging strategies to determine one or more of the following: presence of the drug target, target inhibition, biological pathway inhibition, or pathophysiological alteration by the investigational drug or device

5. FUNDING INFORMATION

Applicants may request a maximum of \$500,000 per year for a period of up to 4 years. Exceptions to these limits may be requested if extremely well justified (see section [9.2.13](#)). Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs including diagnostic or interventional procedures associated with participation in a clinical trial and not considered routine patient care, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

The budget justification must include a timeline for the clinical trial initiation and accrual targets. Applications must provide documentation that the proposed trial will be ready to commence immediately upon award of the CPRIT contract and the trial goals are feasible within the project timeline. For example, drug access through an industry or CTEP arrangement should be documented. When indicated, an approved investigational new drug application (IND) or investigational device exemption (IDE) for devices from the Food and Drug Administration (FDA) should be cited, or if no IND is yet available for the agent(s), then a pre-IND meeting would have been held with the FDA, and the summary letter from that pre-IND meeting would be included as an attachment (see [section 9.2.11](#)).

Please see [section 9.2.13](#) and the IFA for additional information.

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The Principal Investigators (PI) must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.
- This award mechanism allows Multi-PIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for Multi-PI awards).

- For applications that include 1 PI, the PI is required to maintain a minimum 15% level of effort throughout the entire award period. For applications that include MIs, each PI is required to maintain a minimum 10% effort throughout the entire award period.
- A PI may not submit applications to this RFA and to RFA R-23.1-IIRA, RFA R-23.1-IIRACSBC, RFA R-23.1-IIRACCA, or RFA R-23.1-IIRAP.
- A PI may submit only 1 application, either a new, resubmission or renewal application under this RFA during this funding cycle
- A PI may be a part of only one application, whether as a single applicant or as part of a Multi-PI application, under this RFA and RFA R-23.1-IIRA, RFA R-23.1-IIRACCA, RFA R-23.1-IIRACSBC, or RFA R-23.1-IIRAP.
- An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project Co-PIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2023).
- Applications that address prevention and early detection, cancers in children and adolescents, or computational systems biology of cancer should be submitted under the appropriate targeted RFA. As noted in section 4, applications that propose the development and validation of a biomarker prior to use of that biomarker in a prospective clinical trial are not responsive to this RFA and should be directed to the CPRIT Individual Investigator Research Award mechanism RFA R-23.1-IIRA.
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.

- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether these individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 12](#) and [section 13](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted **once** and must follow all resubmission guidelines and be eligible for this mechanism under the criteria in Section 4. If a previously submitted application does not meet the new criteria for this mechanism outlined in Section 4 it must be resubmitted under the IIRA mechanism. More than 1 resubmission is not permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PI for a project or a change of title of the project that was previously submitted to CPRIT or omission or modification of an aim does not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 9.2.5](#).

8. RENEWAL POLICY

An application originally funded by CPRIT as an IIRA, IIRACCA, IIRACSBC, or IIRAP that is appropriate for the IIRACT mechanism may be submitted under this RFA for a competitive renewal. See [section 9.2.6](#). Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 10.2](#).

9. RESPONDING TO THIS RFA

9.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 16, 2022, and must be submitted by 4 PM central time on June 8, 2022. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

9.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

9.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details that will be available when

the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

9.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section wisely. **Based on the Abstract and Significance statement (and the Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from further peer review (see [section 10.1](#)).** Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the research plan. Indicate whether this proposed clinical research addresses cancers with disparities and/or whether the trial will enroll patients from underserved populations.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Summarize how the proposed research creates new paradigms or challenges existing ones or may lead to changes in practice. Indicate whether this research plan represents a new direction for the PI.

9.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detections, prevention, or treatment. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary

will also be used by advocate reviewers ([section 10.2](#)) in evaluating the significance and impact of the proposed work.

9.2.3. Goals and Objectives

List specific goals and objectives for each year of the project. These goals and objectives will also be used during the submission and evaluation of progress reports and assessment of project success.

9.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If a clinical trial is proposed as a component of this application, the timeline must include clearly defined patient accrual milestones.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

9.2.5. Resubmission Summary (2 pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a fresh research plan or modify the original research plan and mark the changes.

However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

9.2.6. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

9.2.7. Summary Checklist (1 page)

Applicants are required to complete a summary checklist. The required template is provided in CARS under [Current Funding Opportunities](#).

9.2.8. Research Plan (11 pages)

Background: Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed. Describe the innovation and potential impact of the research.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required. This section has been lengthened to allow the applicant to present the statistical considerations used to determine a trial design, accrual milestones, and biomarker validation. Describe the population of eligible patients and plans to enroll unique populations, eg, underserved populations.

9.2.9. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

9.2.10. Human Subjects (2 pages)

For the use of human subjects or human biological samples, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of

this award mechanism. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

9.2.11. Protocol Documentation

Provide a full protocol of the clinical trial (if one is planned); a PDF copy of the full protocol can be attached.

9.2.12. Investigational New Drug Application (IND)/Investigational Device Exemption (IDE)

If a clinical trial is proposed that requires an IND or IDE, provide evidence of an approved IND or IDE for devices from the FDA. If no IND is yet available for the agent(s), then provide a summary letter from a pre-IND meeting held with the FDA. If the drug or device is to be provided through an industry or CTEP mechanism, provide documentation that the drug or device will be available.

9.2.13. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

9.2.14. Budget and Justification

Provide a compelling and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, costs associated with the conduct of a clinical trial, animal care costs, and other expenses. While there will be 1 budget for the entire project, an individual budget and budget justification for the conduct of a clinical trial must be included. The justification should include the statistical considerations that led to the clinical trial design, accrual milestones, and validation of biomarkers. Applicants are advised not to interpret the maximum allowable request under this award as a suggestion that they should expand their anticipated budget to this level. However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.

- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT’s Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2023 is \$200,000; CPRIT FY 2023 is from September 1, 2022, through August 31, 2023. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual’s institutional base salary is the annual compensation that the applicant organization pays for an individual’s appointment, whether that individual’s time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.
- Funds can be used to pay for costs that a cancer clinical trial participant may have associated with their participation in a clinical trial, including: 1) transportation, including car mileage, parking, bus fare, taxi or ride hailing fare exclusive of tips, and commercial economy class airfare within the borders of the State of Texas; 2) lodging.

9.2.15. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research. A biographical sketch must be provided for the PI and, if applicable, any additional PIs (if a MI application), as required by the online application receipt system. Up to 2 additional biographical sketches for key personnel may be provided. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

9.2.16. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title,

a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional PIs (if a MI application), must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

9.2.17. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

9.2.18. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components, exceed the specified page, word, or budget limits, or that do not meet the eligibility requirements listed above will be administratively rejected without review.

9.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.

- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable as long as the journal information is stated. Include URLs of publications referenced in the application.
Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45-67.
- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

10. APPLICATION REVIEW

10.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may be preliminarily evaluated by CPRIT Scientific Research Program panel members for scientific merit and impact.

This preliminary evaluation will be based on a subset of material presented in the application—namely, Abstract and Significance, Budget and Justification, and Biographical Sketches. Applications that do not sufficiently capture the reviewers’ interest at this stage will not be considered for further review. Such applications will have been judged to

offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation stage has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

10.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 10.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all of the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

10.3. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in Texas Administrative Code [RULE §703.9](#)

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

10.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

10.4.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention, diagnosis, or treatment for patients? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required creativity and expertise to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of his or her time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer research? This is a critical criterion for evaluation of projects for CPRIT support.

10.4.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

13. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

14. CONTACT INFORMATION

14.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

14.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director of Academic Research.

Tel: 512-305-8491

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Imaging Technology and
Informatics (ITI) (23.1 AR ITI)
Observation Report

Report No. 2022-10-24 23.1_AR_ITI
Program Name: Academic Research
Panel Name: 23.1 Academic Research Imaging Technology and Informatics (ITI)
(23.1_AR_ITI)
Panel Date: October 24, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Imaging Technology and Informatics (ITI) (23.1_AR_ITI) meeting. The meeting was chaired by Martin Pomper and conducted via videoconference on October 24, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were thirteen (13) Conflicts of Interest (COIs) identified prior to and/or during the meeting. Seven (7) applications with COIs were discussed and six (6) applications with COIs were not discussed. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Review Panel - Basic Cancer

Research (23.1 AR BCR-2)

Observation Report

Report No. 2022-10-25 23.1_AR_BCR-2
Program Name: Academic Research
Panel Name: 23.1 Academic Research Review Panel - Basic Cancer Research
(23.1_AR_BCR-2)
Panel Date: October 25, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Review Panel - Basic Cancer Research (23.1_AR_BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 25, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Sixteen (16) applications were discussed, and eighteen (18) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies and answering procedural questions

Eight (8) Conflicts of Interest (COIs) were identified prior to and/or during the meeting. Three (3) applications with COIs were discussed and three (3) applications with COIs were not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Cancer Prevention Research (CPR)
(23.1 AR CPR)
Observation Report

Report No. 2022-10-26 23.1_AR_CPR
Program Name: Academic Research
Panel Name: 23.1 Academic Research Cancer Prevention Research (CPR) (23.1_AR_CPR)
Panel Date: October 26, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Cancer Prevention Research (CPR) (23.1_AR_CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 26, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty (20) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were nine (9) Conflicts of Interest (COIs) identified prior to and/or during the meeting. Four (4) applications with COIs were discussed and five (5) applications with COIs were not discussed. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (23.1 AR C/TCR)
Observation Report

Report No. 2022-10-27 23.1_AR_C/TCR
Program Name: Academic Research
Panel Name: 23.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (23.1_AR_C/TCR)
Panel Date: October 27, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Clinical and Translational Cancer Research (C/TCR) (23.1_AR_C/TCR) meeting. The meeting was chaired by Margaret Tempero and Richard O'Reilly and conducted via videoconference on October 27, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-four (24) applications were discussed and twenty-two (22) applications were not discussed
- Panelists: Two (2) panel chairs, twenty (20) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COI) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Review Panel - Basic Cancer

Research-1 (23.1 AR BCR-1)

Observation Report

Report No. 2022-10-28 23.1_AR_BCR-1
Program Name: Academic Research
Panel Name: 23.1 Academic Research Review Panel - Basic Cancer Research-1
(23.1_AR_BCR-1)
Panel Date: October 28, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Review Panel - Basic Cancer Research-1 (23.1_AR_BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on October 28, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eighteen (18) applications were discussed, and sixteen (16) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. One (1) application with a COI was discussed and five (5) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the closing text.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Cancer Biology (CB)

(23.1 ACR CB)

Observation Report

Report No. 2022-10-31 23.1_ACR_CB
Program Name: Academic Research
Panel Name: 23.1 Academic Research Cancer Biology (CB) (23.1 _ACR_CB)
Panel Date: October 31, 2022
Report Date: November 1, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Cancer Biology (CB) (23.1_ACR_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on October 31, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to the observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and twenty-nine (29) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions
- CPRIT Oversight Committee members: One (1)
- CPRIT Oversight Committee member(s) participation was limited observing the proceedings

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. One (1) application with a COI was discussed and one (1) application with COI was not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and

scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a stylized, cursive 'M' followed by a horizontal line that tapers to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research - Scientific Review Council Meeting
(23.1 SRC)
Observation Report

Report No. 2022-12-22 23.1_SRC
Program Name: Academic Research
Panel Name: 23.1 Academic Research - Scientific Review Council Meeting (23.1_SRC)
Panel Date: December 22, 2022
Report Date: December 23, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research - Scientific Review Council Meeting (23.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 22, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fifty-nine (59) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 23.1

Awards Announced at the February 15, 2023, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 23.1 include: *Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Translation; Individual Investigator Research Awards for Prevention and Early Detection; and Texas Regional Excellence in Cancer Award (TREC)*. Applications submitted in response to the five above listed Individual Investigator mechanisms went through preliminary evaluation as allowed by TAC § 703.6(e)(1). If a peer reviewer identified a conflict of interest during this stage, the application is labeled with a “pe” suffix.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT’s third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP230117pe/ RP230117	Patricia Chalela	The University of Texas Health Science Center at San Antonio	G. Coronado
RP230391pe/ RP230391	Maksim Mamonkin	Baylor College of Medicine	J. DiPersio
RP230184pe/ RP230184	Xiankai Sun	The University of Texas Southwestern Medical Center	A. Wu
RP230271pe/ RP230271	Niki Zacharias Millward	The University of Texas M. D. Anderson Cancer Center	A. Wu; W. Warren
RP230360pe/ RP230360	Douglas Frantz	The University of Texas at San Antonio	J. Conejo-Garcia

* Application not discussed during full review.

Academic Research
Cycle 23.1

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230213	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	T. Brandon
RP230272	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	A. Tomkinson; J. Petrini
RP230344	McBrayer, Samuel K	The University of Texas Southwestern Medical Center	C. Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP230021pe/ RP230021	Scherezade Mama	The University of Texas M. D. Anderson Cancer Center	K. Emmons
RP230044pe	Paul Scheet	The University of Texas M. D. Anderson Cancer Center	L. Mucci
RP230045pe	MinJae Lee	The University of Texas Southwestern Medical Center	G. Coronado
RP230069pe/ RP230069*	Sohail Rao	DHR Health Institute for Research and Development	L. Kushi
RP230097pe/ RP230097	Subrata Sen	The University of Texas M. D. Anderson Cancer Center	G. Petersen
RP230098pe	Julia Heck	University of North Texas	L. Mucci
RP230126pe/ RP230126*	Jose Rauh-Hain	The University of Texas M. D. Anderson Cancer Center	G. Coronado
RP230164pe	Jian Gu	The University of Texas M. D. Anderson Cancer Center	L. Mucci
RP230201pe/ RP230201	Edwin Ostrin	The University of Texas M. D. Anderson Cancer Center	C. Li
RP230279pe	Martha Mims	Baylor College of Medicine	C. Haiman
RP230284pe/ RP230284*	Surendranath Shastri	The University of Texas M. D. Anderson Cancer Center	K. Emmons

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230320pe	Chao Cheng	Baylor College of Medicine	L. Mucci
RP230002pe	Debananda Pati	Baylor College of Medicine	P. Grohar
RP230011pe/ RP230011*	Ziyi Li	The University of Texas M. D. Anderson Cancer Center	J. Issa
RP230292pe	Todd Aguilera	The University of Texas Southwestern Medical Center	W. Hahn
RP230394pe/ RP230394	Alexander Bishop	The University of Texas Health Science Center at San Antonio	P. Grohar
RP230208pe/ RP230208	Raquibul Hannan	The University of Texas Southwestern Medical Center	A. Ribas
RP230057pe/ RP230057*	Junjie Chen	The University of Texas M. D. Anderson Cancer Center	J. Petrini
RP230148pe	Paul Chiao	The University of Texas M. D. Anderson Cancer Center	A. Tomkinson; J. Petrini
RP230187pe	Christopher Amos	Baylor College of Medicine	A. Tomkinson
RP230210pe	Blerta Xhemalce	The University of Texas at Austin	A. Tomkinson
RP230232pe	Anthony Davis	The University of Texas Southwestern Medical Center	A. Tomkinson
RP230267pe	Alison Bertuch	Baylor College of Medicine	J. Karlseder
RP230296pe/ RP230296*	Zamal Ahmed	The University of Texas M. D. Anderson Cancer Center	A. Tomkinson; J. Petrini; W. Chazin
RP230322pe/ RP230322*	E. Paul Hasty	The University of Texas Health Science Center at San Antonio	A. Tomkinson
RP230079pe/ RP230079	Eva Sevick	The University of Texas Health Science Center at Houston	W. Warren
RP230177pe/ RP230177*	Henry Manning	The University of Texas M. D. Anderson Cancer Center	J. Gore

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230194pe/ RP230194	Jia Wu	The University of Texas M. D. Anderson Cancer Center	C. Kahn
RP230206pe/ RP230206	Jingfei Ma	The University of Texas M. D. Anderson Cancer Center	C. Kahn; D. Mankoff; J. Basilion
RP230209pe/ RP230209*	Andrew Wang	The University of Texas Southwestern Medical Center	W. Cai
RP230220pe	Ananth Madhuranthakam	The University of Texas Southwestern Medical Center	A. Wu
RP230238pe/ RP230238*	David Piwnica- Worms	The University of Texas M. D. Anderson Cancer Center	D. Mankoff
RP230252pe	Thomas Yankeelov	The University of Texas at Austin	J. Gore
RP230297pe/ RP230297*	Zhonglin Liu	The Methodist Hospital Research Institute	M. Giger
RP230395pe/ RP230395*	Yaowu Hao	The University of Texas at Arlington	A. Wu
RP230401pe	James Tour	Rice University	C. Kahn
RP230066pe/ RP230066*	FENG-CHUN YANG	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230155pe/ RP230155*	April Risinger	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230156pe/ RP230156*	Kexin Xu	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230159pe	Xiao-Dong Chen	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230189pe	Alexander Pertsemlidis	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230215pe	Gang Huang	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230265pe/ RP230265*	Yuzuru Shiio	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230293pe	Panneerdoss Subbarayalu	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230309pe	Stefano Tiziani	The University of Texas at Austin	J. Conejo-Garcia
RP230367*	Chen, Yidong	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230186*	Spencer, Jennifer	The University of Texas at Austin	G. Coronado

* Application not discussed during full review.

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards for Clinical Translation

Academic Research Cycle 23.1

Final Scores for Fully Reviewed Applications

The Program Integration Committee (PIC) deferred one application that the Scientific Review Council recommended from this mechanism. The deferred application is designated with “^” in the de-identified list. The PIC may consider the deferred applications at a later FY2023 meeting.

Application ID	Final Overall Evaluation Score
RP230285*	2.2
ssa^	2.8
La	3.0
Lm	3.1
Ln	3.6
Lo	3.7
Lp	3.7
Lq	3.7
Lr	3.7
Ls	4.3
Lt	4.4
Lu	5.7

* Recommended for funding

^ Application deferred by the PIC.

Individual Investigator Research Awards for Clinical Translation

Academic Research Cycle 23.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

Application ID	Final Overall Score
Wwa	3.67
Wwb	3.67
Wwc	3.67
Wwd	4.33
Wwe	4.33
Wwf	4.67

Final Overall Evaluation Scores and Rank Order Scores

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

January 16, 2023

Dr. Mahendra C. Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cpit.texas.gov

Dear Dr. Patel and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, and Individual Investigator Research Awards for Prevention and Early Detection

The SRC met on December 22, 2022 to consider the applications recommended by the peer review panels following their meetings held October 24, 2022 to October 31, 2022.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$67,370,879.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Award Mech	Meeting Overall Score	Application Title	PI	PI Organization	Recommended Budget
1	RP230026	IIRACCA	1.0	Identifying Clinical Methotrexate Toxicity Phenotypes Across Phases of Pediatric Leukemia Therapy	Bernhardt, Melanie	Baylor College of Medicine	\$1,392,407
2	RP230036	IIRAP	1.0	Geospatial Approaches to Melanoma Early Detection: The GAMED Project	Nelson, Kelly	The University of Texas M. D. Anderson Cancer Center	\$1,998,196
3	RP230222	IIRA	1.1	Personalized Auricular Point Acupressure to Self-Manage Cancer-Related Pain	Yeh, Chao Hsing	The University of Texas Health Science Center at Houston	\$1,046,680
4	RP230140	IIRA	1.1	Changes in Tumor Microenvironment That Promote Cachexia	Infante, Rodney	The University of Texas Southwestern Medical Center	\$1,050,000
5	RP230093	IIRA	1.8	Targeting the Mlc1-GlialCAM Protein Complex in Invasive Glioma Cells	McCarty, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,050,000

6	RP230018	IIRACCA	1.9	Neuronal Alterations in the Midbrain Dopaminergic System Function: A Novel Mechanism of Radiation-Induced Cognitive Dysfunction	Zhang, Die	The University of Texas M. D. Anderson Cancer Center	\$1,399,730
7	RP230117	IIRAP	1.9	Randomized Controlled Trial to Assess Innovative Smoking Cessation Services for Young Adults in Texas	Chalela, Patricia	The University of Texas Health Science Center at San Antonio	\$1,992,330
8	RP230072	IIRA	1.9	Studying and Therapeutically Targeting Ferroptosis Liability in BRCA1-Deficient Cancer	Gan, Boyi	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
9	RP230360	IIRA	1.9	Rational Design, Synthesis, and Biological Evaluation of Simplified Taccalonolide Analogs for the Treatment of Cancer	Frantz, Douglas	The University of Texas at San Antonio	\$1,049,128
10	RP230135	IIRA	2.0	Blocking DNA Damage Response Induction of "Don't Eat Me" Signals Converts Local Radiotherapy Into Systemic Immunotherapy	Curran, Michael	The University of Texas M. D. Anderson Cancer Center	\$1,049,905
11	RP230344	IIRA	2.0	Development and Evaluation of Lanosterol Synthase Inhibitors in Preclinical GBM Models	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,048,465
12	RP230109	IIRA	2.0	Autophagy and Tumor Endothelium	Terada, Lance	The University of Texas Southwestern Medical Center	\$1,049,994
13	RP230373	IIRA	2.0	Mapping the Geospatial Tumor Clonal Architecture to Restore	Viale, Andrea	The University of Texas M.	\$1,049,985

				Immune Recognition in Pancreatic Cancer		D. Anderson Cancer Center	
14	RP230224	IIRA	2.0	Enhancing Immune Responses in Pancreatic Cancer by Stromal Inhibition of HIF2	Taniguchi, Cullen	The University of Texas M. D. Anderson Cancer Center	\$1,049,997
15	RP230382	IIRA	2.0	Characterization of 3D Genome Organization and Transcriptional Regulation in Prostate Cancer	Mani, Ram	The University of Texas Southwestern Medical Center	\$1,049,641
16	RP230247	IIRA	2.0	A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer	Lin, Sue-Hwa	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
17	RP230063	IIRAP	2.1	Whole-Genome DNA Methylation Markers for Tracking and Predicting Advanced Liver Fibrosis as a Precursor of Liver Cancer in NAFLD	Tsai, Robert	Texas A&M University System Health Science Center	\$2,000,000
18	RP230285	IIRACT	2.2	Harnessing Endoplasmic Reticulum Stress to Overcome Resistance to Immunotherapy in Immune-Cold Breast Cancer	Chen , Xi	Baylor College of Medicine	\$2,000,000
19	RP230160	IIRACSBC	2.2	Overcoming Therapy Resistance by Integrated Computational Modeling of the Bone Metastatic Niche in Prostate and Renal Cancers	Dondossola , Eleonora	The University of Texas M. D. Anderson Cancer Center	\$1,025,623
20	RP230334	IIRA	2.5	Elucidating the Mutagenesis Mechanism of BRAF in Melanoma	Lee, Seongmin	The University of Texas at Austin	\$1,050,000

21	RP230120	IIRACCA	2.5	Clonal Evolution and Chemoresistance of Hepatoblastomas With Hepatocellular Carcinoma Features	Sumazin, Pavel	Baylor College of Medicine	\$1,371,733
22	RP230213	IIRAP	2.6	Multicomponent Interventions to Improve Uptake and Adherence to Lung Cancer Screening	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$1,988,211
23	RP230363	IIRACSBC	2.6	Developing Knowledge-Guided Deep Learning Models to Predict the Binding Between T-Cell Receptors and Neoantigens for Facilitating TCR-T Therapies	Wang, Tao	The University of Texas Southwestern Medical Center	\$1,199,997
24	RP230391	IIRA	2.6	Understanding and Improving CAR T-Cell Therapy of T-ALL and LBL	Mamonkin, Maksim	Baylor College of Medicine	\$1,050,000
25	RP230345	IIRA	2.6	The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T-Cell Therapy	Liu, Wenshe	Texas A&M University	\$1,050,000
26	RP230166	IIRACSBC	2.6	Integrative Modeling of Spatially Resolved Multiomics Data to Identify Bladder Cancer Mucosal Field Effects	Wei, Peng	The University of Texas M. D. Anderson Cancer Center	\$1,199,994
27	RP230154	IIRACCA	2.6	Normalizing Membrane Homeostasis in Microglia/Macrophages of Pediatric High-Grade Gliomas	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$1,400,000
28	RP230271	IIRA	2.7	Targeting Distinct Metabolic Vulnerabilities of Aggressive Renal Cell Carcinoma Variants	Zacharias Millward, Niki	The University of Texas M. D. Anderson	\$1,019,997

						Cancer Center	
29	RP230330	IIRACCA	2.7	Integrate Whole-Slide Imaging and Genomic Data to Study Pediatric Rhabdomyosarcoma	Xiao, Guanghua	The University of Texas Southwestern Medical Center	\$1,303,815
30	RP230050	IIRA	2.7	A Novel Therapeutic Strategy Targeting Pancreatic Cancer	Yao, Wantong	The University of Texas M. D. Anderson Cancer Center	\$1,049,854
31	RP230261	IIRA	2.7	Investigating the Mechanism of NLRP3 Inflammasome Hyperactivation During Hepatocellular Carcinoma Development	Zhong, Zhenyu	The University of Texas Southwestern Medical Center	\$1,049,997
32	RP230019	IIRA	2.8	Deciphering Spatial Immune Contextures Through Integrative Immunoproteogenomics	Lee, Hyun-Sung	Baylor College of Medicine	\$1,050,000
33	RP230161	IIRACT	2.8	¹³ C MRI With Hyperpolarized Pyruvate for Management of Glioblastoma	Park, Jae Mo	The University of Texas Southwestern Medical Center	\$1,727,462
34	RP230307	IIRA	2.8	In Vivo Chimeric Antigen Receptor Macrophages (ChARMs) for Cancer Immunotherapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$1,026,414
35	RP230241	IIRA	2.8	PD-L1 Modifications and Membranous Localization	Li, Yong	Baylor College of Medicine	\$1,049,994
36	RP230375	IIRA	2.8	Targeting Chitinase-3-Like-1 as a Novel Therapy for Hepatocellular Carcinoma	Ju, Cynthia	The University of Texas Health Science Center at Houston	\$1,049,769

37	RP230283	IIRA	2.8	Development of Immunotherapy and Combinatorial Therapy of Sickle Cell Trait-Associated Renal Medullary Carcinoma	Yang, Liuqing	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
38	RP230323	IIRA	2.9	Real-Time, Label-Free, Micro HSI Device and Transformer-Based Attention Networks for Oral Cancer Imaging	Fei, Baowei	The University of Texas at Dallas	\$1,048,933
39	RP230184	IIRA	2.9	Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Drugs for Precision Cancer Medicine	Sun, Xiankai	The University of Texas Southwestern Medical Center	\$1,049,997
40	RP230216	IIRA	2.9	Investigating Cell Competition in Liver Cancer Development	Zhu, Hao	The University of Texas Southwestern Medical Center	\$1,050,000
41	RP230381	IIRA	2.9	JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC	ZHANG, QING	The University of Texas Southwestern Medical Center	\$1,036,126
42	RP230319	IIRACSBC	2.9	Computational Methods for CRISPR-Based Lineage Tracing Systems	Liu, Zhandong	Baylor College of Medicine	\$1,200,000
43	RP230112	IIRA	2.9	The Evolution of Intratumor Heterogeneity of Lung Cancers With or Without Immunotherapy and Its Impact on Patient Survival	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,049,396
44	RP230143	IIRACCA	2.9	The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT	Ludwig, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,399,860

45	RP230240	IIRA	2.9	Therapeutic Targeting of Androgen Receptor in Metastatic Breast Cancer	Fuqua, Suzanne	Baylor College of Medicine	\$1,050,000
46	RP230272	IIRA	3.0	Structure-Based Improvement for Inhibitors of WNK1, a Triple-Negative Breast Cancer Signature Kinase	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	\$1,050,000
47	RP230327	IIRA	3.0	Harnessing the Metabolic Dependencies of Mitochondrial NADK2 as a Therapeutic Strategy for Lung Cancer	Hoxhaj, Gerta	The University of Texas Southwestern Medical Center	\$1,049,997
48	RP230071	IIRA	3.0	Unexpected Mechanisms Underlying Mutation-Induced Protein Mislocalization in Hematologic Malignancies	Liszcak, Glen	The University of Texas Southwestern Medical Center	\$1,049,997
49	RP230012	IIRA	3.0	Targeting a Non-ATPase Proteasome Subunit in Acute Myeloid Leukemia (AML)	Eiring, Anna	Texas Tech University Health Sciences Center at El Paso	\$1,050,000
50	RP230174	IIRACCA	3.0	Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites	Ehrlich, Lauren	The University of Texas at Austin	\$1,400,000
51	RP230196	IIRA	3.0	Identifying the Biological Determinants of Aggressive Meningioma	Patel, Akash	Baylor College of Medicine	\$1,047,289
52	RP230134	IIRACSBC	3.0	Therapeutic Vulnerabilities and Predictors of Response to Chemo(Immuno)Therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC)	Korkut, Anil	The University of Texas M. D. Anderson Cancer Center	\$1,199,966
53	RP230333	IIRA	3.1	Development of a Cell Therapy Platform for Localized and Feedback-Regulated Delivery of Cytokines for the	Veisheh, Omid	Rice University	\$1,050,000

				Treatment of Pancreatic Cancer			
54	RP230162	IIRACCA	3.1	The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma	Kitagawa, Katsumi	The University of Texas Health Science Center at San Antonio	\$1,400,000
55	RP230181	IIRA	3.1	Dissection of CAMKK2's Tumor Cell-Intrinsic and - Extrinsic Roles in Prostate Cancer	Frigo, Daniel	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
56	RP230197	IIRA	3.2	Targeting MYCN Disruption of the Molecular Clock and Tumor Metabolism in Neuroblastoma Oncogenesis	Barbieri, Eveline	Baylor College of Medicine	\$1,050,000

Individual Investigator Research Awards (IIRA)
 Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
 Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
 Individual Investigator Research Awards for Clinical Translation (IIRACT)
 Individual Investigator Research Awards for Prevention and Early Detection (IIRAP).



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2023—Cycle 1
*Individual Investigator Research Awards for
Prevention and Early Detection***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-23.1-IIRAP

**Individual Investigator Research Awards
for Prevention and Early Detection**

**Please also refer to the Instructions for Applicants document,
which will be posted on March 16, 2022**

Application Receipt Opening Date: March 16, 2022

Application Receipt Closing Date: June 8, 2022

FY 2023

Fiscal Year Award Period
September 1, 2022-August 31, 2023

TABLE OF CONTENTS

1. BRIEF DESCRIPTION OF RFA	5
2. KEY POINTS	5
3. ABOUT CPRIT	6
3.1. ACADEMIC RESEARCH PROGRAM PRIORITIES.....	6
4. RATIONALE	7
5. RESEARCH OBJECTIVES	8
6. FUNDING INFORMATION	9
7. ELIGIBILITY	9
8. RESUBMISSION POLICY	11
9. RENEWAL POLICY	11
10. RESPONDING TO THIS RFA	12
10.1. APPLICATION SUBMISSION GUIDELINES.....	12
10.1.1. Submission Deadline Extension.....	12
10.2. APPLICATION COMPONENTS.....	12
10.2.1. Abstract and Significance (5,000 characters).....	13
10.2.2. Layperson’s Summary (2,000 characters).....	13
10.2.3. Goals and Objectives.....	14
10.2.4. Timeline (1 page).....	14
10.2.5. Resubmission Summary (2 pages).....	14
10.2.6. Renewal Summary (2 pages).....	14
10.2.7. Research Plan (10 pages).....	15
10.2.8. Vertebrate Animals (1 page).....	15
10.2.9. Human Subjects (2 pages).....	15
10.2.10. Publications/References.....	15
10.2.11. Budget and Justification.....	15
10.2.12. Biographical Sketches (5 pages each).....	17
10.2.13. Current and Pending Support.....	17
10.2.14. Institutional/Collaborator Support and/or Other Certification (4 pages).....	17
10.2.15. Previous Summary Statement.....	17
10.3. FORMATTING INSTRUCTIONS.....	17
11. APPLICATION REVIEW	19
11.1. PRELIMINARY EVALUATION.....	19
11.2. FULL PEER REVIEW.....	19
11.3. CONFIDENTIALITY OF REVIEW.....	20
11.4. REVIEW CRITERIA.....	21
11.4.1. Primary Criteria.....	21
11.4.2. Secondary Criteria.....	22
12. KEY DATES	22
13. AWARD ADMINISTRATION	22
14. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	23
15. CONTACT INFORMATION	24
15.1. HELPDESK.....	24
15.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS.....	24

RFA VERSION HISTORY

01/14/22 RFA released

Rev 3/16/22 Section 10.2.11 – Budget and Justification

- Added language regarding allowable reimbursement of clinical trial participation costs

1. BRIEF DESCRIPTION OF RFA

- Supports applications which propose clinical and population-based projects designed to develop effective prevention and early detection interventions to reduce cancer risk, mortality, and morbidity among Texans.
- Applicants may request up to a maximum of \$400,000 per year for a period of up to 5 years.
- Multi-PIs (MI) are allowed under this RFA. See the Information for Applicants (IFA) document for applicants for definition and eligibility of MIs.
- Note that CPRIT does not allow the use of the term Co-PI.
- Minimum effort for the PI and/or MIs throughout the project period is required.

2. KEY POINTS

This new version of the Individual Investigator Research Award for Prevention and Early detection invites clinical and population-based projects designed to develop effective prevention, early detection, or behavioral interventions to reduce cancer risk, mortality, and morbidity among Texans. Examples of projects responsive to this RFA include those planning clinical or population-based projects:

- (1) To identify risk factors for cancers affecting Texans including social, environmental, and behavioral factors, genetic markers, and health disparities.
- (2) To validate biomarkers, genomic technologies, or imaging methods in Texas populations at high risk for cancer that will lead to detection of cancers at an early stage.
- (3) To develop and validate innovative interventions for the prevention or early detection of cancers with particular emphasis on Texans at highest risk for cancer.
- (4) To increase implementation and/or dissemination of evidence-based interventions for the prevention and/or early detection of cancers among all Texans as well as Texas populations at high risk for cancer.
- (5) To conduct health services research in Texas populations at highest risk for cancer to identify the most effective ways to address the disparities (eg, through systems change, outreach, access) and delivery of early detection and preventive care.

Basic research using laboratory and/or animal models designed to identify underlying mechanisms causing cancer ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting basic discovery research.

Basic and clinical research to discover or to evaluate chemoprevention strategies ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting basic discovery research or clinical translational research.

Applicants may request up to \$400,000 per year in CPRIT funds over 5 years.

3. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of, or cures for, cancer.
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

3.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure
- Achieving health equity, and reducing cancer disparities

The program priorities for academic research adopted by the Oversight Committee include funding projects that address or utilize the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

4. RATIONALE

Nowhere is there greater potential to reduce the burden of cancer than by reducing its incidence. It is estimated that more than half of all cancer deaths could be prevented. It is also well established that early detection of cancer improves cancer mortality. The goal of this RFA is to promote research to develop effective cancer prevention and early detection approaches for Texans.

Many opportunities exist to make greater progress in reducing cancer mortality in Texas through cancer prevention and early detection. Large numbers of Texans at average risk for cancers for which there are proven prevention and early detection strategies fail to take advantage of these strategies. This is particularly true among the medically underserved and hard to reach populations where numerous barriers inhibit the adoption and implementation of proven strategies for prevention or early detection. Early detection and prevention can improve mortality in individuals with an inherited predisposition to cancer. Yet testing for inherited cancer syndromes in appropriate populations is vastly underused. Novel technologies and noninvasive approaches (eg, liquid biopsies, novel imaging strategies) to detect cancer biomarkers are undergoing rapid advances that offer opportunities to improve surveillance of individuals at high risk for cancer. Behavioral sciences research informs the development and uptake of cancer-reducing strategies, eg, tobacco cessation strategies and obesity control. Greater attention to implementation of evidence-based identification of at-risk individuals may empower them to make and act upon informed, cancer-preventing health decisions.

5. RESEARCH OBJECTIVES

This Request for Applications (RFA) solicits clinical and population-based projects designed to improve current methods and develop new strategies for the prevention and early detection of cancer among Texans. Examples of projects responsive to this RFA include those planning clinical or population-based projects to do the following:

- (1) To identify social, environmental, and behavioral factors, genetic markers, and health disparities that underlie cancer risk and predisposition among Texans at high risk for cancer.
- (2) To validate biomarkers, genomic technologies, or imaging methods in populations at risk for cancer that will lead to detection of cancers at an early stage.
- (3) To develop and validate innovative interventions for the prevention or early detection of cancers with particular emphasis on Texans at highest risk for cancer.
- (4) To conduct behavioral science studies that inform the development of interventions to reduce cancer risk, eg, conducting obesity research, increasing uptake of screening or cancer vaccinations, or reducing use of combustible tobacco and vaping products, particularly in populations with cancer disparities.
- (5) To increase implementation and/or dissemination of evidence-based interventions for the prevention and/or early detection of cancers among all Texans as well as those populations at high risk.
- (6) To conduct health services research in populations at highest risk to identify the most effective ways to address the disparities (eg, through systems change, outreach, access) and delivery of early detection and preventive care.

Basic research using laboratory and/or animal models designed to identify underlying mechanisms causing cancer ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting basic discovery research.

Basic and clinical research to discover or to evaluate chemoprevention strategies ***is not responsive*** to this RFA and should be directed to other CPRIT mechanisms supporting basic discovery research or clinical translational research.

The *degree of relevance* to reducing the burden of cancer in Texas is a critical criterion for evaluation of projects for funding by CPRIT ([section 11.4.1](#)). Although CPRIT is required to spend 10% of its budget on cancer prevention, CPRIT's Cancer Prevention Program focuses

exclusively on the delivery of evidence-based interventions to underserved populations and does not fund prevention research. **Thus, there is a unique opportunity for respondents to this RFA in CPRIT's Academic Research Program to develop collaborations with CPRIT Prevention Program grantees who have developed community-based partnerships and can provide access to Texas populations for research designed to improve current practices. Projects that propose such research collaborations with existing CPRIT Prevention Program awardees including the CPRIT funded *Texas Collaborative Center for Hepatocellular Cancer* (<https://www.bcm.edu/research/labs-and-centers/research-centers/texas-collaborative-center-for-hepatocellular-cancer>) are strongly encouraged.**

6. FUNDING INFORMATION

Applicants may request a maximum up to \$400,000 in total costs per year for up to 5 years for clinical or population-based research, including implementation or dissemination research designed to accelerate the adoption and deployment of sustainable, evidence-based cancer prevention and screening interventions at multiple levels and in different clinical and community settings. Exceptions to these limits may be requested if extremely well justified (see [section 10.2.11](#)). Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs, and travel to scientific/technical meetings or collaborating institutions. Requests for funds to support construction and/or renovation will not be approved under this funding mechanism. State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the total award amount.

7. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution or organization that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism; these entities must use the appropriate award mechanism(s) under CPRIT's Product Development Research Program.
- The Principal Investigator (PI) must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and be a full-time resident of Texas during the time the research that is the subject of the grant is conducted.

- This award mechanism allows Multi-PIs for projects that require a team science approach (see the IFA for guidelines on CPRIT rules for Multi-PI awards).
- For applications that include 1 PI, the PI is required to maintain a minimum 15% level of effort throughout the entire award period. For applications that include MIs, each PI is required to maintain a minimum 10% effort throughout the entire award period.
- A PI may not submit applications to this RFA and to RFA R-23.1-IIRA, RFA R-23.1-IIRACCA, RFA R-23.1-IIRACSBC, or RFA R-23.1-IIRACT.
- A PI may submit only 1 application, either a new, resubmission or renewal application under this RFA during this funding cycle
- A PI may be a part of only one application, whether as a single applicant or as part of a Multi-PI application, under this RFA and RFA R-23.1-IIRA, RFA R-23.1-IIRACCA, RFA R-23.1-IIRACSBC, or RFA R-23.1-IIRACT.
- An individual may serve as a PI on no more than 3 active CPRIT Academic Research grants. Recruitment Grants and Research Training Awards do not count toward the 3-grant maximum; however, CPRIT considers MIRA Project Co-PIs equivalent to a PI. For the purpose of calculating the number of active grants, CPRIT will consider the number of active grants at the time of the award contract effective date (for this cycle expected to be March 1, 2023).
- Applications that address basic or animal-based projects, cancers in children and adolescents, computational systems biology of cancer, or innovative clinical trials should be submitted under the appropriate targeted RFA.
- Collaborating organizations may include public, not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the PI, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant PI, any senior member, or key personnel listed on the grant application, or any officer or director of the

grant applicant's organization or institution is related to a CPRIT Oversight Committee member.

- The applicant must report whether the applicant institution or organization, the PI, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, regardless of whether these individuals are slated to receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 13](#) and [section 14](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

8. RESUBMISSION POLICY

An application previously submitted to CPRIT but not funded may be resubmitted once and must follow all resubmission guidelines and be eligible for this mechanism under the criteria in Section 5. If a previously submitted application does not meet the new criteria for this mechanism outlined in Section 5, it must be resubmitted under the IIRA mechanism. More than 1 resubmission is not permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission. A change in the identity of the PI for a project or a change of title of the project that was previously submitted to CPRIT or omission or modification of an aim do not constitute a new application; the application would be considered a resubmission. This policy is in effect for all applications submitted to date. See [section 10.2.5](#).

9. RENEWAL POLICY

An application funded by CPRIT under this mechanism may be submitted for a competitive renewal. An application originally funded by CPRIT as an IIRA that is now appropriate for the IIRAP mechanism may be submitted under this RFA for a competitive renewal. See [section 10.2.6](#). An application originally funded by CPRIT under this mechanism that does not meet the

new criteria outlined in Section 5 must be submitted under the IIRA mechanism. Competitive renewals are not subject to preliminary evaluation. Renewal applications move directly to the full peer review phase. See [section 11.2](#).

10. RESPONDING TO THIS RFA

10.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and submit an application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on March 16, 2022, and must be submitted by 4 PM central time on June 8, 2022. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

10.1.1. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grants applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#), within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

10.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the IFA for details that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do

not meet the eligibility requirements listed in [section 7](#) will be administratively withdrawn without review.

10.2.1. Abstract and Significance (5,000 characters)

It is the responsibility of the applicant to capture CPRIT's attention primarily with the Abstract and Significance statement alone. Therefore, applicants are advised to prepare this section wisely. **Based on the Abstract and Significance statement (and the Budget and Justification and Biographical Sketches), applications that are judged to offer only modest contributions to the field of cancer research or that do not sufficiently capture the reviewers' interest may be excluded from further peer review (see [section 11.1](#)).** Applicants should not waste this valuable space by stating obvious facts (eg, that cancer is a significant problem; that better diagnostic and therapeutic approaches are needed urgently; or that the type of cancer of interest to the PI is important, vexing, or deadly).

Clearly explain the question or problem to be addressed and the approach to its answer or solution. The specific aims of the application must be obvious from the abstract although they need not be restated verbatim from the research plan.

Clearly address how the proposed project, if successful, will have a major impact on cancer. Indicate whether this research addresses the identification, or mitigation, of cancer disparities. Summarize how the proposed research creates new paradigms or challenges existing ones. Indicate whether this research plan represents a new direction for the PI.

10.2.2. Layperson's Summary (2,000 characters)

Provide a layperson's summary of the proposed work. Describe, in simple, nontechnical terms, the overall goals of the proposed work, the type(s) of cancer addressed, the potential significance of the results, and the impact of the work on advancing the field of cancer research, early detection, prevention, or treatment. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 11.2](#)) in evaluating the significance and impact of the proposed work.

10.2.3. Goals and Objectives

List specific goals and objectives for each year of the project. These goals and objectives will also be used during the submission and evaluation of progress reports and assessment of project success.

10.2.4. Timeline (1 page)

Provide an outline of anticipated major milestones to be tracked. Timelines will be reviewed for reasonableness, and adherence to timelines will be a criterion for continued support of successful applications.

If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

10.2.5. Resubmission Summary (2 pages)

Applicants preparing a resubmission must describe the approach to the resubmission. If a summary statement was prepared for the original application review, applicants are advised to address all noted concerns.

Note: An application previously submitted to CPRIT but not funded may be resubmitted **once** after careful consideration of the reasons for lack of prior success. Applications that received overall numerical scores of 5 or higher are likely to need considerable attention. Applicants may prepare a fresh research plan or modify the original research plan and mark the changes. However, **all resubmitted applications should be carefully reconstructed**; a simple revision of the prior application with editorial or technical changes is not sufficient, and applicants are advised not to direct reviewers to such modest changes.

10.2.6. Renewal Summary (2 pages)

Applicants preparing a renewal must describe and demonstrate that appropriate/adequate progress has been made on the current funded award to warrant further funding. Publications and manuscripts in press that have resulted from work performed during the initial funded period should be listed in the renewal summary.

10.2.7. Research Plan (10 pages)

Background: Present the rationale behind the proposed project, emphasizing the pressing problem in cancer research that will be addressed.

Hypothesis and Specific Aims: Concisely state the hypothesis and/or specific aims to be tested or addressed by the research described in the application. Describe the significance, innovation, and potential impact of the research.

Research Strategy: Describe the experimental design, including methods, anticipated results, potential problems or pitfalls, and alternative approaches. Preliminary data that support the proposed hypothesis are encouraged but not required.

10.2.8. Vertebrate Animals (1 page)

If vertebrate animals will be used, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

10.2.9. Human Subjects (2 pages)

If human subjects or human biological samples will be used, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

10.2.10. Publications/References

Provide a concise and relevant list of publications/references cited for the application.

10.2.11. Budget and Justification

Provide a compelling and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses. Do not exceed \$400,000 per year for studies, including implementation research designed to accelerate the adoption and deployment of sustainable, evidence-based cancer prevention and screening interventions at multiple levels and in different clinical and community settings. Applicants are advised not to interpret the maximum allowable

request under this award as a suggestion that they should expand their anticipated budget to this level. Reasonable budgets clearly work in favor of the applicant.

However, if there is a highly specific and defensible need to request more than the maximum amount in any year(s) of the proposed budget, include a special and clearly labeled section in the budget justification that explains the request. Poorly justified requests of this type will likely have a negative impact on the overall evaluation of the application.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The maximum annual salary (also referred to as direct salary or institutional base salary) that an individual may request under a CPRIT award for FY 2023 is \$200,000; CPRIT FY 2023 is from September 1, 2022, through August 31, 2023. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.
- Funds can be used to pay for costs that a cancer clinical trial participant may have associated with their participation in a clinical trial, including: 1) transportation, including car mileage, parking, bus fare, taxi or ride hailing fare exclusive of tips, and commercial economy class airfare within the borders of the State of Texas; 2) lodging.

10.2.12. Biographical Sketches (5 pages each)

Applicants should provide a biographical sketch that describes their education and training, professional experience, awards and honors, and publications relevant to cancer research.

A biographical sketch must be provided for the PI and, if applicable, any additional PIs (if a MI application), as required by the online application receipt system. Up to 2 additional biographical sketches for key personnel may be provided. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

10.2.13. Current and Pending Support

Describe the funding source and duration of all current and pending support for all personnel who have included a biographical sketch with the application. For each award, provide the title, a 2-line summary of the goal of the project and, if relevant, a statement of overlap with the current application. At a minimum, current and pending support of the PI and, if applicable, any additional PIs (if a MI application), must be provided. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

10.2.14. Institutional/Collaborator Support and/or Other Certification (4 pages)

Applicants may provide letters of institutional support, collaborator support, and/or other certification documentation relevant to the proposed project. A maximum of 4 pages may be provided.

10.2.15. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or that do not meet the eligibility requirements listed above will be administratively rejected without review.

10.3. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only

- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters are also acceptable if the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

11. APPLICATION REVIEW

11.1. Preliminary Evaluation

To ensure the timely and thorough review of only the most innovative and cutting-edge research with the greatest potential for advancement of cancer research, all eligible applications may be preliminarily evaluated by CPRIT Scientific Research Program panel members for scientific merit and impact.

This preliminary evaluation will be based on a subset of material presented in the application—namely, Abstract and Significance, Budget and Justification, and

Biographical Sketches. Applications that do not sufficiently capture the reviewers' interest at this stage will not be considered for further review. Such applications will have been judged to offer only modest contributions to the field of cancer research and will be excluded from further peer review.

The applicant will be notified of the decision to disapprove the application after the preliminary evaluation stage has concluded. Due to the volume of applications to be reviewed, comments made by reviewers at the preliminary evaluation stage may be limited.

11.2. Full Peer Review

Applications that pass preliminary evaluation will undergo further review using a 2-stage peer review process: (1) Full peer review and (2) Prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 11.4](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all the peer review panels and programmatic priorities. Applications approved by the Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of

the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

11.3. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules (Texas Administrative Code [RULE §703.9](#)).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

11.4. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review committees will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

11.4.1. Primary Criteria

Primary criteria will evaluate the scientific merit and potential impact of the proposed work contained in the application. Concerns with any of these criteria potentially indicate a major flaw in the significance and/or design of the proposed study. Primary criteria include the following:

Significance and Impact: Will the results of this research, if successful, significantly change the research of others or the opportunities for better cancer prevention or early detection? Is the application innovative? Does the applicant propose new paradigms or challenge existing ones? Does the project develop state-of-the-art technologies, methods, tools, or resources for cancer research or address important underexplored or unexplored areas? If the research project is successful, will it lead to truly substantial advances in the field rather than add modest increments of insight? Projects that modestly extend current lines of research will not be considered for this award. Projects that represent straightforward extensions of ongoing work, especially work traditionally funded by other mechanisms, will not be competitive.

Research Plan: Is the proposed work presented as a self-contained research project? Does the proposed research have a clearly defined hypothesis or goal that is supported by sufficient preliminary data and/or scientific rationale? Are the methods appropriate, and are potential experimental obstacles and unexpected results discussed?

Applicant Investigator: Does the investigator(s) demonstrate the required creativity and expertise to make a significant contribution to the research? Applicants' credentials will be evaluated in a career stage-specific fashion. Have early-career-stage investigators received excellent training, and do their accomplishments to date offer great promise for a successful career? Has the applicant(s) devoted a sufficient amount of their time (percent effort) to this project?

Relevance: Does the proposed research have a high degree of relevance to cancer prevention research or early detection for Texans? This is a critical criterion for evaluation of projects for CPRIT support.

11.4.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research.

Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

12. KEY DATES

RFA

RFA release January 14, 2022

Application

Online application opens March 16, 2022, 7 AM central time

Application due June 8, 2022, 4 PM central time

Application review June 2022–February 2023

Award

Award notification February 2023

Anticipated start date March 1, 2023

13. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award

contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov. Applicants are advised to review CPRIT's administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

14. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded

to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT’s Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

15. CONTACT INFORMATION

15.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not able to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

15.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director of Academic Research.

Tel: 512-305-8491

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Imaging Technology and
Informatics (ITI) (23.1 AR ITI)
Observation Report

Report No. 2022-10-24 23.1_AR_ITI
Program Name: Academic Research
Panel Name: 23.1 Academic Research Imaging Technology and Informatics (ITI)
(23.1_AR_ITI)
Panel Date: October 24, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Imaging Technology and Informatics (ITI) (23.1_AR_ITI) meeting. The meeting was chaired by Martin Pomper and conducted via videoconference on October 24, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Fifteen (15) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, eighteen (18) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were thirteen (13) Conflicts of Interest (COIs) identified prior to and/or during the meeting. Seven (7) applications with COIs were discussed and six (6) applications with COIs were not discussed. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Review Panel - Basic Cancer

Research (23.1 AR BCR-2)

Observation Report

Report No. 2022-10-25 23.1_AR_BCR-2
Program Name: Academic Research
Panel Name: 23.1 Academic Research Review Panel - Basic Cancer Research
(23.1_AR_BCR-2)
Panel Date: October 25, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Review Panel - Basic Cancer Research (23.1_AR_BCR-2) meeting. The meeting was chaired by Carol Prives and conducted via videoconference on October 25, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Sixteen (16) applications were discussed, and eighteen (18) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies and answering procedural questions

Eight (8) Conflicts of Interest (COIs) were identified prior to and/or during the meeting. Three (3) applications with COIs were discussed and three (3) applications with COIs were not discussed. COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Cancer Prevention Research (CPR)
(23.1 AR CPR)
Observation Report

Report No. 2022-10-26 23.1_AR_CPR
Program Name: Academic Research
Panel Name: 23.1 Academic Research Cancer Prevention Research (CPR) (23.1
_AR_CPR)
Panel Date: October 26, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Cancer Prevention Research (CPR) (23.1_AR_CPR) meeting. The meeting was chaired by Elena Martinez and conducted via videoconference on October 26, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty (20) applications were discussed and twelve (12) applications were not discussed
- Panelists: One (1) panel chair, sixteen (16) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were nine (9) Conflicts of Interest (COIs) identified prior to and/or during the meeting. Four (4) applications with COIs were discussed and five (5) applications with COIs were not discussed. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (23.1 AR C/TCR)
Observation Report

Report No. 2022-10-27 23.1_AR_C/TCR
Program Name: Academic Research
Panel Name: 23.1 Academic Research Clinical and Translational Cancer
Research (C/TCR) (23.1_AR_C/TCR)
Panel Date: October 27, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Clinical and Translational Cancer Research (C/TCR) (23.1_AR_C/TCR) meeting. The meeting was chaired by Margaret Tempero and Richard O'Reilly and conducted via videoconference on October 27, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Twenty-four (24) applications were discussed and twenty-two (22) applications were not discussed
- Panelists: Two (2) panel chairs, twenty (20) expert reviewers, and three (3) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Six (6)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were two (2) Conflicts of Interest (COI) identified prior to and/or during the meeting. The COIs were excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Review Panel - Basic Cancer

Research-1 (23.1 AR BCR-1)

Observation Report

Report No. 2022-10-28 23.1_AR_BCR-1
Program Name: Academic Research
Panel Name: 23.1 Academic Research Review Panel - Basic Cancer Research-1
(23.1_AR_BCR-1)
Panel Date: October 28, 2022
Report Date: October 31, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Review Panel - Basic Cancer Research-1 (23.1_AR_BCR-1) meeting. The meeting was chaired by Eric Fearon and conducted via videoconference on October 28, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eighteen (18) applications were discussed, and sixteen (16) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Four (4)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were six (6) Conflicts of Interest (COIs) identified prior to and/or during the meeting. One (1) application with a COI was discussed and five (5) applications with COIs were not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional

procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Academic Research Cancer Biology (CB)

(23.1 ACR CB)

Observation Report

Report No. 2022-10-31 23.1_ACR_CB
Program Name: Academic Research
Panel Name: 23.1 Academic Research Cancer Biology (CB) (23.1 _ACR_CB)
Panel Date: October 31, 2022
Report Date: November 1, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Cancer Biology (CB) (23.1_ACR_CB) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on October 31, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to the observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and

- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Seventeen (17) applications were discussed and twenty-nine (29) applications were not discussed
- Panelists: One (1) panel chair, fifteen (15) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Four (4)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions
- CPRIT Oversight Committee members: One (1)
- CPRIT Oversight Committee member(s) participation was limited observing the proceedings

There were two (2) Conflicts of Interest (COIs) identified prior to and/or during the meeting. One (1) application with a COI was discussed and one (1) application with COI was not discussed. The COI was excluded from discussions concerning applications for which there was a conflict.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION


In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and

scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research - Scientific Review Council Meeting
(23.1 SRC)
Observation Report

Report No. 2022-12-22 23.1_SRC
Program Name: Academic Research
Panel Name: 23.1 Academic Research - Scientific Review Council Meeting (23.1_SRC)
Panel Date: December 22, 2022
Report Date: December 23, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research - Scientific Review Council Meeting (23.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 22, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fifty-nine (59) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 23.1

Awards Announced at the February 15, 2023, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 23.1 include: *Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Translation; Individual Investigator Research Awards for Prevention and Early Detection; and Texas Regional Excellence in Cancer Award (TREC)*. Applications submitted in response to the five above listed Individual Investigator mechanisms went through preliminary evaluation as allowed by TAC § 703.6(e)(1). If a peer reviewer identified a conflict of interest during this stage, the application is labeled with a “pe” suffix.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT’s third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP230117pe/ RP230117	Patricia Chalela	The University of Texas Health Science Center at San Antonio	G. Coronado
RP230391pe/ RP230391	Maksim Mamonkin	Baylor College of Medicine	J. DiPersio
RP230184pe/ RP230184	Xiankai Sun	The University of Texas Southwestern Medical Center	A. Wu
RP230271pe/ RP230271	Niki Zacharias Millward	The University of Texas M. D. Anderson Cancer Center	A. Wu; W. Warren
RP230360pe/ RP230360	Douglas Frantz	The University of Texas at San Antonio	J. Conejo-Garcia

* Application not discussed during full review.

Academic Research
Cycle 23.1

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230213	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	T. Brandon
RP230272	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	A. Tomkinson; J. Petrini
RP230344	McBrayer, Samuel K	The University of Texas Southwestern Medical Center	C. Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP230021pe/ RP230021	Scherezade Mama	The University of Texas M. D. Anderson Cancer Center	K. Emmons
RP230044pe	Paul Scheet	The University of Texas M. D. Anderson Cancer Center	L. Mucci
RP230045pe	MinJae Lee	The University of Texas Southwestern Medical Center	G. Coronado
RP230069pe/ RP230069*	Sohail Rao	DHR Health Institute for Research and Development	L. Kushi
RP230097pe/ RP230097	Subrata Sen	The University of Texas M. D. Anderson Cancer Center	G. Petersen
RP230098pe	Julia Heck	University of North Texas	L. Mucci
RP230126pe/ RP230126*	Jose Rauh-Hain	The University of Texas M. D. Anderson Cancer Center	G. Coronado
RP230164pe	Jian Gu	The University of Texas M. D. Anderson Cancer Center	L. Mucci
RP230201pe/ RP230201	Edwin Ostrin	The University of Texas M. D. Anderson Cancer Center	C. Li
RP230279pe	Martha Mims	Baylor College of Medicine	C. Haiman
RP230284pe/ RP230284*	Surendranath Shastri	The University of Texas M. D. Anderson Cancer Center	K. Emmons

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230320pe	Chao Cheng	Baylor College of Medicine	L. Mucci
RP230002pe	Debananda Pati	Baylor College of Medicine	P. Grohar
RP230011pe/ RP230011*	Ziyi Li	The University of Texas M. D. Anderson Cancer Center	J. Issa
RP230292pe	Todd Aguilera	The University of Texas Southwestern Medical Center	W. Hahn
RP230394pe/ RP230394	Alexander Bishop	The University of Texas Health Science Center at San Antonio	P. Grohar
RP230208pe/ RP230208	Raquibul Hannan	The University of Texas Southwestern Medical Center	A. Ribas
RP230057pe/ RP230057*	Junjie Chen	The University of Texas M. D. Anderson Cancer Center	J. Petrini
RP230148pe	Paul Chiao	The University of Texas M. D. Anderson Cancer Center	A. Tomkinson; J. Petrini
RP230187pe	Christopher Amos	Baylor College of Medicine	A. Tomkinson
RP230210pe	Blerta Xhemalce	The University of Texas at Austin	A. Tomkinson
RP230232pe	Anthony Davis	The University of Texas Southwestern Medical Center	A. Tomkinson
RP230267pe	Alison Bertuch	Baylor College of Medicine	J. Karlseder
RP230296pe/ RP230296*	Zamal Ahmed	The University of Texas M. D. Anderson Cancer Center	A. Tomkinson; J. Petrini; W. Chazin
RP230322pe/ RP230322*	E. Paul Hasty	The University of Texas Health Science Center at San Antonio	A. Tomkinson
RP230079pe/ RP230079	Eva Sevick	The University of Texas Health Science Center at Houston	W. Warren
RP230177pe/ RP230177*	Henry Manning	The University of Texas M. D. Anderson Cancer Center	J. Gore

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230194pe/ RP230194	Jia Wu	The University of Texas M. D. Anderson Cancer Center	C. Kahn
RP230206pe/ RP230206	Jingfei Ma	The University of Texas M. D. Anderson Cancer Center	C. Kahn; D. Mankoff; J. Basilion
RP230209pe/ RP230209*	Andrew Wang	The University of Texas Southwestern Medical Center	W. Cai
RP230220pe	Ananth Madhuranthakam	The University of Texas Southwestern Medical Center	A. Wu
RP230238pe/ RP230238*	David Piwnica- Worms	The University of Texas M. D. Anderson Cancer Center	D. Mankoff
RP230252pe	Thomas Yankeelov	The University of Texas at Austin	J. Gore
RP230297pe/ RP230297*	Zhonglin Liu	The Methodist Hospital Research Institute	M. Giger
RP230395pe/ RP230395*	Yaowu Hao	The University of Texas at Arlington	A. Wu
RP230401pe	James Tour	Rice University	C. Kahn
RP230066pe/ RP230066*	FENG-CHUN YANG	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230155pe/ RP230155*	April Risinger	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230156pe/ RP230156*	Kexin Xu	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230159pe	Xiao-Dong Chen	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230189pe	Alexander Pertsemlidis	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230215pe	Gang Huang	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230265pe/ RP230265*	Yuzuru Shiio	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230293pe	Panneerdoss Subbarayalu	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230309pe	Stefano Tiziani	The University of Texas at Austin	J. Conejo-Garcia
RP230367*	Chen, Yidong	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230186*	Spencer, Jennifer	The University of Texas at Austin	G. Coronado

* Application not discussed during full review.

De-Identified Overall Evaluation Scores

Individual Investigator Research Awards for Prevention and Early Detection

Academic Research Cycle 23.1

Final Scores for Fully Reviewed Applications

Application ID	Final Overall Evaluation Score
RP230036*	1.0
RP230117*	1.9
RP230063*	2.1
RP230213*	2.6
Ma	3.2
Mb	3.3
Mc	3.6
Md	4.0
Me	4.2
Mf	4.3
Mg	4.3
Mh	4.4
Mi	4.6
Mj	4.7
Mk	5.0
MI	5.3
Mm	5.3

* Recommended for funding

Individual Investigator Research Awards for Prevention and Early Detection

Academic Research Cycle 23.1

Final Scores for Preliminary Evaluation

These are the final overall evaluation scores for applications receiving preliminary evaluation that did not move forward to full review. The final overall evaluation score is an average of the preliminary evaluation scores assigned to each application by the primary reviewers.

Application ID	Final Overall Score
Rra	4.00
Rrb	4.67
Rrc	5.33
Rrd	5.67
Rre	6.33

Final Overall Evaluation Scores and Rank Order Scores

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

January 16, 2023

Dr. Mahendra C. Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cpit.texas.gov

Dear Dr. Patel and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for Individual Investigator Research Awards, Individual Investigator Research Awards for Childhood and Adolescent Cancers, Individual Investigator Research Awards for Computational Systems Biology of Cancer, Individual Investigator Research Awards for Clinical Translation, and Individual Investigator Research Awards for Prevention and Early Detection

The SRC met on December 22, 2022 to consider the applications recommended by the peer review panels following their meetings held October 24, 2022 to October 31, 2022.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$67,370,879.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Award Mech	Meeting Overall Score	Application Title	PI	PI Organization	Recommended Budget
1	RP230026	IIRACCA	1.0	Identifying Clinical Methotrexate Toxicity Phenotypes Across Phases of Pediatric Leukemia Therapy	Bernhardt, Melanie	Baylor College of Medicine	\$1,392,407
2	RP230036	IIRAP	1.0	Geospatial Approaches to Melanoma Early Detection: The GAMED Project	Nelson, Kelly	The University of Texas M. D. Anderson Cancer Center	\$1,998,196
3	RP230222	IIRA	1.1	Personalized Auricular Point Acupressure to Self-Manage Cancer-Related Pain	Yeh, Chao Hsing	The University of Texas Health Science Center at Houston	\$1,046,680
4	RP230140	IIRA	1.1	Changes in Tumor Microenvironment That Promote Cachexia	Infante, Rodney	The University of Texas Southwestern Medical Center	\$1,050,000
5	RP230093	IIRA	1.8	Targeting the Mlc1-GlialCAM Protein Complex in Invasive Glioma Cells	McCarty, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,050,000

6	RP230018	IIRACCA	1.9	Neuronal Alterations in the Midbrain Dopaminergic System Function: A Novel Mechanism of Radiation-Induced Cognitive Dysfunction	Zhang, Die	The University of Texas M. D. Anderson Cancer Center	\$1,399,730
7	RP230117	IIRAP	1.9	Randomized Controlled Trial to Assess Innovative Smoking Cessation Services for Young Adults in Texas	Chalela, Patricia	The University of Texas Health Science Center at San Antonio	\$1,992,330
8	RP230072	IIRA	1.9	Studying and Therapeutically Targeting Ferroptosis Liability in BRCA1-Deficient Cancer	Gan, Boyi	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
9	RP230360	IIRA	1.9	Rational Design, Synthesis, and Biological Evaluation of Simplified Taccalonolide Analogs for the Treatment of Cancer	Frantz, Douglas	The University of Texas at San Antonio	\$1,049,128
10	RP230135	IIRA	2.0	Blocking DNA Damage Response Induction of "Don't Eat Me" Signals Converts Local Radiotherapy Into Systemic Immunotherapy	Curran, Michael	The University of Texas M. D. Anderson Cancer Center	\$1,049,905
11	RP230344	IIRA	2.0	Development and Evaluation of Lanosterol Synthase Inhibitors in Preclinical GBM Models	McBrayer, Samuel	The University of Texas Southwestern Medical Center	\$1,048,465
12	RP230109	IIRA	2.0	Autophagy and Tumor Endothelium	Terada, Lance	The University of Texas Southwestern Medical Center	\$1,049,994
13	RP230373	IIRA	2.0	Mapping the Geospatial Tumor Clonal Architecture to Restore	Viale, Andrea	The University of Texas M.	\$1,049,985

				Immune Recognition in Pancreatic Cancer		D. Anderson Cancer Center	
14	RP230224	IIRA	2.0	Enhancing Immune Responses in Pancreatic Cancer by Stromal Inhibition of HIF2	Taniguchi, Cullen	The University of Texas M. D. Anderson Cancer Center	\$1,049,997
15	RP230382	IIRA	2.0	Characterization of 3D Genome Organization and Transcriptional Regulation in Prostate Cancer	Mani, Ram	The University of Texas Southwestern Medical Center	\$1,049,641
16	RP230247	IIRA	2.0	A Novel Combination Therapeutic Approach to Revitalizing Immunotherapy for Bone Metastatic Prostate Cancer	Lin, Sue-Hwa	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
17	RP230063	IIRAP	2.1	Whole-Genome DNA Methylation Markers for Tracking and Predicting Advanced Liver Fibrosis as a Precursor of Liver Cancer in NAFLD	Tsai, Robert	Texas A&M University System Health Science Center	\$2,000,000
18	RP230285	IIRACT	2.2	Harnessing Endoplasmic Reticulum Stress to Overcome Resistance to Immunotherapy in Immune-Cold Breast Cancer	Chen , Xi	Baylor College of Medicine	\$2,000,000
19	RP230160	IIRACSBC	2.2	Overcoming Therapy Resistance by Integrated Computational Modeling of the Bone Metastatic Niche in Prostate and Renal Cancers	Dondossola , Eleonora	The University of Texas M. D. Anderson Cancer Center	\$1,025,623
20	RP230334	IIRA	2.5	Elucidating the Mutagenesis Mechanism of BRAF in Melanoma	Lee, Seongmin	The University of Texas at Austin	\$1,050,000

21	RP230120	IIRACCA	2.5	Clonal Evolution and Chemoresistance of Hepatoblastomas With Hepatocellular Carcinoma Features	Sumazin, Pavel	Baylor College of Medicine	\$1,371,733
22	RP230213	IIRAP	2.6	Multicomponent Interventions to Improve Uptake and Adherence to Lung Cancer Screening	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	\$1,988,211
23	RP230363	IIRACSBC	2.6	Developing Knowledge-Guided Deep Learning Models to Predict the Binding Between T-Cell Receptors and Neoantigens for Facilitating TCR-T Therapies	Wang, Tao	The University of Texas Southwestern Medical Center	\$1,199,997
24	RP230391	IIRA	2.6	Understanding and Improving CAR T-Cell Therapy of T-ALL and LBL	Mamonkin, Maksim	Baylor College of Medicine	\$1,050,000
25	RP230345	IIRA	2.6	The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T-Cell Therapy	Liu, Wenshe	Texas A&M University	\$1,050,000
26	RP230166	IIRACSBC	2.6	Integrative Modeling of Spatially Resolved Multiomics Data to Identify Bladder Cancer Mucosal Field Effects	Wei, Peng	The University of Texas M. D. Anderson Cancer Center	\$1,199,994
27	RP230154	IIRACCA	2.6	Normalizing Membrane Homeostasis in Microglia/Macrophages of Pediatric High-Grade Gliomas	Hu, Jian	The University of Texas M. D. Anderson Cancer Center	\$1,400,000
28	RP230271	IIRA	2.7	Targeting Distinct Metabolic Vulnerabilities of Aggressive Renal Cell Carcinoma Variants	Zacharias Millward, Niki	The University of Texas M. D. Anderson	\$1,019,997

						Cancer Center	
29	RP230330	IIRACCA	2.7	Integrate Whole-Slide Imaging and Genomic Data to Study Pediatric Rhabdomyosarcoma	Xiao, Guanghua	The University of Texas Southwestern Medical Center	\$1,303,815
30	RP230050	IIRA	2.7	A Novel Therapeutic Strategy Targeting Pancreatic Cancer	Yao, Wantong	The University of Texas M. D. Anderson Cancer Center	\$1,049,854
31	RP230261	IIRA	2.7	Investigating the Mechanism of NLRP3 Inflammasome Hyperactivation During Hepatocellular Carcinoma Development	Zhong, Zhenyu	The University of Texas Southwestern Medical Center	\$1,049,997
32	RP230019	IIRA	2.8	Deciphering Spatial Immune Contextures Through Integrative Immunoproteogenomics	Lee, Hyun-Sung	Baylor College of Medicine	\$1,050,000
33	RP230161	IIRACT	2.8	¹³ C MRI With Hyperpolarized Pyruvate for Management of Glioblastoma	Park, Jae Mo	The University of Texas Southwestern Medical Center	\$1,727,462
34	RP230307	IIRA	2.8	In Vivo Chimeric Antigen Receptor Macrophages (ChARMs) for Cancer Immunotherapy	Jiang, Wen	The University of Texas M. D. Anderson Cancer Center	\$1,026,414
35	RP230241	IIRA	2.8	PD-L1 Modifications and Membranous Localization	Li, Yong	Baylor College of Medicine	\$1,049,994
36	RP230375	IIRA	2.8	Targeting Chitinase-3-Like-1 as a Novel Therapy for Hepatocellular Carcinoma	ju, Cynthia	The University of Texas Health Science Center at Houston	\$1,049,769

37	RP230283	IIRA	2.8	Development of Immunotherapy and Combinatorial Therapy of Sickle Cell Trait-Associated Renal Medullary Carcinoma	Yang, Liuqing	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
38	RP230323	IIRA	2.9	Real-Time, Label-Free, Micro HSI Device and Transformer-Based Attention Networks for Oral Cancer Imaging	Fei, Baowei	The University of Texas at Dallas	\$1,048,933
39	RP230184	IIRA	2.9	Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Drugs for Precision Cancer Medicine	Sun, Xiankai	The University of Texas Southwestern Medical Center	\$1,049,997
40	RP230216	IIRA	2.9	Investigating Cell Competition in Liver Cancer Development	Zhu, Hao	The University of Texas Southwestern Medical Center	\$1,050,000
41	RP230381	IIRA	2.9	JMJD6-DGAT1 Signaling Axis Regulates Lipid Droplets and Tumorigenesis in ccRCC	ZHANG, QING	The University of Texas Southwestern Medical Center	\$1,036,126
42	RP230319	IIRACSBC	2.9	Computational Methods for CRISPR-Based Lineage Tracing Systems	Liu, Zhandong	Baylor College of Medicine	\$1,200,000
43	RP230112	IIRA	2.9	The Evolution of Intratumor Heterogeneity of Lung Cancers With or Without Immunotherapy and Its Impact on Patient Survival	Zhang, Jianjun	The University of Texas M. D. Anderson Cancer Center	\$1,049,396
44	RP230143	IIRACCA	2.9	The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT	Ludwig, Joseph	The University of Texas M. D. Anderson Cancer Center	\$1,399,860

45	RP230240	IIRA	2.9	Therapeutic Targeting of Androgen Receptor in Metastatic Breast Cancer	Fuqua, Suzanne	Baylor College of Medicine	\$1,050,000
46	RP230272	IIRA	3.0	Structure-Based Improvement for Inhibitors of WNK1, a Triple-Negative Breast Cancer Signature Kinase	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	\$1,050,000
47	RP230327	IIRA	3.0	Harnessing the Metabolic Dependencies of Mitochondrial NADK2 as a Therapeutic Strategy for Lung Cancer	Hoxhaj, Gerta	The University of Texas Southwestern Medical Center	\$1,049,997
48	RP230071	IIRA	3.0	Unexpected Mechanisms Underlying Mutation-Induced Protein Mislocalization in Hematologic Malignancies	Liszcak, Glen	The University of Texas Southwestern Medical Center	\$1,049,997
49	RP230012	IIRA	3.0	Targeting a Non-ATPase Proteasome Subunit in Acute Myeloid Leukemia (AML)	Eiring, Anna	Texas Tech University Health Sciences Center at El Paso	\$1,050,000
50	RP230174	IIRACCA	3.0	Myeloid Support of Refractory and Aggressive T-ALL at Distinct Tumor Sites	Ehrlich, Lauren	The University of Texas at Austin	\$1,400,000
51	RP230196	IIRA	3.0	Identifying the Biological Determinants of Aggressive Meningioma	Patel, Akash	Baylor College of Medicine	\$1,047,289
52	RP230134	IIRACSB	3.0	Therapeutic Vulnerabilities and Predictors of Response to Chemo(Immuno)Therapy in Patients With High-Risk, Early-Stage Triple-Negative Breast Cancer (TNBC)	Korkut, Anil	The University of Texas M. D. Anderson Cancer Center	\$1,199,966
53	RP230333	IIRA	3.1	Development of a Cell Therapy Platform for Localized and Feedback-Regulated Delivery of Cytokines for the	Veisheh, Omid	Rice University	\$1,050,000

				Treatment of Pancreatic Cancer			
54	RP230162	IIRACCA	3.1	The Role of EWSR1-FLI1-CENP-A Signaling in Chemoresistance in Ewing Sarcoma	Kitagawa, Katsumi	The University of Texas Health Science Center at San Antonio	\$1,400,000
55	RP230181	IIRA	3.1	Dissection of CAMKK2's Tumor Cell-Intrinsic and -Extrinsic Roles in Prostate Cancer	Frigo, Daniel	The University of Texas M. D. Anderson Cancer Center	\$1,050,000
56	RP230197	IIRA	3.2	Targeting MYCN Disruption of the Molecular Clock and Tumor Metabolism in Neuroblastoma Oncogenesis	Barbieri, Eveline	Baylor College of Medicine	\$1,050,000

Individual Investigator Research Awards (IIRA)
 Individual Investigator Research Awards for Cancer in Children and Adolescents (IIRACCA)
 Individual Investigator Research Awards for Computational Systems Biology of Cancer (IIRACSBC)
 Individual Investigator Research Awards for Clinical Translation (IIRACT)
 Individual Investigator Research Awards for Prevention and Early Detection (IIRAP).



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Prevention
FY 2023—Cycle 1
*Primary Prevention of Cancer***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA P-23.1-PPC

Primary Prevention of Cancer

**Please also refer to the Instructions for Applicants document,
which will be posted on June 2, 2022**

Application Receipt Opening Date: June 2, 2022

Application Receipt Closing Date: August 31, 2022

FY 2023

Fiscal Year Award Period

September 1, 2022-August 31, 2023

TABLE OF CONTENTS

1. ABOUT CPRIT.....	5
1.1 PREVENTION PROGRAM PRIORITIES.....	5
2. FUNDING OPPORTUNITY DESCRIPTION	6
2.1 SUMMARY	6
2.2 PROJECT OBJECTIVES	7
2.3 AWARD DESCRIPTION.....	8
2.4 PRIORITIES.....	10
2.5 OUTCOME METRICS.....	10
2.6 FUNDING INFORMATION	11
2.7 ELIGIBILITY	12
2.8 RESUBMISSION POLICY	13
2.9 EXPANSION POLICY	14
3. KEY DATES	15
4. APPLICATION SUBMISSION GUIDELINES.....	16
4.1 INSTRUCTIONS FOR APPLICANTS DOCUMENT	16
4.2 ONLINE APPLICATION RECEIPT SYSTEM.....	16
4.3 SUBMISSION DEADLINE EXTENSION	16
4.4 APPLICATION COMPONENTS	16
4.4.1 Abstract and Significance (5,000 characters).....	17
4.4.2 Goals and Objectives (700 characters each).....	17
4.4.3 Project Timeline (2 pages).....	18
4.4.4 Project Plan (12 pages; fewer pages permissible).....	18
4.4.5 People Reached (Indirect Contact).....	20
4.4.6 Number of Services Delivered (Direct Contact)	21
4.4.7 Number of Preventive Services Delivered.....	21
4.4.8 Number of Unique People Served (Direct Contact)	21
4.4.9 References	21
4.4.10 Resubmission Summary.....	21
4.4.11 Most Recently Funded Relevant Project Summary (if applicable) (3 pages)	22
4.4.12 CPRIT Grants Summary	22
4.4.13 Budget and Justification.....	22
4.4.14 Current and Pending Support and Sources of Funding.....	24
4.4.15 Biographical Sketches.....	24
4.4.16 Collaborating Organizations	24
4.4.17 Letters of Commitment (10 pages)	25
5. APPLICATION REVIEW.....	25
5.1 REVIEW PROCESS OVERVIEW	25
5.2 REVIEW CRITERIA	26
5.2.1 Primary Evaluation Criteria.....	27
5.2.2 Secondary Evaluation Criteria	28
6. AWARD ADMINISTRATION	29

7. CONTACT INFORMATION 30
 7.1 HELPDESK 30
 7.2 PROGRAM QUESTIONS 30
8. RESOURCES..... 31
9. REFERENCES 33
APPENDIX A: KEY TERMS..... 34
APPENDIX B: WRITING GOALS AND OBJECTIVES..... 37

RFA VERSION HISTORY

Rev	5/6/2022	RFA release
-----	----------	-------------

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and enhance the potential for a medical or scientific breakthrough in the prevention of or cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

1.1 Prevention Program Priorities

Legislation from the 83rd Texas Legislature requires that CPRIT's Oversight Committee establish program priorities on an annual basis. The priorities are intended to provide transparency in how the Oversight Committee directs the orientation of the agency's funding portfolio. The Prevention Program's principles and priorities will also guide CPRIT staff and the Prevention Review Council on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

Established Principles:

- Fund evidence-based interventions and their dissemination
- Support the prevention continuum of primary, secondary, and tertiary (includes survivorship) prevention interventions

CPRIT's Cross-Program Priorities:

- Prevention and early detection initiatives
- Translation of Texas research (discoveries) to innovations
- Enhance Texas' research capacity and life science infrastructure

Prevention Program Priorities

- Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
- Prioritize underserved populations
- Program assessment to identify best practices, use as a quality improvement tool, and guide future program direction

2. FUNDING OPPORTUNITY DESCRIPTION

2.1 Summary

The ultimate goals of the CPRIT Prevention Program are to reduce cancer incidence and mortality, reduce cancer disparities, and improve the lives of cancer survivors. More than half of cancers can be prevented by applying prevention knowledge we already have about modifiable causes of cancer. We can prevent some cancers by promoting and providing hepatitis B and HPV vaccines, supporting environmental approaches that make healthy choices easier, and empowering people to make healthy lifestyle choices related to tobacco use, nutrition, physical activity, and sun safety. This failure to address prevention is particularly impactful for those experiencing cancer disparities (eg, minority population groups, low-income populations). When prevention programs are comprehensive and maximize the ability for all populations to participate, major changes in behaviors and morbidity and mortality can be achieved. [Colditz GA, Emmons KM. Accelerating the Pace of Cancer Prevention- Right Now. *Cancer Prev Res (Phila)*. 2018;11(4):171-184]

There is increasing focus on multilevel interventions for cancer prevention. (Clauser SB, Taplin SH, Foster MK, Fagan P, Kaluzny AD. Multilevel intervention research: lessons learned and pathways forward. *J Natl Cancer Inst Monogr*. 2012;2012[44]:127-133) A multilevel intervention seeks to influence more than one contextual level, ie, individual, group, organization, and community). Multilevel interventions require action targeting 2 or more levels of influence at the same time or in close temporal proximity. Multilevel interventions may involve policy, systems, and environmental change as a way of modifying the environment to make healthy choices practical and available to all community members.

The **Primary Prevention of Cancer (PPC)** award mechanism focuses on increasing implementation of evidence-based strategies to ensure that all Texans benefit from the cancer prevention knowledge that we currently have. CPRIT seeks to fund multilevel interventions to reduce cancer risk, disease burden, and cancer disparities. Modifiable risk behaviors include tobacco use, obesity, physical inactivity, unhealthy eating, alcohol use, sun exposure, HPV vaccination, hepatitis B vaccination, and environmental/occupational cancer exposures.

Applications should also assess and address social determinants that contribute to cancer burden and disparities (eg, cultural factors, unmet needs, access barriers). Interventions and communications should be structured to address the unique circumstances of the population to be served.

Eligible applications must include the delivery of interventions to nonmetropolitan (rural) and/or medically underserved counties in the state. For example, cigarette smoking and smokeless tobacco use are more prevalent in rural populations. Higher rates of obesity, lower rates of physical activity, and poorer diets contribute to cancer-related health disparities in rural populations and high-risk urban populations.

Partnerships with other organizations that can support and leverage resources are strongly encouraged. A coordinated submission of a collaborative partnership program in which all partners have a substantial role in the proposed project is preferred.

2.2 Project Objectives

CPRIT seeks to reduce modifiable risk behaviors via projects that will do one or more of the following:

- Establish collaborations and partnerships with communities to deliver multilevel, evidence-based projects to reduce disparities and achieve health equity
- Deliver multilevel, evidence-based projects that include public and/or professional education, outreach, navigation to and delivery of primary prevention interventions
- Implement policy, systems and environmental changes that are sustainable over time (See <https://www.ccnationalpartners.org/new-resource-policy-systems-and-environmental-change-resource-guide>); examples include:
 - Advocating for/supporting sidewalks, paths, and recreation areas in community design
 - Implementing Farm to School programs (See <https://farmtoschoolcensus.fns.usda.gov/>)

- Increasing availability of healthy food choices in restaurants or cafeterias
- Advocating for/supporting policies for smoke-free zones and public events
- Implementing programs that result in sustained smoking cessation.

2.3 Award Description

The **Primary Prevention of Cancer** RFA solicits applications for eligible projects up to 36 months in duration that will deliver multilevel, evidence-based interventions that improve cancer-related health behaviors. Interventions may address tobacco use, obesity, physical inactivity, unhealthy eating, alcohol use, HPV vaccination, hepatitis B vaccination, and environmental/occupational cancer exposures. Sun safety education may be addressed if combined with another behavioral intervention to reduce risk.

The following are required components of the project:

- **Evidence-Based:** CPRIT's primary prevention grants are intended to fund culturally appropriate effective and efficient systems of delivery of preventive services based on the existing body of knowledge about and evidence for cancer prevention. Evidence-based and promising interventions can be identified via the Community Guide, [<https://www.thecommunityguide.org/>] What Works for Health, [<https://www.countyhealthrankings.org/take-action-to-improve-health/what-works-for-health>], National Comprehensive Cancer Control Program [<https://www.cdc.gov/cancer/ncccp/index.htm>], NCI Evidence-Based Cancer Control Programs [<https://ebccp.cancercontrol.cancer.gov/index.do>] and other sources.
- If evidence-based interventions have not been implemented or evaluated for the specific population or setting proposed, provide evidence that the proposed intervention is appropriate for the population and has a high likelihood of success (ie, an evidence-informed practice). In cases where the evidence base is still developing, the applicant should provide a strong and comprehensive evaluation plan allowing for documentation of new evidence over the life of the project.
- **Multilevel Interventions:** Health behaviors have multiple levels of influences, often including individual, group, organization, and community determinants. Influences on behaviors interact across these different levels and multilevel interventions are the most

effective in changing behavior (See <http://medbox.iiab.me/modules/en-cdc/www.cdc.gov/cancer/crcp/sem.htm>).

- **Geographic Area to be Served:** Preventive service delivery to nonmetropolitan/medically underserved area (MUA) counties must be included in the defined service area. Rural and MUA counties may be identified via web-based tools from the [Texas Department of State Health Services](#) and [US Department of Health and Human Services](#). Service to urban counties that are not medically underserved is allowable as long as the project proposes to also serve nonmetropolitan counties that are medically underserved.
- **Community Partner Networks.** Applicants are strongly encouraged to coordinate and describe a collaboration of community partners that can deliver services to the most counties and the most people possible in a selected service region. Partnerships with other organizations that can support and leverage resources (eg, community-based organizations, local and voluntary agencies, nonprofit agencies, groups that represent priority populations) are encouraged. Letters of commitment or memoranda of understanding describing their specific role in the partnership will strengthen the application.

CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area) in the provision of evidence-based interventions to modify cancer risk factors, changes in provider practice, and systems changes. Applicants must demonstrate how these outcomes will ultimately impact incidence, mortality, morbidity, disparities, or quality of life.

Under this RFA, CPRIT **will not** consider the following:

- Projects focused solely on metropolitan/non-medically underserved counties.
- Projects focusing solely on systems and/or policy change or solely on education and/or outreach that do not include the navigation to and delivery of multilevel interventions to reduce cancer risk.
- Projects focusing solely on case management/patient navigation services. Case management/patient navigation services must be paired with the delivery of a cancer prevention service, including those practices delivered by another provider.
- Cancer preventive services proposed as part of the project that do not comply with established and current national guidelines

- Projects involving prevention/intervention research. Applicants interested in prevention research should review CPRIT’s Academic Research RFAs (available at <http://www.cprit.texas.gov>).

2.4 Priorities

The Prevention Program’s priorities for funding include the following:

(1) Populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.

CPRIT-funded programs must address 1 or more of these priority populations:

- Medically underresourced communities
- Racial, ethnic, and cultural minority groups
- Underinsured and uninsured individuals

(2) Geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence.

While disparities and needs exist across the state, CPRIT will also prioritize applications proposing to serve geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence. For this RFA, projects must propose to serve nonmetropolitan and/or MUAs of the state.

Geographic and Population Balance in Current CPRIT portfolio

At the programmatic level of review conducted by the Prevention Review Council ([section 5.1](#)), priority will be given to projects that target geographic regions of the state and population subgroups that are not adequately covered by the current CPRIT Prevention project portfolio (see <https://www.cprit.texas.gov/our-programs/prevention/portfolio-maps> and <https://www.cprit.texas.gov/grants-funded?search=prevention>).

2.5 Outcome Metrics

Applicants are required to clearly describe their assessment and evaluation methodology. Mixed-methods evaluations are encouraged (eg, qualitative, quality improvement methods). The applicant is required to describe final outcome measures for the project. These measures should be identified in the project plan (including a logic model) and will serve as a measure of program effectiveness.

Planned policy, system, or environmental changes should be identified. In addition, applicants should describe how funds from the CPRIT grant will improve outcomes over baseline. If the applicant is not providing baseline data for a measure, the applicant must provide a well-justified explanation and describe clear plans and method(s) of measurement to collect the data necessary to conduct a meaningful evaluation.

Reporting Requirements

Funded projects are required to report quantitative output and outcome metrics (as appropriate for each project) through the submission of quarterly progress reports, annual reports, and a final report.

If services are being paid for and provided by others, the applicant is required to report on the number of preventive services that are delivered.

2.6 Funding Information

The amount of total funding that applicants may request is dependent on the primary focus of the project and on the type of project: New, Initial Expansion, or Maintenance Expansion. Use the table below to determine the maximum amount of funding and the maximum number of years that may be requested.

Project Type	Maximum Amount of Total Funding	Maximum Duration
New Project	\$1 million	3 years
Initial Expansion	\$1 million	3 years
Initial Expansion – vaccination/tobacco cessation(adults)	\$1.5 million	3 years
Maintenance Expansion	\$2 million	5 years
Maintenance Expansion – vaccination/tobacco cessation (adults)	\$2.5 million	5 years

The funding amount is inclusive of both direct and indirect costs. Grant funds may be used to pay for preventive services, navigation services, project staff salary and benefits, project supplies, equipment, costs for outreach and education of populations, and travel of project personnel to project site(s).

Requests for funds to support construction, renovation, or any other infrastructure needs or requests to support lobbying will not be approved under this mechanism. Grantees may request funds for travel for 2 project staff to attend CPRIT’s conference.

The budget should be proportional to the number of individuals receiving programs and services, and a significant proportion of funds is expected to be used for program delivery as opposed to program development. In addition, CPRIT seeks to fill gaps in funding rather than replace existing funding, supplant funds that would normally be expended by the applicant's organization, or make up for funding reductions from other sources.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

2.7 Eligibility

- The applicant must be a Texas-based entity, such as a community-based organization, health institution, government organization, public or private company, college or university, or academic health institution.
- The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted.
- The designated PD will be responsible for the overall performance of the funded project. The PD must have relevant education and management experience and must reside in Texas during the project performance time.
- The evaluation of the project must be headed by a professional who has demonstrated expertise in the field and who resides in Texas during the time that the project is conducted.
- The applicant may submit more than 1 application, but each application must be for distinctly different services without overlap in the services provided. Applicants who do not meet this criterion will have all applications administratively withdrawn without peer review.
- If an organization has a current CPRIT grant that is the same or similar to the prevention intervention being proposed, the applicant must explain how the projects are nonduplicative or complementary.
- Collaborations are permitted and encouraged, and collaborators may or may not reside in Texas. However, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Collaborators should have specific and well-defined roles. Subcontracting and collaborating organizations may include public, not-for-profit, and for-profit entities. Such

entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds.

- An applicant is not eligible to receive a CPRIT grant award if the applicant PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization or institution is related to a CPRIT Oversight Committee member.
- An applicant organization is eligible to receive a grant award only if the applicant certifies that the applicant organization, including the PD, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation created to benefit CPRIT.
- The applicant must report whether the applicant organization, the PD, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, (whether slated to receive salary or compensation under the grant award or not), are currently ineligible to receive federal grant funds because of scientific misconduct or fraud or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.
- CPRIT grants will be awarded by contract to successful applicants. CPRIT grants are funded on a reimbursement-only basis. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 6](#). All statutory provisions and relevant administrative rules can be found on the CPRIT website.

2.8 Resubmission Policy

- **One resubmission** is permitted. An application is considered a resubmission if the proposed project is the same project as presented in the original submission.

- All applications in response to this RFA will be considered NEW submissions and no resubmission summary form will be available. **Responses to summary statement weaknesses should be included within the project plan.**
- Reviewers of resubmissions are asked to assess whether the resubmission adequately addresses critiques from the previous review. **Applicants should note that addressing previous critiques is advisable; however, it does not guarantee the success of the resubmission.** All resubmitted applications must conform to the structure and guidelines outlined in this RFA.

2.9 Expansion Policy

- Expansion grants are intended to fund expansion of currently or previously funded projects that have demonstrated exemplary success, as evidenced by progress reports and project evaluations, and desire to further enhance their impact on priority populations. Detailed descriptions of **results, barriers, outcomes, and impact of the currently or previously funded project are required** (see outline of Most Recently Funded Project Summary, [section 4.4.12](#)).
- Proposed expansion projects should NOT be new projects but should closely follow the intent and core elements of the currently or previously funded project. Established infrastructure/processes and fully described prior project results are required. Expansion of current projects into geographic areas not well served by the CPRIT Prevention portfolio (see maps at [http:// www.cprit.state.tx.us/our-programs/prevention/portfolio-maps](http://www.cprit.state.tx.us/our-programs/prevention/portfolio-maps)) will receive priority consideration.
- CPRIT expects measurable outcomes of supported activities, such as a significant increase over baseline (for the proposed service area). It is expected that baselines will have already been established and that continued improvement over baseline is demonstrated in the current application. However, in the case of a proposed expansion where no baseline data exist for the priority population, the applicant must present clear plans and describe method(s) of measurement used to collect the data necessary to establish a baseline. Applicants must demonstrate how these outcomes will ultimately impact cancer incidence, mortality, morbidity, or quality of life.

- CPRIT also expects that applications for continuation **will not** require startup time, that applicants can demonstrate that they have overcome barriers encountered, and that applicants have identified **lasting systems changes** that improve results, efficiency, and sustainability. Leveraging of resources and plans for dissemination are expected and should be well described.

Requirements for Initial and Maintenance Expansion Projects

Initial Expansion: For the first expansion application, eligible applicants should propose to expand their programs to include additional types of primary preventive practices or to expand current practices into additional counties. In either case, the expansion must include the delivery of services to nonmetropolitan (rural) and/or medically underserved counties in the state. These may be identified via web-based tools from the [Texas Department of State Health Services](#) and [US Department of Health and Human Services](#).

Maintenance Expansion: For a subsequent expansion, additional primary preventive practices and/or expansion to additional counties is optional; however, the counties and the practices offered in the first expansion should not be decreased. The number of services delivered during the maintenance expansion must be increased substantially if no further geographic or preventive service expansion is proposed.

3. KEY DATES

RFA release	May 6, 2022
Online application opens	June 2, 2022, 7 AM central time
Application due	August 31, 2022, 4 PM central time
Application review	September 2022-January 2023
Award notification	February 2023
Anticipated start date	March 1, 2023

Applicants will be notified of peer review panel assignment prior to the peer review meeting dates.

4. APPLICATION SUBMISSION GUIDELINES

4.1 Instructions for Applicants document

It is **imperative** that applicants read the accompanying instructions document for this RFA that will be available June 2, 2022 (<https://CPRITGrants.org>). Requirements may have changed from previous versions.

4.2 Online Application Receipt System

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The PD must create a user account in the system to start and submit an application. The Co-PD, if applicable, must also create a user account to participate in the application. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (an individual who will help manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on June 2, 2022, and must be submitted by 4 PM central time on August 31, 2022. Detailed instructions for submitting an application are in the *Instructions for Applicants* document, posted on CARS. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

4.3 Submission Deadline Extension

The submission deadline may be extended for 1 or more grant applications upon a showing of good cause. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records.

4.4 Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Refer to the *Instructions for Applicants* document for details.

Submissions that are missing 1 or more components or do not meet the eligibility requirements may be administratively withdrawn without review.

4.4.1 Abstract and Significance (5,000 characters)

Clearly explain the problem(s) to be addressed, the approach(es) to the solution, and how the application is responsive to this RFA. If the project is funded, the abstract will be made public; therefore, no proprietary information should be included in this statement. Initial compliance decisions are based in part upon review of this statement.

The abstract format is as follows (use headings as outlined below):

- **Need:** Include a description of need in the specific service area. Include rates of incidence, mortality, and screening in the service area compared to overall Texas rates. Describe barriers, plans to overcome these barriers, and the priority population to be served.
- **Overall Project Strategy:** Describe the project and how it will address the identified need. Clearly explain what the project is and what it will specifically do, including the services to be provided and the process/system for delivery of services and outreach to the priority population.
- **Specific Goals:** State specifically the overall goals of the proposed project; include the estimated overall numbers of preventive services delivered and number of people (public and/or professionals) served.
- **Significance and Impact:** Explain how the proposed project, if successful, will have a major impact on cancer prevention and control for the population proposed to be served and for the State of Texas.

4.4.2 Goals and Objectives (700 characters each)

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within both the stated Objective **and** the Measure sections (eg, Measure: 2,000 individuals, ages 9-12, will initiate HPV vaccination during the grant period). Refer to the *Instructions for Applicants* document for details.

The maximum number is 3 goals with 3 outcome objectives each. Projects will be evaluated annually on progress toward outcome goals and objectives. See [Appendix B](#) for instructions on writing outcome goals and objectives.

A baseline and method(s) of measurement are required for each objective. Provide both raw

numbers and percent changes for the baseline and target. If a baseline has not been defined, applicants are required to explain plans to establish baseline and describe method(s) of measurement.

4.4.3 Project Timeline (2 pages)

Provide a project timeline for project activities that includes deliverables and dates. Use Years 1, 2, 3, and Months 1, 2, 3, etc, as applicable (eg, Year 1, Months 3-5) instead of specific months or years. Month 1 is the first full month of the grant award.

4.4.4 Project Plan (12 pages; fewer pages permissible)

The required project plan format follows. Applicants must use the headings outlined below.

Background: Briefly present the rationale behind the proposed services, emphasizing the critical barriers to current service delivery that will be addressed. Identify the evidence-based service to be implemented for the priority population. Describe the race, ethnicity, age, and other defining characteristics of the population to be served.

If evidence-based strategies have not been implemented or tested for the specific population or service setting proposed, provide evidence that the proposed service is appropriate for the population and has a high likelihood of success. Baseline data for the priority population and target service area are required where applicable.

Reviewers will be aware of national and state statistics, and these should be used only to compare rates for the proposed service area. Describe the geographic region of the state that the project will serve; maps are encouraged.

Goals and Objectives: Process objectives should be included in the project plan. Outcome goals and objectives will be entered in separate fields in CARS. However, if desired, outcome goals and objectives may be fully repeated or briefly summarized here. See [Appendix B](#) for instructions on writing goals and objectives.

Components of the Project: Clearly describe the need, delivery method, and evidence base (provide references) for the services, as well as anticipated results. Be explicit about the base of evidence and any necessary adaptations for the proposed project. Describe why this project is nonduplicative. If an organization has a current CPRIT grant that is the same or similar to the prevention intervention being proposed, the applicant must explain how the projects are nonduplicative or complementary.

It is important to distinguish between Texas counties where the project proposes to deliver services and counties of residence of population served (see [Appendix A](#) for definitions and *Instructions for Applicants*). Only counties where service delivery occurs should be listed in the Geographic Area to be Served section of the application. Projecting counties of residence of population served is not required but may be described in the project plan.

Clearly demonstrate the ability to provide the proposed service and describe how results will be improved over baseline and the ability to reach the priority population.

If preventive services are being paid for and provided by others, the applicant must explain and report on the number of these services and outcomes.

Evaluation Strategy: A strong commitment to evaluation of the project is required. Describe the plan for outcome and output measurements, including qualitative analysis of policy and system changes. Describe data collection and management methods, data analyses, and anticipated results. Evaluation and reporting of results should be headed by a professional who has demonstrated expertise in the field. If needed, applicants may want to consider seeking expertise at Texas-based academic cancer centers, schools/programs of public health, or the like. Applicants should budget accordingly for the evaluation activity and should involve that professional during grant application preparation to ensure, among other things, that the evaluation plan is linked to the proposed goals and objectives.

Organizational Qualifications and Capabilities: Describe the organization and its track record and success in providing health programs and services. Describe the role and qualifications of the key collaborators/partners in the project. Include information on the organization's financial stability and viability. The applicant should demonstrate how the organizational environment will contribute to a successful project. If equipment or physical resources are required to carry out the project, the applicant should describe the availability of these resources and the organizational capacity to use equipment. To ensure access to preventive services and reporting of services outcomes, applicants should demonstrate that they have provider partnerships and agreements (via memoranda of understanding) or commitments (via letters of commitment) in place.

CPRIT acknowledges that full maintenance and sustainability of projects when CPRIT funding ends may not be feasible, especially in cases involving the delivery of preventive services.

However, it is important to consider sustainability early in the life cycle of a project, particularly

regarding organizational characteristics and processes that are modifiable.

Washington University in St Louis has developed a useful tool ([Program Sustainability Assessment Tool](#)) to assess program capacity for sustainability. The tool assesses several factors that contribute to program sustainability. These factors include environmental support, funding stability, partnerships, organizational capacity, program evaluation, program adaptation, communication, and strategic planning. Applicants are not required to use this tool; however, it provides practical guidance on factors that should be considered and should be included in the application to describe a program's organizational capacity for sustainability.

It is expected that steps toward building capacity for the program will be taken and plans for such be briefly described in the application. The applicant should describe the factors that will contribute to the organization's capacity to facilitate sustainability.

Dissemination and Replication: Dissemination of project results and outcomes, including barriers encountered and successes achieved, is critical to building the evidence base for cancer prevention and control efforts in the state. Dissemination efforts should consider the message, source, audience, and channel (Brownson, R.C., et al. *J Pub Health Manag Pract.* 24(2):102-111, March/April 2018). Dissemination methods may include, but are not limited to, presentations at workshops and seminars, one-on-one meetings, publications, news media, social media, etc.

While passive dissemination methods are common (eg, publications, presentations at professional meetings), plans should include some active dissemination methods (eg, meetings with stakeholders, blogs, social media). Applicants should describe their dissemination plans. The plans should include the kinds of audiences to be targeted and methods for reaching the targeted audiences.

Replication by others is an additional way to disseminate the project. For applicable components, describe how the project or components of the project lend themselves to application by other communities and/or organizations in the state or expansion in the same communities. Describe what components of this project can be adapted to a larger or lower resource setting. Note that some programs may have unique resources and may not lend themselves to replication by others.

4.4.5 People Reached (Indirect Contact)

Provide the estimated overall number of people (members of the public and professionals) to be

reached by the funded project. The applicant is required to itemize separately the types of indirect noninteractive education and outreach activities, with estimates, that led to the calculation of the overall estimates provided. Refer to [Appendix A](#) for definitions.

4.4.6 Number of Services Delivered (Direct Contact)

Provide the estimated overall number of services directly delivered to members of the public and to professionals by the funded project. Each individual service should be counted, regardless of the number of services one person receives. The applicant is required to itemize separately the education, navigation, and cancer prevention activities/services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.7 Number of Preventive Services Delivered

Provide the estimated overall number of services directly delivered to members of the public by the funded project. Each individual clinical service should be counted, regardless of the number of services one person receives. Separately itemize the services, with estimates, that led to the calculation of the overall estimate provided. Refer to [Appendix A](#) for definitions.

4.4.8 Number of Unique People Served (Direct Contact)

Provide the estimated overall number of unique members of the public and professionals served by the funded project. One person may receive multiple services but should only be counted once here. Refer to [Appendix A](#) for definitions.

4.4.9 References

Provide a concise and relevant list of references cited for the application. The successful applicant will provide referenced evidence and literature support for the proposed services.

4.4.10 Resubmission Summary

All applications in response to this RFA will be considered NEW submissions and no resubmission summary form will be available. Responses to summary statement weaknesses should be included within the project plan.

The summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission; the applicant is not responsible for providing this document.

4.4.11 Most Recently Funded Relevant Project Summary (if applicable) (3 pages)

Upload a summary that outlines the progress made with the most recently funded relevant CPRIT award. Applicants must describe results and outcomes of the most recently funded award and demonstrate why further funding is warranted.

In the description, include the following:

- Describe the evidence-based intervention, its purpose, and how it was implemented in the priority population. Describe any adaptations made for the population served.
- List approved goals and objectives of the most recently funded grant.
- For each objective, provide milestones/target dates and target metrics as compared to actual completion dates and metrics.
- Include a discussion of objectives not fully met. Explain any barriers encountered and strategies used to overcome these.
- For the most recently funded project, describe major activities; significant results, including major findings, developments or conclusions (both positive and negative); and key outcomes.
- Describe steps taken toward sustainability for components of the project. Fully describe systems or policy improvements and enhancements.
- Describe how project results were disseminated or plans for future dissemination of results.

4.4.12 CPRIT Grants Summary

Use the template provided on CARS (<https://CPRITGrants.org>). Provide a listing of **all** projects funded by the CPRIT Prevention program for the PD and the Co-PD, regardless of their connection to this application.

4.4.13 Budget and Justification

Provide a brief outline and detailed justification of the budget for the entire proposed period of support, including salaries and benefits, travel, equipment, supplies, contractual expenses, services delivery, and other expenses. CPRIT funds will be distributed on a reimbursement basis.

Applications requesting more than the maximum allowed cost as specified in [Section 2.9](#) will be administratively withdrawn.

Clearly describe any organizational cost sharing or pro bono contributions related to this project, as well as any attempts made or successes to secure other state/federal funds.

- **Average Cost per Person:** The average cost per person will be automatically calculated from the total cost of the project divided by the total number of unique people served (refer to [Appendix A](#)).
- **Average Cost per Service:** The average cost per service will be automatically calculated from the total cost of the project divided by the total number of services delivered (refer to [Appendix A](#)). A significant proportion of funds is expected to be used for program delivery as opposed to program development and organizational infrastructure.
- **Average Cost per Preventive Service:** The average cost per clinical service will be automatically calculated from the total cost of the project divided by the total number of services delivered (refer to [Appendix A](#)).
- **Personnel:** The individual salary cap for CPRIT awards is \$200,000 per year. Describe the source of funding for all project personnel where CPRIT funds are not requested.
- **Travel:** PDs and related project staff are expected to attend CPRIT's conference. CPRIT funds may be used to send up to 2 people to the conference.
- **Equipment:** Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application. Cost sharing of equipment purchases is strongly encouraged.
- **Services Costs:**
 - CPRIT reimburses for services using Medicare reimbursement rates. Describe the source of funding for all services where CPRIT funds are not requested. If preventive services are being paid for and provided by others, the applicant is required to explain and report on the number of services and outcomes that are delivered to the people navigated by the program.
- **Incentives:**
 - Use of incentives or positive rewards to change or elicit behavior is allowed; however, incentives may only be used based on strong evidence of their effectiveness for the purpose and in the priority population identified by the applicant. CPRIT will not fund

cash incentives. The maximum dollar value allowed for an incentive per person, per activity or session, is \$25.

- **Indirect/Shared Costs:** Texas law limits the amount of grant funds that may be spent on indirect/shared expenses to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in [CPRIT's Administrative Rules](#).

4.4.14 Current and Pending Support and Sources of Funding

Use the template provided on the CARS (<https://CPRITGrants.org>). Describe the funding source and duration of **all** current and pending support for the proposed project.

4.4.15 Biographical Sketches

The designated PD will be responsible for the overall performance of the funded project and must have relevant education and management experience. The PD/Co-PD(s) must provide a biographical sketch that describes his or her education and training, professional experience, awards and honors, and publications and/or involvement in programs relevant to cancer prevention and/or service delivery.

- Use the Co-PD Biographical Sketch section **ONLY** if a Co-PD has been identified.
- The evaluation professional must provide a biographical sketch in the Evaluation Professional Biographical Sketch section.
- Up to 3 additional biographical sketches for key personnel may be provided in the Key Personnel Biographical sketch section.

Each biographical sketch must not exceed 5 pages and should use either the “Prevention Programs: Biographical Sketch” template provided on the CARS (<https://CPRITGrants.org>) or the NIH Biographical Sketch format. If a position is not yet filled, please upload a job description.

4.4.16 Collaborating Organizations

List all key participating organizations that will partner with the applicant organization to provide 1 or more components essential to the success of the program (eg, evaluation, preventive practices/services, recruitment to screening). Include anyone listed as key personnel and/or listed under the Current & Pending Support section.

4.4.17 Letters of Commitment (10 pages)

Applicants should provide letters of commitment and/or memoranda of understanding from community organizations, key faculty, or any other component essential to the success of the program. Letters should be specific to the contribution of each organization.

5. APPLICATION REVIEW

5.1 Review Process Overview

All eligible applications will be reviewed using a 2-stage peer review process: (1) evaluation of applications by peer review panels and (2) prioritization of grant applications by the Prevention Review Council (PRC). In the first stage, applications will be evaluated by an independent review panel using the criteria listed below. In the second stage, applications judged to be meritorious by review panels will be evaluated by the PRC and recommended for funding based on comparisons with applications from all of the review panels and programmatic priorities.

Programmatic considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service. The scores are only 1 factor considered during programmatic review. At the programmatic level of review, priority will be given to proposed projects that target geographic regions of the state or population subgroups that are not well represented in the current CPRIT Prevention project portfolio.

Applications approved by PRC will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

Each stage of application review is conducted confidentially, and all CPRIT Peer Review Panel members, PRC members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements

regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Peer Review Panel members and PRC members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer Review Panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules, [chapter 703, section 703.9](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, a Review Panel member, or PRC member.

Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the time period prior to the opening of CARS. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

5.2 Review Criteria

Peer review of applications will be based on primary scored criteria and secondary unscored criteria, identified below. Review committees will evaluate and score each primary criterion and subsequently assign an overall score that reflects an overall assessment of the application. The overall evaluation score will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application and responsiveness to the RFA.

5.2.1 Primary Evaluation Criteria

Impact

- Do the proposed approaches address an important problem or need in primary prevention of cancer? Do the proposed project strategies support desired outcomes in cancer risk and equity? Do the proposed project strategies reach a priority population (eg, low income, minority, rural) at high risk of cancer?
- Will the project reach and serve/impact an appropriate number of people based on the budget allocated?
- If applicable, have partners demonstrated that the collaborative effort will provide a greater impact on cancer prevention and control than the applicant organization's effort separately?
- Does the program address adaptation, if applicable, of the evidence-based intervention to the priority population? Is the base of evidence clearly explained and referenced?

Project Strategy and Feasibility

- Does the proposed project provide preventive practices specified in the RFA?
- Are the overall program approach, strategy, and design clearly described and supported by established theory and practice? Are the proposed objectives and activities feasible within the duration of the award? Has the applicant convincingly demonstrated the short- and long-term impacts of the project?
- Has the applicant proposed policy changes and/or system improvements?
- Are possible barriers addressed and approaches for overcoming them proposed?
- Are the priority population and culturally appropriate methods to reach the priority population clearly described?
- Does the program leverage partners and resources to maximize the reach of the practices proposed? Does the program leverage and complement other state, federal, and nonprofit grants?

Outcomes Evaluation

- Are specific goals and measurable objectives for each year of the project provided?
- Are the proposed outcome measures appropriate for the preventive practices provided, and are the expected changes clinically significant?

- Does the application provide a clear and appropriate plan for data collection and management and data analyses?
- Are clear baseline data provided for the priority population, or are clear plans included to collect baseline data?
- If an evidence-based intervention is being adapted in a population where it has not been implemented or tested, are plans for evaluation of barriers, effectiveness, and fidelity to the model described?
- Is the qualitative analysis of planned policy or system changes described?

Organizational Qualifications and Capabilities

- Do the organization and its collaborators/partners demonstrate the ability to provide the proposed preventive practices?
- Does the described role of each collaborating organization make it clear that each organization adds value to the project and is committed to working together to implement the project?
- Have the appropriate personnel been recruited to design, implement, evaluate, and complete the project?
- Is the organization structurally and financially stable and viable?
- Does the applicant describe the program's organizational capacity for sustainability?
- Does the applicant describe steps that will be taken toward building internal capacity and partnerships?
- Does the applicant describe a plan for systems changes that are sustainable over time (eg, improve results, provider practice, efficiency, cost-effectiveness)?

5.2.2 Secondary Evaluation Criteria

Budget

- Is the budget appropriate and reasonable for the scope and preventive practices of the proposed work?
- Is the cost per person served appropriate and reasonable?
- Is the project a good investment of Texas public funds?

Dissemination and Replication

- Are plans for dissemination of the project’s results and outcomes, including target audiences and methods, clearly described?
- Are active dissemination strategies included and described in the plan?
- Does the applicant describe whether and/or how the project lends itself to replication of all or some components of the project by others in the state?

6. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in Texas Administrative Code, Title 25, chapters 701 to 703. Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in [CPRIT’s Administrative Rules](#). Applicants are advised to review CPRIT’s administrative rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in Texas Administrative Code, Title 25, chapters 701 to 703.

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT’s Administrative Rules, Texas Administrative Code, Title 25, chapters 701 to 703.

CPRIT requires award recipients to submit quarterly, annual, and final progress reports. These reports summarize the progress made toward project goals and address plans for the upcoming year. In addition, quarterly fiscal reporting and reporting on selected metrics will be required per the instructions to award recipients. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract.

7. CONTACT INFORMATION

7.1 Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not in a position to answer questions regarding the scope and focus of applications. Before contacting the Helpdesk, please refer to the *Instructions for Applicants* document (posted on June 2, 2022), which provides a step-by-step guide to using CARS.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

7.2 Program Questions

Questions regarding the CPRIT Prevention program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Prevention Program Office.

Tel: 512-305-8417

Email: Help@CPRITGrants.org

Website: www.cprit.texas.gov

8. RESOURCES

- Department of State Health Services. <https://www.dshs.texas.gov/tcr/data/modifiable-risk-factors.aspx>
- The Community Guide. <https://www.thecommunityguide.org/>
- Implementing Farm to School Programs. <https://farmtoschoolcensus.fns.usda.gov/>
- What Works for Health. <https://www.countyhealthrankings.org/take-action-to-improve-health/what-works-for-health>
- National Comprehensive Cancer Control Program. <https://www.cdc.gov/cancer/ncccp/index.htm>
- NCI Evidence-Based Cancer Control Program. <https://ebccp.cancercontrol.cancer.gov/index.do>
- Cancer Control P.L.A.N.E.T. <https://cancercontrol.cancer.gov>
- Comprehensive Cancer Control. Policy, Systems, and Environmental Change Resource Guide. <https://www.ccnationalpartners.org/new-resource-policy-systems-and-environmental-change-resource-guide>
- Colorectal Cancer Control Program. Social Ecological Model. <http://medbox.iiab.me/modules/en-cdc/www.cdc.gov/cancer/crcp/sem.htm>
- Guide to Clinical Preventive Services: Recommendations of the U.S. Preventive Services Task Force. <http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/>
- Program Sustainability Assessment Tool, copyright 2012, Washington University, St Louis, MO, <https://www.sustaintool.org/about-us/>
- Getting the Word Out: New Approaches for Disseminating Public Health Science Ross C. Brownson, PhD; Amy A. Eyler, PhD; Jenine K. Harris, PhD; Justin B. Moore, PhD, MS; Rachel G. Tabak, PhD, RD, *Journal of Public Health Management & Practice*. 24(2):102-111, March/April 2018. https://journals.lww.com/jphmp/Fulltext/2018/03000/Getting_the_Word_Out_New_Approaches_for.4.aspx

- Centers for Disease Control and Prevention: The Program Sustainability Assessment Tool: A New Instrument for Public Health Programs. http://www.cdc.gov/pcd/issues/2014/13_0184.htm
- Centers for Disease Control and Prevention: Using the Program Sustainability Tool to Assess and Plan for Sustainability. http://www.cdc.gov/pcd/issues/2014/13_0185.htm
- Cancer Prevention and Control Research Network: Putting Public Health Evidence in Action Training Workshop. <http://cpcrn.org/pub/evidence-in-action/>
- Environmental and Occupational Interventions for Primary Prevention of Cancer: A Cross-Sectorial Policy Framework. https://ehp.niehs.nih.gov/doi/10.1289/ehp.1205897?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%20pubmed
- Centers for Disease Control and Prevention. Distinguishing Public Health Research and Public Health Nonresearch. <https://www.cdc.gov/os/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf>

9. REFERENCES

1. <http://www.cdc.gov/hpv/parents/questions-answers.html>
2. Texas Cancer Registry, Cancer Epidemiology and Surveillance Branch, Texas Department of State Health Services. <https://www.cancer-rates.info/tx/>
3. Colditz GA, Emmons KM. Accelerating the Pace of Cancer Prevention- Right Now. *Cancer Prev Res (Phila)*. 2018;11(4):171-184
4. Clauser SB, Taplin SH, Foster MK, Fagan P, Kaluzny AD. Multilevel intervention research: lessons learned and pathways forward. *J Natl Cancer Inst Monogr*. 2012;2012[44]:127-133

APPENDIX A: KEY TERMS

- **Activities:** A listing of the “who, what, when, where, and how” for each objective that will be accomplished
- **Capacity Building:** Any activity (eg, training, identification of alternative resources, building internal assets) that builds durable resources and enables the grantee’s setting or community to continue the delivery of some or all components of the evidence-based intervention
- **Preventive Practices/Services:** Number of evidence-based preventive services delivered by a health care practitioner in an office, clinic, or health care system. Examples include, but are not limited to vaccinations, physical rehabilitation, tobacco cessation counseling or nicotine replacement therapy, case management, primary prevention clinical assessments and services.
- **Counties of Residence of Population Served:** Counties where the project does not plan to have a physical presence but people who live in these counties have received services. This includes counties of residence of people or places of business of professionals who participate in or receive education, navigation or preventive practices/services. Examples include people traveling to receive services as a result of marketing and programs accessible via the website or social media. These counties may be described in the project plan and must be reported in the quarterly progress report.
- **Counties with Service Delivery:** Counties where an activity or service will occur and the project has a physical presence for the services provided. Examples include onsite outreach and educational activities and delivery of services through clinics, mobile vans, or telemedicine consults. These counties must be entered in the Geographic Area to be Served section of the application.
- **Education Services:** Number of evidence-based, culturally appropriate cancer prevention and control education and outreach services delivered to the public and to health care professionals. Examples include education or training sessions (group or individual), focus groups, and knowledge assessments. One individual may receive multiple education services.

- **Evidence-Based Program:** A program that is validated by some form of documented research or applied evidence.
- **Goals:** Broad statements of general purpose to guide planning. Outcome goals should be few in number and focus on aspects of highest importance to the project ([Appendix B](#)).
- **Integration:** The extent the evidence-based intervention is integrated within the culture of the grantee’s setting or community through policies and practice.
- **Navigation Services:** Number of activities/services that offer assistance to help overcome health care system barriers in a timely and informative manner to improve health care access and outcomes. Examples include patient reminders, transportation assistance, and appointment scheduling assistance. One individual may receive multiple navigation services.
- **Number of Preventive Services/Practices:** Number of [preventive services](#) delivered directly to members of the public by the funded project. One individual may receive multiple clinical services.
- **Number of Services (Direct Contact):** Number of services delivered directly to members of the public and/or professionals—direct, interactive public or professional education, outreach, training, navigation service, or clinical service, such as live educational and/or training sessions, vaccine administration, , case management/navigation services, and physician consults. One individual may receive multiple services.
- **Objectives:** Specific, **measurable**, actionable, realistic, and timely projections for outcomes; example: “Increase screening service provision in X population from Y% to Z% by 20xx.” Baseline data for the priority population must be included as part of each objective ([Appendix B](#)). The proposed metric should be included in **both** the objective and the measure.
- **People Reached (Indirect Contact):** Number of members of the public and/or professionals reached via indirect noninteractive public or professional education and outreach activities, such as mass media efforts, brochure distribution, public service announcements, newsletters, and journals. (This category includes individuals who would be reached through activities that are directly funded by CPRIT as well as individuals whowould be reached through activities that occur as

a direct consequence of the CPRIT- funded project's leveraging of other resources/funding to implement the CPRIT-funded project).

- **Unique People Served (Direct Contact):** Number of unique members of the public and/or professionals served via direct, interactive public or professional education, outreach, training, navigation service, or clinical service. This category includes individuals who would be served through activities that are directly funded by CPRIT as well as individuals who would be served through activities that occur as a direct consequence of the CPRIT-funded project's leveraging of other resources/funding to implement the CPRIT-funded project.

APPENDIX B: WRITING GOALS AND OBJECTIVES

List only major **outcome goals** and **measurable objectives** for each year of the project. **Do not include process objectives**; these should be described in the project plan only. Include the proposed metric within **both** the stated Objective and the Measure sections (eg, Measure: 2,000 individuals, ages 9-12, will initiate HPV vaccination during the grant period).

The maximum number is 3 goals with 3 objectives each. Projects will be evaluated annually on progress toward **outcome** goals and objectives.

The following has been adapted with permission from Appalachia Community Cancer Network, NIH Grant U54 CA 153604:

Develop well-defined goals and objectives.

Goals provide a roadmap or plan for where a group wants to go. Goals can be long term (over several years) or short term (over several months). Goals should be based on needs of the community and evidence-based data.

Goals should be:

- Believable – situations or conditions that the group believes can be achieved
- Attainable – possible within a designated time
- Tangible – capable of being understood or realized
- On a timetable – with a completion date
- Win-Win – beneficial to individual members and the coalition

Objectives are measurable steps toward achieving the goal. They are clear statements of specific activities required to achieve the goal. The best objectives have several characteristics in common – S.M.A.R.T. + C:

- Specific – they tell how much (number or percent), who (participants), what (action or activity), and by when (date)
 - Example: 115 uninsured individuals age 50 and older will complete colorectal cancer screening by March 31, 2018.
- Measurable – specific measures that can be collected, detected, or obtained to determine successful attainment of the objective

- Example: How many screened at an event? How many completed pre/post assessment?
- Achievable – not only are the objectives themselves possible, it is likely that your organization will be able to accomplish them
- Relevant to the mission – your organization has a clear understanding of how these objectives fit in with the overall vision and mission of the group
- Timed – developing a timeline is important for when your task will be achieved
- Challenging – objectives should stretch the group to aim on significant improvements that are important to members of the community

Evaluate and refine your objectives

Review your developed objectives and determine the type and level of each using the following information:

There are 2 types of objectives:

- Outcome objectives – measure the “what” of a program; should be in the Goals and Objectives form (see [section 4.4.2](#))
- Process objectives – measure the “how” of a program; should be in the project plan only (see [section 4.4.4](#))

There are 3 levels of objectives:

- Community-level – objectives measure the planned community change
- Program impact – objectives measure the impact the program will have on a specific group of people
- Individual – objectives measures participant changes resulting from a specific program, using these factors:
 - Knowledge – understanding (know screening guidelines; recall the number to call for screening)
 - Attitudes – feeling about something (will consider secondhand smoke dangerous; believe eating 5 or more fruits and vegetable is important)
 - Skills – the ability to do something (complete fecal occult blood test)
 - Intentions – regarding plan for future behavior (will agree to talk to the doctor, will plan to schedule a Pap test)

- Behaviors (past or current) – to act in a particular way (will exercise 30+ minutes a day, will have a mammogram)

Well-defined outcome goals and objectives can be used to track, measure, and report progress toward achievement.

Summary Table

	Outcome – Use in Goals and Objectives	Process – Use in Project Plan only
Community-level	<p>WHAT will change in a community</p> <p><i>Example: As a result of CPRIT funding, fecal immunochemical tests (FIT) will be available to 1,500 uninsured individuals age 50 and over through 10 participating local clinics and doctors.</i></p>	<p>HOW the community change will come about</p> <p><i>Example: Contracts will be signed with participating local providers to enable uninsured individuals over age 50 have access to free colorectal cancer screening in their communities.</i></p>
Program impact	<p>WHAT will change in the target group as a result of a particular program</p> <p><i>Example: As a result of this project, 200 uninsured women between 40 and 49 will receive free breast and cervical cancer screening.</i></p>	<p>HOW the program will be implemented to affect change in a group/population</p> <p><i>Example: 2,000 female clients, between 40 and 49, will receive a letter inviting them to participate in breast and cervical cancer screening.</i></p>
Individual	<p>WHAT an individual will learn as a result of a particular program, or WHAT change an individual will make as a result of a particular program</p> <p><i>Example: As a result of one-to-one education of 500 individuals, at least 20% of participants will participate in a smoking cessation program to quit smoking.</i></p>	<p>HOW the program will be implemented to affect change in an individual’s knowledge or actions</p> <p><i>Example: As a result of one-to-one counseling, all participants will identify at least 1 smoking cessation service and 1 smoking cessation aid.</i></p>

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

23.1 Prevention Panel-1 (23.1 PRV-PP1)

Observation Report

Report No. 2022-12-05 23.1_PRV-PP1
Program Name: Prevention
Panel Name: 23.1 Prevention Panel-1 (23.1 _PRV-PP1)
Panel Date: December 5, 2022
Report Date: December 13, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Prevention Panel-1 (23.1_PRV-PP1) meeting. The meeting was chaired by Ross Brownson and conducted via videoconference on December 5, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;
- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Thirteen (13) applications were discussed and six (6) applications were not discussed
- Panelists: One (1) panel chair, nine (9) expert reviewers, and two (2) advocate reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Seven (7)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There was one (1) Conflict of Interest (COI) identified prior to and/or during the meeting. The COI was on a application not discussed.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, consisting of a large, stylized initial 'M' followed by a long, horizontal, slightly wavy line extending to the right.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Prevention Review Council – Programmatic review
(23.1 PRC-PR)
Observation Report

Report No. 2023-01-13 23.1_PRC-PR
Program Name: Prevention
Panel Name: 23.1 Prevention Review Council – Programmatic review (23.1_PRC-PR)
Panel Date: January 13, 2023
Report Date: January 19, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Prevention Review Council – Programmatic review (23.1_PRC-PR) meeting. The meeting was chaired by Stephen Wyatt and conducted via videoconference on January 13, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Eleven (11) applications were discussed
- Panelists: One (1) panel chair, and two (2) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,



Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Prevention Cycle 23.1

Awards Announced at the February 15, 2023, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Prevention Cycle 23.1 include: *Cancer Screening and Early Detection*; *Dissemination of CPRIT-Funded Cancer Control Interventions*; and *Primary Prevention of Cancer*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
No reported COIs.			
Applications not considered by the PIC or Oversight Committee:			
PP230031	Walter Calmbach	The University of Texas Health Science Center at San Antonio	R. Brownson

De-Identified Overall Evaluation Scores

Primary Prevention of Cancer

Prevention cycle 23.1

Application ID	Final Overall Evaluation Score
PP230018*	2.5
PP230043*	3.2
a	3.7
b	4.1
c	4.5
d	4.5
e	4.8
f	5.0
g	5.4
h	7.0
i	7.3
j	8.5

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Dr. Mahendra Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com
Via email to kirtikpatel@hotmail.com

Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Mr. Roberts and Dr. Patel,

On behalf of the Prevention Review Council (PRC), I am pleased to provide the PRC's recommendations for the FY2023 Cycle 1 Cancer Screening and Early Detection (CSD), Dissemination of CPRIT-Funded Cancer Control Interventions (DI), and Primary Prevention of Cancer (PPC) grant awards.

The PRC met on January 13, 2023, to consider the applications recommended by the peer review panel following their December 5, 2023 meeting. The PRC recommends 8 projects totaling \$13,577,257.

The projects are numerically ranked in the order the PRC recommends the applications be funded. Recommended funding amounts and the overall evaluation score are stated for each grant application. The PRC made no changes to the goals, project objectives, or timelines of the applications.

Our recommendations meet the PRC's standards for grant award funding of projects that are evidence-based, deliver programs or services to underserved populations, and focus on primary, secondary, or tertiary prevention. In making these recommendations the PRC continued to consider the available funding, the composition of the current portfolio, and the programmatic priorities in the RFA which include potential for impact and return on investment, geographic distribution, cancer type and type of program. All the recommended grants address one or more of the Prevention Program priorities.

Sincerely,
Stephen W. Wyatt, DMD, MPH
Chair, CPRIT Prevention Review Council

Attachment

App ID	Mechanis	Application Title	PD	Organization	Requested Budget	Score	Rank Order
PP230018	PPC	Implementation and Evaluation of an Evidence-Based Multilevel Lifestyle Intervention for Underserved/Rural Populations in South Texas: Tu Salud ¡Si	Reininger, Belinda	The University of Texas Health Science Center at Houston	\$999,254	2.5	1
PP230013	CSD	Community Expansion and Re-engagement for Breast Cancer Screening and Patient Navigation	Argenbright, Keith E	The University of Texas Southwestern Medical Center	\$2,500,000	2.7	2
PP230046	CSD	Screen, Treat, or Prevent (STOP) Hepatocellular Cancer-Hepatitis C (HCC-HCV): Expansion to All Adults	Jain, Mamta K	The University of Texas Southwestern Medical Center	\$2,499,616	2.7	3
PP230033	DI	All for Them Texas: A multifaceted dissemination and implementation approach to increase HPV vaccination	Cucarro, Paula	The University of Texas Health Science Center at Houston	\$449,959	3.0	4
PP230002	DI	Taking Texas Tobacco Free: Dissemination to and Implementation within Lung Cancer Screening Programs	Reitzel, Lorraine	University of Houston	\$448,726	3.0	5
PP230038	CSD	Salud en Mis Manos (SEMM): An Evidence-Based Breast & Cervical Cancer Early Detection and Prevention Program for Underserved Latinas.	Savas, Lara S	The University of Texas Health Science Center at Houston	\$2,499,492	3.1	6
PP230041	CSD	PP190052 - Integrated lung cancer screening and tobacco cessation in an urban safety-net system	Gerber, David E	The University of Texas Southwestern Medical Center	\$1,922,312	3.1	7

PP230043	PPC	School-based Human Papillomavirus Vaccination Program in the Rio Grande Valley: Continuation and Expansion in Hidalgo, Cameron, and Willacy Counties	Rodriguez, Ana M	The University of Texas Medical Branch at Galveston	\$2,257,898	3.2	8
----------	-----	--	------------------	---	-------------	-----	---

CSD Cancer Screening and Early Detection
DI Dissemination of CPRIT-Funded Cancer Control Interventions
PPC Primary Prevention of Cancer



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research
FY 2023—Cycle 1
*Texas Regional Excellence in Cancer Award
(TREC)***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-23.1-TREC

Texas Regional Excellence in Cancer

**Please also refer to the Instructions for Applicants document,
which will be posted on November 15, 2021.**

Applications for this award mechanism are subject to institutional eligibility requirements, including an invitation from CPRIT to apply based on an institutional letter of intent. Applicants are advised to consult with their institution's Office of Research and Sponsored Programs (or equivalent).

Letter of Intent due: April 25, 2022
Application Receipt Opening Date: May 16, 2022
Application Receipt Closing Date: September 8, 2022

FY 2023
Fiscal Year Award Period
September 1, 2022-August 31, 2023

TABLE OF CONTENTS

1. KEY POINTS	4
2. ABOUT CPRIT	5
2.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	5
3. GOAL	6
4. BACKGROUND	6
5. PROGRAM COMPONENT DESCRIPTIONS	7
6. FUNDING INFORMATION	8
7. ELIGIBILITY	9
8. RESPONDING TO THIS RFA	10
8.1. LETTER OF INTENT	10
8.2. APPLICATION SUBMISSION GUIDELINES	10
8.3. SUBMISSION DEADLINE EXTENSION	11
8.4. APPLICATION COMPONENTS	11
8.4.1. <i>Abstract and Significance (5,000 characters)</i>	11
8.4.2. <i>Layperson’s Summary (2,000 characters)</i>	11
8.4.3. <i>Goals and Objectives</i>	12
8.4.4. <i>Timeline (Maximum of 1 page)</i>	12
8.4.5. <i>Resubmission Summary (1 page)</i>	12
8.4.6. <i>Overall Description (6 pages)</i>	12
8.4.7. <i>Administrative Core (2 pages)</i>	13
8.4.8. <i>Core Resource(s) (4 pages each)</i>	14
8.4.9. <i>Research Projects to be Funded in Year 1 (4 pages each)</i>	14
8.4.10. <i>Letters of Support (2 pages each)</i>	14
8.4.11. <i>Vertebrate Animals (1 page for each research project or core)</i>	15
8.4.12. <i>Human Subjects (1 page for each research project or core)</i>	15
8.4.13. <i>Budget Justification</i>	15
8.4.14. <i>Biographical Sketches (5 pages each)</i>	16
8.4.15. <i>Current and Pending Support and/or Other Certifications</i>	17
8.4.16. <i>Previous Summary Statement</i>	17
8.5. FORMATTING INSTRUCTIONS	17
9. APPLICATION REVIEW	18
9.1. FULL PEER REVIEW	18
9.2. CONFIDENTIALITY OF REVIEW	19
9.3. REVIEW CRITERIA	20
9.3.1. <i>Primary Criteria</i>	20
9.3.2. <i>Secondary Criteria</i>	21
10. KEY DATES	21
11. AWARD ADMINISTRATION	22
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	22
13. CONTACT INFORMATION	23
13.1. HELPDESK	23
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	23

RFA VERSION HISTORY

RFA release 09/27/2021

1. KEY POINTS

- The Texas Regional Excellence in Cancer (TREC) award is a multicomponent award designed to strengthen cancer research at institutions located in regions of Texas that have historically received low levels of peer-reviewed cancer research funding.
- Applicants may request up to \$6.0 million in CPRIT funds over 5 years to support program leadership, investigator-initiated research projects, recruitment of new junior faculty, and research infrastructure.
- The TREC award will support an established investigator with a strong record of funding to develop a center with a cohesive theme relevant to the cancer problems of the region.
- The TREC award will support investigator-initiated research projects led by faculty that stand alone as individual projects but share a common thematic cancer focus. Each research project is required to propose a timeline that includes a plan to submit an Investigator-Initiated Research Award application to CPRIT and/or the National Institutes of Health (NIH) application by the end of 3 years of TREC support.
- The TREC may be used to support the recruitment of new faculty.
- The TREC may be used to support access to technology and core services necessary for the TREC-sponsored research projects to conduct competitive cancer research.
- Applicants are encouraged to partner with another Texas institution to address areas of technical or content expertise necessary for the TREC projects but not available in their institution. To support these partnerships, the TREC will allow subcontracts to be established with collaborating investigators, mentors, or core facilities located at another Texas institution.
- The TREC award can be renewed once to support further development of an institution's cancer research infrastructure and cancer-focused investigators.
- CPRIT encourages applicants to review the primary peer review criteria described in Section 9.3.1.

2. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer.
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas; and
- Develop and implement the Texas Cancer Plan.

2.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency regarding how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects
- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions
- Computational biology and analytic methods
- Childhood cancers
- Hepatocellular cancer
- Expansion of access to innovative clinical trials

3. GOAL

The TREC award is a CPRIT mechanism designed to strengthen the cancer research environment and to increase the number and quality of scientifically meritorious cancer research projects at institutions in geographic regions of Texas that have historically received low levels of peer reviewed cancer research funding. **A high priority is the development of cancer research programs addressing the cancer challenges affecting regions of Texas without a National Cancer Institute-designated cancer center.**

4. BACKGROUND

The structure of the TREC award is modeled after the National Institutes of Health (NIH) Centers of Biomedical Research Excellence ([COBRE](#)) awards that support the establishment and development of innovative, state-of-the-art biomedical research centers at institutions in states that have historically received low levels of support from the NIH. The COBRE award provides resources to support research projects led by junior faculty and to enhance an institution's research infrastructure. In addition to improving the competitiveness of investigators and the research capacities of an institution, the COBRE program is designed to increase an institution's ability to serve its unique populations, such as rural and medically underserved communities (<https://www.nigms.nih.gov/Research/DRCB/IDeA/pages/COBRE.aspx>).

Over the past decade, CPRIT academic research awards have gone primarily to Texas institutions located along the I-35 corridor or located within the Houston metroplex with dramatic impact on accelerating the cancer research capabilities and accomplishments of those institutions. However, institutions located in other geographic regions of the state have not been as competitive for cancer research funding from [CPRIT](#) or the [National Cancer Institute \(NCI\)](#). **The limited cancer research funding to these regions of Texas raises a concern that cancer-related issues affecting Texans from these geographic regions of Texas will not be adequately addressed.**

As CPRIT plans the next decade of investment in the cancer research capabilities of Texas academic research institutions, the TREC award is designed to provide an opportunity for those institutions located in geographic regions of Texas that historically have received low levels of peer-reviewed cancer research funding to develop a multidisciplinary corps of successful cancer

researchers who will compete nationally for cancer research funding to address the cancer challenges facing their region.

5. PROGRAM COMPONENT DESCRIPTIONS

The TREC award will establish a multicomponent center that supports cancer research in a thematic scientific area and develops a critical mass of investigators competitive for peer-reviewed external cancer research funding. The TREC theme can be in any cancer research area: basic, translational, clinical, prevention, or population research.

Principal Investigator: The institution will identify a Principal Investigator (PI) who is an established investigator with a strong record of funding to lead the program and to provide mentorship to existing and newly recruited program faculty. The PI must be willing and able to commit 20% effort to this leadership during the time the research that is the subject of the grant is conducted.

Research Projects: The TREC is required to support a minimum of 3 and a maximum of 5 investigator-initiated research projects at any given time.

A majority of the research project leaders must be junior investigators appointed as assistant professor or equivalent and have not yet received an NIH R01, NSF-CAREER award, major DOD award, or CPRIT Individual Investigator Research Award. Junior faculty with a K99/R00 award or other faculty transition or development award will be eligible to lead TREC research projects. Individuals holding positions that lack independent faculty status are not eligible to lead TREC research projects.

Established independent investigators of any faculty rank who are making significant changes to their career goals by initiating new lines of research that are significantly different from their current investigative program may also serve as research project leaders. However, they cannot make up the majority of the research project leaders.

Each research project should stand alone but all projects should share a common thematic scientific focus. A research project leader can only be supported by the TREC for a maximum of 3 years and will be expected to move to independent research support after that.

Recruitment: A TREC-supported research project award may be used to support the recruitment of new faculty at any rank with a cancer research focus or expertise relevant to the TREC theme.

Core resources: The TREC may support access to technology and core research services necessary to support the proposed research projects. TREC programs from Health Science Centers are encouraged to plan for core resources to support clinical trials and biospecimen access. Other investigators at the institution may also use the core facilities provided that TREC participants' research needs are met first. Sharing research facilities at other Texas institutions is strongly encouraged, and subcontract awards to support such access are permitted. Renovations or construction are not appropriate for this mechanism.

Mentorship, Evaluation, and Administration: The TREC will support a formal mentoring structure for each research project, an external advisory council, and an administrative core. These components will coordinate the center's governance, mentoring, and evaluation functions.

Applicants are encouraged to partner with another Texas institution for collaboration and mentoring and to provide access to technology or content expertise not available in their institution.

6. FUNDING INFORMATION

The maximum duration for this award mechanism is 5 years. Applicants may request a maximum of \$1,200,000 in total costs annually. Funds may be used for salary and fringe benefits, research supplies, equipment, subject participation costs including diagnostic or interventional procedures associated with participation in a clinical trial and not considered routine patient care, travel to scientific/technical meetings, and travel for external advisory council members or travel to collaborating institutions. Up to \$200,000 annually can be requested to support new faculty recruits to the institution.

Subcontracts with collaborating institutions to provide access to mentors and technical and content expertise are permitted.

State law limits the amount of award funding that may be spent on indirect costs to no more than 5% of the **total** award amount.

7. ELIGIBILITY

Eligibility to apply for a TREC award is open to a Texas institution of higher learning whose campus is located 100 miles or greater from 1 of the 4 Texas NCI-designated cancer centers located in Dallas, Houston, and San Antonio.

- Applicants must complete a preapplication process (see [section 8.1](#)).
- An institution may submit only 1 application under this RFA during this funding cycle. For purposes of this RFA, an institution is defined as that component of a university system that has a President.
- An institution with an active TREC award from CRPIT is not eligible to respond to this RFA.
- A university and a health science center that are components of the same university system and share a contiguous or near-contiguous campus are strongly encouraged to submit a single application that will leverage their combined assets to build a cancer research program to serve their region.
- Academic health science centers with multiple campuses are eligible to participate in a single application under this RFA.
- The Principal Investigator (PI) must be the director of the center and must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, and must reside in Texas during the time the research that is the subject of the grant is conducted. The PI should hold a full-time faculty position, at the level of associate or full professor or the equivalent. Ideally, an institution will identify an established investigator with a record of peer-reviewed funding to lead the TREC.
- This award must be directed by the PI. Multiple PIs are not permitted.
- TREC PI, research project leaders, and core resource must be located on a TREC-eligible campus located 100 miles or greater from an existing NCI-designated cancer center.
- Collaborations with Texas-based institutions to provide access to technology and counsel are permitted and can be supported with TREC funds through subcontracts. Texas institutions are eligible to hold subcontracts with multiple TREC grantees.
- Collaborators may or may not reside in Texas; however, collaborators who do not reside in Texas are not eligible to receive CPRIT funds. Collaborators should have specific and well-defined roles. Subcontracting and collaborating organizations may include public,

not-for-profit, and for-profit entities. Such entities may be located outside of the State of Texas, but non-Texas-based organizations are not eligible to receive CPRIT funds. In no event shall equipment purchased under this award leave the State of Texas.

8. RESPONDING TO THIS RFA

8.1. Letter of Intent

A preapplication process is required to encourage interactions with the CPRIT Academic Research Program staff in the planning and development of an application. A letter of intent (LOI) must be sent electronically by 4 PM central time on April 25, 2022, to research@cprit.texas.gov. Late LOIs will not be accepted.

Because an institution may submit only 1 application under this RFA during this funding cycle, only 1 LOI will be accepted for an eligible institution.

The LOI should be addressed to the CPRIT Chief Scientific Officer and should include the biosketch (NIH format) of the proposed PI and a summary (5-page limit) of the proposed TREC theme and planned components. The LOI must be approved prior to submission of an application in response to this RFA. If approved, CPRIT will provide a letter authorizing submission to include in the TREC application. If submitting a resubmission, the letter of intent must address the revisions to the application.

8.2. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application was submitted. The PI must create a user account in the system to start and apply. Furthermore, the Application Signing Official (a person authorized to sign and submit the application for the organization) and the Grants Contract/Office of Sponsored Projects Official (the individual who will manage the grant contract if an award is made) also must create a user account in CARS. Applications will be accepted beginning at 7 AM central time on May 16, 2022 and must be submitted by 4 PM central

time on September 8, 2022. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.3. Submission Deadline Extension

The submission deadline may be extended upon a showing of extenuating circumstances. A request for a deadline extension based on the need to complete multiple CPRIT or other grant applications will be denied. All requests for extension of the submission deadline must be submitted via email to the CPRIT [Helpdesk](#) within 24 hours of the submission deadline. Submission deadline extensions, including the reason for the extension, will be documented as part of the grant review process records. Please note that deadline extension requests are very rarely approved.

8.4. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. Please refer to the *Instructions for Applicants (IFA)* document for details that will be available on November 15, 2021. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 7](#) will be administratively withdrawn without review.

8.4.1. Abstract and Significance (5,000 characters)

Describe the TREC theme and how the proposed TREC will build on an institutional commitment to cancer research, enhance the applicant institution's cancer research infrastructure, and provide junior faculty and faculty pursuing a cancer focus for the first time with the mentoring and research project funding to help them to acquire preliminary data and to successfully compete for independent peer-reviewed cancer research support. Discuss how the TREC will enhance access to technologies and content expertise not currently available to the TREC faculty. If the TREC will support collaborations and/or partnerships with other Texas institutions, discuss these plans. Discuss how the institution will monitor TREC progress.

8.4.2. Layperson's Summary (2,000 characters)

Describe, in simple, nontechnical terms, the overall goals of the proposed TREC and describe the institutional vision and commitment to building cancer research capacity and how the TREC will

help to realize this vision. Discuss the specific cancer problems addressed and how the proposed projects will impact these. The information provided in this summary will be made publicly available by CPRIT, particularly if the application is recommended for funding. **Do not include any proprietary information in the layperson's summary.** The layperson's summary will also be used by advocate reviewers ([section 9.1](#)) in evaluating the significance and impact of the proposed work.

8.4.3. Goals and Objectives

List specific goals and objectives for each year of the TREC. These goals and objectives will also be used during the submission and evaluation of progress reports and assessment of project success.

8.4.4. Timeline (Maximum of 1 page)

Provide an outline of anticipated major milestones to be tracked. If the application is approved for funding, this section will be included in the award contract, and adherence to timelines will be a criterion for continued support. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.4.5. Resubmission Summary (1 page)

An application previously submitted to CPRIT but not funded may be resubmitted after careful consideration of the reasons for lack of prior success. Applicants preparing a resubmission must describe the approach to the resubmission and address concerns raised in the summary statement prepared for the original application review.

8.4.6. Overall Description (6 pages)

Present a compelling rationale for the establishment of the TREC and the goals the TREC will strive to achieve; discuss the institutional commitment and existing capabilities that will be drawn upon in the implementation of these goals. In this section also do the following:

- Discuss the central theme for the TREC and how the research proposed is designed to increase an institution's ability to impact its unique populations.
- Discuss the selection, capabilities, responsibilities, and the reporting structure within the institution for the TREC PI.

- Discuss how the TREC will be organized and how the different components will interact with each other and with existing programs and resources at the institution.
- Discuss how the TREC will develop and monitor faculty development plans for each research project leader receiving TREC support. Include a discussion of how the institution intends to support TREC faculty as they transition their TREC research support to cancer research grant support through applications submitted to CPRIT and the NIH.
- If the TREC plans to support the recruitment of faculty, discuss how priorities for new faculty recruitment are determined and how the recruitment funds (up to \$200,000/year) will be deployed. Discuss the institutional commitments to the proposed faculty recruitment(s).
- Describe an evaluation plan with clear timelines and milestones to monitor and evaluate the performance of all components of the TREC and the progress of the investigators it supports. Strategies to identify and remedy deficiencies such as poor performance and lack of progress should be described. Discuss plans to form an external advisory committee (EAC) comprising scientists with expertise directly relevant to the TREC theme.
- Discuss any plans to develop formal research partnerships with other Texas institutions and how these partnerships will be governed.

8.4.7. Administrative Core (2 pages)

Describe how the PI will manage and coordinate the research projects, EAC, committees, mentors, and research cores to implement the TREC goals. The PI may elect to identify faculty leaders from the institution to implement and oversee individual TREC components and to serve as an internal advisory committee for the TREC.

Core administrative responsibilities include preparing program and financial reports, managing budgets, and organizing scientific and careerdevelopment activities such as seminar series, workshops, and retreats.

8.4.8. Core Resource(s) (4 pages each)

Describe plans for development of any common resources or to support existing resources to accomplish the goals of the proposed research to support TREC projects. Discuss how TREC resources were selected and how they will be managed and evaluated. Applicants are encouraged to use this component of the TREC award to support access to existing core resources located at other Texas research institutions.

8.4.9. Research Projects to be Funded in Year 1 (4 pages each)

Present the rationale, specific aims, and brief research plan for each proposed research project. Preliminary studies are not required, but they are encouraged. In the absence of preliminary results, applicants should describe prior research that serves as the key support for the proposed project. Each research project should describe its relationship to the central theme of the TREC, and the cancer relevance of the proposed research should be concisely stated. Each project must propose a timeline that includes a plan to submit an Investigator-Initiated Research Award application to CPRIT and/or the NCI by the end of 3 years of CPRIT TREC award support.

8.4.10. Letters of Support (2 pages each)

A letter of support from a senior institutional official (eg, President or Dean) must be included, outlining the institution's plan for developing cancer research and the institutions commitment of resources and facilities to sustain and support the TREC throughout the period of funding and to maintain these resources beyond the period of grant support. The level of institutional commitment will differ among applicant institutions because of the variability of resources available among institutions. Examples of institutional commitment include: tenure track faculty positions and research space for recruitment; support of junior faculty as they transition their TREC research support to extramural funding; research space assigned to the TREC; shared resource development beyond that supported by TREC funds.

Additional letters from collaborators at another Texas institution and letters demonstrating regional and/or local commitment and support for the proposed center may be included in this section.

8.4.11. Vertebrate Animals (1 page for each research project or core)

If vertebrate animals will be used in any research project or core, provide a detailed plan of the protocols that will be followed and justification for the number of animals used with reference to biostatistical input for sample selection and evaluation. Certification of approval by the institutional IACUC of the proposed animal use will be required before funding can occur.

8.4.12. Human Subjects (1 page for each research project or core)

If human subjects or human biological samples will be used in any research project or core, provide a detailed plan for recruitment of subjects and/or the acquisition of samples that will meet the time constraints of this award mechanism. Certification of approval of these plans by the institutional IRB will be required before funding can occur.

8.4.13. Budget Justification

Provide a detailed justification of the budget for each component of the TREC for the entire proposed period of support, including salaries and benefits, supplies, equipment, patient care costs, animal care costs, and other expenses.

A minimum level of effort of 20% FTE is required for the PI to devote to career guidance and administrative oversight of the TREC. The PI may not use TREC funds to supplement research activities within his/her laboratory.

TREC funds may be used to support effort of up to 10% FTE for faculty leaders of TREC components.

Research project leaders must commit a minimum of 20% effort to their TREC research project.

Funds to compensate members of the EAC should be requested in the Administrative Core budget. EAC members can be compensated as consultants via a fee-for-service arrangement.

Funds to compensate mentors should be requested in the Administrative Core budget. Each mentor may be compensated for up to 1 person-month of effort and should be listed in the Administrative Core's budget section of the application and not in the individual research projects' budget sections.

Funds may be used to assist the institution's recruitment of junior faculty who complement the scope of the proposed program. These funds are limited to \$200,000 per year and may be used for salary, supplies, and/or equipment costs.

In preparing the requested budget, applicants should be aware of the following:

- Equipment having a useful life of more than 1 year and an acquisition cost of \$5,000 or more per unit must be specifically approved by CPRIT. An applicant does not need to seek this approval prior to submitting the application.
- Texas law limits the amount of grant funds that may be spent on indirect costs to no more than 5% of the total award amount (5.263% of the direct costs). Guidance regarding indirect cost recovery can be found in CPRIT's Administrative Rules, which are available at www.cpritis.texas.gov. So-called grants management and facilities fees (eg, sponsored programs fees; grants and contracts fees; electricity, gas, and water; custodial fees; maintenance fees) may not be requested. Applications that include such budgetary items will be rejected administratively and returned without review.
- The annual salary (also referred to as direct salary or institutional base salary) that an individual may receive under a CPRIT award for FY 2023 is \$200,000; CPRIT FY 2023 is from September 1, 2022, through August 31, 2023. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

8.4.14. Biographical Sketches (5 pages each)

A biographical sketch must be provided for the PI, research project leaders, any core resource leader, and proposed EAC members. Additional biographical sketches for key collaborators or advisors from other Texas institutions may be provided. Each biographical sketch must not exceed 5 pages. The NIH biosketch format is appropriate.

8.4.15. Current and Pending Support and/or Other Certifications

Describe the funding source and duration of all current and pending support for the PI, research project leaders, and core facility leaders. For each award, provide the title, a 2-line summary of the goal of the project, and, if relevant, a statement of overlap with the current application. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.4.16. Previous Summary Statement

If the application is being resubmitted, the summary statement of the original application review, if previously prepared, will be automatically appended to the resubmission. The applicant is not responsible for providing this document.

8.5. Formatting Instructions

Formatting guidelines for all submitted CPRIT applications are as follows:

- **Language:** English
- **Document Format:** PDF only
- **Font Type/Size:** Arial (11 point), Calibri (11 point), or Times New Roman (12 point)
- **Line Spacing:** Single
- **Page Size:** 8.5 x 11 inches
- **Margins:** 0.75 inch, all directions
- **Color and High-Resolution Images:** Images, graphs, figures, and other illustrations must be submitted as part of the appropriate submitted document. Applicants should include text to explain illustrations that may be difficult to interpret when printed in black and white.
- **Scanning Resolution:** Images and figures must be of lowest reasonable resolution that permits clarity and readability. Unnecessarily large files will NOT be accepted, especially those that include only text.
- **References:** Applicants should use a citation style that includes the full name of the article and that lists at least the first 3 authors. Official journal abbreviations may be used. An example is included below; however, other citation styles meeting these parameters

are also acceptable if the journal information is stated. Include URLs of publications referenced in the application.

Smith, P.T., Doe, J., White, J.M., et al (2006). Elaborating on a novel mechanism for cancer progression. *Journal of Cancer Research*, 135: 45–67.

- **Internet URLs:** Applicants are encouraged to provide the URLs of publications referenced in the application; however, applicants should not include URLs directing reviewers to websites containing additional information about the proposed research.
- **Headers and Footers:** These should not be used unless they are part of a provided template. Page numbers may be included in the footer (see following point).
- **Page Numbering:** Pages should be numbered at the bottom right corner of each page.
- All attachments that require signatures must be filled out, printed, signed, scanned, and then uploaded in PDF format.

9. APPLICATION REVIEW

9.1. Full Peer Review

All applications submitted in response to this RFA will undergo a 2-stage peer review process: (1) Full peer review and (2) prioritization of grant applications by the CPRIT Scientific Review Council. In the first stage, applications will be evaluated by an independent peer review panel consisting of scientific experts as well as advocate reviewers using the criteria listed in [section 9.3](#). In the second stage, applications judged to be most meritorious by the peer review panels will be evaluated and recommended for funding by the CPRIT Scientific Review Council based on comparisons with applications from all the peer review panels and programmatic priorities. Applications approved by Scientific Review Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review. The PIC will consider factors including program priorities set by the Oversight Committee, portfolio balance across programs, and available funding. The CPRIT Oversight Committee will vote to approve each grant award recommendation made by the PIC. The grant award recommendations will be presented at an open meeting of the Oversight Committee and must be approved by two-thirds of the Oversight Committee members present and eligible to vote. The review process is described more fully in CPRIT's Administrative Rules, [chapter 703, sections 703.6 to 703.8](#).

9.2. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Peer Review Panel members, Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Peer Review Panel members and Scientific Review Council members are non-Texas residents.

An applicant will be notified regarding the peer review panel assigned to review the grant application. Peer review panel members are listed by panel on CPRIT's website.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed Conflict of Interest as set forth in CPRIT's Administrative Rules ([Texas Administrative Code RULE §703.9](#)).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee Member, a PIC Member, a Scientific Review Panel member, or a Scientific Review Council member. Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention Officer, the Chief Product Development Research Officer, and the Commissioner of State Health Services. The prohibition on communication begins on the first day that grant applications for the grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. The prohibition on communication does not apply to the period when preapplications or letters of interest are accepted. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant application from further consideration for a grant award.

9.3. Review Criteria

Full peer review of applications will be based on primary scored criteria and secondary unscored criteria, listed below. Review panels will evaluate and score each primary criterion and subsequently assign a global score that reflects an overall assessment of the application. **The overall assessment will not be an average of the scores of individual criteria; rather, it will reflect the reviewers' overall impression of the application. Evaluation of the scientific merit of each application is within the sole discretion of the peer reviewers.**

9.3.1. Primary Criteria

Impact of the TREC as a whole: Do the proposed TREC theme and the proposed research projects have a high degree of relevance to cancer research? Will these and the proposed TREC investments enhance the institution's cancer research capabilities and increase the prospects that TREC supported research faculty will compete successfully for peer reviewed cancer research awards?

Institutional Commitment: Is the TREC theme aligned with an institutional plan to build cancer research at the institution, and is there evidence of strong institutional commitment?

Principal Investigator: Does the TREC PI demonstrate the required experience and accomplishments to provide the necessary leadership of the TREC and to oversee mentorship of junior faculty?

Mentoring and evaluation plan: Is there evidence that the proposed research projects have had mentoring input, and is a mentoring and evaluation plan in place to provide further guidance to maximize opportunities for the project leaders to achieve peer reviewed funding?

Individual Research Projects: Do the research projects proposed for the first year of the TREC award have clearly defined hypotheses or goals supported by sufficient preliminary data and/or scientific rationale? Will the research project leaders have formal mentoring to help them acquire preliminary data and successfully compete for independent research grant support?

Core resources: If core resources are proposed, will these enrich the institution's cancer research environment, and will the core(s) impact the TREC research projects? Has the TREC proposal taken advantage of resources at other Texas cancer centers?

9.3.2. Secondary Criteria

Secondary criteria contribute to the global score assigned to the application. Concerns with these criteria potentially question the feasibility of the proposed research. Secondary criteria include the following:

Research Environment: Does the research team have the needed expertise, facilities, and resources to accomplish all aspects of the proposed research? Are the levels of effort of the key personnel appropriate? Is there evidence of institutional support of the research team and the project?

Vertebrate Animals and/or Human Subjects: Is the vertebrate animals and/or human subjects plan adequate and sufficiently detailed?

Budget: Is the budget appropriate for the proposed work?

Duration: Is the stated duration appropriate for the proposed work?

10. KEY DATES

RFA

RFA release	September 27, 2021
IFA posted	November 15, 2021
Letter of Intent due	April 25, 2022

Application

Online application opens	May 16, 2022, 7 AM central time
Application due	September 8, 2022, 4 PM central time
Application review	September 2022 to November 2022

Award

Award notification	January, 2023
Anticipated start date	February 1, 2023

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT's electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT's electronic signature policy as set forth in [chapter 701, section 701.25](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at <https://www.cprit.texas.gov>. Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [chapter 703, sections 703.10, 703.12](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [chapter 703, section 703.20](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to

the research that is the subject of the award. A grant recipient that is a public or private institution of higher education, as defined by §61.003, Texas Education Code, may credit toward the Grant Recipient's Matching Funds obligation the dollar amount equivalent to the difference between the indirect cost rate authorized by the federal government for research grants awarded to the Grant Recipient and the 5% indirect cost limit imposed by §102.203(c), Texas Health and Safety Code. Grant applicants are advised to consult CPRIT's Administrative Rules, [chapter 703, section 703.11](#), for specific requirements regarding demonstration of available funding. The demonstration of available matching funds must be made at the time the award contract is executed, and annually thereafter, not when the application is submitted.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff are not able to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT program, including questions regarding this or any other funding opportunity, should be directed to the CPRIT Director of Academic Research.

Tel: 512-305-8491

Email: research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research Texas Regional Excellence in
Cancer (TREC) (23.1 ARC TREC)
Observation Report

Report No. 2022-11-29 23.1_ARC_TREC
Program Name: Academic Research
Panel Name: 23.1 Academic Research Texas Regional Excellence in Cancer
(TREC) (23.1_ARC_TREC)
Panel Date: November 29, 2022
Report Date: December 1, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research Texas Regional Excellence in Cancer (TREC) (23.1_ARC_TREC) meeting. The meeting was chaired by Peter Jones and conducted via videoconference on November 29, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Four (4) applications were discussed
- Panelists: One (1) panel chair, twelve (12) expert reviewers, and one (1) advocate reviewer
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Five (5)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Five (5)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions
- CPRIT Oversight Committee Members: None (0)
- CPRIT Oversight Committee Members did not actively participate in the meeting

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log were provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.1 Academic Research - Scientific Review Council Meeting
(23.1 SRC)
Observation Report

Report No. 2022-12-22 23.1_SRC
Program Name: Academic Research
Panel Name: 23.1 Academic Research - Scientific Review Council Meeting (23.1_SRC)
Panel Date: December 22, 2022
Report Date: December 23, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.1 Academic Research - Scientific Review Council Meeting (23.1_SRC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on December 22, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: fifty-nine (59) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Three (3)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Cycle 23.1

Awards Announced at the February 15, 2023, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 23.1 include: *Individual Investigator Research Awards; Individual Investigator Research Awards for Cancer in Children and Adolescents; Individual Investigator Research Awards for Computational Systems Biology of Cancer; Individual Investigator Research Awards for Clinical Translation; Individual Investigator Research Awards for Prevention and Early Detection; and Texas Regional Excellence in Cancer Award (TREC)*. Applications submitted in response to the five above listed Individual Investigator mechanisms went through preliminary evaluation as allowed by TAC § 703.6(e)(1). If a peer reviewer identified a conflict of interest during this stage, the application is labeled with a “pe” suffix.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT’s third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
RP230117pe/ RP230117	Patricia Chalela	The University of Texas Health Science Center at San Antonio	G. Coronado
RP230391pe/ RP230391	Maksim Mamonkin	Baylor College of Medicine	J. DiPersio
RP230184pe/ RP230184	Xiankai Sun	The University of Texas Southwestern Medical Center	A. Wu
RP230271pe/ RP230271	Niki Zacharias Millward	The University of Texas M. D. Anderson Cancer Center	A. Wu; W. Warren
RP230360pe/ RP230360	Douglas Frantz	The University of Texas at San Antonio	J. Conejo-Garcia

* Application not discussed during full review.

Academic Research
Cycle 23.1

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230213	Volk, Robert	The University of Texas M. D. Anderson Cancer Center	T. Brandon
RP230272	Goldsmith, Elizabeth	The University of Texas Southwestern Medical Center	A. Tomkinson; J. Petrini
RP230344	McBrayer, Samuel K	The University of Texas Southwestern Medical Center	C. Rosenfeld
Applications not considered by the PIC or Oversight Committee:			
RP230021pe/ RP230021	Scherezade Mama	The University of Texas M. D. Anderson Cancer Center	K. Emmons
RP230044pe	Paul Scheet	The University of Texas M. D. Anderson Cancer Center	L. Mucci
RP230045pe	MinJae Lee	The University of Texas Southwestern Medical Center	G. Coronado
RP230069pe/ RP230069*	Sohail Rao	DHR Health Institute for Research and Development	L. Kushi
RP230097pe/ RP230097	Subrata Sen	The University of Texas M. D. Anderson Cancer Center	G. Petersen
RP230098pe	Julia Heck	University of North Texas	L. Mucci
RP230126pe/ RP230126*	Jose Rauh-Hain	The University of Texas M. D. Anderson Cancer Center	G. Coronado
RP230164pe	Jian Gu	The University of Texas M. D. Anderson Cancer Center	L. Mucci
RP230201pe/ RP230201	Edwin Ostrin	The University of Texas M. D. Anderson Cancer Center	C. Li
RP230279pe	Martha Mims	Baylor College of Medicine	C. Haiman
RP230284pe/ RP230284*	Surendranath Shastri	The University of Texas M. D. Anderson Cancer Center	K. Emmons

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230320pe	Chao Cheng	Baylor College of Medicine	L. Mucci
RP230002pe	Debananda Pati	Baylor College of Medicine	P. Grohar
RP230011pe/ RP230011*	Ziyi Li	The University of Texas M. D. Anderson Cancer Center	J. Issa
RP230292pe	Todd Aguilera	The University of Texas Southwestern Medical Center	W. Hahn
RP230394pe/ RP230394	Alexander Bishop	The University of Texas Health Science Center at San Antonio	P. Grohar
RP230208pe/ RP230208	Raquibul Hannan	The University of Texas Southwestern Medical Center	A. Ribas
RP230057pe/ RP230057*	Junjie Chen	The University of Texas M. D. Anderson Cancer Center	J. Petrini
RP230148pe	Paul Chiao	The University of Texas M. D. Anderson Cancer Center	A. Tomkinson; J. Petrini
RP230187pe	Christopher Amos	Baylor College of Medicine	A. Tomkinson
RP230210pe	Blerta Xhemalce	The University of Texas at Austin	A. Tomkinson
RP230232pe	Anthony Davis	The University of Texas Southwestern Medical Center	A. Tomkinson
RP230267pe	Alison Bertuch	Baylor College of Medicine	J. Karlseder
RP230296pe/ RP230296*	Zamal Ahmed	The University of Texas M. D. Anderson Cancer Center	A. Tomkinson; J. Petrini; W. Chazin
RP230322pe/ RP230322*	E. Paul Hasty	The University of Texas Health Science Center at San Antonio	A. Tomkinson
RP230079pe/ RP230079	Eva Sevick	The University of Texas Health Science Center at Houston	W. Warren
RP230177pe/ RP230177*	Henry Manning	The University of Texas M. D. Anderson Cancer Center	J. Gore

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230194pe/ RP230194	Jia Wu	The University of Texas M. D. Anderson Cancer Center	C. Kahn
RP230206pe/ RP230206	Jingfei Ma	The University of Texas M. D. Anderson Cancer Center	C. Kahn; D. Mankoff; J. Basilion
RP230209pe/ RP230209*	Andrew Wang	The University of Texas Southwestern Medical Center	W. Cai
RP230220pe	Ananth Madhuranthakam	The University of Texas Southwestern Medical Center	A. Wu
RP230238pe/ RP230238*	David Piwnica- Worms	The University of Texas M. D. Anderson Cancer Center	D. Mankoff
RP230252pe	Thomas Yankeelov	The University of Texas at Austin	J. Gore
RP230297pe/ RP230297*	Zhonglin Liu	The Methodist Hospital Research Institute	M. Giger
RP230395pe/ RP230395*	Yaowu Hao	The University of Texas at Arlington	A. Wu
RP230401pe	James Tour	Rice University	C. Kahn
RP230066pe/ RP230066*	FENG-CHUN YANG	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230155pe/ RP230155*	April Risinger	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230156pe/ RP230156*	Kexin Xu	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230159pe	Xiao-Dong Chen	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230189pe	Alexander Pertsemliadis	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230215pe	Gang Huang	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230265pe/ RP230265*	Yuzuru Shiio	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia

* Application not discussed during full review.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
RP230293pe	Panneerdoss Subbarayalu	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230309pe	Stefano Tiziani	The University of Texas at Austin	J. Conejo-Garcia
RP230367*	Chen, Yidong	The University of Texas Health Science Center at San Antonio	J. Conejo-Garcia
RP230186*	Spencer, Jennifer	The University of Texas at Austin	G. Coronado

* Application not discussed during full review.

De-Identified Overall Evaluation Scores

Texas Regional Excellence in Cancer Award (TREC)

Academic Research Cycle 23.1

Application ID	Final Overall Evaluation Score
RP230419*	2.8
RP230420*	2.8
RP230204*	2.8
Na	4.8

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Ludwig Institute for
Cancer Research Ltd

**Richard D. Kolodner
Ph.D.**

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

January 16, 2023

Dr. Mahendra C. Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Patel and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of research grant recommendations for the Texas Regional Excellence in Cancer Awards.

The SRC met on December 22, 2022 to consider the applications recommended by the peer review panels following their meetings held on December 5, 2022.

Recommended funding amounts and the overall evaluation score are stated for each grant application. The total amount for the applications recommended is \$17,998,422.

These recommendations meet the SRC's standards for grant award funding. These standards include selecting innovative research projects addressing CPRIT's long term goals to achieve a decrease in the burden of cancer in Texas through preventive measures, new diagnostics and treatments, and effective translation of discoveries into products.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Mec.	Meeting Overall Score	Application Title	PI	PI Organization	Recommended Budget
1	RP230419	TREC	2.8	South Texas Center of Excellence in Cancer Research (ST-CECR)	CHAUHAN, SUBHASH	The University of Texas Rio Grande Valley	\$6,000,000
2	RP230420	TREC	2.8	Impacting Cancer Outcomes in Hispanics (ICOHN)	LAKSHMANASWAMY, RAJKUMAR	Texas Tech University Health Sciences Center at El Paso	\$6,000,000
3	RP230204	TREC	2.8	Gene-Environment: Lifestyle Interactions in Cancer	Ramos, Kenneth	Texas A&M University System Health Science Center	\$5,998,422

TREC – Texas Regional Excellence in Cancer



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research Recruitment
FY 2023—Cycles 2-3
*Recruitment of Established Investigators***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-23.1-REI

Recruitment of Established Investigators

**Please also refer to the Instructions for Applicants document, which will be
posted on June 21, 2022**

Applications for this award mechanism are subject to institutional limits and newly established application cycles. Applicants are advised to consult with their institution's Office of Research and Sponsored Programs (or equivalent).

Application Receipt Dates:

June 21, 2022-June 20, 2023

FY 2023

Fiscal Year Award Period

September 1, 2022-August 31, 2023

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
2. RATIONALE	5
3. RECRUITMENT OBJECTIVES	5
4. INSTITUTIONAL COMMITMENT	7
5. FUNDING INFORMATION	7
6. ELIGIBILITY	8
7. RESUBMISSION POLICY	10
8. RESPONDING TO THIS RFA	11
8.1. APPLICATION SUBMISSION GUIDELINES	11
8.2. APPLICATION COMPONENTS	12
8.2.1. <i>Summary of Nomination (2,500 characters)</i>	12
8.2.2. <i>Institutional Commitment (3 pages)</i>	12
8.2.3. <i>Letter of Support from Department Chair (up to 2 pages)</i>	14
8.2.4. <i>Curriculum Vitae (CV)</i>	15
8.2.5. <i>Summary of Goals and Objectives (2,000 characters)</i>	15
8.2.6. <i>Research (4 pages)</i>	15
8.2.7. <i>Publications/References (1 Page)</i>	16
8.2.8. <i>Research Collaboration/Synergy Plan (2 pages)</i>	16
8.2.9. <i>Publications</i>	16
8.2.10. <i>Timeline (1 page)</i>	16
8.2.11. <i>Current and Pending Support</i>	16
8.2.12. <i>Research Environment (1 page)</i>	17
8.2.13. <i>Descriptive Biography (Up to 2 pages)</i>	17
9. APPLICATION REVIEW	17
9.1. REVIEW PROCESS.....	17
9.1.1. <i>Confidentiality of Review</i>	18
9.2. REVIEW CRITERIA	19
10. KEY DATES	20
11. AWARD ADMINISTRATION	20
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	22
13. CONTACT INFORMATION	22
13.1. HELPDESK.....	22
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	22

RFA VERSION HISTORY

6/21/22 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas
- Develop and implement the Texas Cancer Plan

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure
- Achieving health equity and reducing cancer disparities

Priorities Across CPRIT's 3 Programs:

- Prevention and early detection initiatives
- Translation of Texas research (discoveries) to innovations
- Enhancing Texas' research capacity and life science infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects

- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

2. RATIONALE

The aim of this award mechanism is to bolster cancer research in Texas by providing financial support to attract world-class research scientists with distinguished professional careers to Texas universities and cancer research institutes to establish research programs that add research talent to the state. This award will support established academic leaders whose body of work has made an outstanding contribution to cancer research. Awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research, thereby advancing cancer research and prevention efforts and promoting economic development in the State of Texas.

The recruitment of outstanding scientists will greatly enhance programs of scientific excellence in cancer research and will position Texas as a leader in the fight against cancer. Applications may address any research topic related to cancer biology, causation, prevention, detection or screening, treatment, or survivorship. Candidates with research programs addressing CPRIT's priority areas for research are encouraged. These areas include implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions, population research addressing cancer disparities, computational oncology and analytic methods, childhood and adolescent cancers, hepatocellular cancer, and expansion of access to innovative clinical trials.

3. RECRUITMENT OBJECTIVES

The goal of this award mechanism is to recruit exceptional faculty to universities and/or cancer research institutions in the State of Texas. This award honors outstanding senior investigators with proven track records of research accomplishments combined with excellence in leadership

and teaching. All candidates should be recognized research or clinical investigators, held in the highest esteem by professional colleagues nationally and internationally, whose contributions have had a significant influence on their discipline and, likely, beyond. They must have clearly established themselves as exemplary faculty members with exceptional accomplishments in teaching and advising and/or basic, translational, population-based, or clinical cancer research activities. It is expected that the candidate will contribute significantly to and have a major impact on the institution's overall cancer research initiative. Candidates will be leaders capable of initiating and developing creative ideas leading to novel solutions related to cancer prevention and control, detection, diagnosis, and/or treatment. They are also expected to maintain and lead a strong research group and have a stellar, high-impact publication portfolio, as well as continue to secure external funding. Furthermore, recipients will lead and inspire undergraduate and graduate students interested in pursuing research careers and will engage in collegial and collaborative relationships with others within and beyond their traditional discipline in an effort to expand the boundaries of cancer research.

Funding will be given for exceptional candidates who will continue to develop new research methods and techniques in the life, population-based, physical, engineering, or computational sciences and apply them to solving outstanding problems in cancer research that have been inadequately addressed or for which there may be an absence of an established paradigm or technical framework.

Ideal candidates will have specific expertise in cancer-related areas needed to address an institutional priority. Candidates should be at the career level of a full professor or equivalent. This funding mechanism considers expertise, accomplishments, and breadth of experience as vital metrics for guiding CPRIT's investment in that person's originality, insight, and potential for continued contribution. Relevance to cancer research and to CPRIT's priority areas are important evaluation criteria for CPRIT funding.

Applications nominating individuals who carry out patient-oriented research and who have demonstrated exceptional ability to lead innovative discovery campaigns through conduct of clinical trials are appropriate for this mechanism and encouraged.

Additionally, population research that addresses the burden of cancer in Texas is a priority for CPRIT. Applications nominating individuals who have demonstrated exceptional ability to lead

innovative research programs involving any component across the continuum of cancer prevention and control research are appropriate for this mechanism and are highly encouraged. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of “CPRIT Scholar in Cancer Research,” and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

4. INSTITUTIONAL COMMITMENT

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world’s best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of an Established Investigator must be complemented by a strong financial institutional commitment to the recruitment. The institutional commitment should be clearly documented in the application (see [section 8.2.2](#)) and include the amount and sources of salary support and all additional financial support that will be available to the candidate’s research program through the course of the CPRIT award. The financial commitments made to the candidate by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

5. FUNDING INFORMATION

This award is up to 5 years and is not renewable. Grant support will be awarded based upon the breadth and nature of the research program proposed. Grant funds of up to \$6,000,000 (total costs) for the 5-year period may be requested. Applicants are encouraged to tailor the budget as appropriate to the exigencies of the project; grant funds totaling less than \$6,000,000 for the term of the award are acceptable if warranted by the scope of the research. Exceptions exceeding this limit will be entertained only if there is compelling written justification. The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). CPRIT will make every effort to be flexible in the timing for disbursement of funds; recipients will be asked at the beginning of each year for an estimate of their needs for the year. Funds may not be carried over beyond 5 years except under extraordinary circumstances with strong justification for a no-cost extension. In addition, funds for extraordinary equipment needs may be awarded in

the first year of the grant if very well justified and a detailed justification is provided along with an institutional plan should the additional funds not be approved. Scholars may request funds for travel for 2 project staff to attend CPRIT's conference.

Funds from this award mechanism may be used for salary support of this candidate but may not be used to construct or renovate laboratory space.

Note that the annual salary (also referred to as direct salary or institutional base salary) that an individual may be reimbursed from a CPRIT award for FY 2023 is limited to a maximum of \$200,000. In other words, an individual may request salary proportional to the percent of effort up to a maximum of \$200,000. Salary does not include fringe benefits and/or facilities and administrative costs, also referred to as indirect costs. An individual's institutional base salary is the annual compensation that the applicant organization pays for an individual's appointment, whether that individual's time is spent on research, teaching, patient care, or other activities. Base salary excludes any income that an individual may be permitted to earn outside of his or her duties to the applicant organization.

Note: Depending on the availability of funds, review cycles may be reduced, and/or the number of applications per institution may be capped, and nominations submitted in response to this Request for Applications (RFA) during the current receipt period may be announced and awarded either in the current fiscal year (prior to August 31, 2023) or in the first quarter of the next fiscal year (starting September 1, 2023).

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- Candidates must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific candidate.

- A candidate may be nominated by only 1 institution. If more than 1 institution is interested in a given candidate, negotiations as to which institution will nominate him or her must be concluded before the nomination is made.
- An institution is allowed to submit **only 6** Recruitment applications (either a Recruitment of Established Investigator, or a Recruitment of First-Time, Tenure-Track Faculty Member) **during the FY23 application receipt period**. An exception will be made for **up to 3** additional submissions of a Recruitment of Established Investigator application, if the application involves a meaningful collaboration with a Texas Regional Excellence in Cancer eligible institution (see eligible Universities in IFA). Applications that exceed these limits will be returned. Institutions may use their own discretion as to the timing of submission of applications in FY23, with the understanding that the limit of 6 applications per FY23 receipt period will be strictly upheld (with the exception noted above).
- A candidate who has already accepted a position at the recruiting institution prior to the time that the Scientific Review Council reviews the candidate for a recruitment award is not eligible for a recruitment award, as an investment by CPRIT is obviously not necessary. No award is final until approved by the Oversight Committee at a public meeting. However, in recognition of the timeline involved with recruiting highly sought-after candidates who are often considering multiple offers, CPRIT's Academic Research program staff will notify the nominating institution of the Scientific Review Council's review decision following the Review Council meeting. If a position is offered to the candidate during the period following the Scientific Review Council's review decision but prior to the Oversight Committee's final approval, the institution does so at its own risk. There is no guarantee that the recruitment award will be approved by the Oversight Committee.
- The candidate must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, **and reside in Texas for the duration of the appointment**. The candidate must devote at least 70% time to research activities. Candidates whose major responsibilities are clinical care, teaching, or administration are not eligible.
- At the time of the application, the candidate should hold an appointment at the rank of professor (or equivalent) at an accredited academic institution, research institution,

industry, government agency, or private foundation. The candidate must not reside in Texas at the time the application is submitted.

- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.
- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

Resubmissions will not be accepted for the Recruitment of Established Investigators award mechanism. Any nomination for the Recruitment of Established Investigators that was previously submitted to CPRIT and reviewed but was not recommended for funding may not be

resubmitted. A nomination for the Recruitment of Established Investigators that was previously submitted to CPRIT for any of the recruitment RFA mechanisms and reviewed and recommended for funding but declined by the candidate may be submitted in response to this RFA if the candidate meets the eligibility criteria described in [section 6](#), and the application is not in the same fiscal year as the previous application. If a nomination was administratively rejected prior to review, it can be resubmitted in the following cycles. Applications being resubmitted according to the criteria permitted by this section should be submitted as a new application (refer to the *Instructions for Applicants* [IFA] document for more details).

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. Candidates must be nominated by the institution’s president, provost, vice president for research, or appropriate dean. The individual submitting the application (Nominator) must create a user account in the system (which includes the Nominator’s credentials and email address) to start and submit an application. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS.

Dependent upon available funding, applications will be accepted within a 6-review-cycle schedule throughout FY23, as displayed in the table below.

Review Cycle	Open date	Close date
23.1	6/21/2022	8/20/2022
23.2	8/23/2022	10/20/2022
23.3	10/21/2022	12/20/2022
23.4	12/21/2022	2/20/2023
23.5	2/21/2023	4/20/2023
23.6	4/21/2023	6/20/2023

In order to manage the timely review of nominations, it is anticipated that applications submitted by 11:59 PM central time on the closing day of each cycle (see table above for closing date of each cycle) will be reviewed by the 15th day of the following month. For an application to be considered for review during the cycle, that application must be submitted on or before 11:59 PM central time. In the event that the closing date falls on Saturday or Sunday, applications may be submitted on or before 11:59 PM central time the following Monday. CPRIT will not extend the submission deadline. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the *IFA* document that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

8.2.1. Summary of Nomination (2,500 characters)

Provide a brief summary of the nomination. Include the candidate's name, organization from which the candidate is being recruited, and also the department and/or entity within the nominator's organization where the candidate will hold the faculty position.

8.2.2. Institutional Commitment (3 pages)

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of an Established Investigator Faculty should be complemented by a strongly documented institutional commitment to the recruitment. The financial commitments made to the candidate by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

The following guidelines should be followed when documenting the institutional commitment to the candidate:

- The institutional commitment should be clearly documented in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and include the

amount and sources of salary support and all additional financial support that will be available to the candidate's research program through the course of the CPRIT award. The financial commitments made to the candidate by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

- The institutional commitment letter must include the following statement regarding the institution's financial commitment required to meet the 50% match.
 - This institutional financial commitment will not be offset by funds from an investigator-initiated award received by the candidate. If an award dictates that such funds must be used for salary, the corresponding amount of institutional funds committed to pay the candidate's salary will be redirected to allow the candidate to use them for program support.
- Institutional commitment as described above must be presented in a table (example below), that clearly identifies the salary amount, sources of salary, and any additional research support from institutional sources over the course of the CPRIT award. Sources of support for the candidate's full salary, including summer salary, for the duration of the award must be documented. If the candidate is expected to provide salary support from grants during the award period, the institutional commitment must identify the source for salary support in the event grant support is not available. Note that a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the candidate.
- Include a brief job description for the candidate should recruitment be successful.
- Describe the institutional environment and any professional commitments to the candidate including, but not limited to, dedicated personnel, access to students, space assignment, and access to shared equipment, and discuss all other agreements between the institution and the candidate.
- Institutions may provide additional information in support of a candidate's research plan to demonstrate how the institutional commitment, through development of strategic collaborations, will foster a candidate's cancer research. This additional information is highly encouraged when proposing a candidate with exceptional expertise and/or talent that can be directed to cancer research such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research.

- Note that Texas law allows an institution of higher learning to use its federal indirect cost rate credit to comply with the requirement to demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award (see [section 12](#)). However, a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the candidate.

Example of an acceptable Institutional Commitment table:

Candidate’s Name, Institutional Commitments					
	Year 1	Year 2	Year 3	Year 4	Year 5
Salary/Benefits					
Research Support					
Administrative Support					
Moving Expenses					

Total =

Note: CPRIT acknowledges that the institutional commitments by category may change during the course of the award; however, the total financial commitment to the candidate must remain equal to or greater than 50% of the CPRIT award.

8.2.3. Letter of Support from Department Chair (up to 2 pages)

Provide the letter of support from and signed by the chair of the department to which the candidate is being recruited. The following information should be included in the letter:

Recruitment Activities: CPRIT is committed to increasing the life sciences infrastructure in Texas via the recruitment of exceptional cancer researchers, as well as expanding research resources. The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this candidate. Provide the necessary context by describing the institution’s vision for the cancer programs, how the work of the nominee contributes to achieving these goals—including impact on diversity, equity, and inclusion, if applicable—and the expected impact of the recruitment on the institution (or department) and the burden of cancer in Texas (if applicable).

Caliber of Candidate: The letter should include a description of the caliber of the candidate and justification of nomination of the candidate by the institution. CPRIT recognizes that there is variability in the metrics of impact applicable across the continuum of cancer research. For

example, in some disciplines, research findings—although highly impactful on the field—are less likely to be published in the highest ranked journals, ie, *Science*, *Cell*, or *Nature* series. Thus, it is incumbent on the institution to describe the impact of a nominee’s work, including paradigm-shifting, practice-changing, or influence on public policy, population health behavior, or cancer disparities.

Description of Candidate Duties and Certification of 70% Time Commitment to Research:

While scholars may engage in direct patient care activities and/or have some administrative or teaching duties, at least 70% of the candidate’s time must be available for research. Breach of this requirement will constitute grounds for discontinuation of funding. The certification that 70% time will be spent on research must be included.

8.2.4. Curriculum Vitae (CV)

Provide a complete CV and list of publications for the candidate.

8.2.5. Summary of Goals and Objectives (2,000 characters)

List goals and objectives to be achieved during this award. **This section must be completed by the candidate.**

8.2.6. Research (4 pages)

Summarize the key elements of the candidate’s research accomplishments and provide an overview of the proposed research by outlining the background and rationale, hypotheses and aims, strategies, goals, and projected impact of the focus of the research program. Highlight the innovative aspects of this effort and place it into context with regard to what pressing problem in cancer will be addressed. **This section of the application must be prepared by the candidate. References cited in this section should be listed in the Publications/References section (see 8.2.7).**

Candidates for CPRIT Scholar Awards must include the following signed statement at the end of this section. **Applications that do not contain this signed statement will be returned without review.**

“I understand that I do not need to have made a commitment to <*nominating institution*> before this application has been submitted. However, I also understand that only 1 Texas institution may

nominate me for a CPRIT Recruitment Award, and this is the nomination that I have endorsed. I understand that requests to change the recruiting institution during the recruitment process are not allowed after the application is submitted to CPRIT.”

8.2.7. Publications/References (1 Page)

Provide a concise and relevant list of publications/references cited for the application. Any appropriate citation format is acceptable; official journal abbreviations should be used.

8.2.8. Research Collaboration/Synergy Plan (2 pages)

Institutions may provide additional information in support of a candidate’s research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a candidate’s cancer research. This additional information is highly encouraged when proposing a candidate with exceptional expertise and/or talent that can be directed to cancer research, such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research. Biographical sketches of collaborators established in the research collaborative plan must be uploaded as part of the application. This will be in addition to the 2-page synergy plan (see IFA).

8.2.9. Publications

Provide the 5 most significant publications that have resulted from the candidate’s research efforts. Publications should be uploaded as PDFs of full-text articles. Only articles that have been published or that have been accepted for publication (“in press”) should be submitted.

8.2.10. Timeline (1 page)

Provide a general outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.11. Current and Pending Support

State the funding source, duration, and title of all current and pending research support held by the candidate. If the candidate has no current or pending funding, a document stating this must be

submitted. Refer to the sample current and pending support document located in [Current Funding Opportunities](#) for Academic Research in CARS.

8.2.12. Research Environment (1 page)

Briefly describe the research environment available to support the candidate's research program, including core facilities, training programs, and collaborative opportunities.

8.2.13. Descriptive Biography (Up to 2 pages)

Provide a brief descriptive biography of the candidate, including his or her accomplishments, education and training, professional experience, awards and honors, publications relevant to cancer research, and a brief overview of the candidate's goals if selected to receive the award.

This section of the application must be prepared by the candidate. If the application is approved for funding, this section will be made publicly available on CPRIT's website.

Candidates are advised not to include information that they consider confidential or proprietary when preparing this section.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.

9. APPLICATION REVIEW

9.1. Review Process

All eligible applications will be evaluated and scored by the CPRIT Scientific Review Council using the criteria listed in this RFA. Applications may be submitted continuously in response to this RFA but will generally be reviewed on a cycle of 6 review periods per year by the CPRIT Scientific Review Council. Council members may seek additional ad hoc evaluations of candidates. Scientific Review Council members will review applications and provide an individual Overall Evaluation Score that conveys the members' recommendation related to the proposed recruitment. Applications recommended by the Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review, prioritization, and recommendation to the CPRIT Oversight Committee for approval and funding. Approval is based on an application receiving a positive vote from at least two-thirds of the members of the Oversight Committee.

The review process is described more fully in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

The decision of the Scientific Review Council not to recommend an application is final, and such applications may not be resubmitted for a recruitment award. Notification of review decisions is sent to the nominator.

9.1.1. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, or a Scientific Review Council member.

Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.2. Review Criteria

Applications will be assessed based on evaluation of the quality of the candidate and his or her potential for continued superb performance as a cancer researcher. **Also, of critical importance is the strength of the institutional commitment to the candidate. Recruitment efforts are not likely to be successful unless there is a strong commitment from both CPRIT and the host institution.** It is not necessary that a candidate agree to accept the recruitment offer at the time an application is submitted. However, applicant institutions should have a reasonable expectation that recruitment will be successful if an award is granted by CPRIT.

Review criteria will focus on the overall impression of the candidate, his/her proposed research program, and his/her long-term contribution to and impact on the field of cancer research.

Questions to be considered by the reviewers are as follows:

Quality of the Candidate: Has the candidate made significant, transformative, and sustained contributions to basic, translational, clinical, or population-based cancer research? Is the candidate an established and nationally and/or internationally recognized leader in the field? Has the candidate demonstrated excellence in leadership and teaching? Has the candidate provided mentorship, inspiration, and/or professional training opportunities to junior scientists and students? Does the candidate have a strong record of research funding? Does the candidate have a publication history in high-impact journals within cancer research broadly, or within their specialty field, if applicable? Does the candidate show evidence of collaborative interaction with others?

Scientific Merit of Proposed Research: Is the research plan comprehensive and well thought out? Does the proposed research program demonstrate innovation, creativity, and feasibility? Will it expand the boundaries of cancer research beyond traditional methodology by incorporating novel and interdisciplinary techniques? Does the research program integrate with and/or increase collaborative research efforts and relationships at the nominating institution?

Relevance of Candidate's Research: Is the proposed research likely to have a significant impact on reducing the burden of cancer in the near term, or address unique aspects of the burden of cancer in Texas? Does the research contribute to basic, translational, clinical, or population-based cancer research?

Research Environment: Does the institution have the necessary facilities, expertise, and resources to support the candidate’s research program? Is there evidence of strong institutional support? Will the candidate be free of major administrative/clinical responsibilities so that he or she can focus on maintaining and enhancing his or her research program?

10. KEY DATES

RFA

RFA Release June 21, 2022

Application Receipt and Review Timeline

Cycle	Application Receipt Date	Application Closing Date	Anticipated Application Review
23.1	6/21/2022	8/20/2022	9/15/2022
23.2	8/23/2022	10/20/2022	11/10/2022
23.3	10/21/2022	12/20/2022	1/12/2023
23.4	12/21/2022	2/20/2023	3/16/2023
23.5	2/21/2023	4/20/2023	5/11/2023
23.6	4/21/2023	6/20/2023	7/13/2023

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract

provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. CPRIT requires funding acknowledgement to include the award grant ID on all print and visual materials that are funded in whole or in part by CPRIT grants. Examples of print and visual materials include, but are not limited to, publications, brochures, pamphlets, project websites, videos, and media materials. Grantees must have written approval from CPRIT prior to the purchase of any equipment. If the equipment is clearly defined in the grantee's budget submitted with the initiating award requirements, then approval of the grant award constitutes "prior approval" for the purchase. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff members are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Director of Academic Research.

Email: Research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)
23.2 Scientific Review Council Recruitment Review
(23.2 SRC REC)
Observation Report

Report No. 2022-11-10 23.2_SRC_REC
Program Name: Academic Research
Panel Name: 23.2 Scientific Review Council Recruitment Review (23.2_SRC_REC)
Panel Date: November 10, 2022
Report Date: November 11, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.2 Scientific Review Council Recruitment Review (23.2_SRC_REC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on November 10, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Three (3) applications were discussed
- Panelists: One (1) panel chair, and five (5) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.3 Academic Research - Recruitment Review Panel-23.3
(23.3 SRC REC)
Observation Report

Report No. 2023-01-12 23.3_SRC REC
Program Name: Academic Research
Panel Name: 23.3 Academic Research - Recruitment Review Panel-23.3 (23.3_SRC REC)
Panel Date: January 12, 2023
Report Date: January 18, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.3 Academic Research - Recruitment Review Panel-23.3 (23.3_SRC REC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on January 12, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Four (4) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to read 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Recruitment Cycles 23.2-23.3

Awards Announced at the February 15, 2023, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment Cycles 23.2 through 23.3 include: *Recruitment of Established Investigators* and *Recruitment of First-Time, Tenure-Track Faculty Members*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
No reported COIs.			
Applications not considered by the PIC or Oversight Committee:			
No reported COIs.			

De-Identified Overall Evaluation Scores

Recruitment of Established Investigators

Academic Research Recruitment cycles 23.2-23.3

Application ID	Final Overall Evaluation Score
RR230020*	2.0
RR230018*	2.7
g	4.0

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

January 16, 2023

Dr. Mahendra C. Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Patel and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of recruitment grant recommendations. The SRC met on on November 6, 2022 (Cycle 23.2) and January 12, 2023 (Cycle 23.3) to review and finalize applications submitted to CPRIT under the Recruitment of Established Investigator and Recruitment of First-Time, Tenure Track Faculty Members RFA mechanisms.

The SRC recommends six applications, which are included on the attached list. The recommended funding amounts and the overall evaluation scores are stated for the grant applications. There were no recommended changes to funding amounts, goals, timelines, or project objectives requested. The total amount for the applications recommended is \$19,999,977

The recommendation meets the SRC's standards for funding. These include selecting candidates at all career levels that have demonstrated academic excellence, innovation, excellent training, commitment to cancer research and exceptional potential for achieving future impact in basic, translational, population based or clinical research.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Mechanism	Candidate	Organization	Budget	Overall Scores
1	RR230019	RFTFM	Lu Wang	The University of Texas Health Science Center at San Antonio	\$2,000,000	1.6
2	RR230012	RFTFM	Kenneth Hu	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
3	RR230017	RFTFM	Joe Nassour	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.5
4	RR230020	REI	Hongfang Liu	The University of Texas Health Science Center at Houston	\$6,000,000	2.0
5	RR230018	REI	Rudi Fasan	The University of Texas at Dallas	\$6,000,000	2.7
6	RR230015	RFTFM	Ewan McRae	The Methodist Hospital Research Institute	\$1,999,977	2.8

RFTFM- Recruitment of First-Time Tenure Track Faculty

REI- Recruitment of Established Investigators



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO Affidavit Supporting Information

**Academic Research Recruitment
FY 2023—Cycles 2-3
*Recruitment of First-Time, Tenure-Track
Faculty Members***

Request for Applications



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

REQUEST FOR APPLICATIONS
RFA R-23.1-RFT

**Recruitment of First-Time Tenure-Track
Faculty Members**

**Please also refer to the Instructions for Applicants document,
which will be posted on June 21, 2022**

Applications for this award mechanism are subject to institutional limits and newly established application cycles. Applicants are advised to consult with their institution's Office of Research and Sponsored Programs (or equivalent).

Application Receipt Dates:

June 21, 2022-June 20, 2023

FY 2023

Fiscal Year Award Period

September 1, 2022-August 31, 2023

TABLE OF CONTENTS

1. ABOUT CPRIT	4
1.1. ACADEMIC RESEARCH PROGRAM PRIORITIES	4
2. RATIONALE	5
3. RECRUITMENT OBJECTIVES	5
4. INSTITUTIONAL COMMITMENT	7
5. FUNDING INFORMATION	7
6. ELIGIBILITY	8
7. RESUBMISSION POLICY	10
8. RESPONDING TO THIS RFA	10
8.1. APPLICATION SUBMISSION GUIDELINES	10
8.2. APPLICATION COMPONENTS	11
8.2.1. <i>Summary of Nomination (2,000 characters)</i>	12
8.2.2. <i>Institutional Commitment (3 pages)</i>	12
8.2.3. <i>Letter of Support from Department Chair (up to 2 pages)</i>	14
8.2.4. <i>Curriculum Vitae (CV)</i>	15
8.2.5. <i>Summary of Goals and Objectives (2,000 characters)</i>	15
8.2.6. <i>Research (4 pages)</i>	15
8.2.7. <i>Publications/References (1 page)</i>	16
8.2.8. <i>Research Collaboration/Synergy Plan (2 pages)</i>	16
8.2.9. <i>Publications</i>	16
8.2.10. <i>Timeline (1 page)</i>	16
8.2.11. <i>Current and Pending Support</i>	16
8.2.12. <i>Letters of Recommendation</i>	17
8.2.13. <i>Research Environment (1 page)</i>	17
8.2.14. <i>Descriptive Biography (Up to 2 pages)</i>	17
9. APPLICATION REVIEW	17
9.1. REVIEW PROCESS.....	17
9.1.1. <i>Confidentiality of Review</i>	18
9.2. REVIEW CRITERIA.....	19
10. KEY DATES	20
11. AWARD ADMINISTRATION	20
12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS	22
13. CONTACT INFORMATION	22
13.1. HELPDESK.....	22
13.2. SCIENTIFIC AND PROGRAMMATIC QUESTIONS	22

RFA VERSION HISTORY

6/21/22 RFA release

1. ABOUT CPRIT

The State of Texas has established the Cancer Prevention and Research Institute of Texas (CPRIT), which may issue up to \$6 billion in general obligation bonds to fund grants for cancer research and prevention.

CPRIT is charged by the Texas Legislature to do the following:

- Create and expedite innovation in the area of cancer research and in enhancing the potential for a medical or scientific breakthrough in the prevention of or cures for cancer
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in the State of Texas
- Develop and implement the Texas Cancer Plan

1.1. Academic Research Program Priorities

The Texas Legislature has charged the CPRIT Oversight Committee with establishing program priorities on an annual basis. These priorities are intended to provide transparency with regard to how the Oversight Committee directs the orientation of the agency's funding portfolio.

Established Principles:

- Scientific excellence and impact on cancer
- Increasing the life sciences infrastructure
- Achieving health equity and reducing cancer disparities

Priorities Across CPRIT's 3 Programs:

- Prevention and early detection initiatives
- Translation of Texas research (discoveries) to innovations
- Enhancing Texas' research capacity and life science infrastructure

The program priorities for academic research adopted by the Oversight Committee include funding projects that address the following:

- Recruitment of outstanding cancer researchers to Texas
- Investment in core facilities
- A broad range of innovative, investigator-initiated research projects

- Implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions and population research addressing cancer disparities
- Computational oncology and analytic methods
- Childhood and adolescent cancers
- Hepatocellular cancer
- Expanding access to innovative clinical trials

2. RATIONALE

The aim of this award mechanism is to bolster cancer research in Texas by providing financial support to attract very promising investigators who are pursuing their first faculty appointment at the level of assistant professor (first-time, tenure-track faculty members). These individuals must have demonstrated academic excellence, innovation during predoctoral and/or postdoctoral research training, commitment to pursuing cancer research, and exceptional potential for achieving future impact in basic, translational, population-based, or clinical research. Awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research, thereby advancing cancer research and prevention efforts and promoting economic development in the State of Texas.

The recruitment of outstanding scientists will greatly enhance programs of scientific excellence in cancer research and will position Texas as a leader in the fight against cancer. Applications may address any research topic related to cancer biology, causation, prevention, detection or screening, treatment, or survivorship. Candidates with research programs addressing CPRIT's priority areas for research are encouraged. These include implementation research to accelerate the adoption and deployment of evidence-based prevention and screening interventions, computational oncology and analytic methods, population research addressing cancer disparities, childhood and adolescent cancers, hepatocellular cancer, and expansion of access to innovative clinical trials.

3. RECRUITMENT OBJECTIVES

The goal of this award mechanism is to recruit exceptional faculty to universities and/or cancer research institutions in the State of Texas. All candidates are expected to have completed their

doctoral and fellowship training and to have clearly demonstrated truly superior ability as evidenced by their accomplishments during training, proposed research plan, publication record, and letters of recommendation. This CPRIT-supported initiative is designed to enhance innovative programs of excellence by providing research support for promising, early-stage investigators **seeking their first tenure-track position.**

CPRIT will provide start-up funding for newly independent investigators, with the goal of augmenting and expanding the institution's efforts in cancer research. Candidates will be expected to develop research projects within the sponsoring institution. Projects should be appropriate for a newly independent investigator and should foster the development of preliminary data that can be used to prepare applications for future independent research project grants to further both the investigator's research career and the CPRIT mission. The institution will be expected to work with each newly recruited research faculty member to design and execute a faculty career development plan consistent with his or her research emphasis. Relevance to cancer research and to CPRIT's priority areas are important evaluation criteria for CPRIT funding.

Applications nominating individuals who are well prepared to pursue careers in patient-oriented research and who have demonstrated exceptional potential to lead innovative discovery campaigns through conduct of clinical trials are appropriate for this mechanism and encouraged.

Additionally, population research that addresses the burden of cancer in Texas is a priority for CPRIT. Applications nominating individuals who have demonstrated exceptional ability to lead innovative research programs involving any component across the continuum of cancer prevention and control research are appropriate for this mechanism and are highly encouraged.

Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

4. INSTITUTIONAL COMMITMENT

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of a first-time, tenure-track faculty must therefore be complemented by a strong institutional commitment to the candidate's career development that includes financial commitments that are in addition to the CPRIT award. The institutional commitment should be clearly documented in the application (see [section 8.2.2](#)) and include the amount and sources of salary support and all additional financial support that will be available to the candidate's research program through the course of the CPRIT award. The financial commitments made to the candidate for his or her research program by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.

5. FUNDING INFORMATION

This award is up to 5 years and is not renewable, although individuals may apply for other future CPRIT funding as appropriate. Grant funds of up to \$2,000,000 (total costs) for the 5-year period may be requested. Applicants are encouraged to tailor the budget as appropriate to the exigencies of the project; grant funds totaling less than \$2,000,000 for the term of the award are acceptable if warranted by the scope of the research. Funding is to be used by the candidate to support his or her research program. The award request may include indirect costs of up to 5% of the total award amount (5.263% of the direct costs). CPRIT will make every effort to be flexible in the timing for disbursement of funds; recipients will be asked at the beginning of each year for an estimate of their needs for the year. Funds may not be carried over beyond 5 years except under extraordinary circumstances with strong justification for a no-cost extension. In addition, funds for extraordinary equipment needs may be awarded in the first year of the grant if very well justified and a detailed justification is provided along with an institutional plan should the additional funds not be approved. Scholars may request funds for travel for 2 project staff to attend CPRIT's conference.

Funds from this CPRIT award may not be used for salary support of this candidate or to construct or renovate laboratory space.

Note: Depending on the availability of funds, nominations submitted in response to this Request for Applications (RFA) during the current receipt period may be announced and awarded either

in the current fiscal year (prior to August 31, 2023) or in the first quarter of the next fiscal year (starting September 1, 2023).

6. ELIGIBILITY

- The applicant must be a Texas-based entity. Any not-for-profit institution that conducts research is eligible to apply for funding under this award mechanism. A public or private company is not eligible for funding under this award mechanism.
- Candidates must be nominated by the president, provost, vice president for research, or appropriate dean of a Texas-based public or private institution of higher education, including academic health institutions. The application must be submitted on behalf of a specific candidate.
- A candidate may be nominated by only 1 institution. If more than 1 institution is interested in a given candidate, negotiations as to which institution will nominate him or her must be concluded before the nomination is made.
- An institution is allowed to submit **only 6** Recruitment applications (either a Recruitment of Established Investigator, or a Recruitment of First-Time, Tenure-Track Faculty Member) **during the FY23 application receipt period**. An exception will be made for **up to 3** additional submissions of a Recruitment of Established Investigator application, if the application involves a meaningful collaboration with a Texas Regional Excellence in Cancer eligible institution (see eligible Universities in IFA). Applications that exceed these limits will be returned. Institutions may use their own discretion as to the timing of submission of applications in FY23, with the understanding that the limit of 6 applications per FY23 receipt period will be strictly upheld (with the exception noted above).
- A candidate who has already accepted a position as assistant professor tenure track at the recruiting institution prior to the time that the Scientific Review Council reviews the candidate for a recruitment award is not eligible for a recruitment award, as an investment by CPRIT is obviously not necessary. No award is final until approved by the Oversight Committee at a public meeting. However, in recognition of the timeline involved with recruiting highly sought-after candidates who are often considering multiple offers, CPRIT's Academic Research program staff will notify the nominating

institution of the Scientific Review Council's review decision following the Scientific Review Council meeting. If a position is offered to the candidate during the period following the Scientific Review Council's review decision but prior to the Oversight Committee's final approval, the institution does so at its own risk. There is no guarantee that the recruitment award will be approved by the Oversight Committee.

- The candidate must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent, **and reside in Texas for the duration of the appointment.** The candidate must devote at least 70% time to research activities. Candidates whose major responsibilities are clinical care, teaching, or administration are not eligible.
- At the time of the application, the candidate must **not** hold an appointment at the rank of assistant professor or above (or equivalent) at an accredited academic institution, research institution, industry, government agency, or private foundation. Candidates holding non-tenure-track appointments at the rank of assistant professor are **not** eligible for this award. Examples of such appointments include research assistant professor, adjunct research assistant professor, assistant professor (non-tenure track).
- The candidate may or may not reside in Texas at the time the application is submitted and may be nominated for a faculty position at the Texas institution where he or she is completing postdoctoral training or at another Texas institution.
- Applications nominating a candidate for a faculty position at the Texas institution where he or she is completing postdoctoral training that do not clearly demonstrate a subsequent career pathway to independence for the candidate will not be looked upon with favor.
- Successful candidates will be offered tenure-track academic positions at the rank of assistant professor.
- An applicant is eligible to receive a grant award only if the applicant certifies that the applicant institution or organization, including the nominator, any senior member or key personnel listed on the grant application, or any officer or director of the grant applicant's institution or organization (or any person related to 1 or more of these individuals within the second degree of consanguinity or affinity), has not made and will not make a contribution to CPRIT or to any foundation specifically created to benefit CPRIT.
- An applicant is not eligible to receive a CPRIT grant award if the applicant nominator, any senior member or key personnel listed on the grant application, or any officer or

director of the grant applicant's institution or organization is related to a CPRIT Oversight Committee member.

- The applicant must report whether the applicant institution or organization, the nominator, or other individuals who contribute to the execution of the proposed project in a substantive, measurable way, whether or not the individuals will receive salary or compensation under the grant award, are currently ineligible to receive federal grant funds or have had a grant terminated for cause within 5 years prior to the submission date of the grant application.

CPRIT grants will be awarded by contract to successful applicants. Certain contractual requirements are mandated by Texas law or by administrative rules. Although applicants need not demonstrate the ability to comply with these contractual requirements at the time the application is submitted, applicants should make themselves aware of these standards before submitting a grant application. Significant issues addressed by the CPRIT contract are listed in [section 11](#) and [section 12](#). All statutory provisions and relevant administrative rules can be found at www.cprit.texas.gov.

7. RESUBMISSION POLICY

Resubmissions will not be accepted for the Recruitment of First-Time, Tenure-Track Faculty Members award mechanism. Any nomination for the Recruitment of First-Time, Tenure-Track Faculty Members that was previously submitted to CPRIT and reviewed but was not recommended for funding may not be resubmitted. If a nomination was administratively rejected prior to review, it can be resubmitted in the following cycles.

8. RESPONDING TO THIS RFA

8.1. Application Submission Guidelines

Applications must be submitted via the CPRIT Application Receipt System (CARS) (<https://CPRITGrants.org>). **Only applications submitted through this portal will be considered eligible for evaluation.** The applicant is eligible solely for the grant mechanism specified by the RFA under which the grant application is submitted. Candidates must be nominated by the institution's president, provost, vice president for research, or appropriate dean.

The individual submitting the application (Nominator) must create a user account in the system (which includes the Nominator’s credentials and email address) to start and submit an application. Furthermore, the Application Signing Official, who is the person authorized to sign and submit the application for the organization, and the Grants Contract/Office of Sponsored Projects Official, who is the individual who will manage the grant contract if an award is made, also must create a user account in CARS.

Dependent upon available funding, applications will be accepted within a 6-review-cycle schedule throughout FY23, as displayed in the table below.

Review Cycle	Open date	Close date
23.1	6/21/2022	8/20/2022
23.2	8/23/2022	10/20/2022
23.3	10/21/2022	12/20/2022
23.4	12/21/2022	2/20/2023
23.5	2/21/2023	4/20/2023
23.6	4/21/2023	6/20/2023

In order to manage the timely review of nominations, it is anticipated that applications submitted by 11:59 PM central time on the closing day of each cycle (see table above for closing date of each cycle) will be reviewed by the 15th day of the following month. For an application to be considered for review during the cycle, that application must be submitted on or before 11:59 PM central time. In the event that the closing date falls on Saturday or Sunday, applications may be submitted on or before 11:59 PM central time the following Monday. CPRIT will not extend the submission deadline. **Submission of an application is considered an acceptance of the terms and conditions of the RFA.**

8.2. Application Components

Applicants are advised to follow all instructions to ensure accurate and complete submission of all components of the application. For details, please refer to the Instructions for Applicants (IFA) document that will be available when the application receipt system opens. Submissions that are missing 1 or more components or do not meet the eligibility requirements listed in [section 6](#) will be administratively withdrawn without review.

8.2.1. Summary of Nomination (2,000 characters)

Provide a brief summary of the nomination. Include the candidate's name, organization from which the candidate is being recruited, and also the department and/or entity within the nominator's organization where the candidate will hold the faculty position.

8.2.2. Institutional Commitment (3 pages)

CPRIT recruitment awards are intended to provide institutions with a competitive edge in recruiting the world's best talent in cancer research to Texas. The funds provided by CPRIT for the recruitment of a first-time, tenure-track faculty must therefore be complemented by a strongly documented institutional commitment to the candidate's career development that includes financial commitments that are in addition to the CPRIT award.

The following guidelines should be followed when documenting the institutional commitment to the candidate:

- The institutional commitment should be clearly documented in the form of a letter signed by the applicant institution's president, provost, or appropriate dean and include the amount and sources of salary support and all additional financial support that will be available to the candidate's research program through the course of the CPRIT award. The financial commitments made to the candidate by the recruiting institution are required to be equal to or exceed 50% of the proposed CPRIT award across the course of the CPRIT award.
- The institutional commitment letter must include the following statement regarding the institution's financial commitment required to meet the 50% match.
 - This institutional financial commitment will not be offset by funds from a career transition award (K99/R00) or an investigator-initiated award received by the candidate. If an award dictates that such funds must be used for salary, the corresponding amount of institutional funds committed to pay the candidate's salary will be redirected to allow the candidate to use them for program support.
- Institutional commitment as described above must be presented in a table (example below) that clearly identifies the salary amount, sources of salary, and any additional research support from institutional sources over the course of the CPRIT award. Sources

of support for the candidate’s full salary, including summer salary, for the duration of the award must be documented. If the candidate is expected to provide salary support from grants during the award period, the institutional commitment must identify the source for salary support in the event grant support is not available. Note that a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the candidate.

- Include a brief job description for the candidate should recruitment be successful.
- Describe the institutional environment and any professional commitments to the candidate including, but not limited to, dedicated personnel, access to students, space assignment, and access to shared equipment, and discuss all other agreements between the institution and the candidate.
- Institutions may provide additional information in support of a candidate’s research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a candidate’s cancer research. This additional information is highly encouraged when proposing a candidate with exceptional expertise and/or talent that can be directed to cancer research such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research.
- Note that Texas law allows an institution of higher learning to use its federal indirect cost rate credit to comply with the requirement to demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award (see [section 12](#)). However, a federal indirect cost rate credit cannot be used to demonstrate an institutional commitment to the candidate.

Example of an acceptable Institutional Commitment table:

Candidate’s Name, Institutional Commitments					
	Year 1	Year 2	Year 3	Year 4	Year 5
Salary/Benefits					
Research Support					
Administrative Support					
Moving Expenses					

Total =

Note: CPRIT acknowledges that the institutional commitments by category may change during the course of the award; however, the total financial commitment to the candidate must remain equal to or greater than 50% of the CPRIT award.

8.2.3. Letter of Support from Department Chair (up to 2 pages)

Provide the letter of support from and signed by the chair of the department to which the candidate is being recruited. The following information should be included in the letter:

Recruitment Activities: The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this candidate. CPRIT is committed to increasing the life sciences infrastructure in Texas via the recruitment of exceptional cancer researchers, as well as expanding research resources. The letter should provide a description of the recruitment activities, strategies, and priorities that have led to the nomination of this candidate. Provide the necessary context by describing the institution’s vision for the cancer programs, how the work of the nominee contributes to achieving these goals—including impact on diversity, equity, and inclusion, if applicable—and the expected impact of the recruitment on the institution (or department) and the burden of cancer in Texas (if applicable).

Caliber of Candidate: The letter should include a description of the caliber of the candidate and justification of the nomination of the candidate by the institution. CPRIT recognizes that there is variability in the metrics of impact applicable across the continuum of cancer research. For example, in some disciplines, research findings—although highly impactful on the field—are less likely to be published in the highest ranked journals, ie, *Science*, *Cell*, or *Nature* series. Thus, it is incumbent on the institution to describe the impact of a nominee’s work, including paradigm-shifting, practice-changing, or influence on public policy, population health behavior, or cancer disparities.

Description of Candidate Duties and Certification of 70% Time Commitment to Research:

While scholars may engage in direct patient care activities and/or have some administrative or teaching duties, at least 70% of the candidate’s time must be available for research. Breach of this requirement will constitute grounds for discontinuation of funding. The certification that 70% time will be spent on research must be included.

The letter of support from the department chair must also do the following:

1. Describe how the candidate will be independent and autonomous in developing his or her research program at the institution.
2. Present a plan for mentoring that includes the design and execution of a faculty career development plan for the candidate.

8.2.4. Curriculum Vitae (CV)

Provide a complete CV and list of publications for the candidate. Only articles that have been published or that have been accepted for publication (“in press”) should be cited.

8.2.5. Summary of Goals and Objectives (2,000 characters)

List goals and objectives to be achieved during this award. **This section must be completed by the candidate.**

8.2.6. Research (4 pages)

Summarize the key elements of the candidate’s research accomplishments and provide an overview of the proposed research by outlining the background and rationale, hypotheses and aims, strategies, goals, and projected impact of the focus of the research program. Highlight the innovative aspects of this effort and place it into context with regard to what pressing problem in cancer will be addressed. **This section of the application must be prepared by the candidate. References cited in this section should be included in the Publications/References section (see 8.2.7).**

Candidates for CPRIT Scholar Awards must include the following signed statement at the end of this section. **Applications that do not contain this signed statement will be returned without review.**

“I understand that I do not need to have made a commitment to *<nominating institution>* before this application has been submitted. However, I also understand that only 1 Texas institution may nominate me for a CPRIT Recruitment Award, and this is the nomination that I have endorsed. I understand that requests to change the recruiting institution during the recruitment process are not allowed after the application is submitted to CPRIT.”

8.2.7. Publications/References (1 page)

Provide a concise and relevant list of publications/references cited for the application. Any appropriate citation format is acceptable; official journal abbreviations should be used.

8.2.8. Research Collaboration/Synergy Plan (2 pages)

Institutions may provide additional information in support of a candidate's research plan to demonstrate how the institutional commitment through development of strategic collaborations will foster a candidate's cancer research. This additional information is highly encouraged when proposing a candidate with exceptional expertise and/or talent that can be directed to cancer research, such as a computational biologist, chemist, etc, whose prior experience has not been directly focused on cancer research. Biographical sketches of collaborators established in the research collaborative plan must be uploaded as part of the application. This will be in addition to the 2-page synergy plan (see IFA).

8.2.9. Publications

Provide the 3 most significant publications that have resulted from the candidate's research efforts. Publications should be uploaded as PDFs of full-text articles. Only articles that have been published or that have been accepted for publication ("in press") should be submitted.

8.2.10. Timeline (1 page)

Provide a general outline of anticipated major award outcomes to be tracked. Timelines will be reviewed during the evaluation of annual progress reports. If the application is approved for funding, this section will be included in the award contract. Applicants are advised not to include information that they consider confidential or proprietary when preparing this section.

8.2.11. Current and Pending Support

State the funding source, duration, and title of all current and pending research support held by the candidate. If the candidate has no current or pending funding, a document stating this must be submitted. Refer to the sample current and pending support document located in [*Current Funding Opportunities*](#) for Academic Research in CARS.

8.2.12. Letters of Recommendation

Provide 3 letters of recommendation from individuals who are in a position to detail the candidate's academic and scientific research accomplishments, potential for high-impact research, and ability to make a significant contribution to the field of cancer research.

8.2.13. Research Environment (1 page)

Clearly and concisely describe the research environment available to support the candidate's research program, including core facilities, training programs, and collaborative opportunities.

8.2.14. Descriptive Biography (Up to 2 pages)

Provide a brief descriptive biography of the candidate, including his or her accomplishments, education and training, professional experience, awards and honors, publications relevant to cancer research, and a brief overview of the candidate's goals if selected to receive the award.

This section of the application must be prepared by the candidate. If the application is approved for funding, this section will be made publicly available on CPRIT's website.

Candidates are advised not to include information that they consider confidential or proprietary when preparing this section.

Applications that are missing 1 or more of these components; exceed the specified page, word, or budget limits; or do not meet the eligibility requirements listed above will be administratively withdrawn without review.

9. APPLICATION REVIEW

9.1. Review Process

All eligible applications will be evaluated and scored by the CPRIT Scientific Review Council using the criteria listed in this RFA. Applications may be submitted continuously in response to this RFA but will generally be reviewed on a cycle of 6 review periods per year by the CPRIT Scientific Review Council. Council members may seek additional ad hoc evaluations of candidates. Scientific Review Council members will review applications and provide an individual Overall Evaluation Score that conveys the members' recommendation related to the proposed recruitment. Applications recommended by the Council will be forwarded to the CPRIT Program Integration Committee (PIC) for review, prioritization, and recommendation to

the CPRIT Oversight Committee for approval and funding. Approval is based on an application receiving a positive vote from at least two-thirds of the members of the Oversight Committee. The review process is described more fully in CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

The decision of the Scientific Review Council not to recommend an application is final, and such applications may not be resubmitted for a recruitment award. Notification of review decisions is sent to the nominator.

9.1.1. Confidentiality of Review

Each stage of application review is conducted confidentially, and all CPRIT Scientific Review Council members, PIC members, CPRIT employees, and Oversight Committee members with access to grant application information are required to sign nondisclosure statements regarding the contents of the applications. All technological and scientific information included in the application is protected from public disclosure pursuant to Health and Safety Code §102.262(b).

Individuals directly involved with the review process operate under strict conflict-of-interest prohibitions. All CPRIT Scientific Review Council members are non-Texas residents.

By submitting a grant application, the applicant agrees and understands that the only basis for reconsideration of a grant application is limited to an undisclosed conflict of interest as set forth in CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

Communication regarding the substance of a pending application is prohibited between the grant applicant (or someone on the grant applicant's behalf) and the following individuals: an Oversight Committee member, a PIC member, or a Scientific Review Council member.

Applicants should note that the CPRIT PIC comprises the CPRIT Chief Executive Officer, the Chief Scientific Officer, the Chief Prevention and Communications Officer, the Chief Product Development Officer, and the Commissioner of the Department of State Health Services. The prohibition on communication begins on the first day that grant applications for the particular grant mechanism are accepted by CPRIT and extends until the grant applicant receives notice regarding a final decision on the grant application. Intentional, serious, or frequent violations of

this rule may result in the disqualification of the grant applicant from further consideration for a grant award.

9.2. Review Criteria

Applications will be assessed based on evaluation of the quality of the candidate and his or her potential for continued superb performance as a cancer researcher. **Also, of critical importance is the strength of the institutional commitment to the candidate. Recruitment efforts are not likely to be successful unless there is a strong commitment from both CPRIT and the host institution.** It is not necessary that a candidate agree to accept the recruitment offer at the time an application is submitted. However, applicant institutions should have a reasonable expectation that the recruitment will be successful if an award is granted by CPRIT.

Review criteria will focus on the overall impression of the candidate, his or her proposed research program, and his or her long-term potential for contributions to and impact on the field of cancer research. Questions to be considered by the reviewers are as follows:

Quality of the Candidate: Has the candidate demonstrated academic excellence? Has the candidate received excellent predoctoral and postdoctoral training? Does the candidate show exceptional potential for achieving future impact on basic, translational, clinical, or population-based cancer research in the future? Has the candidate demonstrated a commitment to cancer research? Has the candidate demonstrated independence or the potential for independence?

Scientific Merit of Proposed Research: Is the research plan comprehensive and well thought out? Does the proposed research program demonstrate innovation, creativity, and feasibility? Will it have a significant impact on the field of cancer research? Will the proposed research generate preliminary data that can be used for the preparation of applications for future independent research project grants?

Relevance of Candidate's Research: Is the proposed research likely to have a significant impact on reducing the burden of cancer in the near term or address unique aspects of the burden of cancer in Texas? Does the research contribute to basic, translational, clinical, or population-based cancer research?

Letters of Recommendation: Do the letters of recommendation detail the candidate’s academic and clinical research accomplishments, potential for high-impact research, and ability to make a significant contribution to the field of cancer research?

Research Environment: Does the institution have the necessary facilities, expertise, and resources to support the candidate’s research? Is there evidence of strong institutional support? Will the candidate be free of major administrative/clinical responsibilities so that he or she can focus on growing his or her research? Has the institution identified a mentor who will design and execute a faculty career development plan for the candidate?

10. KEY DATES

RFA

RFA Release June 21, 2022

Application Receipt and Review Timeline

Cycle	Application Receipt Date	Application Closing Date	Anticipated Application Review
23.1	6/21/2022	8/20/2022	9/15/2022
23.2	8/23/2022	10/20/2022	11/10/2022
23.3	10/21/2022	12/20/2022	1/12/2023
23.4	12/21/2022	2/20/2023	3/16/2023
23.5	2/21/2023	4/20/2023	5/11/2023
23.6	4/21/2023	6/20/2023	7/13/2023

11. AWARD ADMINISTRATION

Texas law requires that CPRIT grant awards be made by contract between the applicant and CPRIT. CPRIT grant awards are made to institutions or organizations, not to individuals. Awards made under this RFA are not transferable to another institution. Award contract negotiation and execution will commence once the CPRIT Oversight Committee has approved an application for a grant award. CPRIT may require, as a condition of receiving a grant award, that the grant recipient use CPRIT’s electronic Grant Management System to exchange, execute, and verify legally binding grant contract documents and grant award reports. Such use shall be in accordance with CPRIT’s electronic signature policy as set forth in Texas [Administrative Code, Title 25, Chapters 701 to 703.](#)

Texas law specifies several components that must be addressed by the award contract, including needed compliance and assurance documentation, budgetary review, progress and fiscal monitoring, and terms relating to revenue sharing and intellectual property rights. These contract provisions are specified in CPRIT's Administrative Rules, which are available at www.cprit.texas.gov.

Applicants are advised to review CPRIT's Administrative Rules related to contractual requirements associated with CPRIT grant awards and limitations related to the use of CPRIT grant awards as set forth in Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

Prior to disbursement of grant award funds, the grant recipient organization must demonstrate that it has adopted and enforces a tobacco-free workplace policy consistent with the requirements set forth in CPRIT's Administrative Rules, Texas [Administrative Code, Title 25, Chapters 701 to 703](#).

CPRIT requires award recipients to submit an annual progress report. These reports summarize the progress made toward the research goals and address plans for the upcoming year. In addition, fiscal reporting, human studies reporting, and vertebrate animal use reporting will be required as appropriate. CPRIT requires funding acknowledgement to include the award grant ID on all print and visual materials that are funded in whole or in part by CPRIT grants. Examples of print and visual materials include, but are not limited to, publications, brochures, pamphlets, project websites, videos and media materials. Grantees must have written approval from CPRIT prior to the purchase of any equipment. If the equipment is clearly defined in the grantee's budget submitted with the initiating award requirements, then approval of the grant award constitutes "prior approval" for the purchase. Unless prohibited by policy, the institution is also expected to bestow on the newly recruited faculty member the prestigious title of "CPRIT Scholar in Cancer Research," and the faculty member should be strongly encouraged to use this title on letterhead, business cards, publications, and other appropriate documents. The title is to be retained as long as the individual remains in Texas.

Continuation of funding is contingent upon the timely receipt of these reports. Failure to provide timely and complete reports may waive reimbursement of grant award costs and may result in the termination of the award contract. Forms and instructions will be made available at www.cprit.texas.gov.

12. REQUIREMENT TO DEMONSTRATE AVAILABLE FUNDS

Texas law requires that prior to disbursement of CPRIT grant funds, the award recipient must demonstrate that it has an amount of funds equal to one-half of the CPRIT funding dedicated to the research that is the subject of the award. The demonstration of available matching funds must be made at the time the award contract is executed and annually thereafter, not when the application is submitted. Grant applicants are advised to consult CPRIT's Administrative Rules, [Texas Administrative Code, Title 25, Chapters 701 to 703](#), for specific requirements regarding the demonstration of available funding.

13. CONTACT INFORMATION

13.1. Helpdesk

Helpdesk support is available for questions regarding user registration and online submission of applications. Queries submitted via email will be answered within 1 business day. Helpdesk staff members are not in a position to answer questions regarding scientific aspects of applications.

Hours of operation: Monday through Friday, 8 AM to 6 PM central time

Tel: 866-941-7146

Email: Help@CPRITGrants.org

13.2. Scientific and Programmatic Questions

Questions regarding the CPRIT Program, including questions regarding this or other funding opportunities, should be directed to the CPRIT Director of Academic Research.

Email: Research@cprit.texas.gov

Website: www.cprit.texas.gov

Third Party Observer Reports



Cancer Prevention and Research Institute of Texas (CPRIT)

23.2 Scientific Review Council Recruitment Review

(23.2 SRC REC)

Observation Report

Report No. 2022-11-10 23.2_SRC_REC
Program Name: Academic Research
Panel Name: 23.2 Scientific Review Council Recruitment Review (23.2_SRC_REC)
Panel Date: November 10, 2022
Report Date: November 11, 2022

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.2 Scientific Review Council Recruitment Review (23.2_SRC_REC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on November 10, 2022.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

Two (2) BFS independent observers participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Three (3) applications were discussed
- Panelists: One (1) panel chair, and five (5) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Two (2)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.


CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CMRA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney



Cancer Prevention and Research Institute of Texas (CPRIT)
23.3 Academic Research - Recruitment Review Panel-23.3
(23.3 SRC REC)
Observation Report

Report No. 2023-01-12 23.3_SRC REC
Program Name: Academic Research
Panel Name: 23.3 Academic Research - Recruitment Review Panel-23.3 (23.3_SRC REC)
Panel Date: January 12, 2023
Report Date: January 18, 2023

BACKGROUND

As part of CPRIT's ongoing emphasis on continuous improvement in its grants review/management processes and to ensure panel discussions are limited to the merits of the applications and focused on established evaluation criteria, CPRIT continues to engage a third-party independent observer at all in-person and telephone conference peer review meetings. CPRIT has authorized an independent party to function as a neutral third-party observer and has engaged Business and Financial Management Solutions, LLC (BFS) for that purpose.

INTRODUCTION

The subject of this report is the 23.3 Academic Research - Recruitment Review Panel-23.3 (23.3_SRC REC) meeting. The meeting was chaired by Richard Kolodner and conducted via videoconference on January 12, 2023.

PANEL OBSERVATION OBJECTIVES AND SCOPE

The third-party observation engagement was limited to observation of the following objectives:

- CPRIT's established procedure for panelists who have declared a conflict of interest is followed during the meeting (e.g., reviewers hang up from the teleconference or leave the room when an application with which there is a conflict is discussed);
- CPRIT program staff participation at meetings is limited to offering general points of information;

- CPRIT program staff do not engage in the panel's discussion on the merits of applications; and
- The panel focused on the established scoring criteria and/or making recommendations.

SUMMARY OF OBSERVATION RESULTS

One (1) BFS independent observer participated in observing the meeting. GDIT, CPRIT's contracted third-party grant application administrator, facilitated the meeting.

The independent observers noted the following during the meeting:

- Number (#) of applications: Four (4) applications were discussed
- Panelists: One (1) panel chair, and seven (7) expert reviewers
- Panelists' discussions were limited to the application evaluation criteria
- GDIT staff employees: Two (2)
- GDIT staff did not participate in discussions concerning the merits of applications
- CPRIT staff employees: Three (3)
- CPRIT program staff participation was limited to reviewing and clarifying policies, and answering procedural questions

There were no (0) Conflicts of Interest (COIs) identified prior to and/or during the meeting.

A list of all attendees, a sign-in log and informational materials were provided by GDIT to aid in the observation of the COI procedures and objectives. A completed attendance sheet and sign-in log was provided following the meeting to confirm all attendees and COIs.

CONCLUSION

In conclusion, we observed that the activities of the meeting identified herein were limited to the identified objectives noted earlier in this report. Our observations are limited to the information made available.

BFS's third-party observation services did not include an evaluation of the appropriateness or rigor of the review panel's discussions of scientific, technical, or programmatic aspects of the applications. We were not engaged to perform an audit, the objective of which would be the expression of an opinion on the accuracy of voting and scoring. Accordingly, we will not express such an opinion. Had we performed additional procedures; other matters might have come to our attention that would have been reported to you.

This report is intended solely for the information and use of CPRIT, its management and its Oversight Committee members. This report is not intended to be and should not be used by anyone other than these specified parties.

With best regards,

A handwritten signature in blue ink, appearing to be 'Mara Ash', written over the text 'With best regards,'.

Mara Ash, CIA, CGAP, CGFM, CRMA, CICA
Senior Partner
Business & Financial Management Solutions, LLC

cc: Vince Burgess, Chief Compliance Officer
Cameron Eckel, Attorney

Conflicts of Interest Disclosure

Conflicts of Interest Disclosure

CPRIT Academic Research Recruitment Cycles 23.2-23.3

Awards Announced at the February 15, 2023, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment Cycles 23.2 through 23.3 include: *Recruitment of Established Investigators* and *Recruitment of First-Time, Tenure-Track Faculty Members*.

All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC.

COI information used for this table was collected by General Dynamics Information Technology, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Principal Investigator	Organization	Conflict Noted by Reviewer
Applications considered by the PIC and Oversight Committee:			
No reported COIs.			
Applications not considered by the PIC or Oversight Committee:			
No reported COIs.			

De-Identified Overall Evaluation Scores

Recruitment of First-Time, Tenure-Track Faculty Members

Academic Research Recruitment cycles 23.2-23.3

Application ID	Final Overall Evaluation Score
RR230012*	1.0
RR230017*	1.5
RR230019*	1.6
RR230015*	2.8

* Recommended for funding

Final Overall Evaluation Scores and Rank Order Scores

Ludwig Institute for
Cancer Research Ltd

Richard D. Kolodner
Ph.D.

Head, Laboratory of
Cancer Genetics
San Diego Branch

Distinguished Professor of
Cellular & Molecular
Medicine, University of
California San Diego School
of Medicine

rkolodner@health.ucsd.edu

San Diego Branch

UC San Diego School of
Medicine
CMM-East / Rm 3058
9500 Gilman Dr - MC 0660
La Jolla, CA 92093-0660

T 858 534 7804
F 858 534 7750

January 16, 2023

Dr. Mahendra C. Patel
Oversight Committee Presiding Officer
Cancer Prevention and Research Institute of Texas
Via email to curingkids@gmail.com

Mr. Wayne R. Roberts
Chief Executive Officer
Cancer Prevention and Research Institute of Texas
Via email to wroberts@cprit.texas.gov

Dear Dr. Patel and Mr. Roberts,

The Scientific Review Council (SRC) is pleased to submit this list of recruitment grant recommendations. The SRC met on on November 6, 2022 (Cycle 23.2) and January 12, 2023 (Cycle 23.3) to review and finalize applications submitted to CPRIT under the Recruitment of Established Investigator and Recruitment of First-Time, Tenure Track Faculty Members RFA mechanisms.

The SRC recommends six applications, which are included on the attached list. The recommended funding amounts and the overall evaluation scores are stated for the grant applications. There were no recommended changes to funding amounts, goals, timelines, or project objectives requested. The total amount for the applications recommended is \$19,999,977

The recommendation meets the SRC's standards for funding. These include selecting candidates at all career levels that have demonstrated academic excellence, innovation, excellent training, commitment to cancer research and exceptional potential for achieving future impact in basic, translational, population based or clinical research.

Sincerely yours,



Richard D. Kolodner, Ph.D.
Chair, CPRIT Scientific Review Council

Rank	ID	Mechanism	Candidate	Organization	Budget	Overall Scores
1	RR230019	RFTFM	Lu Wang	The University of Texas Health Science Center at San Antonio	\$2,000,000	1.6
2	RR230012	RFTFM	Kenneth Hu	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.0
3	RR230017	RFTFM	Joe Nassour	The University of Texas M. D. Anderson Cancer Center	\$2,000,000	1.5
4	RR230020	REI	Hongfang Liu	The University of Texas Health Science Center at Houston	\$6,000,000	2.0
5	RR230018	REI	Rudi Fasan	The University of Texas at Dallas	\$6,000,000	2.7
6	RR230015	RFTFM	Ewan McRae	The Methodist Hospital Research Institute	\$1,999,977	2.8

RFTFM- Recruitment of First-Time Tenure Track Faculty

REI- Recruitment of Established Investigators

CEO Affidavits



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP230002
Dissemination of CPRIT-Funded
Cancer Control Interventions

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Dissemination of CPRIT-Funded Cancer Control Interventions* Request for Applications (RFA). CPRIT received six applications in response to this RFA, including one withdrawn application and one application on which the Prevention Review Council (PRC) took no action. This application was assigned to the PRC for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:33 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Dissemination of CPRIT-Funded Cancer Control Interventions
APPLICATION ID: PP230002
APPLICATION TITLE: Taking Texas Tobacco Free: Dissemination to and Implementation within Lung Cancer Screening Programs
APPLICANT NAME: Reitzel, Lorraine R
ORGANIZATION: University of Houston
PANEL NAME: 23.1_Prevention DI

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	05/04/2022	01/16/2023
	RFA published in Texas.gov eGrants	05/06/2022	01/16/2023
	CPRIT Application Receipt System (CARS) opened	06/02/2022	01/16/2023
	CPRIT Application Receipt System (CARS) closed	08/31/2022	01/16/2023
	Date application submitted	08/02/2022	01/16/2023
	Method of submission	CARS	01/16/2023
	Within receipt period	YES	01/16/2023
	Request for extension to submit application after CARS closed	N/A	01/16/2023
	Request for extension for late application submission accepted	N/A	01/16/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/16/2023
Assigned to primary reviewers		10/28/2022	01/16/2023
Applicant notified of review panel assignment		N/A	01/17/2023
Primary Reviewer 1 COI signed		10/22/2022	01/16/2023
Primary Reviewer 2 COI signed		10/21/2022	01/16/2023
Primary Reviewer 3 COI signed		N/A	01/16/2023
Primary Reviewer 4 COI signed		N/A	01/16/2023
Peer Review Meeting	Primary Reviewer 1 critique submitted	12/04/2022	01/16/2023
	Primary Reviewer 2 critique submitted	11/04/2022	01/16/2023
	Primary Reviewer 3 critique submitted	N/A	01/16/2023
	Primary Reviewer 4 critique submitted	N/A	01/16/2023
	COI indicated by non-primary reviewer	NONE	01/16/2023
	COI recused from participation	N/A	01/16/2023
	Discussed at Peer Review Meeting	YES	01/16/2023
	Peer Review Meeting	01/06/2023	01/16/2023
	Post review statements signed	01/06/2023	01/16/2023
	Third Party Observer Report	01/12/2023	01/17/2023
	Score report delivered to CPO	01/10/2023	01/16/2023
Recommended for PRC review	YES	01/16/2023	
Final PRC Recommendation	COI indicated by PRC member	NONE	01/16/2023
	COI recused from participation	N/A	01/16/2023
	PRC Meeting	01/13/2023	01/17/2023
	Third Party Observer Report	01/19/2023	01/20/2023
	Recommended for grant award	YES	01/16/2023
	PRC Chair Notification to PIC and OC	01/18/2023	01/18/2023
PIC Review	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
	Recommended for grant award	YES	02/01/2023
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP230013
Cancer Screening and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Cancer Screening and Early Detection* Request for Applications (RFA). CPRIT received nine applications in response to this RFA, including two withdrawn applications and one application on which the Prevention Review Council took no action. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Cancer Screening and Early Detection
APPLICATION ID: PP230013
APPLICATION TITLE: Community Expansion and Re-engagement for Breast Cancer Screening and Patient Navigation
APPLICANT NAME: Argenbright, Keith E
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 23.1_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	05/04/2022	01/17/2023
	RFA published in Texas.gov eGrants	05/06/2022	01/17/2023
	CPRIT Application Receipt System (CARS) opened	06/02/2022	01/17/2023
	CPRIT Application Receipt System (CARS) closed	08/31/2022	01/17/2023
	Date application submitted	08/30/2022	01/17/2023
	Method of submission	CARS	01/17/2023
	Within receipt period	YES	01/17/2023
	Request for extension to submit application after CARS closed	N/A	01/17/2023
	Request for extension for late application submission accepted	N/A	01/17/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/17/2023
Assigned to primary reviewers		09/29/2022	01/17/2023
Applicant notified of review panel assignment		09/28/2022	01/17/2023
Primary Reviewer 1 COI signed		09/21/2022	01/17/2023
Primary (Advocate) Reviewer 2 COI signed		10/11/2022	01/17/2023
Primary Reviewer 3 COI signed		09/20/2022	01/17/2023
Primary Reviewer 4 COI signed		09/20/2022	01/17/2023
Peer Review Meeting		Primary Reviewer 1 critique submitted	11/14/2022
	Primary (Advocate) Reviewer 2 critique submitted	11/20/2022	01/17/2023
	Primary Reviewer 3 critique submitted	11/27/2022	01/17/2023
	Primary Reviewer 4 critique submitted	11/21/2022	01/17/2023
	COI indicated by non-primary reviewer	NONE	01/17/2023
	COI recused from participation	N/A	01/17/2023
	Discussed at Peer Review Meeting	YES	01/17/2023
	Peer Review Meeting	12/05/2022	01/17/2023
	Post review statements signed	12/06/2022	01/17/2023
	Third Party Observer Report	12/13/2022	01/17/2023
	Score report delivered to CPO	12/14/2022	01/17/2023
	Recommended for PRC review	YES	01/17/2023
	Final PRC Recommendation	COI indicated by PRC member	NONE
COI recused from participation		N/A	01/17/2023
PRC Meeting		01/13/2023	01/17/2023
Third Party Observer Report		01/19/2023	01/20/2023
Recommended for grant award		YES	01/17/2023
PRC Chair Notification to PIC and OC		01/18/2023	01/18/2023
PIC Review	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
	Recommended for grant award	YES	02/01/2023
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP230018
Primary Prevention of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Primary Prevention of Cancer* Request for Applications (RFA). CPRIT received 13 applications in response to this RFA, including one application that was withdrawn. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Primary Prevention of Cancer
APPLICATION ID: PP230018
APPLICATION TITLE: Implementation and Evaluation of an Evidence-Based Multilevel Lifestyle Intervention for Underserved/Rural Populations in South Texas: Tu Salud ¡Si Cuenta!
APPLICANT NAME: Reininger, Belinda
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 23.1_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	05/04/2022	01/17/2023
	RFA published in Texas.gov eGrants	05/06/2022	01/17/2023
	CPRIT Application Receipt System (CARS) opened	06/02/2022	01/17/2023
	CPRIT Application Receipt System (CARS) closed	08/31/2022	01/17/2023
	Date application submitted	08/31/2022	01/17/2023
	Method of submission	CARS	01/17/2023
	Within receipt period	YES	01/17/2023
	Request for extension to submit application after CARS closed	N/A	01/17/2023
	Request for extension for late application submission accepted	N/A	01/17/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/17/2023
Assigned to primary reviewers		09/29/2022	01/17/2023
Applicant notified of review panel assignment		09/28/2022	01/17/2023
Primary Reviewer 1 COI signed		09/23/2022	01/17/2023
Primary (Advocate) Reviewer 2 COI signed		09/23/2022	01/17/2023
Primary Reviewer 3 COI signed		09/20/2022	01/17/2023
Primary Reviewer 4 COI signed		09/20/2022	01/17/2023
Peer Review Meeting		Primary Reviewer 1 critique submitted	11/29/2022
	Primary (Advocate) Reviewer 2 critique submitted	11/28/2022	01/17/2023
	Primary Reviewer 3 critique submitted	11/28/2022	01/17/2023
	Primary Reviewer 4 critique submitted	11/28/2022	01/17/2023
	COI indicated by non-primary reviewer	NONE	01/17/2023
	COI recused from participation	N/A	01/17/2023
	Discussed at Peer Review Meeting	YES	01/17/2023
	Peer Review Meeting	12/05/2022	01/17/2023
	Post review statements signed	12/06/2022	01/17/2023
	Third Party Observer Report	12/13/2022	01/17/2023
	Score report delivered to CPO	12/14/2022	01/17/2023
	Recommended for PRC review	YES	01/17/2023
	Final PRC Recommendation	COI indicated by PRC member	NONE
COI recused from participation		N/A	01/17/2023
PRC Meeting		01/13/2023	01/17/2023
Third Party Observer Report		01/19/2023	01/20/2023
Recommended for grant award		YES	01/17/2023
PIC Review	PRC Chair Notification to PIC and OC	01/18/2023	01/18/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP230033
Dissemination of CPRIT-Funded
Cancer Control Interventions

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Dissemination of CPRIT-Funded Cancer Control Interventions* Request for Applications (RFA). CPRIT received six applications in response to this RFA, including one withdrawn application and one application on which the Prevention Review Council (PRC) took no action. This application was assigned to the PRC for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Dissemination of CPRIT-Funded Cancer Control Interventions
APPLICATION ID: PP230033
APPLICATION TITLE: All for Them Texas: A multifaceted dissemination and implementation approach to increase HPV vaccination
APPLICANT NAME: Cuccaro, Paula
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 23.1_Prevention DI

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	05/04/2022	01/16/2023
	RFA published in Texas.gov eGrants	05/06/2022	01/16/2023
	CPRIT Application Receipt System (CARS) opened	06/02/2022	01/16/2023
	CPRIT Application Receipt System (CARS) closed	08/31/2022	01/16/2023
	Date application submitted	08/31/2022	01/16/2023
	Method of submission	CARS	01/16/2023
	Within receipt period	YES	01/16/2023
	Request for extension to submit application after CARS closed	N/A	01/16/2023
	Request for extension for late application submission accepted	N/A	01/16/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/16/2023
Assigned to primary reviewers		10/28/2022	01/16/2023
Applicant notified of review panel assignment		N/A	01/17/2023
Primary Reviewer 1 COI signed		10/22/2022	01/16/2023
Primary Reviewer 2 COI signed		10/21/2022	01/16/2023
Primary Reviewer 3 COI signed		N/A	01/16/2023
Primary Reviewer 4 COI signed		N/A	01/16/2023
Peer Review Meeting	Primary Reviewer 1 critique submitted	12/15/2022	01/16/2023
	Primary Reviewer 2 critique submitted	12/02/2022	01/16/2023
	Primary Reviewer 3 critique submitted	N/A	01/16/2023
	Primary Reviewer 4 critique submitted	N/A	01/16/2023
	COI indicated by non-primary reviewer	NONE	01/16/2023
	COI recused from participation	N/A	01/16/2023
	Discussed at Peer Review Meeting	YES	01/16/2023
	Peer Review Meeting	01/06/2023	01/16/2023
	Post review statements signed	01/06/2023	01/16/2023
	Third Party Observer Report	01/12/2023	01/17/2023
	Score report delivered to CPO	01/10/2023	01/16/2023
	Recommended for PRC review	YES	01/16/2023
Final PRC Recommendation	COI indicated by PRC member	NONE	01/16/2023
	COI recused from participation	N/A	01/16/2023
	PRC Meeting	01/13/2023	01/17/2023
	Third Party Observer Report	01/19/2023	01/20/2023
	Recommended for grant award	YES	01/16/2023
	PRC Chair Notification to PIC and OC	01/18/2023	01/18/2023
PIC Review	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
	Recommended for grant award	YES	02/01/2023
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP230038
Cancer Screening and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Cancer Screening and Early Detection* Request for Applications (RFA). CPRIT received nine applications in response to this RFA, including two withdrawn applications and one application on which the Prevention Review Council took no action. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
 County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
 the 2 day of February, 2023,
 by WAYNE R. ROBERTS.



 Melanie Richardson
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Cancer Screening and Early Detection
APPLICATION ID: PP230038
APPLICATION TITLE: Salud en Mis Manos (SEMM): An Evidence-Based Breast & Cervical Cancer Early Detection and Prevention Program for Underserved Latinas.
APPLICANT NAME: Savas, Lara S
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 23.1_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	05/04/2022	01/17/2023
	RFA published in Texas.gov eGrants	05/06/2022	01/17/2023
	CPRIT Application Receipt System (CARS) opened	06/02/2022	01/17/2023
	CPRIT Application Receipt System (CARS) closed	08/31/2022	01/17/2023
	Date application submitted	08/31/2022	01/17/2023
	Method of submission	CARS	01/17/2023
	Within receipt period	YES	01/17/2023
	Request for extension to submit application after CARS closed	N/A	01/17/2023
	Request for extension for late application submission accepted	N/A	01/17/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/17/2023
Assigned to primary reviewers		09/29/2022	01/17/2023
Applicant notified of review panel assignment		09/28/2022	01/17/2023
Primary Reviewer 1 COI signed		09/20/2022	01/17/2023
Primary (Advocate) Reviewer 2 COI signed		10/11/2022	01/17/2023
Primary Reviewer 3 COI signed		09/21/2022	01/17/2023
Primary Reviewer 4 COI signed		09/20/2022	01/17/2023
Peer Review Meeting		Primary Reviewer 1 critique submitted	11/25/2022
	Primary (Advocate) Reviewer 2 critique submitted	11/19/2022	01/17/2023
	Primary Reviewer 3 critique submitted	11/13/2022	01/17/2023
	Primary Reviewer 4 critique submitted	11/22/2022	01/17/2023
	COI indicated by non-primary reviewer	NONE	01/17/2023
	COI recused from participation	N/A	01/17/2023
	Discussed at Peer Review Meeting	YES	01/17/2023
	Peer Review Meeting	12/05/2022	01/17/2023
	Post review statements signed	12/06/2022	01/17/2023
	Third Party Observer Report	12/13/2022	01/17/2023
	Score report delivered to CPO	12/14/2022	01/17/2023
	Recommended for PRC review	YES	01/17/2023
	Final PRC Recommendation	COI indicated by PRC member	NONE
COI recused from participation		N/A	01/17/2023
PRC Meeting		01/13/2023	01/17/2023
Third Party Observer Report		01/19/2023	01/20/2023
Recommended for grant award		YES	01/17/2023
PRC Chair Notification to PIC and OC		01/18/2023	01/18/2023
PIC Review	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
	Recommended for grant award	YES	02/01/2023
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP230041
Cancer Screening and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Cancer Screening and Early Detection* Request for Applications (RFA). CPRIT received nine applications in response to this RFA, including two withdrawn applications and one application on which the Prevention Review Council took no action. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Cancer Screening and Early Detection
APPLICATION ID: PP230041
APPLICATION TITLE: PP190052 - Integrated lung cancer screening and tobacco cessation in an urban safety-net system
APPLICANT NAME: Gerber, David E
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 23.1_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	05/04/2022	01/17/2023
	RFA published in Texas.gov eGrants	05/06/2022	01/17/2023
	CPRIT Application Receipt System (CARS) opened	06/02/2022	01/17/2023
	CPRIT Application Receipt System (CARS) closed	08/31/2022	01/17/2023
	Date application submitted	08/30/2022	01/17/2023
	Method of submission	CARS	01/17/2023
	Within receipt period	YES	01/17/2023
	Request for extension to submit application after CARS closed	N/A	01/17/2023
	Request for extension for late application submission accepted	N/A	01/17/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/17/2023
Assigned to primary reviewers		09/29/2022	01/17/2023
Applicant notified of review panel assignment		09/28/2022	01/17/2023
Primary Reviewer 1 COI signed		09/21/2022	01/17/2023
Primary (Advocate) Reviewer 2 COI signed		10/11/2022	01/17/2023
Primary Reviewer 3 COI signed		09/26/2022	01/17/2023
Primary Reviewer 4 COI signed		09/20/2022	01/17/2023
Peer Review Meeting		Primary Reviewer 1 critique submitted	11/08/2022
	Primary (Advocate) Reviewer 2 critique submitted	11/19/2022	01/17/2023
	Primary Reviewer 3 critique submitted	11/09/2022	01/17/2023
	Primary Reviewer 4 critique submitted	11/28/2022	01/17/2023
	COI indicated by non-primary reviewer	NONE	01/17/2023
	COI recused from participation	N/A	01/17/2023
	Discussed at Peer Review Meeting	YES	01/17/2023
	Peer Review Meeting	12/05/2022	01/17/2023
	Post review statements signed	12/06/2022	01/17/2023
	Third Party Observer Report	12/13/2022	01/17/2023
	Score report delivered to CPO	12/14/2022	01/17/2023
	Recommended for PRC review	YES	01/17/2023
	Final PRC Recommendation	COI indicated by PRC member	NONE
COI recused from participation		N/A	01/17/2023
PRC Meeting		01/13/2023	01/17/2023
Third Party Observer Report		01/19/2023	01/20/2023
Recommended for grant award		YES	01/17/2023
PRC Chair Notification to PIC and OC		01/18/2023	01/18/2023
PIC Review	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
	Recommended for grant award	YES	02/01/2023
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP230043
Primary Prevention of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Primary Prevention of Cancer* Request for Applications (RFA). CPRIT received 13 applications in response to this RFA, including one application that was withdrawn. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Primary Prevention of Cancer
APPLICATION ID: PP230043
APPLICATION TITLE: School-based Human Papillomavirus Vaccination Program in the Rio Grande Valley: Continuation and Expansion in Hidalgo, Cameron, and Willacy Counties
APPLICANT NAME: Rodriguez, Ana M
ORGANIZATION: The University of Texas Medical Branch at Galveston
PANEL NAME: 23.1_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	05/04/2022	01/17/2023
	RFA published in Texas.gov eGrants	05/06/2022	01/17/2023
	CPRIT Application Receipt System (CARS) opened	06/02/2022	01/17/2023
	CPRIT Application Receipt System (CARS) closed	08/31/2022	01/17/2023
	Date application submitted	08/29/2022	01/17/2023
	Method of submission	CARS	01/17/2023
	Within receipt period	YES	01/17/2023
	Request for extension to submit application after CARS closed	N/A	01/17/2023
	Request for extension for late application submission accepted	N/A	01/17/2023
	Receipt, Referral, and Assignment	Administrative review notification	09/16/2022
Donation(s) made to CPRIT / foundation		NO	01/17/2023
Assigned to primary reviewers		09/29/2022	01/17/2023
Applicant notified of review panel assignment		09/28/2022	01/17/2023
Primary Reviewer 1 COI signed		09/23/2022	01/17/2023
Primary (Advocate) Reviewer 2 COI signed		09/23/2022	01/17/2023
Primary Reviewer 3 COI signed		09/20/2022	01/17/2023
Primary Reviewer 4 COI signed		09/21/2022	01/17/2023
Peer Review Meeting	Primary Reviewer 1 critique submitted	11/29/2022	01/17/2023
	Primary (Advocate) Reviewer 2 critique submitted	11/28/2022	01/17/2023
	Primary Reviewer 3 critique submitted	11/22/2022	01/17/2023
	Primary Reviewer 4 critique submitted	11/21/2022	01/17/2023
	COI indicated by non-primary reviewer	NONE	01/17/2023
	COI recused from participation	N/A	01/17/2023
	Discussed at Peer Review Meeting	YES	01/17/2023
	Peer Review Meeting	12/05/2022	01/17/2023
	Post review statements signed	12/06/2022	01/17/2023
	Third Party Observer Report	12/13/2022	01/17/2023
	Score report delivered to CPO	12/14/2022	01/17/2023
	Recommended for PRC review	YES	01/17/2023
Final PRC Recommendation	COI indicated by PRC member	NONE	01/17/2023
	COI recused from participation	N/A	01/17/2023
	PRC Meeting	01/13/2023	01/17/2023
	Third Party Observer Report	01/19/2023	01/20/2023
	Recommended for grant award	YES	01/17/2023
PIC Review	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
	Recommended for grant award	YES	02/01/2023
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application PP230046
Cancer Screening and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to the *Cancer Screening and Early Detection* Request for Applications (RFA). CPRIT received nine applications in response to this RFA, including two withdrawn applications and one application on which the Prevention Review Council took no action. This application was assigned to the prevention panel 1 for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Prevention
MECHANISM: Cancer Screening and Early Detection
APPLICATION ID: PP230046
APPLICATION TITLE: Screen, Treat, or Prevent (STOP) Hepatocellular Cancer-Hepatitis C (HCC-HCV): Expansion to All Adults
APPLICANT NAME: Jain, Mamta K
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 23.1_Prevention Panel-1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CPO	05/04/2022	01/17/2023
	RFA published in Texas.gov eGrants	05/06/2022	01/17/2023
	CPRIT Application Receipt System (CARS) opened	06/02/2022	01/17/2023
	CPRIT Application Receipt System (CARS) closed	08/31/2022	01/17/2023
	Date application submitted	08/30/2022	01/17/2023
	Method of submission	CARS	01/17/2023
	Within receipt period	YES	01/17/2023
	Request for extension to submit application after CARS closed	N/A	01/17/2023
	Request for extension for late application submission accepted	N/A	01/17/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/17/2023
Assigned to primary reviewers		09/29/2022	01/17/2023
Applicant notified of review panel assignment		09/28/2022	01/17/2023
Primary Reviewer 1 COI signed		09/26/2022	01/17/2023
Primary (Advocate) Reviewer 2 COI signed		09/23/2022	01/17/2023
Primary Reviewer 3 COI signed		09/21/2022	01/17/2023
Primary Reviewer 4 COI signed		09/21/2022	01/17/2023
Peer Review Meeting	Primary Reviewer 1 critique submitted	10/18/2022	01/17/2023
	Primary (Advocate) Reviewer 2 critique submitted	11/28/2022	01/17/2023
	Primary Reviewer 3 critique submitted	11/15/2022	01/17/2023
	Primary Reviewer 4 critique submitted	11/28/2022	01/17/2023
	COI indicated by non-primary reviewer	NONE	01/17/2023
	COI recused from participation	N/A	01/17/2023
	Discussed at Peer Review Meeting	YES	01/17/2023
	Peer Review Meeting	12/05/2022	01/17/2023
	Post review statements signed	12/06/2022	01/17/2023
	Third Party Observer Report	12/13/2022	01/17/2023
	Score report delivered to CPO	12/14/2022	01/17/2023
Recommended for PRC review	YES	01/17/2023	
Final PRC Recommendation	COI indicated by PRC member	NONE	01/17/2023
	COI recused from participation	N/A	01/17/2023
	PRC Meeting	01/13/2023	01/17/2023
	Third Party Observer Report	01/19/2023	01/20/2023
	Recommended for grant award	YES	01/17/2023
PIC Review	PRC Chair Notification to PIC and OC	01/18/2023	01/18/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
Oversight Committee Approval	PIC Review Meeting	02/01/2023	02/01/2023
	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
Oversight Committee Approval	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230018
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 30 applications in response to this RFA, including one application that was withdrawn. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.


Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer three *Individual Investigator Research Award for Cancer in Children and Adolescents* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the three applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have

also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules.


This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP230018
APPLICATION TITLE: Neuronal Alterations in the Midbrain Dopaminergic System Function: A Novel Mechanism of Radiation Induced Cognitive Dysfunction
APPLICANT NAME: Zhang, Die
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Cancer Prevention Research

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA Approved by CSO (revised)	03/15/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/02/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
		Donation(s) made to CPRIT / foundation	NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/15/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/29/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/14/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/08/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/24/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/26/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/22/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
Peer Review Meeting	Assigned to primary reviewers	09/13/2022	01/05/2023	
	Primary Reviewer 1 COI signed	09/12/2022	01/05/2023	
	Primary Reviewer 2 COI signed	10/16/2022	01/05/2023	
	Primary Reviewer 3 COI signed	09/07/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 COI signed	09/08/2022	01/05/2023	
	Primary Reviewer 1 critique submitted	10/15/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	10/18/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	10/12/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	10/14/2022	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	Discussed at Peer Review Meeting	YES	01/05/2023	
	Peer Review Meeting	10/26/2022	01/05/2023	
	Post review statements signed	10/27/2022	12/29/2022	
	Third Party Observer Report	10/31/2022	12/29/2022	
Score report delivered to CSO	11/15/2022	12/29/2022		
Recommended for SRC review	YES	01/05/2023		
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	SRC Meeting	12/22/2022	01/18/2023	
	Third Party Observer Report	12/23/2022	01/17/2023	
	Recommended for grant award	YES	01/05/2023	
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230026
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 30 applications in response to this RFA, including one application that was withdrawn. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer three *Individual Investigator Research Award for Cancer in Children and Adolescents* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the three applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have


also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP230026
APPLICATION TITLE: Identifying Clinical Methotrexate Toxicity Phenotypes Across Phases of Pediatric Leukemia Therapy
APPLICANT NAME: Bernhardt, Melanie B
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 23.1 Cancer Prevention Research

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA Approved by CSO (revised)	03/15/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/07/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
		Donation(s) made to CPRIT / foundation	NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		08/02/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/15/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/14/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/11/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/29/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/10/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/25/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
Peer Review Meeting	Assigned to primary reviewers	09/13/2022	01/05/2023	
	Primary Reviewer 1 COI signed	10/16/2022	01/05/2023	
	Primary Reviewer 2 COI signed	09/08/2022	01/05/2023	
	Primary Reviewer 3 COI signed	09/07/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 COI signed	09/11/2022	01/05/2023	
	Primary Reviewer 1 critique submitted	10/18/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	09/26/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	10/17/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	10/18/2022	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	Discussed at Peer Review Meeting	YES	01/05/2023	
	Peer Review Meeting	10/26/2022	01/05/2023	
	Post review statements signed	10/27/2022	12/29/2022	
	Third Party Observer Report	10/31/2022	12/29/2022	
	Score report delivered to CSO	11/15/2022	12/29/2022	
	Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	SRC Meeting	12/22/2022	01/18/2023	
	Third Party Observer Report	12/23/2022	01/17/2023	
	Recommended for grant award	YES	01/05/2023	
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
	Recommended for grant award	YES	02/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230036
Individual Investigator Research Awards for
Prevention and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Prevention and Early Detection* Request for Applications (RFA). CPRIT received 22 applications in response to this RFA. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle


The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Prevention and Early Detection
APPLICATION ID: RP230036
APPLICATION TITLE: Geospatial Approaches to Melanoma Early Detection - The GAMED Project
APPLICANT NAME: Nelson, Kelly
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Cancer Prevention Research

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA Approved by CSO (revised)	03/15/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/07/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
		Donation(s) made to CPRIT / foundation	NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/29/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/15/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/14/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/08/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/26/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/09/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/23/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
Peer Review Meeting	Assigned to primary reviewers	09/13/2022	01/05/2023	
	Primary Reviewer 1 COI signed	09/07/2022	01/05/2023	
	Primary Reviewer 2 COI signed	09/20/2022	01/05/2023	
	Primary Reviewer 3 COI signed	09/14/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 COI signed	09/08/2022	01/05/2023	
	Primary Reviewer 1 critique submitted	10/12/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	10/18/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	10/26/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	10/12/2022	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	Discussed at Peer Review Meeting	YES	01/05/2023	
	Peer Review Meeting	10/26/2022	01/05/2023	
	Post review statements signed	10/27/2022	12/29/2022	
	Third Party Observer Report	10/31/2022	12/29/2022	
	Score report delivered to CSO	11/15/2022	12/29/2022	
	Recommended for SRC review	YES	01/05/2023	
	Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
COI recused from participation		N/A	01/05/2023	
SRC Meeting		12/22/2022	01/18/2023	
Third Party Observer Report		12/23/2022	01/17/2023	
Recommended for grant award		YES	01/05/2023	
SRC Chair Notification to PIC and OC		01/17/2023	01/17/2023	
PIC Review	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
	Recommended for grant award	YES	02/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230050
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230050
APPLICATION TITLE: A Novel Therapeutic Strategy Targeting Pancreatic Cancer
APPLICANT NAME: Yao, Wantong
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/07/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/04/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/18/2022	01/05/2023
Primary Reviewer 2 COI signed		07/17/2022	01/05/2023
Primary Reviewer 3 COI signed		07/21/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/19/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/06/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/25/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	09/02/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023
	Primary Reviewer 1 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 2 COI signed	09/21/2022	01/05/2023
	Primary Reviewer 3 COI signed	09/13/2022	01/05/2023
	Primary (Advocate) Reviewer 4 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 1 critique submitted	10/17/2022	01/05/2023
	Primary Reviewer 2 critique submitted	10/19/2022	01/05/2023
	Primary Reviewer 3 critique submitted	10/24/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	10/17/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	10/31/2022	01/05/2023
	Post review statements signed	11/01/2022	12/29/2022
	Third Party Observer Report	11/01/2022	12/29/2022
Score report delivered to CSO	11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230063
Individual Investigator Research Awards for
Prevention and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Prevention and Early Detection* Request for Applications (RFA). CPRIT received 22 applications in response to this RFA. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle


The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 2 day of February, 2023, by WAYNE R. ROBERTS.



 Melanie Richardson
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Prevention and Early Detection
APPLICATION ID: RP230063
APPLICATION TITLE: Whole Genome DNA Methylation Markers for Tracking and Predicting Advanced Liver Fibrosis as a Precursor of Liver Cancer in NAFLD.
APPLICANT NAME: Tsai, Robert
ORGANIZATION: Texas A&M University System Health Science Center
PANEL NAME: 23.1 Cancer Prevention Research

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA Approved by CSO (revised)	03/15/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/07/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
		Donation(s) made to CPRIT / foundation	NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/15/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/08/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/22/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/22/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/09/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
Peer Review Meeting	Assigned to primary reviewers	09/13/2022	01/05/2023	
	Primary Reviewer 1 COI signed	09/07/2022	01/05/2023	
	Primary Reviewer 2 COI signed	09/21/2022	01/05/2023	
	Primary Reviewer 3 COI signed	09/20/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 COI signed	09/08/2022	01/05/2023	
	Primary Reviewer 1 critique submitted	10/12/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	10/16/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	10/18/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	10/16/2022	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	Discussed at Peer Review Meeting	YES	01/05/2023	
	Peer Review Meeting	10/26/2022	01/05/2023	
	Post review statements signed	10/27/2022	12/29/2022	
	Third Party Observer Report	10/31/2022	12/29/2022	
	Score report delivered to CSO	11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023		
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	SRC Meeting	12/22/2022	01/18/2023	
	Third Party Observer Report	12/23/2022	01/17/2023	
	Recommended for grant award	YES	01/05/2023	
SRC Chair Notification to PIC and OC	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
PIC Review	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
	Recommended for grant award	YES	02/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230072
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Basic Cancer Research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed


above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230072
APPLICATION TITLE: Studying and therapeutically targeting ferroptosis liability in BRCA1 deficient cancer
APPLICANT NAME: Gan, Boyi
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Basic Cancer Research 2

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	05/24/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
Donation(s) made to CPRIT / foundation		NO	01/05/2023	
Assigned to primary reviewers		08/05/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/14/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/11/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/13/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/25/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/28/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	09/02/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
	Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023
		Primary Reviewer 1 COI signed	09/07/2022	01/05/2023
Primary Reviewer 2 COI signed		09/07/2022	01/05/2023	
Primary Reviewer 3 COI signed		09/07/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/11/2022	01/05/2023	
Primary Reviewer 1 critique submitted		10/19/2022	01/05/2023	
Primary Reviewer 2 critique submitted		10/16/2022	01/05/2023	
Primary Reviewer 3 critique submitted		10/19/2022	01/05/2023	
Primary (Advocate) Reviewer 4 critique submitted		09/20/2022	01/05/2023	
COI indicated by non-primary reviewer		John Petrini	01/05/2023	
COI recused from participation		YES	01/05/2023	
Discussed at Peer Review Meeting		YES	01/05/2023	
Peer Review Meeting		10/25/2022	01/05/2023	
Post review statements signed		10/26/2022	12/29/2022	
Third Party Observer Report		10/31/2022	12/29/2022	
Score report delivered to CSO		11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023		
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	SRC Meeting	12/22/2022	01/18/2023	
	Third Party Observer Report	12/23/2022	01/17/2023	
	Recommended for grant award	YES	01/05/2023	
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230093
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Basic Cancer Research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed


above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230093
APPLICATION TITLE: Targeting the Mlc1-Gli3/PCAM Protein Complex in Invasive Glioma Cells
APPLICANT NAME: McCarty, Joseph H
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Basic Cancer Research 2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/01/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/14/2022	01/05/2023
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023
Primary Reviewer 3 COI signed		07/14/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/11/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/13/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/21/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/14/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	09/02/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
	Peer Review Meeting	Assigned to primary reviewers	09/12/2022
Primary Reviewer 1 COI signed		09/07/2022	01/05/2023
Primary Reviewer 2 COI signed		09/07/2022	01/05/2023
Primary Reviewer 3 COI signed		10/17/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/11/2022	01/05/2023
Primary Reviewer 1 critique submitted		10/19/2022	01/05/2023
Primary Reviewer 2 critique submitted		10/19/2022	01/05/2023
Primary Reviewer 3 critique submitted		10/19/2022	01/05/2023
Primary (Advocate) Reviewer 4 critique submitted		09/25/2022	01/05/2023
COI indicated by non-primary reviewer		NONE	01/05/2023
COI recused from participation		N/A	01/05/2023
Discussed at Peer Review Meeting		YES	01/05/2023
Peer Review Meeting		10/25/2022	01/05/2023
Post review statements signed		10/26/2022	12/29/2022
Third Party Observer Report		10/31/2022	12/29/2022
Score report delivered to CSO	11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230109
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Basic Cancer Research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230109
APPLICATION TITLE: Autophagy and Tumor Endothelium
APPLICANT NAME: Terada, Lance S
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 23.1 Basic Cancer Research 1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/07/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/04/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/26/2022	01/05/2023
Primary Reviewer 2 COI signed		07/26/2022	01/05/2023
Primary Reviewer 3 COI signed		07/22/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/08/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/11/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/23/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	08/31/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
	Peer Review Meeting	Assigned to primary reviewers	09/12/2022
Primary Reviewer 1 COI signed		10/10/2022	01/05/2023
Primary Reviewer 2 COI signed		09/07/2022	01/05/2023
Primary Reviewer 3 COI signed		09/07/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023
Primary Reviewer 1 critique submitted		10/18/2022	01/05/2023
Primary Reviewer 2 critique submitted		10/20/2022	01/05/2023
Primary Reviewer 3 critique submitted		10/24/2022	01/05/2023
Primary (Advocate) Reviewer 4 critique submitted		10/20/2022	01/05/2023
COI indicated by non-primary reviewer		NONE	01/05/2023
COI recused from participation		N/A	01/05/2023
Discussed at Peer Review Meeting		YES	01/05/2023
Peer Review Meeting		10/28/2022	01/05/2023
Post review statements signed		11/02/2022	12/29/2022
Third Party Observer Report		10/31/2022	12/29/2022
Score report delivered to CSO		11/15/2022	12/29/2022
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/05/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230117
Individual Investigator Research Awards for
Prevention and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Prevention and Early Detection* Request for Applications (RFA). CPRIT received 22 applications in response to this RFA. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 2 day of February, 2023, by WAYNE R. ROBERTS.



 Melanie Richardson
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:34 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Prevention and Early Detection
APPLICATION ID: RP230117
APPLICATION TITLE: Randomized Controlled Trial to Assess Innovative Smoking Cessation Services for Young Adults in Texas
APPLICANT NAME: Chalela, Patricia
ORGANIZATION: The University of Texas Health Science Center at San Antonio
PANEL NAME: 23.1 Cancer Prevention Research

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA Approved by CSO (revised)	03/15/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/08/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
		Donation(s) made to CPRIT / foundation	NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/14/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/11/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/10/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/05/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/09/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	Gloria Coronado	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
Peer Review Meeting	Assigned to primary reviewers	09/13/2022	01/05/2023	
	Primary Reviewer 1 COI signed	09/07/2022	01/05/2023	
	Primary Reviewer 2 COI signed	09/07/2022	01/05/2023	
	Primary Reviewer 3 COI signed	09/09/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 COI signed	09/11/2022	01/05/2023	
	Primary Reviewer 1 critique submitted	09/23/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	09/28/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	10/16/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	10/18/2022	01/05/2023	
	COI indicated by non-primary reviewer	Gloria Coronado	01/05/2023	
	COI recused from participation	YES	01/05/2023	
	Discussed at Peer Review Meeting	YES	01/05/2023	
	Peer Review Meeting	10/26/2022	01/05/2023	
	Post review statements signed	10/27/2022	12/29/2022	
	Third Party Observer Report	10/31/2022	12/29/2022	
	Score report delivered to CSO	11/15/2022	12/29/2022	
	Recommended for SRC review	YES	01/05/2023	
	Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
COI recused from participation		N/A	01/05/2023	
SRC Meeting		12/22/2022	01/18/2023	
Third Party Observer Report		12/23/2022	01/17/2023	
Recommended for grant award		YES	01/05/2023	
SRC Chair Notification to PIC and OC		01/17/2023	01/17/2023	
PIC Review	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
	Recommended for grant award	YES	02/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230120
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 30 applications in response to this RFA, including one application that was withdrawn. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer three *Individual Investigator Research Award for Cancer in Children and Adolescents* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the three applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have


also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP230120
APPLICATION TITLE: Clonal evolution and chemoresistance of Hepatoblastomas with hepatocellular carcinoma features
APPLICANT NAME: Sumazin, Pavel
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 23.1 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA Approved by CSO (revised)	03/15/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/08/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
		Donation(s) made to CPRIT / foundation	NO	01/05/2023
		Assigned to primary reviewers	08/04/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/27/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/14/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/26/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/24/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/14/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	09/02/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023	
	Primary Reviewer 1 COI signed	10/12/2022	01/05/2023	
	Primary Reviewer 2 COI signed	09/20/2022	01/05/2023	
	Primary Reviewer 3 COI signed	09/07/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 COI signed	09/07/2022	01/05/2023	
	Primary Reviewer 1 critique submitted	10/23/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	10/22/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	10/21/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	09/12/2022	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	Discussed at Peer Review Meeting	YES	01/05/2023	
	Peer Review Meeting	10/31/2022	01/05/2023	
	Post review statements signed	11/01/2022	12/29/2022	
	Third Party Observer Report	11/01/2022	12/29/2022	
Score report delivered to CSO	11/15/2022	12/29/2022		
Recommended for SRC review	YES	01/05/2023		
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	SRC Meeting	12/22/2022	01/18/2023	
	Third Party Observer Report	12/23/2022	01/17/2023	
	Recommended for grant award	YES	01/05/2023	
	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
PIC Review	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
	Recommended for grant award	YES	02/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230135
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

Type text here

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230135
APPLICATION TITLE: Blocking DNA damage response induction of “don’t eat me” signals converts local radiotherapy into systemic immunotherapy
APPLICANT NAME: Curran, Michael A
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Clinical and Translational Cancer Research

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/02/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/28/2022	01/05/2023
Primary Reviewer 2 COI signed		07/15/2022	01/05/2023
Primary Reviewer 3 COI signed		07/14/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/12/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/28/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/25/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/06/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	09/13/2022	01/05/2023
	Primary Reviewer 1 COI signed	09/08/2022	01/05/2023
	Primary Reviewer 2 COI signed	09/15/2022	01/05/2023
	Primary Reviewer 3 COI signed	09/07/2022	01/05/2023
	Primary (Advocate) Reviewer 4 COI signed	09/12/2022	01/05/2023
	Primary Reviewer 1 critique submitted	10/16/2022	01/05/2023
	Primary Reviewer 2 critique submitted	10/14/2022	01/05/2023
	Primary Reviewer 3 critique submitted	10/02/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	10/08/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	10/27/2022	01/05/2023
	Post review statements signed	10/28/2022	12/29/2022
Third Party Observer Report	10/31/2022	12/29/2022	
Score report delivered to CSO	11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230140
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed


above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230140
APPLICATION TITLE: Changes in Tumor Microenvironment that Promote Cachexia
APPLICANT NAME: Infante, Rodney
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 23.1 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/07/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/04/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/14/2022	01/05/2023
Primary Reviewer 2 COI signed		07/28/2022	01/05/2023
Primary Reviewer 3 COI signed		07/14/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/24/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/25/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/17/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	09/02/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023
	Primary Reviewer 1 COI signed	09/12/2022	01/05/2023
	Primary Reviewer 2 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 3 COI signed	09/07/2022	01/05/2023
	Primary (Advocate) Reviewer 4 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 1 critique submitted	10/23/2022	01/05/2023
	Primary Reviewer 2 critique submitted	09/27/2022	01/05/2023
	Primary Reviewer 3 critique submitted	10/17/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	10/17/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	10/31/2022	01/05/2023
	Post review statements signed	11/01/2022	12/29/2022
	Third Party Observer Report	11/01/2022	12/29/2022
Score report delivered to CSO	11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230154
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 30 applications in response to this RFA, including one application that was withdrawn. This application was assigned to the Basic Cancer Research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer three *Individual Investigator Research Award for Cancer in Children and Adolescents* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the three applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have

also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP230154
APPLICATION TITLE: Normalizing membrane homeostasis in microglia/macrophages of pediatric high-grade gliomas
APPLICANT NAME: Hu, Jian
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Basic Cancer Research I

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA Approved by CSO (revised)	03/15/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	05/24/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
		Donation(s) made to CPRIT / foundation	NO	01/05/2023
Assigned to primary reviewers		08/04/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/20/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/28/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/21/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/24/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/29/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	08/31/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023	
	Primary Reviewer 1 COI signed	10/07/2022	01/05/2023	
	Primary Reviewer 2 COI signed	09/07/2022	01/05/2023	
	Primary Reviewer 3 COI signed	10/18/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 COI signed	09/07/2022	01/05/2023	
	Primary Reviewer 1 critique submitted	10/24/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	10/21/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	10/23/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	10/20/2022	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	Discussed at Peer Review Meeting	YES	01/05/2023	
	Peer Review Meeting	10/28/2022	01/05/2023	
	Post review statements signed	11/02/2022	12/29/2022	
	Third Party Observer Report	10/31/2022	12/29/2022	
	Score report delivered to CSO	11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023		
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	SRC Meeting	12/22/2022	01/05/2023	
	Third Party Observer Report	12/23/2022	01/17/2023	
	Recommended for grant award	YES	01/05/2023	
	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
PIC Review	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
	Recommended for grant award	YES	02/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230160
Individual Investigator Research Awards for
Computational Systems Biology of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Computational Systems Biology of Cancer* Request for Applications (RFA). CPRIT received 23 applications in response to this RFA. This application was assigned to the Basic Cancer Research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.


The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer two *Individual Investigator Research Awards for Computational Systems Biology of Cancer* applications recommended by the SRC. CPRIT's Chief Scientific Officer proposed deferring the two applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne B. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Computational Systems Biology of Cancer
APPLICATION ID: RP230160
APPLICATION TITLE: Overcoming therapy resistance by integrated computational modeling of the bone metastatic niche in prostate and renal cancers
APPLICANT NAME: Dondossola, Eleonora
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Basic Cancer Research 1

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/06/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
Donation(s) made to CPRIT / foundation		NO	01/05/2023	
Assigned to primary reviewers		08/04/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/27/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/28/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/15/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/28/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/29/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/23/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	08/31/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
	Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023
		Primary Reviewer 1 COI signed	10/13/2022	01/05/2023
Primary Reviewer 2 COI signed		10/18/2022	01/05/2023	
Primary Reviewer 3 COI signed		09/08/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023	
Primary Reviewer 1 critique submitted		10/15/2022	01/05/2023	
Primary Reviewer 2 critique submitted		10/23/2022	01/05/2023	
Primary Reviewer 3 critique submitted		10/16/2022	01/05/2023	
Primary (Advocate) Reviewer 4 critique submitted		10/06/2022	01/05/2023	
COI indicated by non-primary reviewer		NONE	01/05/2023	
COI recused from participation		N/A	01/05/2023	
Discussed at Peer Review Meeting		YES	01/05/2023	
Peer Review Meeting		10/28/2022	01/05/2023	
Post review statements signed		11/02/2022	12/29/2022	
Third Party Observer Report		10/31/2022	12/29/2022	
Score report delivered to CSO		11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023		
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	SRC Meeting	12/22/2022	01/05/2023	
	Third Party Observer Report	12/23/2022	01/17/2023	
	Recommended for grant award	YES	01/05/2023	
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230166
Individual Investigator Research Awards for
Computational Systems Biology of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Computational Systems Biology of Cancer* Request for Applications (RFA). CPRIT received 23 applications in response to this RFA. This application was assigned to the Basic Cancer Research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.


The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer two *Individual Investigator Research Awards for Computational Systems Biology of Cancer* applications recommended by the SRC. CPRIT's Chief Scientific Officer proposed deferring the two applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.

Melanie Richardson

Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Computational Systems Biology of Cancer
APPLICATION ID: RP230166
APPLICATION TITLE: Integrative modeling of spatially resolved multi-omics data to identify bladder cancer mucosal field effects
APPLICANT NAME: Wei, Peng
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Basic Cancer Research 1

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/07/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/04/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/28/2022	01/05/2023
Primary Reviewer 2 COI signed		07/20/2022	01/05/2023
Primary Reviewer 3 COI signed		07/27/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/29/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/21/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/29/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	08/31/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
	Peer Review Meeting	Assigned to primary reviewers	09/12/2022
Primary Reviewer 1 COI signed		10/18/2022	01/05/2023
Primary Reviewer 2 COI signed		10/07/2022	01/05/2023
Primary Reviewer 3 COI signed		10/13/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023
Primary Reviewer 1 critique submitted		10/24/2022	01/05/2023
Primary Reviewer 2 critique submitted		10/24/2022	01/05/2023
Primary Reviewer 3 critique submitted		10/26/2022	01/05/2023
Primary (Advocate) Reviewer 4 critique submitted		10/20/2022	01/05/2023
COI indicated by non-primary reviewer		NONE	01/05/2023
COI recused from participation		N/A	01/05/2023
Discussed at Peer Review Meeting		YES	01/05/2023
Peer Review Meeting		10/28/2022	01/05/2023
Post review statements signed		11/02/2022	12/29/2022
Third Party Observer Report		10/31/2022	12/29/2022
Score report delivered to CSO		11/15/2022	12/29/2022
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/05/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230204
Texas Regional Excellence in Cancer Award (TREC)

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Texas Regional Excellence in Cancer Award (TREC)* Request for Applications (RFA). CPRIT received four applications in response to this RFA. This application was assigned to the Texas Regional Excellence in Cancer Award (TREC) panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Texas Regional Excellence in Cancer Award
APPLICATION ID: RP230204
APPLICATION TITLE: GENE – ENVIRONMENT - LIFESTYLE INTERACTIONS IN CANCER
APPLICANT NAME: Ramos, Kenneth
ORGANIZATION: Texas A&M University System Health Science Center
PANEL NAME: 23.1 TREC Meeting

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	09/24/2021	01/05/2023
	RFA Approved by CSO (revised)	08/08/2022	01/05/2023
	RFA published in Texas.gov eGrants	09/27/2021	01/05/2023
	CPRIT Application Receipt System (CARS) opened	05/16/2022	01/05/2023
	CPRIT Application Receipt System (CARS) closed	09/08/2022	01/05/2023
	Date application submitted	09/08/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	09/20/2022
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		10/14/2022	01/05/2023
Applicant notified of review panel assignment		N/A	01/05/2023
Primary Reviewer 1 COI signed		09/21/2022	01/05/2023
Primary Reviewer 2 COI signed		10/07/2022	01/05/2023
Primary Reviewer 3 COI signed		10/06/2022	01/05/2023
Primary Reviewer 4 COI signed		09/21/2022	01/05/2023
Primary (Advocate) Reviewer 5 COI signed		09/21/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	01/05/2023
	Primary Reviewer 2 critique submitted	N/A	01/05/2023
	Primary Reviewer 3 critique submitted	N/A	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	N/A	01/05/2023
	Preliminary Evaluation score summary sent to Chair	N/A	01/05/2023
	Recommended for full review	N/A	01/05/2023
	Applicant notified of outcome	N/A	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	10/14/2022	01/05/2023
	Primary Reviewer 1 COI signed	09/21/2022	01/05/2023
	Primary Reviewer 2 COI signed	10/07/2022	01/05/2023
	Primary Reviewer 3 COI signed	10/06/2022	01/05/2023
	Primary Reviewer 4 COI signed	09/21/2022	01/05/2023
	Primary (Advocate) Reviewer 5 COI signed	09/21/2022	01/05/2023
	Primary Reviewer 1 critique submitted	10/25/2022	01/05/2023
	Primary Reviewer 2 critique submitted	11/21/2022	01/05/2023
	Primary Reviewer 3 critique submitted	11/19/2022	01/05/2023
	Primary Reviewer 4 critique submitted	11/01/2022	01/05/2023
	Primary (Advocate) Reviewer 5 critique submitted	11/09/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	11/29/2022	01/05/2023
	Post review statements signed	11/29/2022	01/05/2023
	Third Party Observer Report	12/01/2022	01/05/2023
	Score report delivered to CSO	12/08/2022	01/05/2023
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/05/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
PIC Review	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
	Recommended for grant award	YES	02/01/2023
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230213
Individual Investigator Research Awards for
Prevention and Early Detection

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Prevention and Early Detection* Request for Applications (RFA). CPRIT received 22 applications in response to this RFA. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."



 Wayne R. Roberts,
 CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on the 2 day of February, 2023, by WAYNE R. ROBERTS.



 Melanie Richardson
 Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Prevention and Early Detection
APPLICATION ID: RP230213
APPLICATION TITLE: Multi-component Interventions to Improve Uptake and Adherence to Lung Cancer Screening
APPLICANT NAME: Volk, Robert J
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Cancer Prevention Research

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA Approved by CSO (revised)	03/15/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/06/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	07/07/2022	01/05/2023
		Donation(s) made to CPRIT / foundation	NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/28/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/11/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/09/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/10/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/09/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
Peer Review Meeting	Assigned to primary reviewers	09/13/2022	01/05/2023	
	Primary Reviewer 1 COI signed	09/09/2022	01/05/2023	
	Primary Reviewer 2 COI signed	09/07/2022	01/05/2023	
	Primary Reviewer 3 COI signed	10/13/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 COI signed	09/11/2022	01/05/2023	
	Primary Reviewer 1 critique submitted	10/16/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	10/18/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	10/17/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	10/18/2022	01/05/2023	
	COI indicated by non-primary reviewer	Thomas Brandon	01/05/2023	
	COI recused from participation	YES	01/05/2023	
	Discussed at Peer Review Meeting	YES	01/05/2023	
	Peer Review Meeting	10/26/2022	01/05/2023	
	Post review statements signed	10/27/2022	12/29/2022	
	Third Party Observer Report	10/31/2022	12/29/2022	
	Score report delivered to CSO	11/15/2022	12/29/2022	
	Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	SRC Meeting	12/22/2022	01/18/2023	
	Third Party Observer Report	12/23/2022	01/17/2023	
	Recommended for grant award	YES	01/05/2023	
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
	Recommended for grant award	YES	02/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230222
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Cancer Prevention Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230222
APPLICATION TITLE: Personalized Auricular Point Acupressure to Self-Manage Cancer-Related Pain
APPLICANT NAME: Yeh, Chao Hsing H
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: 23.1 Cancer Prevention Research

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/08/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/14/2022	01/05/2023
Primary Reviewer 2 COI signed		07/15/2022	01/05/2023
Primary Reviewer 3 COI signed		07/28/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/11/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/22/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/08/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/26/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
	Peer Review Meeting	Assigned to primary reviewers	09/13/2022
Primary Reviewer 1 COI signed		09/07/2022	01/05/2023
Primary Reviewer 2 COI signed		09/12/2022	01/05/2023
Primary Reviewer 3 COI signed		09/07/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/11/2022	01/05/2023
Primary Reviewer 1 critique submitted		10/12/2022	01/05/2023
Primary Reviewer 2 critique submitted		10/16/2022	01/05/2023
Primary Reviewer 3 critique submitted		10/18/2022	01/05/2023
Primary (Advocate) Reviewer 4 critique submitted		10/18/2022	01/05/2023
COI indicated by non-primary reviewer		NONE	01/05/2023
COI recused from participation		N/A	01/05/2023
Discussed at Peer Review Meeting		YES	01/05/2023
Peer Review Meeting		10/26/2022	01/05/2023
Post review statements signed		10/27/2022	12/29/2022
Third Party Observer Report		10/31/2022	12/29/2022
Score report delivered to CSO		11/15/2022	12/29/2022
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230224
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed


above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230224
APPLICATION TITLE: Enhancing Immune Responses in Pancreatic Cancer by Stromal Inhibition of HIF2
APPLICANT NAME: Taniguchi, Cullen M
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/02/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/04/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/14/2022	01/05/2023
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023
Primary Reviewer 3 COI signed		07/27/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/24/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/17/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/25/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	09/02/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023
	Primary Reviewer 1 COI signed	09/12/2022	01/05/2023
	Primary Reviewer 2 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 3 COI signed	09/13/2022	01/05/2023
	Primary (Advocate) Reviewer 4 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 1 critique submitted	10/23/2022	01/05/2023
	Primary Reviewer 2 critique submitted	10/06/2022	01/05/2023
	Primary Reviewer 3 critique submitted	10/24/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	10/17/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	10/31/2022	01/05/2023
	Post review statements signed	11/01/2022	12/29/2022
	Third Party Observer Report	11/01/2022	12/29/2022
Score report delivered to CSO	11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230247
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed


above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230247
APPLICATION TITLE: A novel combination therapeutic approach to revitalizing immunotherapy for bone metastatic prostate cancer
APPLICANT NAME: Lin, Sue-Hwa
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/07/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/04/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/14/2022	01/05/2023
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023
Primary Reviewer 3 COI signed		07/27/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/22/2022	01/05/2023
	Primary Reviewer 2 critique submitted	09/03/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/25/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	09/02/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023
	Primary Reviewer 1 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 2 COI signed	10/25/2022	01/05/2023
	Primary Reviewer 3 COI signed	09/07/2022	01/05/2023
	Primary (Advocate) Reviewer 4 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 1 critique submitted	10/14/2022	01/05/2023
	Primary Reviewer 2 critique submitted	10/28/2022	01/05/2023
	Primary Reviewer 3 critique submitted	10/23/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	10/17/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	10/31/2022	01/05/2023
	Post review statements signed	11/01/2022	12/29/2022
	Third Party Observer Report	11/01/2022	12/29/2022
Score report delivered to CSO	11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230261
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed


above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230261
APPLICATION TITLE: Investigating the mechanism of NLRP3 inflammasome hyperactivation during hepatocellular carcinoma development
APPLICANT NAME: Zhong, Zhenyu
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 23.1 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/07/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
Donation(s) made to CPRIT / foundation		NO	01/05/2023	
Assigned to primary reviewers		08/04/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/27/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/27/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/27/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/25/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/26/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/26/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	09/02/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
	Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023
		Primary Reviewer 1 COI signed	09/07/2022	01/05/2023
Primary Reviewer 2 COI signed		10/12/2022	01/05/2023	
Primary Reviewer 3 COI signed		09/07/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023	
Primary Reviewer 1 critique submitted		10/25/2022	01/05/2023	
Primary Reviewer 2 critique submitted		10/23/2022	01/05/2023	
Primary Reviewer 3 critique submitted		10/25/2022	01/05/2023	
Primary (Advocate) Reviewer 4 critique submitted		09/13/2022	01/05/2023	
COI indicated by non-primary reviewer		NONE	01/05/2023	
COI recused from participation		N/A	01/05/2023	
Discussed at Peer Review Meeting		YES	01/05/2023	
Peer Review Meeting		10/31/2022	01/05/2023	
Post review statements signed		11/01/2022	12/29/2022	
Third Party Observer Report		11/01/2022	12/29/2022	
Score report delivered to CSO		11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023		
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	SRC Meeting	12/22/2022	01/18/2023	
	Third Party Observer Report	12/23/2022	01/17/2023	
	Recommended for grant award	YES	01/05/2023	
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230271
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Imaging Technology and Informatics panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230271
APPLICATION TITLE: Targeting distinct metabolic vulnerabilities of aggressive renal cell carcinoma variants
APPLICANT NAME: Zacharias Millward, Niki
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Imaging Technology and Informatics

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/03/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
Donation(s) made to CPRIT / foundation		NO	01/05/2023	
Assigned to primary reviewers		08/04/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/15/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/24/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/12/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/26/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/21/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/13/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	Anna Wu, Warren Warren	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
	Peer Review Meeting	Assigned to primary reviewers	09/13/2022	01/05/2023
		Primary Reviewer 1 COI signed	09/08/2022	01/05/2023
Primary Reviewer 2 COI signed		09/12/2022	01/05/2023	
Primary Reviewer 3 COI signed		09/07/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/12/2022	01/05/2023	
Primary Reviewer 1 critique submitted		10/15/2022	01/05/2023	
Primary Reviewer 2 critique submitted		10/10/2022	01/05/2023	
Primary Reviewer 3 critique submitted		10/12/2022	01/05/2023	
Primary (Advocate) Reviewer 4 critique submitted		10/07/2022	01/05/2023	
COI indicated by non-primary reviewer		Anna Wu, Warren Warren	01/05/2023	
COI recused from participation		YES	01/05/2023	
Discussed at Peer Review Meeting		YES	01/05/2023	
Peer Review Meeting		10/24/2022	01/05/2023	
Post review statements signed		10/24/2022	12/29/2022	
Third Party Observer Report		10/31/2022	12/29/2022	
Score report delivered to CSO	11/15/2022	12/29/2022		
Recommended for SRC review	YES	01/05/2023		
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	SRC Meeting	12/22/2022	01/18/2023	
	Third Party Observer Report	12/23/2022	01/17/2023	
	Recommended for grant award	YES	01/05/2023	
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230285
Individual Investigator Research Awards for
Clinical Translation

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Clinical Translation* Request for Applications (RFA). CPRIT received 19 applications in response to this RFA including one application that was withdrawn. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer one *Individual Investigator Research Awards for Clinical Translation* application recommended by the SRC. CPRIT's Chief Scientific Officer proposed deferring the application because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne B. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Clinical Translation
APPLICATION ID: RP230285
APPLICATION TITLE: Harnessing Endoplasmic Reticulum Stress to Overcome Resistance to Immunotherapy in Immune-cold Breast Cancer
APPLICANT NAME: Chen , Xi
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 23.1 Clinical and Translational Cancer Research

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA Approved by CSO (revised)	03/15/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/07/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
		Donation(s) made to CPRIT / foundation	NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/17/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/28/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/28/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/12/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/23/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/19/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/24/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
Peer Review Meeting	Assigned to primary reviewers	09/13/2022	01/05/2023	
	Primary Reviewer 1 COI signed	10/06/2022	01/05/2023	
	Primary Reviewer 2 COI signed	09/20/2022	01/05/2023	
	Primary Reviewer 3 COI signed	09/14/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 COI signed	09/12/2022	01/05/2023	
	Primary Reviewer 1 critique submitted	10/17/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	10/19/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	10/18/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	09/17/2022	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	Discussed at Peer Review Meeting	YES	01/05/2023	
	Peer Review Meeting	10/27/2022	01/05/2023	
	Post review statements signed	10/28/2022	12/29/2022	
	Third Party Observer Report	10/31/2022	12/29/2022	
	Score report delivered to CSO	11/15/2022	12/29/2022	
	Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	SRC Meeting	12/22/2022	01/18/2023	
	Third Party Observer Report	12/23/2022	01/17/2023	
	Recommended for grant award	YES	01/05/2023	
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
	Recommended for grant award	YES	02/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230330
Individual Investigator Research Awards for
Cancer in Children and Adolescents

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Cancer in Children and Adolescents* Request for Applications (RFA). CPRIT received 30 applications in response to this RFA, including one application that was withdrawn. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle

- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle
The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.


An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer three *Individual Investigator Research Award for Cancer in Children and Adolescents* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the three applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Cancer in Children and Adolescents
APPLICATION ID: RP230330
APPLICATION TITLE: Integrate whole slide imaging and genomic data to study pediatric rhabdomyosarcoma
APPLICANT NAME: Xiao, Guanghua
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 23.1 Clinical and Translational Cancer Research

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA Approved by CSO (revised)	03/15/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/07/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	07/07/2022	01/05/2023
		Donation(s) made to CPRIT / foundation	NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/29/2022	01/05/2023	
Primary Reviewer 3 COI signed		08/02/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/09/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/22/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/28/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/27/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
Peer Review Meeting	Assigned to primary reviewers	09/13/2022	01/05/2023	
	Primary Reviewer 1 COI signed	09/07/2022	01/05/2023	
	Primary Reviewer 2 COI signed	09/10/2022	01/05/2023	
	Primary Reviewer 3 COI signed	10/13/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 COI signed	09/09/2022	01/05/2023	
	Primary Reviewer 1 critique submitted	10/20/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	10/20/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	10/23/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	09/27/2022	01/05/2023	
	COI indicated by non-primary reviewer	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	Discussed at Peer Review Meeting	YES	01/05/2023	
	Peer Review Meeting	10/27/2022	01/05/2023	
	Post review statements signed	10/28/2022	12/29/2022	
	Third Party Observer Report	10/31/2022	12/29/2022	
	Score report delivered to CSO	11/15/2022	12/29/2022	
	Recommended for SRC review	YES	01/05/2023	
	Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
COI recused from participation		N/A	01/05/2023	
SRC Meeting		12/22/2022	01/18/2023	
Third Party Observer Report		12/23/2022	01/17/2023	
Recommended for grant award		YES	01/05/2023	
SRC Chair Notification to PIC and OC		01/17/2023	01/17/2023	
PIC Review	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
	Recommended for grant award	YES	02/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230334
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Basic Cancer Research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed


above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:35 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230334
APPLICATION TITLE: Elucidating the mutagenesis mechanism of BRAF in melanoma
APPLICANT NAME: Lee, Seongmin
ORGANIZATION: The University of Texas at Austin
PANEL NAME: 23.1 Basic Cancer Research 2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/08/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/17/2022	01/05/2023
Primary Reviewer 2 COI signed		07/26/2022	01/05/2023
Primary Reviewer 3 COI signed		07/14/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/13/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/25/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/29/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/21/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	09/02/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023
	Primary Reviewer 1 COI signed	09/08/2022	01/05/2023
	Primary Reviewer 2 COI signed	09/12/2022	01/05/2023
	Primary Reviewer 3 COI signed	10/20/2022	01/05/2023
	Primary (Advocate) Reviewer 4 COI signed	09/13/2022	01/05/2023
	Primary Reviewer 1 critique submitted	10/18/2022	01/05/2023
	Primary Reviewer 2 critique submitted	10/18/2022	01/05/2023
	Primary Reviewer 3 critique submitted	10/24/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	10/14/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	10/25/2022	01/05/2023
	Post review statements signed	10/26/2022	12/29/2022
	Third Party Observer Report	10/31/2022	12/29/2022
Score report delivered to CSO	11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230344
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230344
APPLICATION TITLE: Development and evaluation of lanosterol synthase inhibitors in preclinical GBM models
APPLICANT NAME: McBrayer, Samuel K
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 23.1 Clinical and Translational Cancer Research

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/07/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/28/2022	01/05/2023
Primary Reviewer 2 COI signed		07/28/2022	01/05/2023
Primary Reviewer 3 COI signed		07/28/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/12/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/19/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/24/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/29/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	09/13/2022	01/05/2023
	Primary Reviewer 1 COI signed	09/20/2022	01/05/2023
	Primary Reviewer 2 COI signed	09/14/2022	01/05/2023
	Primary Reviewer 3 COI signed	09/08/2022	01/05/2023
	Primary (Advocate) Reviewer 4 COI signed	09/12/2022	01/05/2023
	Primary Reviewer 1 critique submitted	10/19/2022	01/05/2023
	Primary Reviewer 2 critique submitted	10/18/2022	01/05/2023
	Primary Reviewer 3 critique submitted	10/16/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	10/08/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	10/27/2022	01/05/2023
	Post review statements signed	10/28/2022	12/29/2022
	Third Party Observer Report	10/31/2022	12/29/2022
Score report delivered to CSO	11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230345
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230345
APPLICATION TITLE: The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T Cell Therapy
APPLICANT NAME: Liu, Wenshe R
ORGANIZATION: Texas A&M University
PANEL NAME: 23.1 Clinical and Translational Cancer Research

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/08/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/21/2022	01/05/2023
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023
Primary Reviewer 3 COI signed		07/28/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/09/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/23/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/22/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/14/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
	Peer Review Meeting	Assigned to primary reviewers	09/13/2022
Primary Reviewer 1 COI signed		09/24/2022	01/05/2023
Primary Reviewer 2 COI signed		09/07/2022	01/05/2023
Primary Reviewer 3 COI signed		09/14/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/09/2022	01/05/2023
Primary Reviewer 1 critique submitted		10/19/2022	01/05/2023
Primary Reviewer 2 critique submitted		09/26/2022	01/05/2023
Primary Reviewer 3 critique submitted		10/16/2022	01/05/2023
Primary (Advocate) Reviewer 4 critique submitted		09/27/2022	01/05/2023
COI indicated by non-primary reviewer		NONE	01/05/2023
COI recused from participation		N/A	01/05/2023
Discussed at Peer Review Meeting		YES	01/05/2023
Peer Review Meeting		10/27/2022	01/05/2023
Post review statements signed		10/28/2022	12/29/2022
Third Party Observer Report		10/31/2022	12/29/2022
Score report delivered to CSO		11/15/2022	12/29/2022
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230360
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Basic Cancer Research 1 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed


above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230360
APPLICATION TITLE: Rational design, synthesis and biological evaluation of simplified taccalonolide analogs for the treatment of cancer
APPLICANT NAME: Frantz, Douglas E
ORGANIZATION: The University of Texas at San Antonio
PANEL NAME: 23.1 Basic Cancer Research 1

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022	
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022	
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022	
	Date application submitted	06/08/2022	01/05/2023	
	Method of submission	CARS	01/05/2023	
	Within receipt period	YES	01/05/2023	
	Request for extension to submit application after CARS closed	N/A	01/05/2023	
	Request for extension for late application submission accepted	N/A	01/05/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/05/2023
Donation(s) made to CPRIT / foundation		NO	01/05/2023	
Assigned to primary reviewers		08/04/2022	01/05/2023	
Applicant notified of review panel assignment		07/08/2022	12/29/2022	
Primary Reviewer 1 COI signed		07/14/2022	01/05/2023	
Primary Reviewer 2 COI signed		07/15/2022	01/05/2023	
Primary Reviewer 3 COI signed		07/16/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023	
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/28/2022	01/05/2023	
	Primary Reviewer 2 critique submitted	08/21/2022	01/05/2023	
	Primary Reviewer 3 critique submitted	08/20/2022	01/05/2023	
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023	
	COI indicated by non-primary reviewer	Jose Conejo-Garcia	01/05/2023	
	Preliminary Evaluation score summary sent to Chair	08/31/2022	01/05/2023	
	Recommended for full review	YES	01/05/2023	
	Applicant notified of outcome	09/30/2022	01/05/2023	
	Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023
		Primary Reviewer 1 COI signed	10/20/2022	01/05/2023
Primary Reviewer 2 COI signed		09/08/2022	01/05/2023	
Primary Reviewer 3 COI signed		09/13/2022	01/05/2023	
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023	
Primary Reviewer 1 critique submitted		10/22/2022	01/05/2023	
Primary Reviewer 2 critique submitted		10/15/2022	01/05/2023	
Primary Reviewer 3 critique submitted		10/18/2022	01/05/2023	
Primary (Advocate) Reviewer 4 critique submitted		10/14/2022	01/05/2023	
COI indicated by non-primary reviewer		Jose Conejo-Garcia	01/05/2023	
COI recused from participation		YES	01/05/2023	
Discussed at Peer Review Meeting		YES	01/05/2023	
Peer Review Meeting		10/28/2022	01/05/2023	
Post review statements signed		11/02/2022	12/29/2022	
Third Party Observer Report		10/31/2022	12/29/2022	
Score report delivered to CSO		11/15/2022	12/29/2022	
Recommended for SRC review		YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023	
	COI recused from participation	N/A	01/05/2023	
	SRC Meeting	12/22/2022	01/05/2023	
	Third Party Observer Report	12/23/2022	01/17/2023	
	Recommended for grant award	YES	01/05/2023	
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023	
	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	N/A		
	Authority to advance funds requested	N/A		
Advance authority approved by Oversight Committee	N/A			



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230363
Individual Investigator Research Awards for
Computational Systems Biology of Cancer

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards for Computational Systems Biology of Cancer* Request for Applications (RFA). CPRIT received 23 applications in response to this RFA. This application was assigned to the Basic Cancer Research 2 panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.


The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer two *Individual Investigator Research Awards for Computational Systems Biology of Cancer* applications recommended by the SRC. CPRIT's Chief Scientific Officer proposed deferring the two applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne E. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards for Computational Systems Biology of Cancer
APPLICATION ID: RP230363
APPLICATION TITLE: Developing knowledge guided deep learning models to predict the binding between T cell receptors and neoantigens for facilitating TCR-T therapies
APPLICANT NAME: Wang, Tao
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 23.1 Basic Cancer Research 2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/08/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/27/2022	01/05/2023
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023
Primary Reviewer 3 COI signed		07/19/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/13/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/25/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/21/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/28/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	09/02/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023
	Primary Reviewer 1 COI signed	10/17/2022	01/05/2023
	Primary Reviewer 2 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 3 COI signed	10/16/2022	01/05/2023
	Primary (Advocate) Reviewer 4 COI signed	09/13/2022	01/05/2023
	Primary Reviewer 1 critique submitted	10/19/2022	01/05/2023
	Primary Reviewer 2 critique submitted	10/19/2022	01/05/2023
	Primary Reviewer 3 critique submitted	10/20/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	10/17/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	10/25/2022	01/05/2023
	Post review statements signed	10/26/2022	12/29/2022
Third Party Observer Report	10/31/2022	12/29/2022	
Score report delivered to CSO	11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230373
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.

The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed

above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230373
APPLICATION TITLE: Mapping the geospatial tumor clonal architecture to restore immune recognition in pancreatic cancer.
APPLICANT NAME: Viale, Andrea
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: 23.1 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/08/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/04/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/14/2022	01/05/2023
Primary Reviewer 2 COI signed		07/14/2022	01/05/2023
Primary Reviewer 3 COI signed		07/27/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/25/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/22/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/25/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	09/02/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023
	Primary Reviewer 1 COI signed	09/12/2022	01/05/2023
	Primary Reviewer 2 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 3 COI signed	09/07/2022	01/05/2023
	Primary (Advocate) Reviewer 4 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 1 critique submitted	10/23/2022	01/05/2023
	Primary Reviewer 2 critique submitted	09/28/2022	01/05/2023
	Primary Reviewer 3 critique submitted	10/18/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	10/17/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	10/31/2022	01/05/2023
	Post review statements signed	11/01/2022	12/29/2022
	Third Party Observer Report	11/01/2022	12/29/2022
Score report delivered to CSO	11/15/2022	12/29/2022	
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230382
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Cancer Biology panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as “Final Scores for Preliminary Evaluations.” As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson’s decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as ‘Final Scores for Fully Reviewed Applications.’

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT’s scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel’s decision is based upon a number of factors, including the final score.

An application’s score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT’s review policies in creating the panel’s list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT’s Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application’s grant pedigree. The grant pedigree for the application listed


above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230382
APPLICATION TITLE: Characterization of 3D Genome Organization and Transcriptional Regulation in Prostate Cancer
APPLICANT NAME: Mani, Ram S
ORGANIZATION: The University of Texas Southwestern Medical Center
PANEL NAME: 23.1 Cancer Biology

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/07/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	06/21/2022
Administrative review notification		07/07/2022	01/05/2023
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/04/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/27/2022	01/05/2023
Primary Reviewer 2 COI signed		07/17/2022	01/05/2023
Primary Reviewer 3 COI signed		07/22/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/07/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/26/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/07/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/25/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	Preliminary Evaluation score summary sent to Chair	09/02/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	09/12/2022	01/05/2023
	Primary Reviewer 1 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 2 COI signed	09/21/2022	01/05/2023
	Primary Reviewer 3 COI signed	09/08/2022	01/05/2023
	Primary (Advocate) Reviewer 4 COI signed	09/07/2022	01/05/2023
	Primary Reviewer 1 critique submitted	10/21/2022	01/05/2023
	Primary Reviewer 2 critique submitted	10/19/2022	01/05/2023
	Primary Reviewer 3 critique submitted	10/21/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	09/12/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	10/31/2022	01/05/2023
	Post review statements signed	11/01/2022	12/29/2022
	Third Party Observer Report	11/01/2022	12/29/2022
	Score report delivered to CSO	11/15/2022	12/29/2022
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230391
Individual Investigator Research Awards

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Individual Investigator Research Awards* Request for Applications (RFA). CPRIT received 235 applications in response to this RFA, including two applications that were withdrawn. This application was assigned to the Clinical and Translational Cancer Research panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- Two de-identified lists of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

The de-identified list for the applications that did not move past the preliminary evaluation review stage in this cycle is listed as "Final Scores for Preliminary Evaluations." As explained in 25 T.A.C. § 703.6(e)(1)(C), it is the responsibility of the peer review panel chairperson to determine which grant applications move forward to full review from preliminary evaluation. The chairperson's decision is based on several factors including the preliminary evaluation scores by the assigned primary reviewers and their comments.

The de-identified list for the applications that received full review is listed as 'Final Scores for Fully Reviewed Applications.'

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

I note that some applications that were not recommended for grant awards have scores that are equal to or more favorable than some applications that were recommended for grant awards. Each of CPRIT's scientific research review panels individually determines the applications that the panel forwards to the Scientific Review Council (SRC) for grant award consideration. The panel's decision is based upon a number of factors, including the final score.

An application's score establishes its position relative to other applications reviewed by its assigned panel, but not relative to other panels. CPRIT has no policy that specifies a score that guarantees an application will or will not be recommended for funding. In this round, within each panel, no grant application with a less favorable score was recommended ahead of an application with a more favorable score.


The comprehensive list of de-identified application scores created for the purpose of this affidavit compiles the information for all panels into a single list. However, no individual panel was aware of the scores assigned by the other review panels. While one panel may determine that certain factors justify recommending an application for a grant award that has a score greater than 3.1, another panel may decide based on the totality of factors that an application with a score greater than 3.1 should not move forward. I am satisfied that the individual panels followed CPRIT's review policies in creating the panel's list of recommended awards.

Upon recommendation from the Chief Scientific Officer, the PIC unanimously voted to defer 19 *Individual Investigator Research Awards* applications recommended by the SRC. CPRIT's Chief Scientific Officer proposed deferring the 19 applications because the total award recommendations from the SRC exceeded the amount of agency funds available. The PIC may consider the deferred applications at a future FY2023 meeting.

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed


above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC

I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Individual Investigator Research Awards
APPLICATION ID: RP230391
APPLICATION TITLE: Understanding and improving CAR T-cell therapy of T-ALL and LBL
APPLICANT NAME: Mamonkin, Maksim
ORGANIZATION: Baylor College of Medicine
PANEL NAME: 23.1 Clinical and Translational Cancer Research

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	01/12/2022	12/16/2022
	RFA published in Texas.gov eGrants	01/14/2022	12/16/2022
	CPRIT Application Receipt System (CARS) opened	03/16/2022	12/16/2022
	CPRIT Application Receipt System (CARS) closed	06/08/2022	12/16/2022
	Date application submitted	06/06/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		08/05/2022	01/05/2023
Applicant notified of review panel assignment		07/08/2022	12/29/2022
Primary Reviewer 1 COI signed		07/15/2022	01/05/2023
Primary Reviewer 2 COI signed		07/21/2022	01/05/2023
Primary Reviewer 3 COI signed		07/14/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/12/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	08/25/2022	01/05/2023
	Primary Reviewer 2 critique submitted	08/23/2022	01/05/2023
	Primary Reviewer 3 critique submitted	08/22/2022	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	John DiPersio	01/05/2023
	Preliminary Evaluation score summary sent to Chair	08/30/2022	01/05/2023
	Recommended for full review	YES	01/05/2023
	Applicant notified of outcome	09/30/2022	01/05/2023
	Peer Review Meeting	Assigned to primary reviewers	09/13/2022
Primary Reviewer 1 COI signed		09/15/2022	01/05/2023
Primary Reviewer 2 COI signed		09/20/2022	01/05/2023
Primary Reviewer 3 COI signed		09/07/2022	01/05/2023
Primary (Advocate) Reviewer 4 COI signed		09/12/2022	01/05/2023
Primary Reviewer 1 critique submitted		10/19/2022	01/05/2023
Primary Reviewer 2 critique submitted		10/19/2022	01/05/2023
Primary Reviewer 3 critique submitted		10/20/2022	01/05/2023
Primary (Advocate) Reviewer 4 critique submitted		10/08/2022	01/05/2023
COI indicated by non-primary reviewer		John DiPersio	01/05/2023
COI recused from participation		YES	01/05/2023
Discussed at Peer Review Meeting		YES	01/05/2023
Peer Review Meeting		10/27/2022	01/05/2023
Post review statements signed		10/28/2022	12/29/2022
Third Party Observer Report		10/31/2022	12/29/2022
Score report delivered to CSO		11/15/2022	12/29/2022
Recommended for SRC review	YES	01/05/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/18/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
Advance authority approved by Oversight Committee	N/A		



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230419
Texas Regional Excellence in Cancer Award (TREC)

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Texas Regional Excellence in Cancer Award (TREC)* Request for Applications (RFA). CPRIT received four applications in response to this RFA. This application was assigned to the Texas Regional Excellence in Cancer Award (TREC) panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Texas Regional Excellence in Cancer Award
APPLICATION ID: RP230419
APPLICATION TITLE: South Texas Center of Excellence in Cancer Research (ST-CECR)
APPLICANT NAME: CHAUHAN, SUBHASH C
ORGANIZATION: The University of Texas Rio Grande Valley
PANEL NAME: 23.1 TREC Meeting

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	09/24/2021	01/05/2023
	RFA Approved by CSO (revised)	08/08/2022	01/05/2023
	RFA published in Texas.gov eGrants	09/27/2021	01/05/2023
	CPRIT Application Receipt System (CARS) opened	05/16/2022	01/05/2023
	CPRIT Application Receipt System (CARS) closed	09/08/2022	01/05/2023
	Date application submitted	09/08/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	09/20/2022
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		10/14/2022	01/05/2023
Applicant notified of review panel assignment		N/A	01/05/2023
Primary Reviewer 1 COI signed		09/22/2022	01/05/2023
Primary Reviewer 2 COI signed		09/29/2022	01/05/2023
Primary Reviewer 3 COI signed		09/21/2022	01/05/2023
Primary Reviewer 4 COI signed		09/22/2022	01/05/2023
Primary (Advocate) Reviewer 5 COI signed		09/21/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	01/05/2023
	Primary Reviewer 2 critique submitted	N/A	01/05/2023
	Primary Reviewer 3 critique submitted	N/A	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	N/A	01/05/2023
	Preliminary Evaluation score summary sent to Chair	N/A	01/05/2023
	Recommended for full review	N/A	01/05/2023
	Applicant notified of outcome	N/A	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	10/14/2022	01/05/2023
	Primary Reviewer 1 COI signed	09/22/2022	01/05/2023
	Primary Reviewer 2 COI signed	09/29/2022	01/05/2023
	Primary Reviewer 3 COI signed	09/21/2022	01/05/2023
	Primary Reviewer 4 COI signed	09/22/2022	01/05/2023
	Primary (Advocate) Reviewer 5 COI signed	09/21/2022	01/05/2023
	Primary Reviewer 1 critique submitted	11/23/2022	01/05/2023
	Primary Reviewer 2 critique submitted	11/21/2022	01/05/2023
	Primary Reviewer 3 critique submitted	11/11/2022	01/05/2023
	Primary Reviewer 4 critique submitted	11/18/2022	01/05/2023
	Primary (Advocate) Reviewer 5 critique submitted	11/09/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	11/29/2022	01/05/2023
	Post review statements signed	11/29/2022	01/05/2023
	Third Party Observer Report	12/01/2022	01/05/2023
	Score report delivered to CSO	12/08/2022	01/05/2023
	Recommended for SRC review	YES	01/05/2023
	Final SRC Recommendation	COI indicated by SRC member	NONE
COI recused from participation		N/A	01/05/2023
SRC Meeting		12/22/2022	01/05/2023
Third Party Observer Report		12/23/2022	01/17/2023
Recommended for grant award		YES	01/05/2023
SRC Chair Notification to PIC and OC		01/17/2023	01/17/2023
PIC Review	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
	Recommended for grant award	YES	02/01/2023
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RP230420
Texas Regional Excellence in Cancer Award (TREC)

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Texas Regional Excellence in Cancer Award (TREC)* Request for Applications (RFA). CPRIT received four applications in response to this RFA. This application was assigned to the Texas Regional Excellence in Cancer Award (TREC) panel for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."




Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.



Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Research
MECHANISM: Texas Regional Excellence in Cancer Award
APPLICATION ID: RP230420
APPLICATION TITLE: Impacting Cancer Outcomes in Hispanics (ICOHN)
APPLICANT NAME: LAKSHMANASWAMY, RAJKUMAR
ORGANIZATION: Texas Tech University Health Sciences Center at El Paso
PANEL NAME: 23.1 TREC Meeting

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	09/24/2021	01/05/2023
	RFA Approved by CSO (revised)	08/08/2022	01/05/2023
	RFA published in Texas.gov eGrants	09/27/2021	01/05/2023
	CPRIT Application Receipt System (CARS) opened	05/16/2022	01/05/2023
	CPRIT Application Receipt System (CARS) closed	09/08/2022	01/05/2023
	Date application submitted	09/07/2022	01/05/2023
	Method of submission	CARS	01/05/2023
	Within receipt period	YES	01/05/2023
	Request for extension to submit application after CARS closed	N/A	01/05/2023
	Request for extension for late application submission accepted	N/A	01/05/2023
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	01/05/2023
Assigned to primary reviewers		10/14/2022	01/05/2023
Applicant notified of review panel assignment		N/A	01/05/2023
Primary Reviewer 1 COI signed		09/22/2022	01/05/2023
Primary Reviewer 2 COI signed		09/21/2022	01/05/2023
Primary Reviewer 3 COI signed		10/06/2022	01/05/2023
Primary Reviewer 4 COI signed		09/21/2022	01/05/2023
Primary (Advocate) Reviewer 5 COI signed		09/21/2022	01/05/2023
Preliminary Evaluation	Primary Reviewer 1 critique submitted	N/A	01/05/2023
	Primary Reviewer 2 critique submitted	N/A	01/05/2023
	Primary Reviewer 3 critique submitted	N/A	01/05/2023
	Primary (Advocate) Reviewer 4 critique submitted	N/A	01/05/2023
	COI indicated by non-primary reviewer	N/A	01/05/2023
	Preliminary Evaluation score summary sent to Chair	N/A	01/05/2023
	Recommended for full review	N/A	01/05/2023
	Applicant notified of outcome	N/A	01/05/2023
Peer Review Meeting	Assigned to primary reviewers	10/14/2022	01/05/2023
	Primary Reviewer 1 COI signed	09/22/2022	01/05/2023
	Primary Reviewer 2 COI signed	09/21/2022	01/05/2023
	Primary Reviewer 3 COI signed	10/06/2022	01/05/2023
	Primary Reviewer 4 COI signed	09/21/2022	01/05/2023
	Primary (Advocate) Reviewer 5 COI signed	09/21/2022	01/05/2023
	Primary Reviewer 1 critique submitted	11/18/2022	01/05/2023
	Primary Reviewer 2 critique submitted	11/14/2022	01/05/2023
	Primary Reviewer 3 critique submitted	11/19/2022	01/05/2023
	Primary Reviewer 4 critique submitted	11/07/2022	01/05/2023
	Primary (Advocate) Reviewer 5 critique submitted	11/09/2022	01/05/2023
	COI indicated by non-primary reviewer	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	Discussed at Peer Review Meeting	YES	01/05/2023
	Peer Review Meeting	11/29/2022	01/05/2023
	Post review statements signed	11/29/2022	01/05/2023
	Third Party Observer Report	12/01/2022	01/05/2023
	Score report delivered to CSO	12/08/2022	01/05/2023
	Recommended for SRC review	YES	01/05/2023
Final SRC Recommendation	COI indicated by SRC member	NONE	01/05/2023
	COI recused from participation	N/A	01/05/2023
	SRC Meeting	12/22/2022	01/05/2023
	Third Party Observer Report	12/23/2022	01/17/2023
	Recommended for grant award	YES	01/05/2023
	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
PIC Review	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
	Recommended for grant award	YES	02/01/2023
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	N/A	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR230012
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Kenneth Hu, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received four applications in response to this RFA during cycles 23.2 and 23.3. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR230012
APPLICATION TITLE: Recruitment of First-Time, Tenure-Track Faculty Members - Kenneth Hu
APPLICANT NAME: Draetta, Gulio
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: Recruitment FY23_Cycle 2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/21/2022	10/07/2022
	RFA published in Texas.gov eGrants	06/21/2022	10/07/2022
	CPRIT Application Receipt Cycle opened	08/23/2022	12/06/2022
	CPRIT Application Receipt Cycle closed	10/20/2022	12/06/2022
	Date application submitted	10/20/2022	12/06/2022
	Method of submission	CARS	12/06/2022
	Within receipt period	YES	12/06/2022
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/06/2022
Assigned to primary reviewers		11/01/2022	12/06/2022
Applicant notified of review panel assignment		N/A	12/06/2022
Primary Reviewer 1 COI signed		10/26/2022	12/06/2022
Primary Reviewer 2 COI signed		10/26/2022	12/06/2022
Peer Review Meeting		Primary Reviewer 1 critique submitted	11/09/2022
	Primary Reviewer 2 critique submitted	11/08/2022	12/06/2022
	COI indicated by non-primary reviewer	NONE	12/06/2022
	COI recused from participation	N/A	12/06/2022
	Discussed at Peer Review Meeting	YES	12/06/2022
	Peer Review Meeting	11/10/2022	12/06/2022
	Post review statements signed	11/10/2022	01/06/2023
	Third Party Observer Report	11/11/2022	01/06/2023
	Score report delivered to CSO	11/17/2022	01/06/2023
	Recommended for SRC review	YES	12/06/2022
Final SRC Recommendation	COI indicated by SRC member	NONE	12/06/2022
	COI recused from participation	N/A	12/06/2022
	SRC Meeting	11/10/2022	01/06/2023
	Third Party Observer Report	11/11/2022	01/06/2023
	Recommended for grant award	YES	12/06/2022
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	02/01/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	

CPRIT retains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR230015
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Ewan McRae, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received four applications in response to this RFA during cycles 23.2 and 23.3. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR230015
APPLICATION TITLE: Recruitment of First-Time, Tenure-Track Faculty Member: Dr. Ewan McRae
APPLICANT NAME: Sostman, Henry D
ORGANIZATION: The Methodist Hospital Research Institute
PANEL NAME: Recruitment FY23_Cycle 2

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/21/2022	10/07/2022	
	RFA published in Texas.gov eGrants	06/21/2022	10/07/2022	
	CPRIT Application Receipt Cycle opened	08/23/2022	12/06/2022	
	CPRIT Application Receipt Cycle closed	10/20/2022	12/06/2022	
	Date application submitted	10/20/2022	12/06/2022	
	Method of submission	CARS	12/06/2022	
	Within receipt period	YES	12/06/2022	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	12/06/2022
Donation(s) made to CPRIT / foundation		NO	12/06/2022	
Assigned to primary reviewers		11/01/2022	12/06/2022	
Applicant notified of review panel assignment		N/A	12/06/2022	
Primary Reviewer 1 COI signed		10/26/2022	12/06/2022	
Primary Reviewer 2 COI signed		10/31/2022	12/06/2022	
Peer Review Meeting		Primary Reviewer 1 critique submitted	11/07/2022	12/06/2022
		Primary Reviewer 2 critique submitted	11/09/2022	12/06/2022
	COI indicated by non-primary reviewer	NONE	12/06/2022	
	COI recused from participation	N/A	12/06/2022	
	Discussed at Peer Review Meeting	YES	12/06/2022	
	Peer Review Meeting	11/10/2022	12/06/2022	
	Post review statements signed	11/10/2022	01/06/2023	
	Third Party Observer Report	11/11/2022	01/06/2023	
	Score report delivered to CSO	11/17/2022	01/06/2023	
	Recommended for SRC review	YES	12/06/2022	
Final SRC Recommendation	COI indicated by SRC member	NONE	12/06/2022	
	COI recused from participation	N/A	12/06/2022	
	SRC Meeting	11/10/2022	01/06/2023	
	Third Party Observer Report	11/11/2022	01/06/2023	
	Recommended for grant award	YES	12/06/2022	
	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	02/01/2023	
	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
	Recommended for grant award	YES	02/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		

CPRIT retains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR230017
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Joe Nassour, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received four applications in response to this RFA during cycles 23.2 and 23.3. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.

CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle

In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR230017
APPLICATION TITLE: Recruitment of First-Time, Tenure-Track Faculty Members - Joe Nassour
APPLICANT NAME: Draetta, Gulio
ORGANIZATION: The University of Texas M. D. Anderson Cancer Center
PANEL NAME: Recruitment FY23_Cycle 2

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/21/2022	10/07/2022
	RFA published in Texas.gov eGrants	06/21/2022	10/07/2022
	CPRIT Application Receipt Cycle opened	08/23/2022	12/06/2022
	CPRIT Application Receipt Cycle closed	10/20/2022	12/06/2022
	Date application submitted	10/20/2022	12/06/2022
	Method of submission	CARS	12/06/2022
	Within receipt period	YES	12/06/2022
	Receipt, Referral, and Assignment	Administrative review notification	N/A
Donation(s) made to CPRIT / foundation		NO	12/06/2022
Assigned to primary reviewers		11/01/2022	12/06/2022
Applicant notified of review panel assignment		N/A	12/06/2022
Primary Reviewer 1 COI signed		10/26/2022	12/06/2022
Primary Reviewer 2 COI signed		10/31/2022	12/06/2022
Peer Review Meeting		Primary Reviewer 1 critique submitted	11/01/2022
	Primary Reviewer 2 critique submitted	11/09/2022	12/06/2022
	COI indicated by non-primary reviewer	NONE	12/06/2022
	COI recused from participation	N/A	12/06/2022
	Discussed at Peer Review Meeting	YES	12/06/2022
	Peer Review Meeting	11/10/2022	12/06/2022
	Post review statements signed	11/10/2022	01/06/2023
	Third Party Observer Report	11/11/2022	01/06/2023
	Score report delivered to CSO	11/17/2022	01/06/2023
	Recommended for SRC review	YES	12/06/2022
Final SRC Recommendation	COI indicated by SRC member	NONE	12/06/2022
	COI recused from participation	N/A	12/06/2022
	SRC Meeting	11/10/2022	12/06/2022
	Third Party Observer Report	11/11/2022	01/06/2023
	Recommended for grant award	YES	12/06/2022
PIC Review	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	02/01/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
Oversight Committee Approval	Recommended for grant award	YES	02/01/2023
	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	

CPRIT retains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR230018
Recruitment of Established Investigators
Nomination of Rudi Fasan, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of Established Investigators* Request for Applications (RFA). CPRIT received three applications in response to this RFA during cycles 23.2 and 23.3. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of Established Investigators
APPLICATION ID: RR230018
APPLICATION TITLE: Nomination of Dr Rudi Fasan for CPRIT Recruitment of Established Investigators
APPLICANT NAME: Pancrazio, Joseph J
ORGANIZATION: The University of Texas at Dallas
PANEL NAME: Recruitment FY23_Cycle 3

Category	Compliance Requirement	Information	Attestation Date
Pre-Receipt	RFA Approved by CSO	06/21/2022	10/07/2022
	RFA published in Texas.gov eGrants	06/21/2022	10/07/2022
	CPRIT Application Receipt Cycle opened	10/21/2022	01/17/2023
	CPRIT Application Receipt Cycle closed	12/20/2022	01/17/2023
	Date application submitted	12/15/2022	01/17/2023
	Method of submission	CARS	01/17/2023
	Within receipt period	YES	01/17/2023
	Receipt, Referral, and Assignment	Administrative review notification	12/23/2022
Donation(s) made to CPRIT / foundation		NO	01/17/2023
Assigned to primary reviewers		01/03/2023	01/17/2023
Applicant notified of review panel assignment		N/A	01/17/2023
Primary Reviewer 1 COI signed		12/27/2022	01/17/2023
Primary Reviewer 2 COI signed		12/28/2022	01/17/2023
Peer Review Meeting		Primary Reviewer 1 critique submitted	01/10/2023
	Primary Reviewer 2 critique submitted	01/10/2023	01/17/2023
	COI indicated by non-primary reviewer	NONE	01/17/2023
	COI recused from participation	N/A	01/17/2023
	Discussed at Peer Review Meeting	YES	01/17/2023
	Peer Review Meeting	01/12/2023	01/17/2023
	Post review statements signed	01/12/2023	01/17/2023
	Third Party Observer Report	01/18/2023	01/19/2023
	Score report delivered to CSO	01/17/2023	01/17/2023
	Recommended for SRC review	YES	01/17/2023
Final SRC Recommendation	COI indicated by SRC member	NONE	01/17/2023
	COI recused from participation	N/A	01/17/2023
	SRC Meeting	01/12/2023	01/17/2023
	Third Party Observer Report	01/18/2023	01/19/2023
	Recommended for grant award	YES	01/17/2023
	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023
PIC Review	Candidate not accepted position prior to SRC date	YES	02/01/2023
	COI indicated by PIC member	None	02/01/2023
	COI recused from participation	N/A	02/01/2023
	PIC Review Meeting	02/01/2023	02/01/2023
	Recommended for grant award	YES	02/01/2023
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A	
	COI Indicated by Oversight Committee member	N/A	
	COI Recused from participation	N/A	
	Donation(s) made to CPRIT / foundation	N/A	
	Presented to CPRIT Oversight Committee	N/A	
	Award approved by Oversight Committee	NO	
	Authority to advance funds requested	N/A	
	Advance authority approved by Oversight Committee	N/A	

CPRIT retains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR230019
Recruitment of First-Time, Tenure-Track Faculty Members
Nomination of Lu Wang, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of First-Time, Tenure-Track Faculty Members* Request for Applications (RFA). CPRIT received four applications in response to this RFA during cycles 23.2 and 23.3. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of First-Time, Tenure-Track Faculty Members
APPLICATION ID: RR230019
APPLICATION TITLE: Recruitment of First-Time Tenure Track, Lu Wang
APPLICANT NAME: Hromas, Robert
ORGANIZATION: The University of Texas Health Science Center at San Antonio
PANEL NAME: Recruitment FY23_Cycle 3

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/21/2022	10/07/2022	
	RFA published in Texas.gov eGrants	06/21/2022	10/07/2022	
	CPRIT Application Receipt Cycle opened	10/21/2022	01/17/2023	
	CPRIT Application Receipt Cycle closed	12/20/2022	01/17/2023	
	Date application submitted	12/20/2022	01/17/2023	
	Method of submission	CARS	01/17/2023	
	Within receipt period	YES	01/17/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/17/2023
Donation(s) made to CPRIT / foundation		NO	01/17/2023	
Assigned to primary reviewers		01/03/2023	01/17/2023	
Applicant notified of review panel assignment		N/A	01/17/2023	
Primary Reviewer 1 COI signed		12/27/2022	01/17/2023	
Primary Reviewer 2 COI signed		12/23/2022	01/17/2023	
Peer Review Meeting		Primary Reviewer 1 critique submitted	01/10/2023	01/17/2023
		Primary Reviewer 2 critique submitted	01/08/2023	01/17/2023
	COI indicated by non-primary reviewer	NONE	01/17/2023	
	COI recused from participation	N/A	01/17/2023	
	Discussed at Peer Review Meeting	YES	01/17/2023	
	Peer Review Meeting	01/12/2023	01/17/2023	
	Post review statements signed	01/12/2023	01/17/2023	
	Third Party Observer Report	01/18/2023	01/19/2023	
	Score report delivered to CSO	01/17/2023	01/17/2023	
	Recommended for SRC review	YES	01/17/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/17/2023	
	COI recused from participation	N/A	01/17/2023	
	SRC Meeting	01/12/2023	01/17/2023	
	Third Party Observer Report	01/18/2023	01/19/2023	
	Recommended for grant award	YES	01/17/2023	
	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
PIC Review	Candidate not accepted asst. prof. tenure track position prior to SRC date	YES	02/01/2023	
	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
	Recommended for grant award	YES	02/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		

CPRIT retains the identity of the attesting party.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

CEO AFFIDAVIT
Application RR230020
Recruitment of Established Investigators
Nomination of Hongfang Liu, Ph.D.

THE STATE OF TEXAS

COUNTY OF TRAVIS

BEFORE ME, the undersigned authority, on this day personally appeared Wayne R. Roberts, who swore or affirmed to tell the truth, and stated as follows:

“My name is Wayne R. Roberts, the Chief Executive Officer (CEO) of the Cancer Prevention and Research Institute of Texas (CPRIT). I am of sound mind and capable of making this sworn statement. I submit this affidavit pursuant to the legal requirement imposed by V.T.C.A., Health & Safety Code § 102.251(c).

My affidavit addresses the grant review process for the application stated above that is recommended for a CPRIT grant award by the Program Integration Committee (PIC). This application was submitted pursuant to *Recruitment of Established Investigators* Request for Applications (RFA). CPRIT received three applications in response to this RFA during cycles 23.2 and 23.3. This application was assigned to the Scientific Review Council (SRC) for review. A preliminary evaluation process as described by 25 T.A.C. § 703.6(e)(1) was not used for applications in this cycle.


CPRIT staff and CPRIT’s third-party grants management vendor have recorded information and prepared documents during the course of their employment that are related to CPRIT’s grant review process described by Health & Safety Code Chapter 102. I have reviewed the information prepared by CPRIT staff and CPRIT’s third-party grants management vendor in my capacity as CPRIT’s CEO to prepare this affidavit. Some information (“CEO Affidavit-Supporting Information”) is applicable to all applications recommended for awards submitted pursuant to this RFA. The information listed below has been compiled as one packet and is incorporated herein by reference:

- The applicable Request for Applications (RFA) for this grant cycle
- An overview of the conflict of interest process, including any conflict of interest waivers granted
- The third-party observer report(s) documenting that CPRIT’s grant review processes were followed by the review panel evaluating the applications in this grant cycle
- A de-identified list of the overall evaluation scores for applications submitted pursuant to the applicable RFA for this grant cycle

- A final overall evaluation score and rank order score submitted by the SRPP committees for the grant applications recommended by the PIC in this cycle


In addition to the CEO Affidavit-Supporting Information that is applicable to all applications submitted pursuant to the applicable RFA and recommended for grant awards this cycle, I have also reviewed the application's grant pedigree. The grant pedigree for the application listed above has been attached to this affidavit. The application pedigree provides an overview of the conflict of interest process applicable to this application, including any conflicts of interest reported by the review panel or by the PIC.


I personally reviewed the information for the grant application listed above and referenced herein. Based upon my review of the information and to the best of my knowledge, I swear or affirm that the peer review process for the grant application was consistent, in all material aspects, with the process described in the statute and CPRIT's administrative rules. This statement is true."


Wayne R. Roberts,
CEO, Cancer Prevention and Research Institute of Texas

State of Texas
County of Travis

SWORN to and SUBSCRIBED before me, the undersigned authority, on
the 2 day of February, 2023,
by WAYNE R. ROBERTS.


Melanie Richardson
Notary Public, State of Texas



CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS

APPLICATION PEDIGREE

Date and time exported: 02/02/2023 07:36 PM CT

FY: 2023
CYCLE: 1
PROGRAM: Recruitment
MECHANISM: Recruitment of Established Investigators
APPLICATION ID: RR230020
APPLICATION TITLE: Nomination of Dr Hongfang Liu for CPRIT Recruitment of Established Investigators
APPLICANT NAME: Morano, Kevin A
ORGANIZATION: The University of Texas Health Science Center at Houston
PANEL NAME: Recruitment FY23_Cycle 3

Category	Compliance Requirement	Information	Attestation Date	
Pre-Receipt	RFA Approved by CSO	06/21/2022	10/07/2022	
	RFA published in Texas.gov eGrants	06/21/2022	10/07/2022	
	CPRIT Application Receipt Cycle opened	10/21/2022	01/17/2023	
	CPRIT Application Receipt Cycle closed	12/20/2022	01/17/2023	
	Date application submitted	12/19/2022	01/17/2023	
	Method of submission	CARS	01/17/2023	
	Within receipt period	YES	01/17/2023	
	Receipt, Referral, and Assignment	Administrative review notification	N/A	01/17/2023
Donation(s) made to CPRIT / foundation		NO	01/17/2023	
Assigned to primary reviewers		01/03/2023	01/17/2023	
Applicant notified of review panel assignment		N/A	01/17/2023	
Primary Reviewer 1 COI signed		12/27/2022	01/17/2023	
Primary Reviewer 2 COI signed		12/23/2022	01/17/2023	
Peer Review Meeting		Primary Reviewer 1 critique submitted	01/10/2023	01/17/2023
		Primary Reviewer 2 critique submitted	01/11/2023	01/17/2023
	COI indicated by non-primary reviewer	NONE	01/17/2023	
	COI recused from participation	N/A	01/17/2023	
	Discussed at Peer Review Meeting	YES	01/17/2023	
	Peer Review Meeting	01/12/2023	01/17/2023	
	Post review statements signed	01/12/2023	01/17/2023	
	Third Party Observer Report	01/18/2023	01/19/2023	
	Score report delivered to CSO	01/17/2023	01/17/2023	
	Recommended for SRC review	YES	01/17/2023	
Final SRC Recommendation	COI indicated by SRC member	NONE	01/17/2023	
	COI recused from participation	N/A	01/17/2023	
	SRC Meeting	01/12/2023	01/17/2023	
	Third Party Observer Report	01/18/2023	01/19/2023	
	Recommended for grant award	YES	01/17/2023	
	SRC Chair Notification to PIC and OC	01/17/2023	01/17/2023	
PIC Review	Candidate not accepted position prior to SRC date	YES	02/01/2023	
	COI indicated by PIC member	None	02/01/2023	
	COI recused from participation	N/A	02/01/2023	
	PIC Review Meeting	02/01/2023	02/01/2023	
	Recommended for grant award	YES	02/01/2023	
Oversight Committee Approval	CEO Notification to Oversight Committee	N/A		
	COI Indicated by Oversight Committee member	N/A		
	COI Recused from participation	N/A		
	Donation(s) made to CPRIT / foundation	N/A		
	Presented to CPRIT Oversight Committee	N/A		
	Award approved by Oversight Committee	NO		
	Authority to advance funds requested	N/A		
	Advance authority approved by Oversight Committee	N/A		

CPRIT retains the identity of the attesting party.